JP2005534282A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005534282A5 JP2005534282A5 JP2003565500A JP2003565500A JP2005534282A5 JP 2005534282 A5 JP2005534282 A5 JP 2005534282A5 JP 2003565500 A JP2003565500 A JP 2003565500A JP 2003565500 A JP2003565500 A JP 2003565500A JP 2005534282 A5 JP2005534282 A5 JP 2005534282A5
- Authority
- JP
- Japan
- Prior art keywords
- nmu1
- diseases
- disorders
- polypeptide
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 181
- 210000004027 cells Anatomy 0.000 claims description 160
- 229920001184 polypeptide Polymers 0.000 claims description 131
- 201000010099 disease Diseases 0.000 claims description 125
- 230000000694 effects Effects 0.000 claims description 110
- 230000027455 binding Effects 0.000 claims description 101
- 229920000023 polynucleotide Polymers 0.000 claims description 89
- 239000002157 polynucleotide Substances 0.000 claims description 89
- 102000004965 antibodies Human genes 0.000 claims description 81
- 108090001123 antibodies Proteins 0.000 claims description 81
- 150000007523 nucleic acids Chemical class 0.000 claims description 80
- 201000011510 cancer Diseases 0.000 claims description 73
- 108020004707 nucleic acids Proteins 0.000 claims description 70
- 239000000203 mixture Substances 0.000 claims description 58
- 230000000051 modifying Effects 0.000 claims description 50
- 241000124008 Mammalia Species 0.000 claims description 47
- 201000010238 heart disease Diseases 0.000 claims description 47
- 208000005209 Hematologic Disease Diseases 0.000 claims description 46
- 200000000018 inflammatory disease Diseases 0.000 claims description 46
- 239000003814 drug Substances 0.000 claims description 43
- 201000008779 central nervous system disease Diseases 0.000 claims description 40
- 201000009673 liver disease Diseases 0.000 claims description 39
- 206010061590 Blood disease Diseases 0.000 claims description 36
- 229920000272 Oligonucleotide Polymers 0.000 claims description 36
- 208000001293 Peripheral Nervous System Disease Diseases 0.000 claims description 34
- 239000003446 ligand Substances 0.000 claims description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims description 30
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims description 27
- 200000000011 liver disorder Diseases 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 16
- 239000007787 solid Substances 0.000 claims description 16
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 15
- 230000001809 detectable Effects 0.000 claims description 14
- 206010007541 Cardiac disease Diseases 0.000 claims description 13
- 210000000578 Peripheral Nerves Anatomy 0.000 claims description 11
- 150000003384 small molecules Chemical class 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 8
- 201000002138 hematopoietic system disease Diseases 0.000 claims description 7
- 210000004671 Cell-Free System Anatomy 0.000 claims description 4
- 208000009025 Nervous System Disease Diseases 0.000 claims description 4
- 108010014251 Muramidase Proteins 0.000 claims description 2
- 102000016943 Muramidase Human genes 0.000 claims description 2
- 239000004325 lysozyme Substances 0.000 claims description 2
- 229960000274 lysozyme Drugs 0.000 claims description 2
- 235000010335 lysozyme Nutrition 0.000 claims description 2
- 230000002489 hematologic Effects 0.000 claims 2
- 230000014509 gene expression Effects 0.000 description 149
- 102000004169 proteins and genes Human genes 0.000 description 78
- 108090000623 proteins and genes Proteins 0.000 description 78
- 235000018102 proteins Nutrition 0.000 description 70
- 238000000034 method Methods 0.000 description 69
- 239000000523 sample Substances 0.000 description 66
- 229920001850 Nucleic acid sequence Polymers 0.000 description 65
- 210000001519 tissues Anatomy 0.000 description 62
- 238000004166 bioassay Methods 0.000 description 54
- 102000003688 G-protein coupled receptors Human genes 0.000 description 53
- 108090000045 G-protein coupled receptors Proteins 0.000 description 53
- 238000003752 polymerase chain reaction Methods 0.000 description 49
- 102000005962 receptors Human genes 0.000 description 49
- 108020003175 receptors Proteins 0.000 description 49
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 40
- 230000003321 amplification Effects 0.000 description 37
- 238000003199 nucleic acid amplification method Methods 0.000 description 37
- 229920002676 Complementary DNA Polymers 0.000 description 36
- 241000282414 Homo sapiens Species 0.000 description 36
- 108020004999 Messenger RNA Proteins 0.000 description 35
- 229920002106 messenger RNA Polymers 0.000 description 35
- 125000003729 nucleotide group Chemical group 0.000 description 34
- 150000001413 amino acids Chemical group 0.000 description 33
- 239000002773 nucleotide Substances 0.000 description 33
- 239000000126 substance Substances 0.000 description 33
- 239000000047 product Substances 0.000 description 32
- 239000002299 complementary DNA Substances 0.000 description 31
- 238000009396 hybridization Methods 0.000 description 30
- 230000015572 biosynthetic process Effects 0.000 description 27
- 108020001507 fusion proteins Proteins 0.000 description 25
- 102000037240 fusion proteins Human genes 0.000 description 25
- 230000002401 inhibitory effect Effects 0.000 description 25
- 230000000295 complement Effects 0.000 description 22
- 239000003153 chemical reaction reagent Substances 0.000 description 21
- 230000003042 antagnostic Effects 0.000 description 19
- 239000005557 antagonist Substances 0.000 description 19
- 229920002033 ribozyme Polymers 0.000 description 19
- 210000004379 Membranes Anatomy 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 18
- 238000005755 formation reaction Methods 0.000 description 18
- 238000005259 measurement Methods 0.000 description 18
- 239000012528 membrane Substances 0.000 description 18
- 238000000746 purification Methods 0.000 description 18
- 230000001225 therapeutic Effects 0.000 description 18
- 239000003112 inhibitor Substances 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 16
- 238000001514 detection method Methods 0.000 description 16
- 230000019491 signal transduction Effects 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 108091006011 G proteins Proteins 0.000 description 15
- 108091000058 GTP-Binding Proteins Proteins 0.000 description 15
- 102000030007 GTP-Binding Proteins Human genes 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 15
- 230000003834 intracellular Effects 0.000 description 15
- 210000004556 Brain Anatomy 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- 230000004913 activation Effects 0.000 description 14
- 230000001105 regulatory Effects 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- 230000035897 transcription Effects 0.000 description 14
- 210000004185 Liver Anatomy 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 13
- 238000003776 cleavage reaction Methods 0.000 description 13
- 229940079593 drugs Drugs 0.000 description 13
- 239000000975 dye Substances 0.000 description 13
- 102000005614 monoclonal antibodies Human genes 0.000 description 13
- 108010045030 monoclonal antibodies Proteins 0.000 description 13
- 208000006673 Asthma Diseases 0.000 description 12
- 210000003169 Central Nervous System Anatomy 0.000 description 12
- 229920001405 Coding region Polymers 0.000 description 12
- 239000000556 agonist Substances 0.000 description 12
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 12
- 239000003550 marker Substances 0.000 description 12
- 229960000060 monoclonal antibodies Drugs 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 238000011144 upstream manufacturing Methods 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 11
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 11
- 108091006028 chimera Proteins 0.000 description 11
- 239000003623 enhancer Substances 0.000 description 11
- 230000002708 enhancing Effects 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 230000002194 synthesizing Effects 0.000 description 11
- 229940088597 Hormone Drugs 0.000 description 10
- 241000700605 Viruses Species 0.000 description 10
- 239000011324 bead Substances 0.000 description 10
- 239000005556 hormone Substances 0.000 description 10
- 238000000159 protein binding assay Methods 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 229940088598 Enzyme Drugs 0.000 description 9
- 108010070675 Glutathione Transferase family Proteins 0.000 description 9
- 102000005720 Glutathione Transferase family Human genes 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 9
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 9
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 9
- -1 Yoyo-l Chemical compound 0.000 description 9
- 230000002159 abnormal effect Effects 0.000 description 9
- 230000000692 anti-sense Effects 0.000 description 9
- 238000010367 cloning Methods 0.000 description 9
- 238000007877 drug screening Methods 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 230000002068 genetic Effects 0.000 description 9
- 230000001939 inductive effect Effects 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 230000001404 mediated Effects 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 210000004369 Blood Anatomy 0.000 description 8
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 8
- 210000004408 Hybridomas Anatomy 0.000 description 8
- 208000010125 Myocardial Infarction Diseases 0.000 description 8
- 101700030810 NMUR1 Proteins 0.000 description 8
- 102100000777 NMUR1 Human genes 0.000 description 8
- 101700080605 NUC1 Proteins 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 239000000969 carrier Substances 0.000 description 8
- 230000001684 chronic Effects 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 238000003780 insertion Methods 0.000 description 8
- 238000002372 labelling Methods 0.000 description 8
- 239000002609 media Substances 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000006011 modification reaction Methods 0.000 description 8
- 101700006494 nucA Proteins 0.000 description 8
- 210000000056 organs Anatomy 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- 238000011002 quantification Methods 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 210000001124 Body Fluids Anatomy 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 7
- 102000018358 Immunoglobulins Human genes 0.000 description 7
- 108060003951 Immunoglobulins Proteins 0.000 description 7
- 108020004511 Recombinant DNA Proteins 0.000 description 7
- 230000001154 acute Effects 0.000 description 7
- 230000001580 bacterial Effects 0.000 description 7
- 230000033228 biological regulation Effects 0.000 description 7
- 235000013601 eggs Nutrition 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 201000004044 liver cirrhosis Diseases 0.000 description 7
- 230000003211 malignant Effects 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 230000002829 reduced Effects 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 102000003995 transcription factors Human genes 0.000 description 7
- 108090000464 transcription factors Proteins 0.000 description 7
- 230000003612 virological Effects 0.000 description 7
- 206010003210 Arteriosclerosis Diseases 0.000 description 6
- 108090000994 Catalytic RNA Proteins 0.000 description 6
- 108060000200 EC 4.6.1.1 Proteins 0.000 description 6
- 102000019460 EC 4.6.1.1 Human genes 0.000 description 6
- 210000002216 Heart Anatomy 0.000 description 6
- 210000004072 Lung Anatomy 0.000 description 6
- 206010025323 Lymphomas Diseases 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 230000000240 adjuvant Effects 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 230000001413 cellular Effects 0.000 description 6
- 230000002860 competitive Effects 0.000 description 6
- 230000001605 fetal Effects 0.000 description 6
- 230000003902 lesions Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 230000000865 phosphorylative Effects 0.000 description 6
- 238000003127 radioimmunoassay Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 210000004204 Blood Vessels Anatomy 0.000 description 5
- 210000001185 Bone Marrow Anatomy 0.000 description 5
- 210000000170 Cell Membrane Anatomy 0.000 description 5
- 206010012289 Dementia Diseases 0.000 description 5
- 102100011343 GLB1 Human genes 0.000 description 5
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 5
- 229960003180 Glutathione Drugs 0.000 description 5
- 108010024636 Glutathione Proteins 0.000 description 5
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 5
- 230000036499 Half live Effects 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 5
- 108060001084 Luciferase family Proteins 0.000 description 5
- 210000000329 Myocytes, Smooth Muscle Anatomy 0.000 description 5
- 108010061543 Neutralizing Antibodies Proteins 0.000 description 5
- 108010038807 Oligopeptides Proteins 0.000 description 5
- 102000015636 Oligopeptides Human genes 0.000 description 5
- 210000003491 Skin Anatomy 0.000 description 5
- 229920000978 Start codon Polymers 0.000 description 5
- 230000036462 Unbound Effects 0.000 description 5
- 238000001042 affinity chromatography Methods 0.000 description 5
- 201000001320 atherosclerosis Diseases 0.000 description 5
- 108010005774 beta-Galactosidase Proteins 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 230000024881 catalytic activity Effects 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000021615 conjugation Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 230000000984 immunochemical Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000000520 microinjection Methods 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 239000000376 reactant Substances 0.000 description 5
- 230000001850 reproductive Effects 0.000 description 5
- 108091007521 restriction endonucleases Proteins 0.000 description 5
- 238000007423 screening assay Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 230000002485 urinary Effects 0.000 description 5
- 201000011528 vascular disease Diseases 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 4
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 210000000349 Chromosomes Anatomy 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 230000004568 DNA-binding Effects 0.000 description 4
- 108010013369 EC 3.4.21.9 Proteins 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 206010024324 Leukaemias Diseases 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 206010061289 Metastatic neoplasm Diseases 0.000 description 4
- 206010025310 Other lymphomas Diseases 0.000 description 4
- 101700040790 PH Proteins 0.000 description 4
- 210000000496 Pancreas Anatomy 0.000 description 4
- 206010061536 Parkinson's disease Diseases 0.000 description 4
- 210000002307 Prostate Anatomy 0.000 description 4
- 210000003079 Salivary Glands Anatomy 0.000 description 4
- 210000002784 Stomach Anatomy 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- 102100009508 TMPRSS15 Human genes 0.000 description 4
- 210000003932 Urinary Bladder Anatomy 0.000 description 4
- 210000004291 Uterus Anatomy 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 230000000890 antigenic Effects 0.000 description 4
- 108091007172 antigens Proteins 0.000 description 4
- 102000038129 antigens Human genes 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000003197 catalytic Effects 0.000 description 4
- 238000000423 cell based assay Methods 0.000 description 4
- 238000005094 computer simulation Methods 0.000 description 4
- 230000001086 cytosolic Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000009510 drug design Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000010195 expression analysis Methods 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000001502 gel electrophoresis Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000001976 improved Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 230000001394 metastastic Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 108091008117 polyclonal antibodies Proteins 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 230000002285 radioactive Effects 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 230000002103 transcriptional Effects 0.000 description 4
- 238000002424 x-ray crystallography Methods 0.000 description 4
- 210000004100 Adrenal Glands Anatomy 0.000 description 3
- 102000017910 Adrenergic receptor family Human genes 0.000 description 3
- 108060003345 Adrenergic receptor family Proteins 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N Ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 208000007502 Anemia Diseases 0.000 description 3
- 210000000988 Bone and Bones Anatomy 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 210000001072 Colon Anatomy 0.000 description 3
- 210000002808 Connective Tissue Anatomy 0.000 description 3
- 210000004351 Coronary Vessels Anatomy 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 210000002889 Endothelial Cells Anatomy 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108010074860 Factor Xa Proteins 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 108060003339 GPLD1 Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 3
- 210000000987 Immune System Anatomy 0.000 description 3
- 206010022114 Injury Diseases 0.000 description 3
- 229920002459 Intron Polymers 0.000 description 3
- 210000001165 Lymph Nodes Anatomy 0.000 description 3
- 210000004293 Mammary Glands, Human Anatomy 0.000 description 3
- 210000000214 Mouth Anatomy 0.000 description 3
- 210000002027 Muscle, Skeletal Anatomy 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 210000003516 Pericardium Anatomy 0.000 description 3
- 210000003800 Pharynx Anatomy 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 210000000278 Spinal Cord Anatomy 0.000 description 3
- 210000000952 Spleen Anatomy 0.000 description 3
- 210000001550 Testis Anatomy 0.000 description 3
- 210000001685 Thyroid Gland Anatomy 0.000 description 3
- 241000723873 Tobacco mosaic virus Species 0.000 description 3
- 210000003437 Trachea Anatomy 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000001261 affinity purification Methods 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000003143 atherosclerotic Effects 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- 230000004059 degradation Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 150000001982 diacylglycerols Chemical class 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000002612 dispersion media Substances 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 201000011240 frontotemporal dementia Diseases 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000003899 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000002757 inflammatory Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 210000004962 mammalian cells Anatomy 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000004952 protein activity Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 235000004400 serine Nutrition 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000004936 stimulating Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 201000002510 thyroid cancer Diseases 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 2
- NKCXQMYPWXSLIZ-PSRDDEIFSA-N (2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-m Chemical compound O=C([C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)O)C(C)C)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O NKCXQMYPWXSLIZ-PSRDDEIFSA-N 0.000 description 2
- 208000009956 Adenocarcinoma Diseases 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 206010001897 Alzheimer's disease Diseases 0.000 description 2
- 206010002383 Angina pectoris Diseases 0.000 description 2
- 206010003119 Arrhythmia Diseases 0.000 description 2
- 206010003668 Atrial tachycardia Diseases 0.000 description 2
- 206010003736 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- 210000000481 Breast Anatomy 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M Caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 210000001736 Capillaries Anatomy 0.000 description 2
- 206010007521 Cardiac arrhythmias Diseases 0.000 description 2
- 206010007556 Cardiac failure acute Diseases 0.000 description 2
- 210000000845 Cartilage Anatomy 0.000 description 2
- 210000001638 Cerebellum Anatomy 0.000 description 2
- 210000003679 Cervix Uteri Anatomy 0.000 description 2
- 108010035563 Chloramphenicol O-Acetyltransferase Proteins 0.000 description 2
- 210000000688 Chromosomes, Artificial, Human Anatomy 0.000 description 2
- 230000035700 Clearance Rate Effects 0.000 description 2
- 206010057668 Cognitive disease Diseases 0.000 description 2
- 206010070976 Craniocerebral injury Diseases 0.000 description 2
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 2
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 2
- 238000007702 DNA assembly Methods 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-N Deoxycytidine triphosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-N 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N Deoxyguanosine triphosphate Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- 108010091358 EC 2.4.2.8 Proteins 0.000 description 2
- 102000018251 EC 2.4.2.8 Human genes 0.000 description 2
- 108010092799 EC 2.7.7.49 Proteins 0.000 description 2
- 102000033147 ERVK-25 Human genes 0.000 description 2
- 210000003372 Endocrine Glands Anatomy 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 206010014950 Eosinophilia Diseases 0.000 description 2
- 210000000981 Epithelium Anatomy 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- 230000035693 Fab Effects 0.000 description 2
- 210000002458 Fetal Heart Anatomy 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 101700058973 GAL4 Proteins 0.000 description 2
- 101710008404 GAPDH Proteins 0.000 description 2
- 102100006425 GAPDH Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- QGWNDRXFNXRZMB-UUOKFMHZSA-N Guanosine diphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O QGWNDRXFNXRZMB-UUOKFMHZSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headache Diseases 0.000 description 2
- 206010019641 Hepatic cirrhosis Diseases 0.000 description 2
- 208000006454 Hepatitis Diseases 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 201000001971 Huntington's disease Diseases 0.000 description 2
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 108010058683 Immobilized Proteins Proteins 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 210000004969 Inflammatory Cells Anatomy 0.000 description 2
- 210000003734 Kidney Anatomy 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 102100011539 LGALS4 Human genes 0.000 description 2
- 101710015850 LGALS4 Proteins 0.000 description 2
- 102100005410 LINE-1 retrotransposable element ORF2 protein Human genes 0.000 description 2
- 229920000126 Latex Polymers 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 210000002264 Mammary Glands, Animal Anatomy 0.000 description 2
- 210000003574 Melanophores Anatomy 0.000 description 2
- 206010027175 Memory impairment Diseases 0.000 description 2
- 208000008466 Metabolic Disease Diseases 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N Methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 208000008085 Migraine Disorders Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 210000004165 Myocardium Anatomy 0.000 description 2
- 241000237536 Mytilus edulis Species 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-hydroxy-Succinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 208000004296 Neuralgia Diseases 0.000 description 2
- 108091005503 Nucleic proteins Proteins 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 210000001672 Ovary Anatomy 0.000 description 2
- 210000003101 Oviducts Anatomy 0.000 description 2
- 206010062585 Peripheral arterial occlusive disease Diseases 0.000 description 2
- 206010034636 Peripheral vascular disease Diseases 0.000 description 2
- 210000002826 Placenta Anatomy 0.000 description 2
- 208000008601 Polycythemia Diseases 0.000 description 2
- 208000004550 Postoperative Pain Diseases 0.000 description 2
- 208000000399 Procedural Pain Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000008425 Protein Deficiency Diseases 0.000 description 2
- 102000000033 Purinergic Receptors Human genes 0.000 description 2
- 108010080192 Purinergic Receptors Proteins 0.000 description 2
- 108020004518 RNA Probes Proteins 0.000 description 2
- 239000003391 RNA probe Substances 0.000 description 2
- 206010037912 Raynaud's phenomenon Diseases 0.000 description 2
- 229920001914 Ribonucleotide Polymers 0.000 description 2
- 108010003581 Ribulose-Bisphosphate Carboxylase Proteins 0.000 description 2
- 101710043164 Segment-4 Proteins 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 229940094937 Thioredoxin Drugs 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 210000001541 Thymus Gland Anatomy 0.000 description 2
- 210000002105 Tongue Anatomy 0.000 description 2
- 208000005765 Traumatic Brain Injury Diseases 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 241000255985 Trichoplusia Species 0.000 description 2
- 101700038759 VP1 Proteins 0.000 description 2
- 206010047302 Ventricular tachycardia Diseases 0.000 description 2
- 206010047461 Viral infection Diseases 0.000 description 2
- 208000001756 Virus Disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 230000001800 adrenalinergic Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 201000006287 attention deficit hyperactivity disease Diseases 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 200000000014 benign neoplasm Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 108091005941 blue fluorescent protein Proteins 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000005251 capillar electrophoresis Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006473 carboxylation reaction Methods 0.000 description 2
- 201000001084 cerebrovascular disease Diseases 0.000 description 2
- 229940098124 cesium chloride Drugs 0.000 description 2
- 108020001747 chimeric receptor Proteins 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 201000009541 complex regional pain syndrome Diseases 0.000 description 2
- 230000023298 conjugation with cellular fusion Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000002596 correlated Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000010192 crystallographic characterization Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-J dATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-J 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000007878 drug screening assay Methods 0.000 description 2
- 239000003596 drug target Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 230000002616 endonucleolytic Effects 0.000 description 2
- 230000029578 entry into host Effects 0.000 description 2
- 230000002255 enzymatic Effects 0.000 description 2
- 230000001747 exhibiting Effects 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 101700005460 hemA Proteins 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 108060003552 hemocyanin family Proteins 0.000 description 2
- 201000001066 hemolytic-uremic syndrome Diseases 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 125000003372 histidine group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000001631 hypertensive Effects 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 230000003100 immobilizing Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 230000001965 increased Effects 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002452 interceptive Effects 0.000 description 2
- 230000000302 ischemic Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl β-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 108091022076 maltose binding proteins Proteins 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000001823 molecular biology technique Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 235000020638 mussel Nutrition 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 238000001668 nucleic acid synthesis Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 230000036961 partial Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001575 pathological Effects 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000001323 posttranslational Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000002685 pulmonary Effects 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 201000001947 reflex sympathetic dystrophy Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000001177 retroviral Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 238000003345 scintillation counting Methods 0.000 description 2
- 125000003616 serine group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 238000003530 single readout Methods 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 201000010874 syndrome Diseases 0.000 description 2
- 108060008226 thioredoxin family Proteins 0.000 description 2
- 102000002933 thioredoxin family Human genes 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 230000000699 topical Effects 0.000 description 2
- 230000001131 transforming Effects 0.000 description 2
- 230000001052 transient Effects 0.000 description 2
- 238000010396 two-hybrid screening Methods 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000017613 viral reproduction Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 1
- KYRUKRFVOACELK-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(4-hydroxyphenyl)propanoate Chemical compound C1=CC(O)=CC=C1CCC(=O)ON1C(=O)CCC1=O KYRUKRFVOACELK-UHFFFAOYSA-N 0.000 description 1
- YGPZWPHDULZYFR-DPAQBDIFSA-N (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical group C1C=C2C[C@@H](N)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 YGPZWPHDULZYFR-DPAQBDIFSA-N 0.000 description 1
- VJYIFXVZLXQVHO-UHFFFAOYSA-N 1-(2-chlorophenyl)sulfonyl-3-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)urea Chemical compound COC1=NC(C)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)Cl)=N1 VJYIFXVZLXQVHO-UHFFFAOYSA-N 0.000 description 1
- YAMUFBLWGFFICM-PTGWMXDISA-N 1-O-oleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C YAMUFBLWGFFICM-PTGWMXDISA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- INAPMGSXUVUWAF-XCMZKKERSA-N 1D-myo-inositol 6-phosphate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-XCMZKKERSA-N 0.000 description 1
- MHKBMNACOMRIAW-UHFFFAOYSA-N 2,3-dinitrophenol Chemical compound OC1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O MHKBMNACOMRIAW-UHFFFAOYSA-N 0.000 description 1
- HEGSGKPQLMEBJL-UHFFFAOYSA-N 2-(hydroxymethyl)-6-octoxyoxane-3,4,5-triol Chemical compound CCCCCCCCOC1OC(CO)C(O)C(O)C1O HEGSGKPQLMEBJL-UHFFFAOYSA-N 0.000 description 1
- XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (Z,12R)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- GYJNVSAUBGJVLV-UHFFFAOYSA-N 3-(dimethylazaniumyl)propane-1-sulfonate Chemical compound CN(C)CCCS(O)(=O)=O GYJNVSAUBGJVLV-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- GUQQBLRVXOUDTN-XOHPMCGNSA-N 3-[dimethyl-[3-[[(4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]propyl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 GUQQBLRVXOUDTN-XOHPMCGNSA-N 0.000 description 1
- MGBKJKDRMRAZKC-UHFFFAOYSA-N 3-aminobenzene-1,2-diol Chemical compound NC1=CC=CC(O)=C1O MGBKJKDRMRAZKC-UHFFFAOYSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UMZBRFQRSA-N 4-[(3R,5S,7R,12S)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid Chemical class C([C@H]1C[C@H]2O)[C@H](O)CCC1(C)C1C2C2CCC(C(CCC(O)=O)C)C2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-UMZBRFQRSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 101700033661 ACTB Proteins 0.000 description 1
- 102100011550 ACTB Human genes 0.000 description 1
- 101710032514 ACTI Proteins 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- 102100007409 APRT Human genes 0.000 description 1
- 101710006647 APRT Proteins 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229960004373 Acetylcholine Drugs 0.000 description 1
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N Acridine orange Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 208000005298 Acute Pain Diseases 0.000 description 1
- 206010000880 Acute myeloid leukaemia Diseases 0.000 description 1
- 108010024223 Adenine Phosphoribosyltransferase Proteins 0.000 description 1
- OIRDTQYFTABQOQ-SXVXDFOESA-N Adenosine Natural products Nc1ncnc2c1ncn2[C@@H]3O[C@@H](CO)[C@H](O)[C@@H]3O OIRDTQYFTABQOQ-SXVXDFOESA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 210000000577 Adipose Tissue Anatomy 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000002353 Alcoholic Hepatitis Diseases 0.000 description 1
- 208000010002 Alcoholic Liver Cirrhosis Diseases 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 208000008637 Anti-Glomerular Basement Membrane Disease Diseases 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 206010002967 Aplastic anaemia Diseases 0.000 description 1
- 206010003130 Arrhythmia supraventricular Diseases 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 210000001367 Arteries Anatomy 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 206010003658 Atrial fibrillation Diseases 0.000 description 1
- 206010003662 Atrial flutter Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000005783 Autoimmune Thyroiditis Diseases 0.000 description 1
- 206010003816 Autoimmune disease Diseases 0.000 description 1
- 210000000467 Autonomic Pathways Anatomy 0.000 description 1
- 210000003719 B-Lymphocytes Anatomy 0.000 description 1
- 210000004227 Basal Ganglia Anatomy 0.000 description 1
- 229940093761 Bile Salts Drugs 0.000 description 1
- 206010004661 Biliary cirrhosis primary Diseases 0.000 description 1
- NNUSCVFWUPARGJ-UHFFFAOYSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=NC(CC=2[C](C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N=2)CCC(O)=O)=C(CCC(O)=O)[C]1C NNUSCVFWUPARGJ-UHFFFAOYSA-N 0.000 description 1
- 210000000601 Blood Cells Anatomy 0.000 description 1
- 210000001772 Blood Platelets Anatomy 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000006218 Bradycardia Diseases 0.000 description 1
- 208000001183 Brain Injury Diseases 0.000 description 1
- 229910000906 Bronze Inorganic materials 0.000 description 1
- 208000007257 Budd-Chiari Syndrome Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 208000009899 Burkitt Lymphoma Diseases 0.000 description 1
- XOJVVFBFDXDTEG-UHFFFAOYSA-N Bute hydrocarbon Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101710010587 CASP13 Proteins 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102400000113 Calcitonin Human genes 0.000 description 1
- 229960004015 Calcitonin Drugs 0.000 description 1
- 206010058019 Cancer pain Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010007554 Cardiac failure Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000008787 Cardiovascular Disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N Catechol Chemical group OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 210000003710 Cerebral Cortex Anatomy 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 210000003467 Cheek Anatomy 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N Chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960004926 Chlorobutanol Drugs 0.000 description 1
- 239000005496 Chlorsulfuron Substances 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 208000005595 Chronic Idiopathic Jaundice Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010008909 Chronic hepatitis Diseases 0.000 description 1
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 230000036881 Clu Effects 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000002573 Connective Tissue Disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 208000001819 Crigler-Najjar Syndrome Diseases 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N Cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N DATI Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 101710007887 DHFR Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 206010061428 Decreased appetite Diseases 0.000 description 1
- 206010067889 Dementia with Lewy body Diseases 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 206010012378 Depression Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- 208000001636 Diabetic Neuropathy Diseases 0.000 description 1
- 206010012680 Diabetic neuropathy Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010073508 Drug reaction with eosinophilia and systemic symptom Diseases 0.000 description 1
- 201000004943 Dubin-Johnson syndrome Diseases 0.000 description 1
- 208000001187 Dyskinesias Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 102000014469 EC 4.6.1.2 Human genes 0.000 description 1
- 108010078321 EC 4.6.1.2 Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N Endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 229940079360 Enema for Constipation Drugs 0.000 description 1
- 208000003401 Eosinophilic Granuloma Diseases 0.000 description 1
- 206010015037 Epilepsy Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N Ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 210000003499 Exocrine Glands Anatomy 0.000 description 1
- 210000002744 Extracellular Matrix Anatomy 0.000 description 1
- 229920003958 FORMION® Polymers 0.000 description 1
- 208000005741 Failed Back Surgery Syndrome Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N Fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- 229940028334 Follicle Stimulating Hormone Drugs 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N Fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 101710042219 GAL6 Proteins 0.000 description 1
- 101700014779 GLB1 Proteins 0.000 description 1
- 101710008339 GOLPH3 Proteins 0.000 description 1
- 102100014497 GOLPH3 Human genes 0.000 description 1
- 102100004985 GUSB Human genes 0.000 description 1
- 208000001130 Gallstone Diseases 0.000 description 1
- 210000004211 Gastric Acid Anatomy 0.000 description 1
- 206010017758 Gastric cancer Diseases 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- 206010018048 Gaucher's disease Diseases 0.000 description 1
- 210000004392 Genitalia Anatomy 0.000 description 1
- 208000009139 Gilbert Disease Diseases 0.000 description 1
- 206010018267 Gilbert's syndrome Diseases 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 208000005017 Glioblastoma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 206010018620 Goodpasture's syndrome Diseases 0.000 description 1
- 206010018651 Graft versus host disease Diseases 0.000 description 1
- 201000004779 Graves' disease Diseases 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N Guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 101700048347 HIS5 Proteins 0.000 description 1
- 206010018987 Haemorrhage Diseases 0.000 description 1
- 206010019009 Haemorrhagic disease Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019280 Heart failure Diseases 0.000 description 1
- 208000000622 Hemorrhagic Disorders Diseases 0.000 description 1
- 208000002287 Hemorrhoids Diseases 0.000 description 1
- 229960002897 Heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 206010019860 Hereditary angioedema Diseases 0.000 description 1
- 206010020243 Hodgkin's disease Diseases 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 208000006572 Human Influenza Diseases 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010020718 Hyperplasia Diseases 0.000 description 1
- 229960000310 ISOLEUCINE Drugs 0.000 description 1
- 108090000745 Immune Sera Proteins 0.000 description 1
- 210000004201 Immune Sera Anatomy 0.000 description 1
- 229940042743 Immune sera Drugs 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 1
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 1
- 206010022000 Influenza Diseases 0.000 description 1
- 206010022489 Insulin resistance Diseases 0.000 description 1
- 208000001024 Intrahepatic Cholestasis Diseases 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 206010022972 Iron deficiency anaemia Diseases 0.000 description 1
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 description 1
- 206010061255 Ischaemia Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-Methionine Natural products CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 description 1
- PYIDGJJWBIBVIA-UYTYNIKBSA-N Lauryl glucoside Chemical compound CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 description 1
- 229920001320 Leader sequence (mRNA) Polymers 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 description 1
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 description 1
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- 208000002741 Leukoplakia Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 210000003041 Ligaments Anatomy 0.000 description 1
- 210000000088 Lip Anatomy 0.000 description 1
- 206010024627 Liposarcoma Diseases 0.000 description 1
- 208000007903 Liver Failure Diseases 0.000 description 1
- DLBFLQKQABVKGT-UHFFFAOYSA-L Lucifer yellow Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 1
- 210000002751 Lymph Anatomy 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 210000003563 Lymphoid Tissue Anatomy 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 240000006217 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920002393 Microsatellite Polymers 0.000 description 1
- 206010027599 Migraine Diseases 0.000 description 1
- 208000000060 Migraine with Aura Diseases 0.000 description 1
- 206010052787 Migraine without aura Diseases 0.000 description 1
- 229920002220 Minisatellite Polymers 0.000 description 1
- 208000003250 Mixed Connective Tissue Disease Diseases 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 210000001616 Monocytes Anatomy 0.000 description 1
- 208000005264 Motor Neuron Disease Diseases 0.000 description 1
- 206010028003 Motor neurone disease Diseases 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 229940051866 Mouthwash Drugs 0.000 description 1
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor family Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor family Proteins 0.000 description 1
- 210000002464 Muscle, Smooth, Vascular Anatomy 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 206010028417 Myasthenia gravis Diseases 0.000 description 1
- 206010028537 Myelofibrosis Diseases 0.000 description 1
- UMWKZHPREXJQGR-UHFFFAOYSA-N N-methyl-N-(2,3,4,5,6-pentahydroxyhexyl)decanamide Chemical compound CCCCCCCCCC(=O)N(C)CC(O)C(O)C(O)C(O)CO UMWKZHPREXJQGR-UHFFFAOYSA-N 0.000 description 1
- SBWGZAXBCCNRTM-UHFFFAOYSA-N N-methyl-N-(2,3,4,5,6-pentahydroxyhexyl)octanamide Chemical compound CCCCCCCC(=O)N(C)CC(O)C(O)C(O)C(O)CO SBWGZAXBCCNRTM-UHFFFAOYSA-N 0.000 description 1
- 101800000135 N-terminal protein Proteins 0.000 description 1
- 101700062818 NP Proteins 0.000 description 1
- 210000003739 Neck Anatomy 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 210000000944 Nerve Tissue Anatomy 0.000 description 1
- 206010052639 Nerve injury Diseases 0.000 description 1
- 206010029305 Neurological disorder Diseases 0.000 description 1
- 206010029331 Neuropathy peripheral Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 208000004235 Neutropenia Diseases 0.000 description 1
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000010175 Opsin Human genes 0.000 description 1
- 208000008798 Osteoma Diseases 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 101800001452 P1 proteinase Proteins 0.000 description 1
- 101710043203 P23p89 Proteins 0.000 description 1
- 206010033364 Paget's disease of nipple Diseases 0.000 description 1
- 210000001983 Palate, Hard Anatomy 0.000 description 1
- 208000008900 Pancreatic Ductal Carcinoma Diseases 0.000 description 1
- 206010033616 Pancreatic disease Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010067229 Paraneoplastic syndrome Diseases 0.000 description 1
- 208000003715 Parkinsonian Disorders Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 210000002976 Pectoralis Muscles Anatomy 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 210000003899 Penis Anatomy 0.000 description 1
- 206010061339 Perineal pain Diseases 0.000 description 1
- 210000001428 Peripheral Nervous System Anatomy 0.000 description 1
- 229960005190 Phenylalanine Drugs 0.000 description 1
- 108090000553 Phospholipase D Proteins 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 201000011585 Pick's disease Diseases 0.000 description 1
- 210000003635 Pituitary Gland Anatomy 0.000 description 1
- 206010062081 Plasma cell disease Diseases 0.000 description 1
- 206010035534 Platelet disease Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 208000005987 Polymyositis Diseases 0.000 description 1
- 206010036115 Polyneuropathy in malignant disease Diseases 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000007232 Portal Hypertension Diseases 0.000 description 1
- 206010036376 Post herpetic neuralgia Diseases 0.000 description 1
- 206010057239 Post laminectomy syndrome Diseases 0.000 description 1
- 206010065016 Post-traumatic pain Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000003476 Primary Myelofibrosis Diseases 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M Propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 206010037075 Protozoal infection Diseases 0.000 description 1
- 206010037175 Psychiatric disease Diseases 0.000 description 1
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
- 208000003782 Raynaud Disease Diseases 0.000 description 1
- 108091005674 Receptor kinase Proteins 0.000 description 1
- 108010033725 Recombinant Proteins Proteins 0.000 description 1
- 102000007312 Recombinant Proteins Human genes 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 201000007981 Reye syndrome Diseases 0.000 description 1
- 206010072736 Rheumatic disease Diseases 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 102000004330 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 210000001202 Rhombencephalon Anatomy 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 210000003705 Ribosomes Anatomy 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039234 Rotor's syndrome Diseases 0.000 description 1
- 101710009148 SERPINA1 Proteins 0.000 description 1
- 101710022981 SERPING1 Proteins 0.000 description 1
- 102100009270 SERPING1 Human genes 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 Saccharin Drugs 0.000 description 1
- 235000003534 Saccharomyces carlsbergensis Nutrition 0.000 description 1
- 229940081969 Saccharomyces cerevisiae Drugs 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 229940076279 Serotonin Drugs 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 210000004927 Skin cells Anatomy 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M Sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000008513 Spinal Cord Injury Diseases 0.000 description 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001179 Synovial Fluid Anatomy 0.000 description 1
- 206010042863 Synovial sarcoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- 206010043345 Testicular pain Diseases 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 229940033663 Thimerosal Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L Thiomersal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229920000401 Three prime untranslated region Polymers 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010043554 Thrombocytopenia Diseases 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 208000005485 Thrombocytosis Diseases 0.000 description 1
- 108020004440 Thymidine Kinase Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 229960002175 Thyroglobulin Drugs 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- MZZINWWGSYUHGU-UHFFFAOYSA-J ToTo-1 Chemical compound [I-].[I-].[I-].[I-].C12=CC=CC=C2C(C=C2N(C3=CC=CC=C3S2)C)=CC=[N+]1CCC[N+](C)(C)CCC[N+](C)(C)CCC[N+](C1=CC=CC=C11)=CC=C1C=C1N(C)C2=CC=CC=C2S1 MZZINWWGSYUHGU-UHFFFAOYSA-J 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 206010044126 Tourette's disease Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010044652 Trigeminal neuralgia Diseases 0.000 description 1
- 241000009298 Trigla lyra Species 0.000 description 1
- 229920002605 Triple-stranded DNA Polymers 0.000 description 1
- 206010068760 Ulcers Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 108020003635 Untranslated Regions Proteins 0.000 description 1
- 229920000146 Untranslated region Polymers 0.000 description 1
- 206010046477 Urethral syndrome Diseases 0.000 description 1
- PGAVKCOVUIYSFO-XVFCMESISA-N Uridine triphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 206010046766 Uterine cancer Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010063661 Vascular encephalopathy Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 208000009935 Visceral Pain Diseases 0.000 description 1
- 208000002670 Vitamin B 12 Deficiency Diseases 0.000 description 1
- 206010047802 Waldenstrom's macroglobulinaemias Diseases 0.000 description 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 description 1
- 201000001203 Wilson disease Diseases 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 201000004525 Zellweger syndrome Diseases 0.000 description 1
- MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 1
- ZYVSOIYQKUDENJ-MNGCYDFMSA-N [6-[[(6S,7S)-6-[4-[4-(5-acetyloxy-4-hydroxy-4,6-dimethyloxan-2-yl)oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-7-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-4,10-dihydroxy-3-methyl-5-oxo-7,8-dihydro-6H-anthracen-2-yl]oxy]-4-(4- Chemical compound C([C@H]([C@@H](C(=O)C1=C(O)C2=C(O)C=3C)OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(OC(C)=O)C(C)(O)C6)C5)C4)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)C1=CC2=CC=3OC(OC(C)C1OC(C)=O)CC1OC1CC(O)C(OC)C(C)O1 ZYVSOIYQKUDENJ-MNGCYDFMSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 201000005510 acute lymphocytic leukemia Diseases 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 108010025188 alcohol oxidase Proteins 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 229930002877 anthocyanins Natural products 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 230000001475 anti-trypsic Effects 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000089 arabinosyl group Chemical class C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 1
- 244000052616 bacterial pathogens Species 0.000 description 1
- 108010003152 bacteriophage T7 RNA polymerase Proteins 0.000 description 1
- 230000003385 bacteriostatic Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 108020004256 beta-Lactamases Proteins 0.000 description 1
- 102000006635 beta-Lactamases Human genes 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 102000024070 binding proteins Human genes 0.000 description 1
- 108091007650 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000036782 biological activation Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000000740 bleeding Effects 0.000 description 1
- 231100000319 bleeding Toxicity 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 201000002393 blood protein disease Diseases 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 201000006474 brain ischemia Diseases 0.000 description 1
- 239000010974 bronze Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N cAMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 201000000274 carcinosarcoma Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229920002092 cellular RNA Polymers 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000012539 chromatography resin Substances 0.000 description 1
- 230000002759 chromosomal Effects 0.000 description 1
- 201000006934 chronic myeloid leukemia Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000003636 conditioned culture media Substances 0.000 description 1
- 201000006233 congestive heart failure Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 201000008739 coronary artery disease Diseases 0.000 description 1
- 230000001054 cortical Effects 0.000 description 1
- 150000001893 coumarin derivatives Chemical class 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001186 cumulative Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000002559 cytogenic Effects 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000004985 diamines Chemical group 0.000 description 1
- 230000003205 diastolic Effects 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940000406 drug candidates Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002257 embryonic structures Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- 230000002449 erythroblastic Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
- 201000008808 fibrosarcoma Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000003260 fluorescence intensity Methods 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 101710034616 gVIII-1 Proteins 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 201000002406 genetic disease Diseases 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 201000000615 hard palate cancer Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 201000008064 heavy chain disease Diseases 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002363 herbicidal Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 108091006077 heterotrimeric G proteins Proteins 0.000 description 1
- 102000034443 heterotrimeric G proteins Human genes 0.000 description 1
- 101700014181 his2 Proteins 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000001744 histochemical Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 201000007231 hypersensitivity reaction disease Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002055 immunohistochemical Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 201000007364 inherited blood coagulation disease Diseases 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 238000007852 inverse PCR Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000019948 ion homeostasis Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000004601 liver benign neoplasm Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000000877 morphologic Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 201000009251 multiple myeloma Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 101700045377 mvp1 Proteins 0.000 description 1
- 201000005962 mycosis fungoide Diseases 0.000 description 1
- 201000003793 myelodysplastic syndrome Diseases 0.000 description 1
- 230000002071 myeloproliferative Effects 0.000 description 1
- 230000002107 myocardial Effects 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006218 nasal suppository Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000000926 neurological Effects 0.000 description 1
- 210000002569 neurons Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 230000031787 nutrient reservoir activity Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 101710031992 pRL90232 Proteins 0.000 description 1
- 201000008175 pain disease Diseases 0.000 description 1
- 201000005989 paraneoplastic polyneuropathy Diseases 0.000 description 1
- 244000045947 parasites Species 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 230000001314 paroxysmal Effects 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 230000004963 pathophysiological condition Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000006678 peppermint Nutrition 0.000 description 1
- 235000015132 peppermint Nutrition 0.000 description 1
- 235000007735 peppermint Nutrition 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 108010082527 phosphinothricin N-acetyltransferase Proteins 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- 101710035540 plaa2 Proteins 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 1
- 230000001402 polyadenylating Effects 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 150000003141 primary amines Chemical group 0.000 description 1
- 201000002728 primary biliary cirrhosis Diseases 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 230000000644 propagated Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000036678 protein binding Effects 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 229940121649 protein inhibitors Drugs 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000004850 proteinâprotein interaction Effects 0.000 description 1
- 210000001938 protoplasts Anatomy 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000000268 renotropic Effects 0.000 description 1
- 230000000241 respiratory Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000000552 rheumatic Effects 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 101700019592 sep-1 Proteins 0.000 description 1
- 230000001568 sexual Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 230000003381 solubilizing Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000003393 splenic Effects 0.000 description 1
- 210000004215 spores Anatomy 0.000 description 1
- 230000000087 stabilizing Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000005700 syncytium formation by plasma membrane fusion Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000000542 thalamic Effects 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 238000010399 three-hybrid screening Methods 0.000 description 1
- 201000007023 thrombotic thrombocytopenic purpura Diseases 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000000472 traumatic Effects 0.000 description 1
- 230000001960 triggered Effects 0.000 description 1
- 108060008647 trpB Proteins 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 210000004881 tumor cells Anatomy 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000021037 unidirectional conjugation Effects 0.000 description 1
- 229950010342 uridine triphosphate Drugs 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 200000000024 vascular cognitive impairment Diseases 0.000 description 1
- 201000004810 vascular dementia Diseases 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000003156 vasculitic Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000001086 yeast two-hybrid system Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Description
æ¬çºæã¯ååçç©åŠã®åéã«é¢ãïŒããå
·äœçã«ã¯ãæ¬çºæã¯ãããïŒïŒµïŒã®æ žé
žé
åããã³ã¢ããé
žé
åã䞊ã³ã«åºä¹³é¡ã«ããããè¡æ¶²çŸæ£ãå¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãçãããã³èèã®é害ã®åŠçœ®ã®ããã®ãã®èª¿ç¯ã«é¢ããã
ã¿ã³ãã¯è³ªå
±åœ¹å容äœ
ïŒïŒµïŒã¯ïŒåè貫éåã¿ã³ãã¯è³ªå ±åœ¹å容äœïŒïŒ§ïŒ°ïŒ£ïŒ²ïŒã§ãããå€ãã®å»åŠçã«éèŠãªçäœããã»ã¹ã¯ãã¿ã³ãã¯è³ªãé¢äžããã·ã°ãã«äŒéçµè·¯ã«ããåªä»ãããŠããïŒLefkowitz et.al. 1991ïŒãã¿ã³ãã¯è³ªå ±åœ¹å容äœïŒïŒ§ïŒ°ïŒ£ïŒ²ïŒã®ãã¡ããªãŒã«ã¯ããã«ã¢ã³ãç¥çµäŒéç©è³ªãæé·å åãããã³ãŠã€ã«ã¹ã«å¯Ÿããå容äœãå«ãŸãããã®å ·äœäŸãšããŠã¯ãããŒããã³ãã«ã«ã·ããã³ãã¢ãã¬ããªã³äœåæ§ãã«ã¢ã³ããšã³ãã»ãªã³ãïœïŒ¡ïŒïŒ°ãã¢ããã·ã³ãã¢ã»ãã«ã³ãªã³ãã»ãããã³ããã¹ã¿ãã³ãããã³ãã³ãããã³ãåµèåºæ¿ãã«ã¢ã³ããªãã·ã³ãå ç®çŽ°èååéºäŒåâïŒããããã·ã³ãèæ°ç©è³ªããµã€ãã¡ã¬ããŠã€ã«ã¹ãã¿ã³ãã¯è³ªèªèº«ããšãã§ã¯ã¿ãŒã¿ã³ãã¯è³ªïŒäŸãã°ãã¹ããªããŒãŒïŒ£ãã¢ããã«é žã·ã¯ã©ãŒãŒããã³ãã¹ããžãšã¹ãã©ãŒãŒïŒãããã³ã¢ã¯ãã¥ãšãŒã¿ãŒã¿ã³ãã¯è³ªïŒäŸãã°ãããã€ã³ãããŒãŒïŒ¡ããã³ãããã€ã³ãããŒãŒïŒ£ïŒãªã©ã®ç©è³ªã«å¯Ÿããå容äœãæããããã
ïŒïŒµïŒã¯ïŒåè貫éåã¿ã³ãã¯è³ªå ±åœ¹å容äœïŒïŒ§ïŒ°ïŒ£ïŒ²ïŒã§ãããå€ãã®å»åŠçã«éèŠãªçäœããã»ã¹ã¯ãã¿ã³ãã¯è³ªãé¢äžããã·ã°ãã«äŒéçµè·¯ã«ããåªä»ãããŠããïŒLefkowitz et.al. 1991ïŒãã¿ã³ãã¯è³ªå ±åœ¹å容äœïŒïŒ§ïŒ°ïŒ£ïŒ²ïŒã®ãã¡ããªãŒã«ã¯ããã«ã¢ã³ãç¥çµäŒéç©è³ªãæé·å åãããã³ãŠã€ã«ã¹ã«å¯Ÿããå容äœãå«ãŸãããã®å ·äœäŸãšããŠã¯ãããŒããã³ãã«ã«ã·ããã³ãã¢ãã¬ããªã³äœåæ§ãã«ã¢ã³ããšã³ãã»ãªã³ãïœïŒ¡ïŒïŒ°ãã¢ããã·ã³ãã¢ã»ãã«ã³ãªã³ãã»ãããã³ããã¹ã¿ãã³ãããã³ãã³ãããã³ãåµèåºæ¿ãã«ã¢ã³ããªãã·ã³ãå ç®çŽ°èååéºäŒåâïŒããããã·ã³ãèæ°ç©è³ªããµã€ãã¡ã¬ããŠã€ã«ã¹ãã¿ã³ãã¯è³ªèªèº«ããšãã§ã¯ã¿ãŒã¿ã³ãã¯è³ªïŒäŸãã°ãã¹ããªããŒãŒïŒ£ãã¢ããã«é žã·ã¯ã©ãŒãŒããã³ãã¹ããžãšã¹ãã©ãŒãŒïŒãããã³ã¢ã¯ãã¥ãšãŒã¿ãŒã¿ã³ãã¯è³ªïŒäŸãã°ãããã€ã³ãããŒãŒïŒ¡ããã³ãããã€ã³ãããŒãŒïŒ£ïŒãªã©ã®ç©è³ªã«å¯Ÿããå容äœãæããããã
ã¯ãå°ãªããšãïŒåã®ç°ãªã芪氎æ§ã«ãŒããé£çµãããèã貫éããïŒåã®ä¿åããããã¡ã€ã³ãæã£ãŠãããïŒïŒïŒŽïŒã¬ã»ãã¿ãŒãšããŠãç¥ãããïŒã¯ãå°ãªããšãïŒåã®ç°ãªã芪氎æ§ã«ãŒããé£çµãããçŽïŒïŒãªããïŒïŒã®ã¢ããé
žã®ãããïŒåã®ä¿åãããçæ°Žæ§ã¹ãã¬ãããå«ããã®ãšããŠç¹åŸŽä»ããããŠãããæ®ã©ã®ïŒ§ïŒ°ïŒ£ïŒ²ã¯ãæåã®äºã€ã®çŽ°èå€ã«ãŒãã®åã
ã«åäžã®ä¿åãããã·ã¹ãã€ã³æ®åºãæã£ãŠãããããããžã¹ã«ãã£ãçµåã圢æããæ©èœçã¿ã³ãã¯è³ªæ§é ãå®å®åããããšèããããŠããããã®ïŒåã®è貫éé åã¯ïŒŽïŒïŒãïŒïŒãïŒïŒãïŒïŒãïŒïŒãïŒïŒãããã³ïŒŽïŒïŒãšåŒã°ãããïŒïŒã¯ã·ã°ãã«äŒéã«é¢ãã£ãŠãããã·ã¹ãã€ã³æ®åºã®çé
žåããã³è質åïŒãã«ããã«åãŸãã¯ãã¡ã«ãã·ã«åïŒã¯ã幟ã€ãã®ïŒ§ïŒ°ïŒ£ïŒ²ã®ã·ã°ãã«äŒéã«åœ±é¿ãåãŒãåŸããæ®ã©ã®ïŒ§ïŒ°ïŒ£ïŒ²ã¯ã第äžçŽ°è質ã«ãŒãããã³ïŒãŸãã¯ã«ã«ããã·æ«ç«¯å
éšã«çé
žåã®å¯èœæ§ããéšäœãå«ãã§ããã幟ã€ãã®ïŒ§ïŒ°ïŒ£ïŒ²ãäŸãã°Î²âã¢ãã¬ããªã³äœåæ§ã¬ã»ãã¿ãŒã§ã¯ããããã€ã³ãããŒãŒïŒ¡ããã³ïŒãŸãã¯ç¹ç°çã¬ã»ãã¿ãŒãããŒãŒã«ããçé
žåã«ãã£ãŠã¬ã»ãã¿ãŒã®è±æäœã仲ä»ãããã
幟ã€ãã®ã¬ã»ãã¿ãŒã«ã€ããŠã¯ãã®ãªã¬ã³ãçµåéšäœããæ°åã®ïŒ§ïŒ°ïŒ£ïŒ²è貫éãã¡ã€ã³ã«ãã圢æããã芪氎æ§ãœã±ãããå«ããšèããããããã®èŠªæ°Žæ§ãœã±ããã¯ãã®çæ°Žæ§æ®åºã«åãå²ãŸããŠãããåè貫éããªãã¯ã¹ã®èŠªæ°Žæ§åŽã¯ãå
åŽãåãã極æ§ãªã¬ã³ãçµåéšäœã圢æããŠãããšä»®å®ãããŠãããïŒïŒã¯ããªã¬ã³ãçµåéšäœãäŸãã°ïŒŽïŒïŒã¢ã¹ãã©ã®ã³é
žæ®åºãæã£ãŠãã幟ã€ãã®ïŒ§ïŒ°ïŒ£ïŒ²ãšé¢é£ããŠãããïŒïŒã®ã»ãªã³ãïŒïŒã®ã¢ã¹ãã©ã®ã³ãããã³ïŒŽïŒïŒãŸãã¯ïŒŽïŒïŒã®ãã§ãã«ã¢ã©ãã³ãŸãã¯ããã·ã³ããŸããªã¬ã³ãçµåã«é¢é£ããŠããã
ã¯çŽ°èå
éšã§ãããäžéäœïŒ§ã¿ã³ãã¯è³ªã«ãããçš®ã
ã®çŽ°èå
é
µçŽ ãã€ãªã³ãã£ã³ãã«ããã³èŒžéäœãšå
±åœ¹ããŠãããçš®ã
ã®ïŒ§ã¿ã³ãã¯è³ªÎ±ãµããŠãããã¯åªå
çã«ç¹å®ã®ãšãã§ã¯ã¿ãŒãåºæ¿ãã现èã®æ§ã
ãªçäœæ©èœã調æŽãããã®çŽ°è質æ®åºã®çé
žåã¯ã幟ã€ãã®ïŒ§ïŒ°ïŒ£ïŒ²ã®èª¿ç¯ã«ãšã£ãŠéèŠãªæ©æ§ã§ãããäŸãã°ãæã圢ã®ã·ã°ãã«äŒéã«ãããŠã¯ããã«ã¢ã³çµåã®å¹æã¯ã现èå
éšã§ã®é
µçŽ ã¢ããã«ã·ã¯ã©ãŒãŒã®æŽ»æ§åã§ããããã«ã¢ã³ã«ããé
µçŽ ã®æŽ»æ§åã¯ãã¯ã¬ãªããã®ååšã«äŸåãããã¯ãã«ã¢ã³çµåã«ã圱é¿ãåãŒããã¿ã³ãã¯è³ªã¯ãã«ã¢ã³ã¬ã»ãã¿ãŒãã¢ããã«ã·ã¯ã©ãŒãŒã«çµåããããã¿ã³ãã¯è³ªã¯ãã«ã¢ã³ã¬ã»ãã¿ãŒã«ãã£ãŠæŽ»æ§åããããšãããçµåããã«äº€æããããããšããæããåãã掻æ§åã¢ããã«ã·ã¯ã©ãŒãŒã«çµåãããã¿ã³ãã¯è³ªèªèº«ã«ãã觊åªããããããžã®å æ°Žå解ããã¿ã³ãã¯è³ªããã®åºæ¬çãªäžæŽ»æ§åãžãšæ»ãããããã£ãŠïŒ§ã¿ã³ãã¯è³ªã¯ãã¬ã»ãã¿ãŒãããšãã§ã¯ã¿ãŒãžãšã·ã°ãã«ãäžç¶ãã仲ä»ç©è³ªãšããŠã®ããããŠã·ã°ãã«ã®æç¶ãå¶åŸ¡ããæèšãšããŠã®ãäºéã®åœ¹å²ãæãããŠããã
éå»ïŒïŒå¹Žéã«ããããïŒïŒŽïŒå容äœãæšçãšããïŒïŒïŒè¿ãã®æ²»çè¬ãæåè£ã«äžåžãããŠããããã®äºã¯ããããã®ã¬ã»ãã¿ãŒãæ²»çè¬ãšããŠç¢ºç«ãããæãçŽä»ãã®æŽå²ãæã£ãŠããããšã瀺ããã®ã§ãããæããã«ã现èãçèãåè«ãšãã£ãææçãããã³ãŠã€ã«ã¹ææçããšããããŠã€ã«ã¹ã«ããææçãçãåæ¯ãå«ãã¢ã¬ã«ã®ãŒãæ¥æ§å¿äžå
šãå«ãå¿çŸæ£ãäœè¡å§çãé«è¡å§çãçå¿çãå¿çæ¢å¡ãè¡æ¶²ã®çŸæ£ãç§å°¿çæ®åšç³»ã®çŸæ£ã尿倱çŠããã³è¯æ§åç«è
ºè¥å€§ã骚ç²é¬çãããã³çŒçãã¢ã«ããã€ããŒç
ããã³ããŒãã³ãœã³ç
ãå«ãæ«æ¢¢ç¥çµç³»ããã³äžæ¢ç¥çµç³»ã®é害ããæããããããããã«éå®ãããªãæ©èœäžå
šãŸãã¯çŸæ£ãäºé²ãæ¹åãŸãã¯æ¯æ£ã«ãããŠåœ¹å²ãæããåŸãããããªãå容äœã®åå®ããã³ç¹åŸŽã¥ããå¿
èŠãšãããŠããã
ïœïœïŒïœïœæ³ïŒçºçŸãããã¡ã€ãªã³ã°
ïœïœïŒïœïœã¯æè¿éçºãããæè¡ã§ãããããªã¡ã©ãŒãŒé£éåå¿ïŒïŒ°ïŒ£ïŒ²ïŒäžã®ãªã¢ã«ã¿ã€ã ã§ã®ãã€ããªãã€ãŒãŒã·ã§ã³ãããŒãããã®èå ã¬ããŒã¿ãŒè²çŽ ã®æŸåºãç£ç©ã®çŽ¯ç©éã«æ¯äŸãããå®éã¯ãåå¿åæã®ãçŽç·éšåã«åºã¥ããããã¯ã°ã©ãŠã³ãäžã®èå ãæåã«æ€åºãããã¹ã¬ãã·ã¥ããŒã«ããµã€ã¯ã«ïŒthreshold cycleïŒïŒïŒ£ïŒŽïŒã決å®ããããšã«ããè¡ãã
ïœïœïŒïœïœã¯æè¿éçºãããæè¡ã§ãããããªã¡ã©ãŒãŒé£éåå¿ïŒïŒ°ïŒ£ïŒ²ïŒäžã®ãªã¢ã«ã¿ã€ã ã§ã®ãã€ããªãã€ãŒãŒã·ã§ã³ãããŒãããã®èå ã¬ããŒã¿ãŒè²çŽ ã®æŸåºãç£ç©ã®çŽ¯ç©éã«æ¯äŸãããå®éã¯ãåå¿åæã®ãçŽç·éšåã«åºã¥ããããã¯ã°ã©ãŠã³ãäžã®èå ãæåã«æ€åºãããã¹ã¬ãã·ã¥ããŒã«ããµã€ã¯ã«ïŒthreshold cycleïŒïŒïŒ£ïŒŽïŒã決å®ããããšã«ããè¡ãã
éºäŒåçºçŸæè¡ã¯ãæšçã®åå®ããªãŒãæé©åãããã³äœçšæ©åºã®åå®ãªã©ã®è¬ç©ééããã³è¬ç©éçºã®ããã€ãã®åéã«ãããŠæçšã§ããããïœïœïŒïœïœæè¡ã¯ãæ£åžžçµç¹ãšç
ççµç¹ã®çºçŸãããã¡ã€ã«ãšã®éããæ¯èŒããã®ã«äœ¿çšããããšãã§ãããçºçŸãããã¡ã€ãªã³ã°ã¯ãæ§ã
ãªçŸæ£ãäžæ¹èª¿ç¯ãŸãã¯äžæ¹èª¿ç¯ããéºäŒåã®åå®ã«çšããããŠãããçºçŸãããã¡ã€ãªã³ã°ã®èå³æ·±ãå¿çšã¯ãçŸæ£ãé²è¡éãšè¬ç©åŠçœ®ã®éãŸãã¯æ£è
察å¥åžžè
ã®éºäŒåçºçŸã«ãããå€åã®äžæçãªç£èŠã§ããããã®ã¢ãããŒãã®åæã¯ãççåŠçãŸãã¯åãå·»ãåºæ¿ïŒäŸãã°è¬ç©ïŒã«å¿çããéºäŒåçºçŸãã¿ãŒã³ã®å€åããçŸæ£ãèªçºããéºäŒåãŸãã¯è¬ç©æšçã«ã€ããŠã®éæ¥çãªææãããšããŠäŸããããšããããšã§ãããããã«ãå
šäœçãªãé»åçºçŸãã¿ãŒã³ã«å¯Ÿãã確ç«ãããå¹åãæããè¬ç©ã®å¹æã¯ãæ°ããè¬ç©ããããšæ¯èŒããããšãã§ããæéãå³ã¡éºäŒåã«ãã眲åïŒgenetic signatureïŒãæäŸãåŸãã
ïŒïŒµïŒ
ïŒïŒµïŒã®ãã¯ã¬ãªããé åã¯ãå ¬éãããŠããããŒã¿ããŒã¹ã«ãŠãã¢ã¯ã»ã¹çªå·ïŒ¡ïŒŠïŒïŒïŒïŒïŒïŒã§ã¢ã¯ã»ã¹å¯èœã§ãããé åçªå·ïŒã§ç€ºãããã ïŒïŒµïŒã®ã¢ããé žé åã¯é åçªå·ïŒã§ç€ºãããã
ïŒïŒµïŒã®ãã¯ã¬ãªããé åã¯ãå ¬éãããŠããããŒã¿ããŒã¹ã«ãŠãã¢ã¯ã»ã¹çªå·ïŒ¡ïŒŠïŒïŒïŒïŒïŒïŒã§ã¢ã¯ã»ã¹å¯èœã§ãããé åçªå·ïŒã§ç€ºãããã ïŒïŒµïŒã®ã¢ããé žé åã¯é åçªå·ïŒã§ç€ºãããã
ïŒïŒµïŒã¯ãç¥çµããããã®å容äœãšããŠèšèŒããã[Shan et al., 2000]ãå容äœïŒ®ïŒïŒµïŒã¯ãâïŒïŒïŒïŒïŒïŒïŒïŒïŒãâïŒïŒïŒïŒïŒïŒïŒïŒïŒãâïŒïŒïŒïŒïŒïŒïŒïŒïŒã«å
¬éãããŠãããè³ã«ãããïŒïŒµïŒã®çºçŸã¯ãç¹å®ã®è³çµç¹ã§ã¯ããã§ã¯ãªãããæ¢ã«èšèŒãããŠãã[Raddatz et al., 2000]ãïŒïŒµïŒã¯ãå®æœäŸïŒã«ç€ºãããã«ãããŠã¹å容äœïŒŠïŒâïŒã«å¯ŸããŠæãé«ãçžåæ§ïŒïŒïŒïŒ
ïŒã瀺ãã
ïŒçºæã®èŠæšïŒ
æ¬çºæã¯ãæ°ããªãïŒïŒµïŒããªããããããã³ããªãã¯ã¬ãªããã®çŸæ£ã®é¢é£ã«é¢ãããæ¬çºæã¯ãããã«åºä¹³é¡ã«ãããè¡æ¶²çŸæ£ãå¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãçãããã³èèã®é害ã®åŠçœ®ã®ããã®æ²»çç©è³ªã®ã¹ã¯ãªãŒãã³ã°æ¹æ³ã«é¢ãããæ¬çºæã¯ããã«ãïŒïŒµïŒããªãããããïŒïŒµïŒããªãã¯ã¬ãªãããŸãã¯ïŒ®ïŒïŒµïŒã®èª¿ç¯ç©è³ªãïŒïŒµïŒæŽ»æ§ã®èª¿ç¯ç©è³ªãå«æãããåºä¹³é¡ã«ãããè¡æ¶²çŸæ£ãå¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãçãããã³èèã®é害ã®åŠçœ®ã®ããã®å»è¬çµæç©ã«é¢ãããæ¬çºæã¯ãããã«åºä¹³é¡ã«ãããè¡æ¶²çŸæ£ãå¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãçãããã³èèã®é害ã®èšºææ¹æ³ãå å«ããã
æ¬çºæã¯ãæ°ããªãïŒïŒµïŒããªããããããã³ããªãã¯ã¬ãªããã®çŸæ£ã®é¢é£ã«é¢ãããæ¬çºæã¯ãããã«åºä¹³é¡ã«ãããè¡æ¶²çŸæ£ãå¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãçãããã³èèã®é害ã®åŠçœ®ã®ããã®æ²»çç©è³ªã®ã¹ã¯ãªãŒãã³ã°æ¹æ³ã«é¢ãããæ¬çºæã¯ããã«ãïŒïŒµïŒããªãããããïŒïŒµïŒããªãã¯ã¬ãªãããŸãã¯ïŒ®ïŒïŒµïŒã®èª¿ç¯ç©è³ªãïŒïŒµïŒæŽ»æ§ã®èª¿ç¯ç©è³ªãå«æãããåºä¹³é¡ã«ãããè¡æ¶²çŸæ£ãå¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãçãããã³èèã®é害ã®åŠçœ®ã®ããã®å»è¬çµæç©ã«é¢ãããæ¬çºæã¯ãããã«åºä¹³é¡ã«ãããè¡æ¶²çŸæ£ãå¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãçãããã³èèã®é害ã®èšºææ¹æ³ãå å«ããã
ïŒçºæã®è©³çŽ°ãªèšèŒïŒ
çšèªã®å®çŸ©
ããªãªãŽãã¯ã¬ãªãããã¯ãããªã¡ã©ãŒãŒé£éåå¿ïŒïŒ°ïŒ£ïŒ²ïŒã«ãããŠãªãªãŽããŒãã¢ã³ããªããŒãŸãã¯ãããŒããšããŠçšããããååãªæ°ã®å¡©åºãæãããã¯ã¬ãªããæ®åºã®éã§ããããªãªãŽãã¯ã¬ãªããã¯ãã²ãã ãŸãã¯ïœïŒ€ïŒ®ïŒ¡é å調補ããç¹å®ã®çŽ°èãŸãã¯çµç¹ã«ãããŠåæ§ã®ïŒ€ïŒ®ïŒ¡ãŸãã¯ïŒ²ïŒ®ïŒ¡ã®ååšãå¢å¹ ããæããã«ãããŸãã¯ç¢ºèªããããã«çšããããããªãªãŽãã¯ã¬ãªãããŸãã¯ãªãªãŽããŒã¯ãå°ãªããšãçŽïŒïŒãã¯ã¬ãªããã§ãã£ãŠçŽïŒïŒãã¯ã¬ãªããã奜ãŸããã¯çŽïŒïŒãã¯ã¬ãªãããæããé åã®äžéšãå«ãã§ããã
çšèªã®å®çŸ©
ããªãªãŽãã¯ã¬ãªãããã¯ãããªã¡ã©ãŒãŒé£éåå¿ïŒïŒ°ïŒ£ïŒ²ïŒã«ãããŠãªãªãŽããŒãã¢ã³ããªããŒãŸãã¯ãããŒããšããŠçšããããååãªæ°ã®å¡©åºãæãããã¯ã¬ãªããæ®åºã®éã§ããããªãªãŽãã¯ã¬ãªããã¯ãã²ãã ãŸãã¯ïœïŒ€ïŒ®ïŒ¡é å調補ããç¹å®ã®çŽ°èãŸãã¯çµç¹ã«ãããŠåæ§ã®ïŒ€ïŒ®ïŒ¡ãŸãã¯ïŒ²ïŒ®ïŒ¡ã®ååšãå¢å¹ ããæããã«ãããŸãã¯ç¢ºèªããããã«çšããããããªãªãŽãã¯ã¬ãªãããŸãã¯ãªãªãŽããŒã¯ãå°ãªããšãçŽïŒïŒãã¯ã¬ãªããã§ãã£ãŠçŽïŒïŒãã¯ã¬ãªããã奜ãŸããã¯çŽïŒïŒãã¯ã¬ãªãããæããé åã®äžéšãå«ãã§ããã
ããããŒããã¯ã倩ç¶ã®ãŸãã¯çµæãã®ïŒæ¬éãŸãã¯ïŒæ¬éã®æ žé
žããèªå°ããããŸãã¯ååŠçã«åæããããšãã§ããããããã¯ãåäžãŸãã¯åæ§ã®é
åã®ååšãæ€åºããã®ã«æçšã§ããããã®ãããªãããŒãã¯ãããã¯ç¿»èš³ãKlenow fill-inåå¿ããŸãã¯åœåéã§åšç¥ã®ä»ã®æ¹æ³ãçšããŠã¬ããŒã¿ãŒååã«ããæšèããããšãã§ãããæ žé
žãããŒãããµã¶ã³ãããŒã¶ã³ãŸãã¯in situ ãã€ããªããŒã·ã§ã³ã«ãããŠçšããŠãããç¹å®ã®ã¿ã³ãã¯è³ªãã³ãŒããããŸãã¯ïŒ²ïŒ®ïŒ¡ã现èãçµç¹ãŸãã¯åšå®ã«ååšãããåŠãã決å®ããããšãã§ããã
ãããªãã¯ã¬ãªããã®æçãã¯ãçŽïŒïœïœä»¥äžã®ãã¯ã¬ãªããã奜ãŸããã¯çŽïŒïœïœä»¥äžã®ãã¯ã¬ãªãããæãããã¯ã¬ãªããé
åã®å
šéšãŸãã¯äžéšãå«ãæ žé
žã§ããã
ãã¬ããŒã¿ãŒååãã¯ãç¹å®ã®ãã¯ã¬ãªãããŸãã¯ã¢ããé
žé
åãäŒåããããã«ããç¹å®ã®é
åã®ååšã確å®ãããŸãã¯ç¹å®ã®é
åã®å®éãå¯èœãªãæŸå°æ§ãã¯ã¬ãªãããé
µçŽ ãèå
æ§ãååŠçºå
æ§ãŸãã¯çºè²æ§ã®è©Šè¬ã§ããã
ããã¡ã©ãååã¯ãæ¬çºæã®ãã¯ã¬ãªããé
åã®å
šéšãŸãã¯äžéšãã以äžã®ïŒ®ïŒïŒµïŒã®ç¹æ§ã®ããããïŒã€ãŸãã¯ããã€ããå€ãããšæåŸ
ãåŸããããªãæ žé
žé
åãå«æãããã¯ã¿ãŒã«å°å
¥ããããšã«ãã£ãŠãæ§ç¯ããããšãã§ããïŒçŽ°èå
ã®äœçœ®ãååžããªã¬ã³ãçµåã¢ãã£ããã£ãŒãçžäºäœçšã¢ãã£ããã£ãŒãå解ïŒå転çãã·ã°ãã«äŒéãªã©ã
ïŒïŒµïŒããªããããã«ã€ããŠãã掻æ§ãªãã¯ãïŒïŒµïŒã®çç©åŠçããã³ïŒãŸãã¯æå掻æ§ãä¿æããïŒïŒµïŒã®åœ¢æ
ãæçãŸãã¯ãã¡ã€ã³ãæå³ããã
ã倩ç¶ã®ïŒ®ïŒïŒµïŒãã¯ãéºäŒåæäœãããŠããªã现èã«ãã£ãŠç£çããããªãããããæå³ããã¢ã»ãã«åãã«ã«ããã·ã«åãã°ãªã³ã·ã«åããªã³é
žåãè質ä»å ãããã³ã¢ã·ã«åãæããããããããã«éå®ãããªãããªããããã®ç¿»èš³åŸä¿®é£Ÿããçããæ§ã
ãªããªãããããå
·äœçã«äŒå³ããã
ãèªå°äœãã¯ããŠãããã³åãæšèïŒäžèšåç
§ïŒããã®ã¬ãŒã·ã§ã³ïŒããªãšãã¬ã³ã°ãªã³ãŒã«ã«ããèªå°äœåïŒãããã³ååŠæ¿å
¥ãŸãã¯ããã®ã¿ã³ãã¯è³ªã«éåžžååšããªããªã«ããã³ã®ãããªã¢ããé
žã®çœ®æçã®æè¡ã«ãã£ãŠååŠçã«ä¿®é£Ÿãããããªãããããæå³ããã
ãä¿åçã¢ããé
žçœ®æãã¯ãïŒã€ã®ã¢ããé
žãé¡äŒŒã®æ§é ããã³ïŒãŸãã¯ååŠç¹æ§ãæããå¥ã®ã¢ããé
žã§çœ®æãäŸãã°ããã€ã·ã³ãã€ãœãã€ã·ã³ãŸãã¯ããªã³ã§ãã¢ã¹ãã©ã®ã³é
žãã°ã«ã¿ãã³é
žã§ããŸãã¯ãã¬ãªãã³ãã»ãªã³ã§çœ®æããããšã«ãã£ãŠçããã
ãæ¿å
¥ããŸãã¯ãæ¬ å€±ãã¯ãå
žåçã«ã¯ãçŽïŒãïŒã¢ããé
žã®ç¯å²ã§ãããå¯èœãªå€åã¯ããããããåæã«ãã補é ããããšã«ãã£ãŠå®éšçã«æ±ºå®ããŠãããããé
åãžã®ãã¯ã¬ãªããã®æ¿å
¥ãæ¬ å€±ãŸãã¯çœ®æã¯ãçµæãæè¡ãçšããŠèšç»çã«è¡ãã
ãã·ã°ãã«é
åããŸãã¯ããªãŒããŒé
åãã¯ãææã§ãããªãã°ãããªããããã现èèãžåããããã®ã«çšããããšãã§ããããã®ãããªé
åã¯ãæ¬çºæã®ããªããããã«èªç¶ã«ååšããŠããããŸãã¯çµæãæè¡ã«ããç°çš®ã®äŸçµŠæºã«ç±æ¥ããã
ããªãªãŽãããããã¯ãã¢ããé
žæ®åºã®çãéã§ããããªãªãŽãã¯ã¬ãªããããçºçŸãåŸãããªãªãŽããããã¯ãå°ãªããšãïŒãïŒãïŒïŒã¢ããé
žãå€ããŠïŒïŒãïŒïŒãïŒïŒã¢ããé
žãå
žåçã«ã¯ïŒãïŒïŒã¢ããé
žã§ãã£ãŠãçç©åŠçããã³ïŒãŸãã¯æå掻æ§ã瀺ãã«ååãªé·ãã®ã¢ããé
žæ®åºã®éãå
å«ããã
ãé»å®³å€ãã¯ãååŠçãŸãã¯ççåŠçåå¿ãŸãã¯å¿çã劚ãããŸãã¯é»æ¢ããä»»æã®ç©è³ªã§ãããäžè¬çãªé»å®³å€ãšããŠã¯ãã¢ã³ãã»ã³ã¹ååãæäœããã³ã¢ã³ã¿ãŽãã¹ããæãããããããã«éå®ãããªãã
ãæšæºããªãè¡šçŸã¯ãæ¯èŒã®ããã®éçãŸãã¯è³ªçãªå€§ããã§ãããããã¯ãçµ±èšçã«é©åœãªæ°ã®æ£åžžãªãµã³ãã«ã«åºã¥ããã®ã§ããã蚺æã¢ãã»ã€ãè¡ãå Žåãèšåºè©Šéšãè¡ãå ŽåããŸãã¯æ£è
ã®æ²»çãããã¡ã€ã«ãéµå®ããå Žåã®æ¯èŒã®åºç€ãšããŠçšããããã«äœæãããã®ã§ããã
æ¬æ现æžã«ãããŠçšãããåç©ãã¯ãããã家åºçšïŒãã³ãã€ããªã©ïŒã蟲æ¥çšïŒãŠã·ããŠãããããžãªã©ïŒãŸãã¯è©ŠéšçšïŒããŠã¹ãã©ããããŠãµã®ãªã©ïŒã®åç©ãå
å«ãããã®ãšå®çŸ©ãããã
æ¬çºæã®æå³ã«ããããïŒïŒµïŒããªãã¯ã¬ãªãããã¯ã以äžãããªã矀ããéžæãããæ žé
žååã§ãããšç解ãããïŒ
ïŒïœïŒé åçªå·ïŒã®ã¢ããé žé åãå«ãããªãããããã³ãŒãããæ žé žååã
ïŒïœïœïŒé åçªå·ïŒã®é åãå«ãæ žé žååã
ïŒïœïœïœïŒé åçªå·ïŒã®é åãæããæ žé žååã
ïŒïœïœïŒãã®çžè£éããã¹ããªã³ãžã§ã³ããªæ¡ä»¶äžã§ïŒïœïŒïŒïœïœïŒãŸãã¯ïŒïœïœïœïŒã®æ žé žååãšãã€ããªãã€ãºããæ žé žååïŒããã³
ïŒïœïŒãã®é åããéºäŒã³ãŒãã®çž®éã«ããïŒïœïœïœïŒã®æ žé žååã®é åãšã¯ç°ãªãæ žé žåå
ã§ãã£ãŠãããã«è©²æ žé žååã«ãã£ãŠã³ãŒããããããªããããã¯ïŒ®ïŒïŒµïŒæŽ»æ§ãæããã
ïŒïœïŒé åçªå·ïŒã®ã¢ããé žé åãå«ãããªãããããã³ãŒãããæ žé žååã
ïŒïœïœïŒé åçªå·ïŒã®é åãå«ãæ žé žååã
ïŒïœïœïœïŒé åçªå·ïŒã®é åãæããæ žé žååã
ïŒïœïœïŒãã®çžè£éããã¹ããªã³ãžã§ã³ããªæ¡ä»¶äžã§ïŒïœïŒïŒïœïœïŒãŸãã¯ïŒïœïœïœïŒã®æ žé žååãšãã€ããªãã€ãºããæ žé žååïŒããã³
ïŒïœïŒãã®é åããéºäŒã³ãŒãã®çž®éã«ããïŒïœïœïœïŒã®æ žé žååã®é åãšã¯ç°ãªãæ žé žåå
ã§ãã£ãŠãããã«è©²æ žé žååã«ãã£ãŠã³ãŒããããããªããããã¯ïŒ®ïŒïŒµïŒæŽ»æ§ãæããã
æ¬çºæã®æå³ã«ããããïŒïŒµïŒããªãããããã¯ã以äžãããªã矀ããéžæãããæ žé
žååã§ãããšç解ãããïŒ
ïŒïœïŒé åçªå·ïŒã®é åãæããããªãããã
ïŒïœïœïŒé åçªå·ïŒã®é åãå«ãããªãããã
ïŒïœïœïœïŒïŒ®ïŒïŒµïŒããªãã¯ã¬ãªããã«ãã£ãŠã³ãŒããããããªããããïŒããã³
ïŒïœïœïŒïŒïœïŒãïŒïœïœïŒãŸãã¯ïŒïœïœïœïŒã®ããªãããããšå°ãªããšãïŒïŒïŒ ãïŒïŒïŒ ãïŒïŒïŒ ãïŒïŒïŒ ãŸãã¯ïŒïŒïŒ ã®çžåæ§ã瀺ãããªãããã
ã§ãã£ãŠãããã«è©²ããªããããã¯ïŒ®ïŒïŒµïŒæŽ»æ§ãæããã
ïŒïœïŒé åçªå·ïŒã®é åãæããããªãããã
ïŒïœïœïŒé åçªå·ïŒã®é åãå«ãããªãããã
ïŒïœïœïœïŒïŒ®ïŒïŒµïŒããªãã¯ã¬ãªããã«ãã£ãŠã³ãŒããããããªããããïŒããã³
ïŒïœïœïŒïŒïœïŒãïŒïœïœïŒãŸãã¯ïŒïœïœïœïŒã®ããªãããããšå°ãªããšãïŒïŒïŒ ãïŒïŒïŒ ãïŒïŒïŒ ãïŒïŒïŒ ãŸãã¯ïŒïŒïŒ ã®çžåæ§ã瀺ãããªãããã
ã§ãã£ãŠãããã«è©²ããªããããã¯ïŒ®ïŒïŒµïŒæŽ»æ§ãæããã
ïŒïŒµïŒãã³ãŒããããã¯ã¬ãªããé
åïŒãŸãã¯ãã®çžè£çãªé
åïŒã¯ãååçç©åŠã®åéã®åœæ¥è
ã«åšç¥ã®æè¡ã«ãããŠæ°å€ãã®å¿çšãããããããã®æè¡ã«ã¯ããã€ããªãã€ãŒãŒã·ã§ã³ãããŒããšããŠã®äœ¿çšãã®ããã®ãªãªãŽããŒã®æ§ç¯ç©ã«ããã䜿çšãæè²äœããã³éºäŒåãããã³ã°ã«ããã䜿çšãïŒïŒµïŒã®çµæãçç£ã«ããã䜿çšãããã³ã¢ã³ãã»ã³ã¹ïŒ€ïŒ®ïŒ¡ãŸãã¯ïŒ²ïŒ®ïŒ¡ãããã®ååŠçé¡çžäœã®äœæã«ããã䜿çšãªã©ãæãããããæ¬æ现æžã«èšèŒã®ïŒ®ïŒïŒµïŒãã³ãŒããããã¯ã¬ãªããã®äœ¿çšã¯ãåšç¥æè¡ã®äŸç€ºã§ãããåœæ¥è
ã«ç¥ãããŠããæè¡ã«ããããããã®äœ¿çšãéå®ããããšãæå³ãããã®ã§ã¯ãªããããã«ãæ¬æ现æžã«é瀺ã®ãã¯ã¬ãªããé
åãæªã éçºãããŠããªãããçŸåšç¥ãããŠãããã¯ã¬ãªããé
åã®ç¹æ§ãäŸãã°ïŒã€äžçµã®éºäŒåã³ãŒããç¹ç°çãªå¡©åºå¯Ÿçžäºäœçšãªã©ããé Œã¿ãšããæ°ããæè¡ååçç©åŠã®æè¡ã«äœ¿çšããããšãã§ããã
éºäŒã³ãŒãã®çž®éã®çµæãšããŠãå€ãã®ïŒ®ïŒïŒµïŒãã³ãŒããããã¯ã¬ãªããé
åã補é ãåŸãããšã¯åœæ¥è
ã«èªèããããããããã®ããã€ãã¯åã«æ¢ç¥ã®å€©ç¶ã®ïŒ®ïŒïŒµïŒã®ãã¯ã¬ãªããé
åã«å¯ŸããŠæå°éã®çžåæ§ãæããã§ããããæ¬çºæã¯ãå¯èœãªã³ãã³ã®éžæã«åºã¥ããçµåããéžæããããšã«ãã£ãŠäœæããããšãã§ãããã¯ã¬ãªããé
åã®ãããšããããå¯èœãªå€ç°ãäŒå³ããããããã®çµåãã¯ã倩ç¶ã®ïŒ®ïŒïŒµïŒã®ãã¯ã¬ãªããé
åã«å¯ŸããŠé©çšãããæšæºã®ïŒã€äžçµã®éºäŒåã³ãŒãã«ãããã£ãŠäœæãããã®å€ç°ã®ãã¹ãŠãå
·äœçã«èšèŒãããŠãããã®ãšè§£éãããã
ïŒïŒµïŒãã³ãŒããããã¯ã¬ãªããé
åããã®èªå°äœãŸãã¯ãã®å€ç°äœã¯å¥œãŸããã¯ã¹ããªã³ãžã§ã³ããªæ¡ä»¶äžã§å€©ç¶ã®ïŒ®ïŒïŒµïŒã®ãã¯ã¬ãªããé
åã«ãã€ããªãã€ãºããããšãå¯èœã§ããããå®è³ªçã«ç°ãªãã³ãã³ã®äœ¿çšãæããïŒïŒµïŒãã³ãŒããããã¯ã¬ãªããé
åãŸãã¯ãã®èªå°äœãç£çããããšã¯æçšã§ããããã³ãã³ã¯ã宿䞻ãç¹å®ã®ã³ãã³ãå©çšããé »åºŠã«ãããã£ãŠç¹å®ã®åæ žãŸãã¯çæ žçç©ã®çºçŸå®¿äž»ã«ãããããããã®çºçŸããæ¯çãå¢å€§ããããã«éžæããããšãã§ãããã³ãŒããããã¢ããé
žé
åãæ¹å€ããããšãªããïŒïŒµïŒãã³ãŒããããã¯ã¬ãªããé
åããã³ïŒãŸãã¯ãã®èªå°äœãå®è³ªçã«æ¹å€ããä»ã®çç±ãšããŠã¯ãããæãŸããç¹æ§ãäŸãã°å€©ç¶ã®é
åããç£çãã転åç©ãããé·ãåæžæããæããã補é ããããšãæããããã
ïŒïŒµïŒãã³ãŒããããã¯ã¬ãªããé
åã¯ãååã«ç¢ºç«ãããçµæãæè¡ã«ãã£ãŠæ§ã
ãªãã¯ã¬ãªããé
åã«çµåãããããšãã§ãããïŒïŒµïŒã«é£çµããã®ã«æçšãªãã¯ã¬ãªããé
åãšããŠã¯ãäŸãã°ããã©ã¹ãããã³ã¹ãããλãã¡ãŒãžèªå°äœããã¡ãŒãžãããªã©ã®ã¯ããŒãã³ã°ãã¯ã¿ãŒã®åé¡ãæãããããææã®ãã¯ã¿ãŒãšããŠã¯ãçºçŸãã¯ã¿ãŒãè€è£œãã¯ã¿ãŒããããŒãäœæãã¯ã¿ãŒãé
å決å®ãã¯ã¿ãŒçãæãããããäžè¬ã«ãææã®ãã¯ã¿ãŒã«ãå°ãªããšãïŒã€ã®çç©ã«ãããŠæ©èœçãªè€è£œåºç¹ãå¶éãšã³ããã¯ã¬ã¢ãŒãŒæåæ§éšäœãããã³ïŒãŸãã¯ãã以äžã®å®¿äž»çŽ°èç³»ã®ããã®éžæããŒã«ãŒãå«ãŸããããšãã§ããã
æ¬çºæã®ãããªãæ
æ§ã¯ãïŒïŒµïŒãã³ãŒããããã¯ã¬ãªããé
åã«ãã€ããªãã€ãºããããšãå¯èœãªïŒ®ïŒïŒµïŒã«ç¹ç°çãªãã€ããªãã€ãŒãŒã·ã§ã³ãããŒããæäŸããããšã§ããããã®ãããªãããŒãã¯ãŸããåæ§ã®ïŒ§ïŒ°ïŒ£ïŒ²ã³ãŒãé
åã®æ€åºã«çšããããšãã§ãã奜ãŸããã¯ïŒ®ïŒïŒµïŒé
åãšå°ãªããšãïŒïŒïŒ
åäžã®ãã¯ã¬ãªãããå«ããæ¬çºæã®ãã€ããªãã€ãŒãŒã·ã§ã³ãããŒãã¯ãé
åçªå·ïŒã§ç€ºããããã¯ã¬ãªããé
åãŸãã¯å€©ç¶ã®éºäŒåã®ããã¢ãŒã¿ãŒããšã³ãã³ãµãŒãŸãã¯ã€ã³ããã³ãå«ãã²ãã é
åããèªå°ããããšãã§ããããã€ããªãã€ãŒãŒã·ã§ã³ãããŒãã¯ãåœåéã§åšç¥ã®æè¡ãçšããŠæ§ã
æ
£ãããŒã¿ãŒååã«ãã£ãŠæšèããããšãã§ããã
ïŒïŒµïŒããªããããã®å€ãã®æ¬ 倱ãŸãã¯çªç¶å€ç°é¡çžäœããïŒïŒµïŒããªãã¯ã¬ãªããã®æå¹ãªãã€ããªãã€ãŒãŒã·ã§ã³ãããŒããšãªãããšã¯èªèããããããããã£ãŠãæ¬çºæã¯ããã®ãããªïŒ®ïŒïŒµïŒãã³ãŒãããæ žé
žé
åãšã¹ããªã³ãžã§ã³ããªæ¡ä»¶äžã§ãã€ããªãã€ãºããæ žé
žé
åã«é¢ããã
ãã¹ããªã³ãžã§ã³ããªæ¡ä»¶ãã¯ãå®è³ªçã«é¢é£ããæ žé
žé
åã®ãã€ããªãã€ãŒãŒã·ã§ã³ãå¯èœãªæ¡ä»¶ãæå³ãããäŸãã°ããã®ãããªæ¡ä»¶ã¯ãå°ãªããšãïŒïŒïŒ
ã®é
ååäžæ§ã奜ãŸããã¯å°ãªããšãïŒïŒïŒ
ã®é
ååäžæ§ããã奜ãŸããã¯å°ãªããšãïŒïŒïŒ
ã®é
ååäžæ§ãæããé
åã®ãã€ããªãã€ãŒãŒã·ã§ã³ãäžè¬ã«å¯èœã§ããããã€ããªãã€ãŒãŒã·ã§ã³æ¡ä»¶ããã³ãããŒãã¯ãååã«ç¹åŸŽä»ããããæ¹æ³ã«ãããŠèª¿æŽããŠããç±æ¥ãããŒãã®éžæçãªãã€ããªãã€ãŒãŒã·ã§ã³ãéæããããšãã§ãããæ¬çºæãæå³ããã¹ããªã³ãžã§ã³ããªæ¡ä»¶ã¯ãïŒïœïŒ ãïŒïŒïŒïŒ a4ïŒpïŒïŒïŒïŒãïŒïŒ
ïŒïœïŒïœïŒïŒ³ïŒ€ïŒ³äžïŒïŒâã§ããã
ã¹ããªã³ãžã§ã³ããªæ¡ä»¶äžã§ïŒ®ïŒïŒµïŒããªãã¯ã¬ãªãããã³ãŒãããæ žé
žã«ãã€ããªãã€ãºããæ žé
žååã¯ãæ©èœçã«åå®ããããšãã§ããããã€ããªãã€ãŒãŒã·ã§ã³ãããŒãã®ããã®äœ¿çšã®äŸãšããŠã¯ä»¥äžã®ãã®ãæãããããããã«éå®ãããªãïŒçµç¹ååŠç䜿çšãäŸãã°ïŒ®ïŒïŒµïŒãçºçŸããçµç¹ã®åå®ïŒäŸãã°ãµã³ãã«çµç¹ã®çš®é¡ãåå®ããããã®ããŸãã¯ç°åžžãªã¬ãã«ã®ïŒ®ïŒïŒµïŒãçºçŸãã现èãåå®ããããã®ãïœïŒ²ïŒ®ïŒ¡ã¬ãã«ã®æž¬å®ïŒããã³ïŒ®ïŒïŒµïŒã«ãããå€åã®æ€åºã
ã¯ãïŒïŒµïŒãã³ãŒããããã¯ã¬ãªããé
åã«åºã¥ããªãªãŽãã¯ã¬ãªããã®ããã®ãããªã䜿çšãæäŸãããã«ãããŠçšãããããã®ãããªãããŒãã¯ãçµæãäœãååŠçåæç©ãŸãã¯äž¡è
ã®çµåãã§ãã£ãŠããããªãªãŽããŒã¯ãå
·äœçãªçµç¹ã«ãããïŒïŒµïŒã®åå®ãŸãã¯èšºæç䜿çšã®ããã«æé©åãããæ¡ä»¶äžã§çšããããå¥åã®ãã¯ã¬ãªããé
åãå«ãã§ããŠããããåäžã®ïŒã€ã®ãªãªãŽããŒãå³ã¡ãªãªãŽããŒã®å
¥ãåã®ã»ããããŸãã¯ããã«ã¯ãªãªãŽããŒã®çž®éããŒã«ã¯ãå¯æ¥ã«é¢é£ãããŸãã¯ïŒ²ïŒ®ïŒ¡ã®åå®ã®ããã«ã¹ããªã³ãžã§ã³ã·ãŒãããäœãæ¡ä»¶äžã§çšããããšãã§ããã
ããªã¡ã©ãŒãŒé£éåå¿ïŒããïŒãã©ã€ããŒãèšèšããããã®ã«ãŒã«ããããã³ã«ãåç
§ããŠãããã«ç¢ºç«ãããçž®éãã©ã€ããŒãå³ã¡ãäžããããé
åã®äœçœ®ããããããŒã¬ã¹ãªãã©ã€ããŒã®èª¿è£œç©ãèšèšããïŒïŒµïŒã«å¯ŸããŠçžåæ§ãé«ããåäžã§ã¯ãªãæ žé
žé
åãå¢å¹
ãããããšãã§ãããïŒã€ã®ãã©ã€ããŒã®ã¿ãæ¢ç¥ã®é
åã«ç¹ç°çã«ãã€ããªãã€ãºããã«å¿
èŠãªãã©ã€ããŒãšãªãæ¹çãããã«åŸããããäŸãã°ãé©åœãªæ žé
žãã©ã€ããŒããå¢å¹
ããŠãã©ã€ããŒã®ïŒã€ã®ãã€ããªãã€ãŒãŒã·ã§ã³ããŒãããŒããããããšèããããæ žé
žã«ã©ã€ã²ãŒã·ã§ã³ããããšãã§ããããã®æ¹æ³ã§ã¯ããã©ã€ããŒã®ïŒã€ã®ã¿ããå¢å¹
ãããšæãããæ žé
žã®é
åã«åºã¥ããŠããå¿
èŠãããã
æ žé
žãå¢å¹
ããããã®ïŒ°ïŒ£ïŒ²æ³ã¯ãå°ãªããšãïŒã€ã®ãã©ã€ããŒãçšãããããããã©ã€ããŒã®ïŒã€ã¯ãå¢å¹
ãããæ žé
žã®ç¬¬ïŒã®éã«ãã€ããªãã€ãºããããšãã§ããé
µçŽ äž»å°ã®æ žé
žåæãæåã®æ¹åã§ãã©ã€ã ããããšãã§ãããä»æ¹ã¯ã第ïŒã®éã®éã®é
åã«ãã€ããªãã€ãºããããšãã§ãïŒå¢å¹
ãããé
åãïŒæ¬éã§ããå Žåããã®é
åã¯ãæåã¯æšæž¬äžã®ãã®ã§ããããæåã®å¢å¹
ãµã€ã¯ã«ã§åæãããïŒã第ïŒã®æ¹åãšã¯å察æ¹åã§ãã®é
åããã®æ žé
žåæããã©ã€ã ããããšãã§ãã第ïŒã®ãã©ã€ããŒã«ã€ããŠã®ãã€ããªãã€ãŒãŒã·ã§ã³éšäœã«åãããå
·äœçã«ã¯å¥œãŸããã¹ããªã³ãžã§ã³ããªãã€ããªãã€ãŒãŒã·ã§ã³æ¡ä»¶äžã§ã®ããã®ãããªå¢å¹
ãè¡ãããã®æ¡ä»¶ã¯ããç¥ãããŠããã
ïŒïŒµïŒã®ããã®ç¹ç°çãªãã€ããªãã€ãŒãŒã·ã§ã³ãããŒãã補é ããããã®ä»ã®æ段ãšããŠã¯ãïŒïŒµïŒãŸãã¯ïŒ®ïŒïŒµïŒèªå°äœãã³ãŒãããæ žé
žé
åã®ãïœïŒ²ïŒ®ïŒ¡ãããŒãã®è£œé ã®ããã®ãã¯ã¿ãŒãžã®ã¯ããŒãã³ã°ãæããããããã®ãããªãã¯ã¿ãŒã¯ãåœåéã§åšç¥ã§ãããåæ¥çã«å
¥æå¯èœã§ãããïŒãŸãã¯ïŒ³ïŒ°ïŒïŒ²ïŒ®ïŒ¡ããªã¡ã©ãŒãŒã®ãããªé©åœãªïŒ²ïŒ®ïŒ¡ããªã¡ã©ãŒãŒããã³é©åœãªã¬ããŒã¿ãŒååãå ããããšã«ããããããŒããåæããããã«in vivoã§çšããããšãã§ããã
å
šäœçã«ååŠåæã«ãããé
åãŸãã¯ãã®äžéšåã補é ããããšãã§ãããåæåŸãæ žé
žé
åããåœåéã§åšç¥ã®æè¡ãçšããŠãå€ãã®å
¥æå¯èœãªïŒ€ïŒ®ïŒ¡ãã¯ã¿ãŒããã³ãããã®ããããã®å®¿äž»çŽ°èã®ããããã«æ¿å
¥ããããšãã§ãããããã«ãååŠåæãçšããŠçªç¶å€ç°ããã®ãã¯ã¬ãªããé
åã«å°å
¥ããããšãã§ããããããã¯ãçªç¶å€ç°ãæãŸããé
åã®éšåãåæããååšããã²ãã ãŸãã¯çµæãé
åã®ããé·ãéšåã§çµæããããšãã§ããã
ïŒïŒµïŒããªãã¯ã¬ãªãããçšããçµæãã®ããç¥ãããæ¹æ³ãçšããŠã粟補ããããªãªãŽãããããŸãã¯ããªããããã補é ããããšãã§ããããªãªãŽããããã¯ãåæ žãŸãã¯çæ žã®æ§ã
ãªå®¿äž»çŽ°èã§çºçŸãåŸãã宿䞻现èã¯ããã¯ã¬ãªããé
åãç±æ¥ããçš®ãšåãçš®ã«ç±æ¥ãããã®ã§ããããŸãã¯ç°ãªãçš®ã«ç±æ¥ãããã®ã§ãã£ãŠããããçµæãæè¡ã«ãããªãªãŽãã¯ã¬ãªããã補é ããå©ç¹ãšããŠã¯ã粟補ã«é©åœãªéã®ã¿ã³ãã¯è³ªãåŸãããåçŽãªç²Ÿè£œææ³ãå©çšå¯èœã§ãããšããç¹ãæããããã
æ žé
žã®å®éç枬å®
ããã®çŸæ£ã®ååéºäŒå解æã®éèŠãªã¹ãããã¯ãã°ãã°ãæ žé žã®ã³ããŒæ°ã®èšæ°ããã³ç¹å®ã®çµç¹ã«ãããéºäŒåã®çžå¯ŸçãªçºçŸã§ããã
ããã®çŸæ£ã®ååéºäŒå解æã®éèŠãªã¹ãããã¯ãã°ãã°ãæ žé žã®ã³ããŒæ°ã®èšæ°ããã³ç¹å®ã®çµç¹ã«ãããéºäŒåã®çžå¯ŸçãªçºçŸã§ããã
æ žé
žã®å®éçãªæž¬å®ãè¡ãããã®ããã€ãã®ç°ãªã£ãæ¹æ³ãçŸåšå©çšå¯èœã§ãããäŸãã°æ¯èŒã²ãã ãã€ããªãã€ãŒãŒã·ã§ã³ïŒïŒ£ïŒ§ïŒšïŒãèå
in situãã€ããªãã€ãŒãŒã·ã§ã³ïŒïŒŠïŒ©ïŒ³ïŒšïŒãªã©ã®ãæè²äœããŒã¹ã®æè¡ã¯ãè
«ç现èã«ãããŠå€åããã²ãã ã®é åã现èéºäŒåŠçã«ç¹å®ããããšã容æã«ããã
ã²ãã ã®å€åããé åã¯ãçŸæ£ïŒ€ïŒ®ïŒ¡ãåæãããããæ¥åæ§å€åããŒã«ãŒã®æ¬ 倱ã«ã€ããŠæ£åžžãªïŒ€ïŒ®ïŒ¡ãšæ¯èŒããããããæ¥åæ§ã®æ¬ 倱解æïŒïŒ¬ïŒ¯ïŒšïŒãçšããŠããã«çµã蟌ãããšãã§ãããæåã®å®éšã¯ãå¶éé
µçŽ æçé·å€åïŒïŒ²ïŒŠïŒ¬ïŒ°ïœïŒïŒ»JohnsonïŒïŒïŒïŒïŒïŒ],ãŸãã¯è¶
å¯å€ãããµãã©ã€ã[Barnes, 2000]ãçšãããããæ°å¹Žã¯ããã€ã¯ããµãã©ã€ãã®ããŒã«ãŒã®ïŒ°ïŒ£ïŒ²å¢å¹
ããã³æŸå°èœæšèããã[JeffreysïŒïŒïŒïŒïŒïŒ]ãŸãã¯èå
æšèãããç£ç©[WeberïŒïŒïŒïŒïŒïŒ]ã®é»æ°æ³³åãçšããŠæåã«ïŒ¬ïŒ¯ïŒšãè¡ããæ£åžžãªïŒ€ïŒ®ïŒ¡ãšçŸæ£ïŒ€ïŒ®ïŒ¡ãšã®æ¯èŒããªãããŠããã
ä»ã®æ°å€ãã®æ¹æ³ããŸããæ žé
žãå®éããããã«éçºãããŠãã [Gergen (1992)]ãããã«æè¿ã«ãªã£ãŠããµã³ãã«äžã®æ žé
žã®éã枬å®ããããšãå¯èœãªïŒ°ïŒ£ïŒ²ããã³ïŒ²ïŒŽâæ³ãéçºããããïŒã€ã®æ¹æ³ã¯ãäŸãã°ãåå¿ç£ç©ã®åœ¢æãæ°Žå¹³ç¶æ
ã«ãªãåã«åå¿ã®å¯Ÿæ°æã®ïŒ°ïŒ£ïŒ²ç£ç©éã枬å®ãã[Thomas (1980)]ã
ãã¹ãŠã®ãµã³ãã«ã«æ¯èŒçäžå®ã®éã§å«ãŸããŠããéºäŒåé
åã¯ãæšæºåã«æå¹ãªãµã³ãã«å¢å¹
ã«å
žåçã«çšãããããäœãããã®æ¹æ³ã«ã¯ããã€ãã®æ¬ ç¹ãããããã®æ¹æ³ã¯ãåãµã³ãã«ã®æ žé
žæå
¥éãçããããµã³ãã«éã®å¢å¹
å¹çã解æãããŸã§åäžã§ããå¿
èŠããããããã«ãã²ã«é»æ°æ³³åãŸãã¯ãã¬ãŒãè£è¶³ãã€ããªãã€ãŒãŒã·ã§ã³çã®ïŒ°ïŒ£ïŒ²å®éã®æ
£çšçæ¹æ³ãçšããŠããã®æ¹æ³ãå¿
èŠãšããåå¿ã®å¯Ÿæ°æã®éã«ãã¹ãŠã®ãµã³ãã«ãå®éã«è§£æããããšããããšã決å®ããã®ã¯å°é£ã§ããã
å®é競åïŒïŒ±ïŒ£ïŒâãšåŒã°ãããããªãæ¹æ³ã¯ããã®ååã瀺ãããã«ãååå¿ã«ãããå
éšå¯Ÿç
§ç«¶åç©è³ªã®å
å«ãé Œã¿ã«ãã[Piatak (1993) BioTechniques]ãååå¿ã®å¹çãå
éšç«¶åç©è³ªã«æšæºåãããå
éšç«¶åç©è³ªã®æ¢ç¥ã®éãå
žåçã«åãµã³ãã«ã«å ãããæ¢ç¥ã®æšçç£ç©ãæ¢ç¥ã®ç«¶åç£ç©ãšæ¯èŒããŠçžå¯Ÿçãªéã枬ãããã®äžè¬çæ¹æ³ã§ã¯ãæšçååãšåãå¹çã§å¢å¹
ããå
éšæšæºãéçºããããšãé£ããã
ïŒâè¢å
ãã¯ã¬ã¢ãŒãŒè§£æ
èå ãã¯ã¬ã¢ãŒãŒè§£æã¯ããããŒããçšããŠå¢å¹ ç£ç©ã®åœ¢æãã¢ãã¿ãŒãããªã¢ã«ã¿ã€ã ã®å®éæ³ã§ãããå¢å¹ ç£ç©ã®åœ¢æãã¢ãã¿ãŒãããã®æ¹æ³ã®åºç€ã¯ãäºéæšèããèå ãªãªãŽãã¯ã¬ãªãããããŒããçšããŠïŒ°ïŒ£ïŒ²ç£ç©ã®èç©ãç¶ç¶çã®æž¬å®ããããšã«ãããåçŽã«ãïœïœïŒïœïœæ³ããšããŠæç®ã«ãã°ãã°åŒçšãããŠãã[Piatak (1993), Science; Heid (1996); Gibson, (1996) Holland, (1991)]ã
èå ãã¯ã¬ã¢ãŒãŒè§£æã¯ããããŒããçšããŠå¢å¹ ç£ç©ã®åœ¢æãã¢ãã¿ãŒãããªã¢ã«ã¿ã€ã ã®å®éæ³ã§ãããå¢å¹ ç£ç©ã®åœ¢æãã¢ãã¿ãŒãããã®æ¹æ³ã®åºç€ã¯ãäºéæšèããèå ãªãªãŽãã¯ã¬ãªãããããŒããçšããŠïŒ°ïŒ£ïŒ²ç£ç©ã®èç©ãç¶ç¶çã®æž¬å®ããããšã«ãããåçŽã«ãïœïœïŒïœïœæ³ããšããŠæç®ã«ãã°ãã°åŒçšãããŠãã[Piatak (1993), Science; Heid (1996); Gibson, (1996) Holland, (1991)]ã
ãã®ãããªã¢ãã»ã€ã«çšãããããŒãã¯ãå
žåçã«ã¯ïŒã€ã®ç°ãªãèå
è²çŽ ã§æšèããçãïŒçŽïŒïŒãïŒïŒå¡©åºïŒãªãªãŽãã¯ã¬ãªããã§ããããã®ãããŒãã®ïŒâæ«ç«¯ãã¬ããŒã¿ãŒè²çŽ ã«çµåããïŒâæ«ç«¯ãã¯ãšã³ãã³ã°è²çŽ ã«çµåããããè²çŽ ããããŒãã®ä»ã®äœçœ®ã«çµåãããããšãã§ããããããŒãã¯ããããŒãçµåéšäœãšå°ãªããšãå®è³ªçãªé
åçžè£æ§ãæããæ§ã«èšèšããããã®äœçœ®ã®ãã©ã³ãã³ã°é åã«çµåããäžæµããã³äžæµã®ïŒ°ïŒ£ïŒ²ãã©ã€ããŒãåå¿æ··åç©ã«å ããããããŒããã€ã³ã¿ã¯ãã§ãããšããïŒã€ã®èå
éã®ãšãã«ã®ãŒé·ç§»ãèµ·ãããã¯ãšã³ãã£ãŒãã¬ããŒã¿ãŒããã®çºå
ãã¯ãšã³ããããã®çºå
æç¶æéäžã«ãïœïœããªã¡ã©ãŒãŒçã®æ žé
žããªã¡ã©ãŒãŒã®ïŒâãã¯ã¬ã¢ãŒãŒæŽ»æ§ã«ãã£ãŠãããŒããéè£ãåããããã«ãããªãªãŽãã¯ã¬ãªããâã¯ãšã³ãã£ãŒããã¬ããŒã¿ãŒãæŸåºãããã¬ããŒã¿ãŒçºå
匷床ã®å¢å ãããããããããé©åœãªæ€åºåšã«ãã枬å®ããããšãã§ããã
èå
åæã®éã«çãããããªèå
çºå
ã枬å®ããããã«ç¹å¥ã«èª¿æŽãããæ€åºåšã®ïŒã€ã¯ãApplied Biosystems, Inc.瀟ïŒFoster City,CalifïŒè£œã®ïŒ¡ïŒ¢ïŒ©ïŒïŒïŒïŒãŸãã¯ïŒïŒïŒïŒïŒšïŒŽã§ãããïŒïŒïŒïŒã¯ãïŒïŒãŸãã¯ïŒïŒïŒãŠã§ã«ã®ïŒ°ïŒ£ïŒ²ãã¥ãŒãåã®åãŠã§ã«ã«é£çµããå
ãã¡ã€ããŒãçšããããã®è£
眮ã¯æšèãå±èµ·ããããã®ã¬ãŒã¶ãŒãå«ã¿ãå¢å¹
ã®éç¶ç¶çã«ã¢ãã¿ãªã³ã°ããªããåè©Šéšç®¡ããã®èå
ã¹ãã¯ãã«ã®åŒ·åºŠã枬å®ããããšãã§ãããåãã¥ãŒãã¯ïŒïŒïŒç§æ¯ã«åè©Šéšãè¡ãã
è£
眮ã«äŸçµŠãããŠããã³ã³ãã¥ãŒã¿ãœãããŠã§ã¢ã¯ãå¢å¹
ã®çµéã«æž¡ã£ãŠã¬ããŒã¿ãŒããã³ã¯ãšã³ãã£ãŒã®èå
匷床ãèšé²ããããšãå¯èœã§ããã次ãã§ãèšé²ãããå€ã¯ãç¶ç¶çã«æšæºåãããã¬ããŒã¿ãŒåŒ·åºŠã®å¢å ãèšç®ããã®ã«çšãããããçºå
匷床ã®å¢å€§ãæéãå³ã¡å¢å¹
ãµã€ã¯ã«ã«å¯ŸããŠããããããŠãå¢å¹
ã®ç¶ç¶çãªæž¬å®ãè¡ããåå¢å¹
åå¿ã«ãããäœçœ®ãå®éããããã«ãå¢å¹
ãããããç£ç©å¢å¹
ã®å¯Ÿç
§æã®ããæç¹ã§è©Šéšãããããã¯ãããã¯ã°ã©ãŠã³ãã®äžã®èå
éŸå€ãå²ãåœãŠãŠãåå¢å¹
ãããããéŸå€ãšäº€å·®ããç¹ïŒéŸãµã€ã¯ã«æ°ãŸãã¯ïŒ£ïœãšããŠå®çŸ©ãããïŒãæ±ããããšã«ãã£ãŠè¡ããéŸãµã€ã¯ã«æ°ã®å·®ãçšããŠåãã¥ãŒãå
ã«å«ãŸããæšçã®çžå¯Ÿçéãç®åºãããååå¿ãïŒïŒïŒïŒ
ã®ïŒ°ïŒ£ïŒ²å¹çã§ãããšèãããšãïŒã®ïŒ£ïœã®å·®ã¯ãåçºã®ãã³ãã¬ãŒãã®éã§ïŒåã®å·®ç°ã瀺ããèå
å€ã¯ãæšæºæ²ç·ãšé¢é£ããŠçšããŠãååšããå¢å¹
ç£ç©ã®éã決å®ããããšãã§ããã
éãããŒãããŒã¹ã®æ€åºæ³
圢æããå¢å¹ ç£ç©ã枬å®ããããã«æ§ã ãªéžæè¢ãå©çšå¯èœã§ãããïŒã€ã®æ¹æ³ã¯ãè²çŽ çã®ãäºæ¬éã®ïŒ€ïŒ®ïŒ¡ã®ã¿ã«çµåããæšèãå©çšããããã®ã¿ã€ãã®æ¹æ³ã§ã¯ãå¢å¹ ç£ç©ïŒäºæ¬å·®ã®ïŒã¯æº¶æ¶²äžã®è²çŽ ååãšçµåããŠè€åäœã圢æãããé©åœãªè²çŽ ã«ããã溶液äžã®éé¢ã®è²çŽ ååãšå¢å¹ ç£ç©ã«çµåããè²çŽ ååãšãåºå¥ããããšãã§ãããäŸãã°ãããèå è²çŽ ã¯ãå¢å¹ ç£ç©ãšçµåãããšãã®ã¿èå ãçºããããã®äžè¬çãªã¿ã€ãã®æ¹æ³ã«çšããããšãã§ããè²çŽ ã®äŸãšããŠã¯ãSyber GreenïŒç»é²åæšïŒããã³Pico GreenïŒMolecular Probe, Inc.ïŒEugene, Oreg.ïŒç€Ÿè£œïŒãèåãšããžãŠã ããšãŠåããããžãŠã ãã¯ãã¢ãã€ã·ã³ãã¢ã¯ãªãžã³ãªã¬ã³ãžãHoechst 33258, Toto-1,Yoyo-l, DAPI(4',6-ãžã¢ããžã-2-pãã§ãã«ã€ã³ããŒã«å¡©é žå¡©)ãæãããããããã«éå®ãããªãã
圢æããå¢å¹ ç£ç©ã枬å®ããããã«æ§ã ãªéžæè¢ãå©çšå¯èœã§ãããïŒã€ã®æ¹æ³ã¯ãè²çŽ çã®ãäºæ¬éã®ïŒ€ïŒ®ïŒ¡ã®ã¿ã«çµåããæšèãå©çšããããã®ã¿ã€ãã®æ¹æ³ã§ã¯ãå¢å¹ ç£ç©ïŒäºæ¬å·®ã®ïŒã¯æº¶æ¶²äžã®è²çŽ ååãšçµåããŠè€åäœã圢æãããé©åœãªè²çŽ ã«ããã溶液äžã®éé¢ã®è²çŽ ååãšå¢å¹ ç£ç©ã«çµåããè²çŽ ååãšãåºå¥ããããšãã§ãããäŸãã°ãããèå è²çŽ ã¯ãå¢å¹ ç£ç©ãšçµåãããšãã®ã¿èå ãçºããããã®äžè¬çãªã¿ã€ãã®æ¹æ³ã«çšããããšãã§ããè²çŽ ã®äŸãšããŠã¯ãSyber GreenïŒç»é²åæšïŒããã³Pico GreenïŒMolecular Probe, Inc.ïŒEugene, Oreg.ïŒç€Ÿè£œïŒãèåãšããžãŠã ããšãŠåããããžãŠã ãã¯ãã¢ãã€ã·ã³ãã¢ã¯ãªãžã³ãªã¬ã³ãžãHoechst 33258, Toto-1,Yoyo-l, DAPI(4',6-ãžã¢ããžã-2-pãã§ãã«ã€ã³ããŒã«å¡©é žå¡©)ãæãããããããã«éå®ãããªãã
å¥ã®ãªã¢ã«ã¿ã€ã æ€åºæè¡ã¯ããã©ã€ããŒã«çµåããèå
éã®ãšãã«ã®ãŒèå
ãšãã«ã®ãŒé·ç§»ã®å€åã枬å®ãã[Livak, (1995)]ã
ãããŒãããŒã¹ã®æ€åºæ¹æ³
ãããã®æ€åºæ¹æ³ã¯ãå¢å¹ ãã©ã€ããŒã®å¯Ÿã®éã®åº§ãšãã€ããªãã€ãºãããããŒãã®æ§é ãŸãã¯ã³ã³ãã©ã¡ãŒã·ã§ã³ã«å¯Ÿããå€åãé¢ä¿ãããããã€ãã®å Žåã§ã¯ããã®å€åã¯ãå¢å¹ éçšã®éã®æ žé žããªã¡ã©ãŒãŒã«ãã£ãŠè§Šåªããããã³ãã¬ãŒãäŸåççºçŸã«ãã£ãŠåŒãèµ·ããããããã®å¢å¹ ã¯ã圢æããå¢å¹ ç£ç©ã®éã®éæ¥çãªæž¬å®å€ã§ããæ€åºå¯èœãªã·ã°ãã«ãçããã
ãããã®æ€åºæ¹æ³ã¯ãå¢å¹ ãã©ã€ããŒã®å¯Ÿã®éã®åº§ãšãã€ããªãã€ãºãããããŒãã®æ§é ãŸãã¯ã³ã³ãã©ã¡ãŒã·ã§ã³ã«å¯Ÿããå€åãé¢ä¿ãããããã€ãã®å Žåã§ã¯ããã®å€åã¯ãå¢å¹ éçšã®éã®æ žé žããªã¡ã©ãŒãŒã«ãã£ãŠè§Šåªããããã³ãã¬ãŒãäŸåççºçŸã«ãã£ãŠåŒãèµ·ããããããã®å¢å¹ ã¯ã圢æããå¢å¹ ç£ç©ã®éã®éæ¥çãªæž¬å®å€ã§ããæ€åºå¯èœãªã·ã°ãã«ãçããã
äŸãã°ãããã€ãã®æ¹æ³ã¯ã䌞匵åå¿ã®éã®ãããŒãã®å解ãŸãã¯æ¶åãé¢ä¿ããããããã®æ¹æ³ã¯ãæ žé
žããªã¡ã©ãŒãŒã«é¢ããïŒââïŒâãã¯ã¬ã¢ãŒãŒæŽ»æ§ã®çµæã§ããããã®æŽ»æ§ãæããããªã¡ã©ãŒãŒã¯ããã®åº§ã«ååšãããã®çžè£é
åã«ã¢ããŒã«ãããªãªãŽãã¯ã¬ãªãããããŒãããã¢ããã¯ã¬ãªãããŸãã¯å°ãããªãªãŽãã¯ã¬ãªãããéè£ããã
äžæµãã©ã€ããŒã®ïŒâæ«ç«¯ã¯ãæ žé
žããªã¡ã©ãŒãŒã«ã€ããŠã®æåã®çµåéšäœããããããããªã¡ã©ãŒãŒã¯ãäžæµãã©ã€ããŒã®äŒžåŒµãšè§ŠåªãããããŒããšçµåããã®ã§ãæ žé
žããªã¡ã©ãŒãŒã¯ããããŒãã®ïŒâæ«ç«¯ã®éšåã眮æãããã®ãã¯ã¬ã¢ãŒãŒæŽ»æ§ã«ãã£ãŠãããŒããããã¯ã¬ãªãããŸãã¯ãªãªãŽãã¯ã¬ãªãããéè£ããã
äžæµãã©ã€ããŒããã³ãããŒãã¯ãããããã¢ããŒã«ãããŠçžè£éãäºãã«è¿æ¥ããããã«èšèšããããšãã§ãããäºå®ãäžæµãã©ã€ããŒã®ïŒâæ«ç«¯ããã³ãããŒãã®ïŒâæ«ç«¯ã¯äºãã«æ¥ããããã®å Žåã§ã¯ãäžæµãã©ã€ããŒã®äŒžåŒµã¯ãæ žé
žããªã¡ã©ãŒãŒããããŒãã®éè£ãéå§ããã®ã«ã¯å¿
èŠã§ã¯ãªããä»åšãã¯ã¬ãªãããäžæµãã©ã€ããŒãšãããŒããšãåé¢ããŠãããããªå Žåã§ã¯ãæ žé
žããªã¡ã©ãŒãŒããããŒãã®ïŒâæ«ç«¯ã«ééããåã«ãã©ã€ããŒã®äŒžåŒµãå¿
èŠã§ããããã£ããæ¥è§Šãèµ·ãããéååãç¶ç¶ãããšãæ žé
žããªã¡ã©ãŒãŒã®ïŒââïŒâãšã³ããã¯ã¬ã¢ãŒãŒæŽ»æ§ã«ãã£ãŠãã¢ããã¯ã¬ãªãããŸãã¯ãªãªãŽãã¯ã¬ãªããã®ãããŒãã®ïŒâæ«ç«¯ããã®éè£ãéå§ãããããããŒãã®æ¶åã¯ããããŒãã®æ®åéšåãçžè£éãã解é¢ãããŸã§ç¶ãã
溶液äžã§ãïŒã€ã®æ«ç«¯éšåã¯ãäºãã«ãã€ããªãã€ãºããŠãã¢ãã³ã«ãŒãã圢æããããšãã§ããããã®ã³ã³ãã©ã¡ãŒã·ã§ã³ã§ã¯ãã¬ããŒã¿ãŒããã³ã¯ãšã³ãã£ãŒè²çŽ ã¯ãã¬ããŒã¿ãŒããã®èå
ãã¯ãšã³ãã£ãŒã«ããå¹æçã«ã¯ãšã³ããããããã«ååã«è¿æ¥ããŠããã察ç
§çã«ããã€ããªãã€ãºãããããŒãã¯ãã¯ãšã³ãã³ã°ã®çšåºŠãæžå°ããç·ç¶ã®ã³ã³ãã©ã¡ãŒã·ã§ã³ãšãªãããããã£ãŠãïŒã€ã®è²çŽ ã«ã€ããŠçºå
ã®å€åãã¢ãã¿ãŒããããšã«ãããå¢å¹
ç£ç©ã®åœ¢æãéæ¥çã«ã¢ãã¿ãŒããããšãå¯èœã§ããã
ãããŒã
ãã®é åãè©Šéšåº§ãŸãã¯åç §åº§ã®æçã«å®è³ªçã«çžè£çã«ãªãããã«æšèããããããŒããéžæãããäžã§èª¬æããããã«ããããŒããçµåããæ žé žéšäœã¯ãäžæµãã©ã€ããŒã®ãã©ã€ããŒçµåéšäœãšäžæµã®å¢å¹ ãã©ã€ããŒãšã®éã«äœçœ®ãããã
ãã®é åãè©Šéšåº§ãŸãã¯åç §åº§ã®æçã«å®è³ªçã«çžè£çã«ãªãããã«æšèããããããŒããéžæãããäžã§èª¬æããããã«ããããŒããçµåããæ žé žéšäœã¯ãäžæµãã©ã€ããŒã®ãã©ã€ããŒçµåéšäœãšäžæµã®å¢å¹ ãã©ã€ããŒãšã®éã«äœçœ®ãããã
ãã©ã€ããŒ
æ¬å¢å¹ ã«ãããŠçšãããã©ã€ããŒã¯ãå¢å¹ ãã座ã®ãã©ã³ãã³ã°é åã§é åãšãã€ããªãã€ãºããããšãå¯èœãšãªãããã«éžæããããã©ã€ããŒã¯ãå¢å¹ ããæ žé žã®ç°ãªãéãšå°ãªããšãå®è³ªçãªçžè£æ§ãæããæ§ã«éžæããããããŒããå¢å¹ ç£ç©ã®åœ¢æãæ€åºããããã«çšããå Žåããã©ã€ããŒããããŒããçµåããããã«ãå³ã¡ããããŒãã®äžæµããã³äžæµã«äœçœ®ããããã«éžæããã
æ¬å¢å¹ ã«ãããŠçšãããã©ã€ããŒã¯ãå¢å¹ ãã座ã®ãã©ã³ãã³ã°é åã§é åãšãã€ããªãã€ãºããããšãå¯èœãšãªãããã«éžæããããã©ã€ããŒã¯ãå¢å¹ ããæ žé žã®ç°ãªãéãšå°ãªããšãå®è³ªçãªçžè£æ§ãæããæ§ã«éžæããããããŒããå¢å¹ ç£ç©ã®åœ¢æãæ€åºããããã«çšããå Žåããã©ã€ããŒããããŒããçµåããããã«ãå³ã¡ããããŒãã®äžæµããã³äžæµã«äœçœ®ããããã«éžæããã
ãã©ã€ããŒã¯ãéååã®ããã®è¬å€ã®ååšäžã§äŒžåŒµç£ç©ã®åæãéå§ããããšãã§ããããã«ååãªé·ãã§ãªããã°ãªããªãããã©ã€ããŒã®é·ããšçµæã¯ãäŸãã°ãã¢ããŒãªã³ã°åå¿ãè¡ã枩床ããããŒãçµåéšäœãšãã©ã€ããŒã®ãããšã®è¿æ¥ããã©ã€ããŒããã³ãããŒãã®çžå¯Ÿæ¿åºŠããã³ãããŒãã®å
·äœçãªæ žé
žçµæãå«ããå€ãã®ãã©ã¡ãŒã¿ã«äŸåãããå
žåçã«ã¯ããã©ã€ããŒã¯ãïŒïŒãïŒïŒãã¯ã¬ãªãããå«ããäœãããã©ã€ããŒã®é·ãã¯ãã©ã€ããŒçµåéšäœããã³äžèšã®å åã®è€éãã«äŸåããŠããé·ããŠãçããŠãããã
ãããŒãããã³ãã©ã€ããŒã®æšè
æ¬çºæã®ãããŒããŸãã¯ãã©ã€ããŒãæšèããããã«çšãããå¢å¹ ç£ç©ã®éã«å¯Ÿå¿ããã·ã°ãã«ãããããããšãã§ããæšèã¯ãæ§ã ãªåœ¢æ ãåãããšãã§ãããïŒâèå ãã¯ã¬ã¢ãŒãŒæ³ã«é¢ããŠäžã«ç€ºããããã«ãèå ã·ã°ãã«ã¯ã枬å®ããããšãã§ããã·ã°ãã«ã§ãããäœããäŸãã°ãæŸå°èœãæ¯è²ãåžå 床ãç£æ§ç²åãŸãã¯é µçŽ 掻æ§ãã¢ãã¿ãŒããããšã«ããã枬å®ãè¡ãããšãã§ããããããã£ãŠãå©çšããããšãã§ããæšèãšããŠã¯ãèå ãçºè²å£ãæŸå°æ§åäœå çŽ ãé»åå¯åºŠã®é«ãè©Šè¬ãé µçŽ ããã³ç¹å®ã®çµåããŒãããŒãæãããªã¬ã³ãïŒäŸãã°ããªãã³âã¢ããžã³ïŒãæããããããããã«éå®ãããªãã
æ¬çºæã®ãããŒããŸãã¯ãã©ã€ããŒãæšèããããã«çšãããå¢å¹ ç£ç©ã®éã«å¯Ÿå¿ããã·ã°ãã«ãããããããšãã§ããæšèã¯ãæ§ã ãªåœ¢æ ãåãããšãã§ãããïŒâèå ãã¯ã¬ã¢ãŒãŒæ³ã«é¢ããŠäžã«ç€ºããããã«ãèå ã·ã°ãã«ã¯ã枬å®ããããšãã§ããã·ã°ãã«ã§ãããäœããäŸãã°ãæŸå°èœãæ¯è²ãåžå 床ãç£æ§ç²åãŸãã¯é µçŽ 掻æ§ãã¢ãã¿ãŒããããšã«ããã枬å®ãè¡ãããšãã§ããããããã£ãŠãå©çšããããšãã§ããæšèãšããŠã¯ãèå ãçºè²å£ãæŸå°æ§åäœå çŽ ãé»åå¯åºŠã®é«ãè©Šè¬ãé µçŽ ããã³ç¹å®ã®çµåããŒãããŒãæãããªã¬ã³ãïŒäŸãã°ããªãã³âã¢ããžã³ïŒãæããããããããã«éå®ãããªãã
èå
ã®å€åãã¢ãã¿ãŒããããšã¯ãå¢å¹
ç£ç©ã®èç©ãã¢ãã¿ãŒããããã®ç¹ã«æçšãªæ¹æ³ã§ããããããŒããŸãã¯ãã©ã€ããŒã«çµåãããããã®ãïŒããããã³ïŒªïŒ¯ïŒ¥ïŒãããã¯ãã¹ãŠApplied BiosystemsïŒFoster City, Calif.ïŒããå
¥æå¯èœã§ããïŒãã«ã·ãã¡ãŒã€ãšããŒããã³ã¯ããªã³èªå°äœçã®ããã«ãªã¬ã»ã€ã³ããã³æ§ã
ãªãã«ãªã¬ã»ã€ã³èªå°äœãå«ãæ°å€ãã®æšèãåæ¥çã«å
¥æå¯èœã§ããã
æšèã¯ãæ§ã
ãªæè¡ãçšããŠãïŒâæ«ç«¯ããã³ïŒãŸãã¯ïŒâæ«ç«¯ããã³ïŒãŸãã¯å
éšã®ãã¯ã¬ãªããã§ãããŒããŸãã¯ãã©ã€ããŒã«çµåããããšãã§ãããããã«ãæšèã¯ããããŒããŸãã¯ãã©ã€ããŒã«çµåããæ§ã
ãªå€§ããã®ã¹ããŒãµãŒã¢ãŒã ã«çµåããããšãã§ããããããã®ã¹ããŒãµãŒã¢ãŒã ã¯ããããŒããŸãã¯ãã©ã€ããŒã«çµåããè€æ°ã®æšèéã®è·é¢ãåŸãã®ã«æçšã§ããã
ããã€ãã®å Žåã§ã¯ãåäžã®æšèãçšããããšãã§ããããïŒâèå
ãã¯ã¬ã¢ãŒãŒã¢ãã»ã€ã®ãããªå¥ã®å Žåã§ã¯ãäŸãã°ãïŒãŸãã¯ãã以äžã®æšèããããŒãã«çµåããããããŒããè€æ°ã®æšèãå«ãã§ããå Žåã«ã¯ãäžè¬ã«ãæ žé
žããªã¡ã©ãŒãŒã®ïŒââïŒâãã¯ã¬ã¢ãŒãŒæŽ»æ§ã«ãããããŒãã®æ¶åã®éãæšèã®åé¢ãå¯èœã«ããã®ã«ååãªæšèéã®ã¹ããŒã¹ãç¶æããããšãæãŸããã
çŸæ£ã®çç¶ã瀺ãæ£è
æ°å€ãã®çŸæ£ããããç¹å®ã®éºäŒåã®ã³ããŒæ°ã®å€åã«é¢é£ããŠãããçŸæ£ã®çç¶ãæããæ£è ã«ã€ããŠããªã¢ã«ã¿ã€ã æ³ãçšããŠããã®æ£è ãæããŠããçç¶ã«é¢é£ããçŸæ£ãšé¢ä¿ããããšãç¥ãããŠããã³ããŒæ°ã®å€åãæããŠãããã©ããã調ã¹ãããšãã§ããã
æ°å€ãã®çŸæ£ããããç¹å®ã®éºäŒåã®ã³ããŒæ°ã®å€åã«é¢é£ããŠãããçŸæ£ã®çç¶ãæããæ£è ã«ã€ããŠããªã¢ã«ã¿ã€ã æ³ãçšããŠããã®æ£è ãæããŠããçç¶ã«é¢é£ããçŸæ£ãšé¢ä¿ããããšãç¥ãããŠããã³ããŒæ°ã®å€åãæããŠãããã©ããã調ã¹ãããšãã§ããã
ïŒïŒµïŒçºçŸ
ïŒïŒµïŒèåã¿ã³ãã¯è³ª
èåã¿ã³ãã¯è³ªã¯ãïŒïŒµïŒã¢ããé žé åã«å¯Ÿããæäœãäœæãããããããã³æ§ã ãªåæç³»ã«ãããŠçšããããã«æçšã§ãããäŸãã°ãèåã¿ã³ãã¯è³ªãçšããŠãïŒïŒµïŒããããã®äžéšåãšçžäºäœçšããã¿ã³ãã¯è³ªãåå®ããããšãã§ããããã®ç®çã®ããã«ãã¿ã³ãã¯è³ªã¢ãã£ããã£ã¯ãããã°ã©ãã£ãŒãŸãã¯ã¿ã³ãã¯è³ªã¿ã³ãã¯è³ªçžäºäœçšã«é¢ããã©ã€ãã©ãªãŒããŒã¹ã®ã¢ãã»ã€ãäŸãã°é µæ¯ããŒãã€ããªãããŸãã¯ãã¡ãŒãžãã£ã¹ãã¬ã€ã·ã¹ãã ããçšããããšãã§ããããã®ãããªæ¹æ³ã¯åœåéã«ãããŠåšç¥ã§ãããè¬ç©ã¹ã¯ãªãŒãã³ã°ã«çšããããšãã§ããã
ïŒïŒµïŒèåã¿ã³ãã¯è³ª
èåã¿ã³ãã¯è³ªã¯ãïŒïŒµïŒã¢ããé žé åã«å¯Ÿããæäœãäœæãããããããã³æ§ã ãªåæç³»ã«ãããŠçšããããã«æçšã§ãããäŸãã°ãèåã¿ã³ãã¯è³ªãçšããŠãïŒïŒµïŒããããã®äžéšåãšçžäºäœçšããã¿ã³ãã¯è³ªãåå®ããããšãã§ããããã®ç®çã®ããã«ãã¿ã³ãã¯è³ªã¢ãã£ããã£ã¯ãããã°ã©ãã£ãŒãŸãã¯ã¿ã³ãã¯è³ªã¿ã³ãã¯è³ªçžäºäœçšã«é¢ããã©ã€ãã©ãªãŒããŒã¹ã®ã¢ãã»ã€ãäŸãã°é µæ¯ããŒãã€ããªãããŸãã¯ãã¡ãŒãžãã£ã¹ãã¬ã€ã·ã¹ãã ããçšããããšãã§ããããã®ãããªæ¹æ³ã¯åœåéã«ãããŠåšç¥ã§ãããè¬ç©ã¹ã¯ãªãŒãã³ã°ã«çšããããšãã§ããã
ïŒïŒµïŒèåã¿ã³ãã¯è³ªã¯ãããããçµåã§äºãã«èåããïŒã€ã®ããªããããã»ã°ã¡ã³ããå«ãã§ãªãã第ïŒã®ããªããããã»ã°ã¡ã³ãã¯ãäžèšã®ãããªãé
åçªå·ïŒã®å°ãªããšãïŒïŒãïŒïŒãïŒïŒïŒãïŒïŒïŒãïŒïŒïŒãïŒïŒïŒãïŒïŒïŒãïŒïŒïŒãïŒïŒïŒãïŒïŒïŒããŸãã¯ïŒïŒïŒã®é£ç¶ããã¢ããé
žé
åãŸãã¯ãã®çç©åŠçã«æŽ»æ§ãªå€ç°äœãå«ãã§ãªãã第ïŒã®ããªããããã»ã°ã¡ã³ãã¯ãŸãå®å
šé·ã®ïŒ®ïŒïŒµïŒãå«ãã§ãªãããšãããã
第ïŒã®ããªããããã»ã°ã¡ã³ãã¯å®å
šé·ã®ã¿ã³ãã¯è³ªãŸãã¯ã¿ã³ãã¯è³ªæçã§ãã£ãŠãããèåã¿ã³ãã¯è³ªæ§é ã«ãããŠäžè¬ã«çšããããã¿ã³ãã¯è³ªãšããŠã¯ãβâã¬ã©ã¯ãã·ããŒãŒãïœâã°ã«ã¯ããããŒãŒãç·è²èå
ã¿ã³ãã¯è³ªïŒïŒ§ïŒŠïŒ°ïŒãèªå·±èå
ã¿ã³ãã¯è³ªïŒéè²èå
ã¿ã³ãã¯è³ªïŒïŒ¢ïŒŠïŒ°ïŒãå«ãïŒãã°ã«ã¿ããªã³ââãã©ã³ã¹ãã§ã©ãŒãŒ ïŒïŒ§ïŒ³ïŒŽïŒãã«ã·ãã§ã©ãŒãŒãããŒã¹ã©ãã£ã·ã¥ã»ãã«ãªãã·ããŒãŒïŒïŒšïŒ²ïŒ°ïŒããã³ã¯ãã©ã ãã§ãã³ãŒã«ã¢ã»ãã«ãã©ã³ã¹ãã§ã©ãŒãŒïŒïŒ£ïŒ¡ïŒŽïŒãæããããããããã«éå®ãããªããããã«ãèåã¿ã³ãã¯è³ªæ§é ã«ãããŠããã¹ããžã³ïŒïŒšïœïœïŒã¿ã°ãã¿ã°ãã€ã³ãã«ãšã³ã¶ããã°ã«ããã³ïŒïŒšïŒ¡ïŒã¿ã°ãïŒïœïœã¿ã°ãâã¿ã°ããã³ããªã¬ããã·ã³ïŒïŒŽïœïœïŒã¿ã°ãå«ããšãããŒãã¿ã°ãçšãããããä»ã®èåæ§ç¯ç©ãšããŠã¯ããã«ããŒã¹çµåèçœè³ªïŒïŒïŒ¢ïŒ°ïŒãâã¿ã°ãïœ
ïœïŒ€ïŒ®ïŒ¡çµåãã¡ã€ã³ïŒïŒ€ïŒ¢ïŒ€ïŒèåç©ãïŒïŒ€ïŒ®ïŒ¡çµåãã¡ã€ã³èåç©ãåçŽãã«ãã¹ãŠã€ã«ã¹ïŒïŒšïŒ³ïŒ¶ïŒïŒ¢ïŒ°ïŒïŒã¿ã³ãã¯è³ªèåç©ããã³ïŒ§âã¿ã³ãã¯è³ªèåç©ïŒäŸãã°ãïŒã¢ã«ãã¡ïŒïŒïŒãïœãïœïŒãæãããããèåã¿ã³ãã¯è³ªã¯ãŸããïŒïŒµïŒã®é£ã«äœçœ®ã«éè£éšäœãå«ãããšãã§ããã
ããªãã¯ã¬ãªããã®èª¿è£œ
倩ç¶ã®ïŒ®ïŒïŒµïŒããªãã¯ã¬ãªããã¯ãèæåãè質ãªã©ã®ä»ã®çŽ°èæåãå«ãŸãªãããã«åé¢ããããšãã§ãããããªãã¯ã¬ãªããã¯ã现èã«ãã£ãŠç£çããæšæºçãªæ žé žç²Ÿè£œæè¡ãçšããŠåé¢ããããšãã§ãããããŸãã¯ããªã¡ã©ãŒãŒé£éåå¿ïŒïŒ°ïŒ£ïŒ²ïŒçã®å¢å¹ æè¡ããããã¯èªååãããåæè£ çœ®ãçšããŠåæããããšãã§ãããããªãã¯ã¬ãªãããåé¢ããæ¹æ³ã¯ãåžžå¥çã§åœåéã«ãããŠåšç¥ã§ãããããªãã¯ã¬ãªãããåŸãããã®ãã®ãããªä»»æã®æ¹æ³ãçšããŠåé¢ãããïŒïŒµïŒããªãã¯ã¬ãªãããåŸãããšãã§ãããäŸãã°ãå¶éé µçŽ ããã³ãããŒããçšããŠãïŒïŒµïŒãã¯ã¬ãªããé åãå«ãããªãã¯ã¬ãªããæçãåé¢ããããšãã§ãããåé¢ãããããªãã¯ã¬ãªããã¯ãä»ã®ååãå°ãªããšãïŒïŒãïŒïŒããŸãã¯ïŒïŒïŒ å«ãŸãªã調補ç©äžã«ååšããã
倩ç¶ã®ïŒ®ïŒïŒµïŒããªãã¯ã¬ãªããã¯ãèæåãè質ãªã©ã®ä»ã®çŽ°èæåãå«ãŸãªãããã«åé¢ããããšãã§ãããããªãã¯ã¬ãªããã¯ã现èã«ãã£ãŠç£çããæšæºçãªæ žé žç²Ÿè£œæè¡ãçšããŠåé¢ããããšãã§ãããããŸãã¯ããªã¡ã©ãŒãŒé£éåå¿ïŒïŒ°ïŒ£ïŒ²ïŒçã®å¢å¹ æè¡ããããã¯èªååãããåæè£ çœ®ãçšããŠåæããããšãã§ãããããªãã¯ã¬ãªãããåé¢ããæ¹æ³ã¯ãåžžå¥çã§åœåéã«ãããŠåšç¥ã§ãããããªãã¯ã¬ãªãããåŸãããã®ãã®ãããªä»»æã®æ¹æ³ãçšããŠåé¢ãããïŒïŒµïŒããªãã¯ã¬ãªãããåŸãããšãã§ãããäŸãã°ãå¶éé µçŽ ããã³ãããŒããçšããŠãïŒïŒµïŒãã¯ã¬ãªããé åãå«ãããªãã¯ã¬ãªããæçãåé¢ããããšãã§ãããåé¢ãããããªãã¯ã¬ãªããã¯ãä»ã®ååãå°ãªããšãïŒïŒãïŒïŒããŸãã¯ïŒïŒïŒ å«ãŸãªã調補ç©äžã«ååšããã
ïŒïŒµïŒïœïŒ€ïŒ®ïŒ¡ååã¯ãïŒïŒµïŒïœïŒ²ïŒ®ïŒ¡ããã³ãã¬ãŒãããŠçšããŠæšæºçãªååçç©åŠã®æè¡ã«ãã£ãŠäœæããããšãã§ãããïŒïŒµïŒïœïŒ€ïŒ®ïŒ¡ååã¯ãã®åŸã§åœåéã§åšç¥ã®ååçç©åŠã®æè¡ãçšããŠè€è£œããããšãã§ãããçã®å¢å¹
æè¡ãçšããŠãããã²ãã ãŸãã¯ïœïŒ€ïŒ®ïŒ¡ã®ããããããã³ãã¬ãŒããšããŠçšããæ¬çºæã®ãããªãããªãã¯ã¬ãªãããåŸãããšãã§ããã
ãããã¯ãååŠåææ³ãçšããŠãïŒïŒµïŒããªãã¯ã¬ãªãããåæããããšãã§ãããéºäŒã³ãŒãã®çž®éã«ãã£ãŠãåæããããäŸãã°ãé
åçªå·ïŒã«ç€ºãã¢ããé
žé
åãæããïŒïŒµïŒãŸãã¯çç©åŠçã«æŽ»æ§ãªãã®å€ç°äœãã³ãŒãããããã«å¥ã®ãã¯ã¬ãªããé
åãå¯èœã§ããã
ããªãã¯ã¬ãªããã®äŒžåŒµ
æ§ã ãªïŒ°ïŒ£ïŒ²ãããŒã¹ãšããæ¹æ³ãçšããŠããïŒïŒµïŒãã³ãŒãããæ žé žé åã䌞匵ããããšãã§ããäŸãã°ãããã¢ãŒã¿ãŒã調ç¯ãšã¬ã¡ã³ããªã©ã®ïŒ®ïŒïŒµïŒéºäŒåã®äžæµé åãæ€åºããããšãã§ãããäŸãã°ãå¶ééšäœïŒ°ïŒ£ïŒ²ã¯ãŠãããŒãµã«ãã©ã€ããŒãçšããŠãæ¢ç¥ã®åº§ã«é£æ¥ããæªç¥ã®é åãèªã¿åºãããšãã§ããããªã³ã«ãŒé åã«å¯Ÿãããã©ã€ããŒããã³æ¢ç¥ã®é åã«ç¹ç°çãªãã©ã€ããŒã®ååšäžã§æåã«ã²ãã ãå¢å¹ ãããå¢å¹ ããé åããåããªã³ã«ãŒãã©ã€ããŒãšãæåã®ãã©ã€ããŒã®å éšã®å¥ã®ç¹ç°çãã©ã€ããŒãçšããŠç¬¬ïŒã®ïŒ°ïŒ£ïŒ²ã«ä»ããåã®ç£ç©ãé©åœãªïŒ²ïŒ®ïŒ¡ããªã¡ã©ãŒãŒãçšããŠè»¢åããé転åé µçŽ ãçšããŠé åã決å®ããã
æ§ã ãªïŒ°ïŒ£ïŒ²ãããŒã¹ãšããæ¹æ³ãçšããŠããïŒïŒµïŒãã³ãŒãããæ žé žé åã䌞匵ããããšãã§ããäŸãã°ãããã¢ãŒã¿ãŒã調ç¯ãšã¬ã¡ã³ããªã©ã®ïŒ®ïŒïŒµïŒéºäŒåã®äžæµé åãæ€åºããããšãã§ãããäŸãã°ãå¶ééšäœïŒ°ïŒ£ïŒ²ã¯ãŠãããŒãµã«ãã©ã€ããŒãçšããŠãæ¢ç¥ã®åº§ã«é£æ¥ããæªç¥ã®é åãèªã¿åºãããšãã§ããããªã³ã«ãŒé åã«å¯Ÿãããã©ã€ããŒããã³æ¢ç¥ã®é åã«ç¹ç°çãªãã©ã€ããŒã®ååšäžã§æåã«ã²ãã ãå¢å¹ ãããå¢å¹ ããé åããåããªã³ã«ãŒãã©ã€ããŒãšãæåã®ãã©ã€ããŒã®å éšã®å¥ã®ç¹ç°çãã©ã€ããŒãçšããŠç¬¬ïŒã®ïŒ°ïŒ£ïŒ²ã«ä»ããåã®ç£ç©ãé©åœãªïŒ²ïŒ®ïŒ¡ããªã¡ã©ãŒãŒãçšããŠè»¢åããé転åé µçŽ ãçšããŠé åã決å®ããã
ã€ã³ããŒã¹ïŒ°ïŒ£ïŒ²ããŸããæ¢ç¥ã®é åã«åºã¥ãããã€ããŒãžã§ã³ããã©ã€ããŒãçšããŠé
åãå¢å¹
ãŸãã¯äŒžåŒµããããã«äœ¿çšããããšãã§ãããOLIGO4. 06 ãã©ã€ããŒè§£æãœãããŠã§ã¢(National Biosciences Inc.,Plymouth, Minn.)çã®åæ¥çã«å
¥æå¯èœãªãœãããŠã§ã¢ãçšããŠãé·ãïŒïŒãïŒïŒãã¯ã¬ãªãããå«éïŒïŒïŒ
以äžã§ãçŽïŒïŒãïŒïŒâã§æšçé
åãã¢ããŒã«ãããã©ã€ããŒãèšèšããããšãã§ããããã®æ¹æ³ã¯ãããã€ãã®å¶éé
µçŽ ãçšããŠéºäŒåã®æ¢ç¥ã®é åã®é©åœãªæçã調補ããã次ãã§ãã®æçãååå
ã©ã€ã²ãŒã·ã§ã³ã«ããç°ç¶ã«ãããã³ãã¬ãŒããšããŠçšããã
䜿çšã§ãããããªãæ¹æ³ã¯ãææã§ãããããã¯ããããã³é
µæ¯ã®äººå·¥æè²äœïŒ€ïŒ®ïŒ¡ã®æ¢ç¥ã®é
åã«é£æ¥ããã®ïŒ°ïŒ£ïŒ²å¢å¹
ãé¢ããããã®æ¹æ³ã§ã¯ãè€æ°ã®é
µçŽ æ¶åãšã©ã€ã²ãŒã·ã§ã³ãçšããŠéºäŒãæäœããïŒæ¬éã®é
åãããè¡ãåã«ïŒ€ïŒ®ïŒ¡ååã®æªç¥ã®æçå
ã«é
眮ãããããšãã§ããã
å®å
šé·ã®ïœïŒ€ïŒ®ïŒ¡ãã¹ã¯ãªãŒãã³ã°ããå Žåããã倧ããªïœïŒ€ïŒ®ïŒ¡ãå«ãããã«ãµã€ãºéžæãããã©ã€ãã©ãªãŒãçšããããšã奜ãŸãããéºäŒåã®ïŒâé åãå«ãé
åãããå€ãå«ãç¹ã§ãã©ã³ãã ã«ãã©ã€ãã³ã°ãããã©ã€ãã©ãªãŒã奜ãŸãããã©ã³ãã ã«ãã©ã€ãã³ã°ãããã©ã€ãã©ãªãŒã®äœ¿çšã¯ããªãªãŽïœïŒïŒŽïŒã©ã€ãã©ãªãŒãå®å
šé·ã®ïœïŒ€ïŒ®ïŒ¡ãçããªãç¶æ³ã§ã¯ãç¹ã«å¥œãŸããã§ããããã²ãã ã©ã€ãã©ãªãŒã¯ãïŒâé転å調ç¯é åãžé
åã䌞匵ããã®ã«æçšã§ããã
åæ¥çã«å
¥æå¯èœãªãã£ãã©ãªãŒé»æ°æ³³åã·ã¹ãã ãçšããŠã倧ããã解æãŸãã¯ïŒ°ïŒ£ïŒ²ã®ãã¯ã¬ãªããé
åã確èªãŸãã¯ç£ç©ã®é
åã決å®ããããšãã§ãããäŸãã°ããã£ãã©ãªãŒé
å決å®ã¯ãé»æ°æ³³åã®åé¢ã®ããã«æµåæ§ããªããŒãã¬ãŒã¶ãŒå±èµ·ãããïŒã€ã®ç°ãªãèå
ææïŒåãã¯ã¬ãªããã€ããŠïŒã€ïŒãããã³æŸå°ãããæ³¢é·ã®ïŒ£ïŒ£ïŒ€ã«ã¡ã©ã«ããæ€åºãçšããããšãã§ãããåºåïŒå
匷床ãé»æ°çä¿¡å·ã«å€æããããšãã§ãããé©åœãªè£
眮ãšãœãããŠã§ã¢ïŒäŸãã°ãGENOTYPERããã³Sequence NAVIGATOR, Perkin Elmer)ãçšããè©Šæã®æå
¥ããã³ã³ãã¥ãŒã¿è§£æãŸã§ã®å
šèª²çšãšé»åããŒã¿è¡šç€ºãã³ã³ãã¥ãŒã¿å¶åŸ¡ããããšãã§ããããã£ãã©ãªãŒé»æ°æ³³åã¯ãç¹å®ã®è©Šæã«ãããéãããéã«ååšãåŸãã®å°ããéšåã®é
å決å®ã«ç¹ã«å¥œãŸããã
ããªããããã®ååŸ
ïŒïŒµïŒã¯ãäŸãã°ãã现èããã®ç²Ÿè£œã«ãã£ãŠãïŒïŒµïŒããªãã¯ã¬ãªããã®çºçŸã«ãã£ãŠããŸãã¯çŽæ¥çååŠåæã«ãã£ãŠååŸã§ããã
ïŒïŒµïŒã¯ãäŸãã°ãã现èããã®ç²Ÿè£œã«ãã£ãŠãïŒïŒµïŒããªãã¯ã¬ãªããã®çºçŸã«ãã£ãŠããŸãã¯çŽæ¥çååŠåæã«ãã£ãŠååŸã§ããã
èçœç²Ÿè£œ
ïŒïŒµïŒã¯ãïŒïŒµïŒããªãã¯ã¬ãªããã§ãã©ã³ã¹ãã§ã¯ããã宿䞻现èãå å«ããã該ã¬ã»ãã¿ãŒãçºçŸããä»»æã®ãã现èãã粟補ã§ããã粟補ïŒïŒµïŒã¯ã现èå ã®ïŒ®ïŒïŒµïŒã«éåžžä»éãããã®ä»ã®ååç©ãäŸãã°æãçš®ã®èçœãçæ°Žåç©ããŸãã¯è質ãããåœåéã§åšç¥ã®æ¹æ³ãçšããŠåé¢ããããã®ãããªæ¹æ³ã¯ããµã€ãºæé€ã¯ãããã°ã©ãã£ãŒãç¡«é žã¢ã³ã¢ããŠã åç»ãã€ãªã³äº€æã¯ãããã°ã©ãã£ãŒã芪åã¯ãããã°ã©ãã£ãŒãããã³èª¿è£œçšã²ã«é»æ°æ³³åãå å«ãããããããã«éå®ãããªãã
ïŒïŒµïŒã¯ãïŒïŒµïŒããªãã¯ã¬ãªããã§ãã©ã³ã¹ãã§ã¯ããã宿䞻现èãå å«ããã該ã¬ã»ãã¿ãŒãçºçŸããä»»æã®ãã现èãã粟補ã§ããã粟補ïŒïŒµïŒã¯ã现èå ã®ïŒ®ïŒïŒµïŒã«éåžžä»éãããã®ä»ã®ååç©ãäŸãã°æãçš®ã®èçœãçæ°Žåç©ããŸãã¯è質ãããåœåéã§åšç¥ã®æ¹æ³ãçšããŠåé¢ããããã®ãããªæ¹æ³ã¯ããµã€ãºæé€ã¯ãããã°ã©ãã£ãŒãç¡«é žã¢ã³ã¢ããŠã åç»ãã€ãªã³äº€æã¯ãããã°ã©ãã£ãŒã芪åã¯ãããã°ã©ãã£ãŒãããã³èª¿è£œçšã²ã«é»æ°æ³³åãå å«ãããããããã«éå®ãããªãã
ããªãã¯ã¬ãªããã®çºçŸ
ïŒïŒµïŒãçºçŸããããããæ¿å ¥ãããã³ãŒãåé åã®è»¢åãšçºçŸã«å¿ èŠãªèŠçŽ ãå«ãçºçŸãã¯ã¿ãŒäžã«ïŒ®ïŒïŒµïŒããªãã¯ã¬ãªãããæ¿å ¥ããããšãã§ãããïŒïŒµïŒãã³ãŒãããŠããé åããã³é©åœãªè»¢åããã³ç¿»èš³èª¿ç¯èŠçŽ ãå«ãçºçŸãã¯ã¿ãŒãçµã¿ç«ãŠããããåœæ¥è ã«åšç¥ã®æ¹æ³ãå©çšã§ããããããã®æ¹æ³ã«ã¯ãã€ã³ãããçµæãæè¡ãåææè¡ãããã³ã€ã³ããéºäŒåçµæããããã
ïŒïŒµïŒãçºçŸããããããæ¿å ¥ãããã³ãŒãåé åã®è»¢åãšçºçŸã«å¿ èŠãªèŠçŽ ãå«ãçºçŸãã¯ã¿ãŒäžã«ïŒ®ïŒïŒµïŒããªãã¯ã¬ãªãããæ¿å ¥ããããšãã§ãããïŒïŒµïŒãã³ãŒãããŠããé åããã³é©åœãªè»¢åããã³ç¿»èš³èª¿ç¯èŠçŽ ãå«ãçºçŸãã¯ã¿ãŒãçµã¿ç«ãŠããããåœæ¥è ã«åšç¥ã®æ¹æ³ãå©çšã§ããããããã®æ¹æ³ã«ã¯ãã€ã³ãããçµæãæè¡ãåææè¡ãããã³ã€ã³ããéºäŒåçµæããããã
ïŒïŒµïŒãã³ãŒãããŠããé
åãå«ã¿ãããŠçºçŸããæ§ã
ãªçºçŸãã¯ã¿ãŒïŒå®¿äž»ç³»ãå©çšã§ããããããã«ã¯ã埮çç©ãäŸãã°çµæããã¯ããªãªãã¡ãŒãžããã©ã¹ããããŸãã¯ã³ã¹ããçºçŸãã¯ã¿ãŒã«ãã圢質転æããã现èïŒé
µæ¯çºçŸãã¯ã¿ãŒã«ãã圢質転æãããé
µæ¯ããŠã€ã«ã¹çºçŸãã¯ã¿ãŒïŒäŸãã°ããã¥ããŠã€ã«ã¹ïŒã«ããææãåããæè«çŽ°èç³»ããŠã€ã«ã¹çºçŸãã¯ã¿ãŒïŒäŸãã°ã«ãªãã©ã¯ãŒã¢ã¶ã€ã¯ãŠã€ã«ã¹ãïœïŒïŒ¶ïŒã¿ãã³ã¢ã¶ã€ã¯ãŠã€ã«ã¹ãïŒïŒ¶ïŒããããã¯çŽ°èçºçŸãã¯ã¿ãŒïŒäŸãã°ïŒŽïœãŸãã¯ïœïŒ¢ïŒ²ïŒïŒïŒãã©ã¹ããïŒã«ãã圢質転æãããæ€ç©çŽ°èç³»ããŸãã¯åç©çŽ°èç³»ãå
å«ãããããããã«éå®ãããèš³ã§ã¯ãªãã
調ç¯èŠçŽ ãŸãã¯èª¿ç¯é
åã¯ã宿䞻现èèçœãšçžäºäœçšããŠè»¢åãšç¿»èš³ãå®è¡ããããã¯ã¿ãŒã®é翻蚳é åãšã³ãã³ãµãŒãããã¢ãŒã¿ãŒãïŒâããã³ïŒâé翻蚳é åã§ãããä¿ãèŠçŽ ã¯ãã®åŒ·ããšç¹ç°æ§ã«ãããŠç°ãªã£ãŠãããå©çšãããã¯ã¿ãŒç³»ããã³å®¿äž»ã«å¿ããŠãæ§æçããã³èªå°çããã¢ãŒã¿ãŒãå
å«ãããå€æ°ã®å¥œé©ãªè»¢åããã³ç¿»èš³èŠçŽ ã䜿çšã§ãããäŸãã°ã现èç³»ã§ã¯ããŒãã³ã°ãè¡ãå ŽåãBLUESCRIPTãã¡ãŒãžããïŒStraã¿ã°ene, LaJollaïŒCalif.ïŒãŸãã¯pSPORTïŒãã©ã¹ããïŒLife TechnologiesïŒçã®ãã€ããªããlacZããã¢ãŒã¿ãŒã®ãããªèªå°çããã¢ãŒã¿ãŒã䜿çšã§ãããããã¥ããŠã€ã«ã¹ã®ããªãããªã³ããã¢ãŒã¿ãŒã¯æè«çŽ°èã«äœ¿çšã§ãããæ€ç©çŽ°èã®ã²ãã ããïŒäŸãã°ç±ã·ã§ãã¯ãRUBISCOãããã³è²¯èµèçœéºäŒåïŒããŸãã¯æ€ç©ãŠã€ã«ã¹ããïŒäŸãã°ããŠã€ã«ã¹ããã¢ãŒã¿ãŒãŸãã¯ãªãŒããŒé
åïŒèªå°ããããã¢ãŒã¿ãŒãŸãã¯ãšã³ãã³ãµãŒã該ãã¯ã¿ãŒäžã«ã¯ããŒãã³ã°ããããšãã§ãããåºä¹³åç©çŽ°èç³»ã§ã¯ãåºä¹³åç©éºäŒåç±æ¥ã®ããŸãã¯åºä¹³åç©ãŠã€ã«ã¹ç±æ¥ã®ããã¢ãŒã¿ãŒã奜ãŸãããïŒïŒµïŒãã³ãŒãããŠãããã¯ã¬ãªããé
åãè€æ°ã³ããŒå«ãã»ã«ã©ã€ã³ãäœè£œããå¿
èŠãããå Žåã¯ãïŒïŒãŸãã¯ïŒ¥ïŒ¢ïŒ¶ã«åºã¥ããã¯ã¿ãŒãé©åœãªéžæããŒã«ãŒãšå
±ã«äœ¿çšããããšãã§ããã
现èããã³é
µæ¯çºçŸç³»
现èç³»ã§ã¯ãã«å¯ŸããŠæå³ããçšéã«å¿ããŠå¹Ÿã€ãã®çºçŸãã¯ã¿ãŒãéžæã§ãããäŸãã°ãæäœã®èªå°ã®ãã倧éã®ïŒ§ïŒšïŒ³ãå¿ èŠã§ããå Žåã¯ã容æã«ç²Ÿè£œã§ããèåèçœã®é«ã¬ãã«çºçŸãæ什ãããã¯ã¿ãŒã䜿çšã§ããããã®ãããªãã¯ã¿ãŒã¯ãBLUESCRIPT(Stratagene)ã®ãããªå€æ©èœE.coliã¯ããŒãã³ã°ããã³çºçŸãã¯ã¿ãŒãå å«ããããããã«éå®ãããèš³ã§ã¯ãªããBLUESCRIPTãã¯ã¿ãŒã«ãããŠã¯ãïŒïŒµïŒãã³ãŒãããŠããé åããβâã¬ã©ã¯ãã·ããŒãŒã®ã¢ããæ«ç«¯ïŒïœ ïœãšããã«ç¶ãïŒæ®åºã®é åãšå ±ã«ãã¬ãŒã å ã§è©²ãã¯ã¿ãŒäžã«ã©ã€ã²ãŒã·ã§ã³ããããšãã§ãããã®çµæãã€ããªããèçœãç£çããããïœïŒ©ïŒ®ãã¯ã¿ãŒïŒVan Heeke & Schuster, J.Biol.Chem. 264, 5503-5509, 1989ïŒãŸãã¯ïœïŒ§ïŒ¥ïŒžãã¯ã¿ãŒïŒPromega, Madison, Wis.ïŒããŸããã°ã«ã¿ããªã³ïŒ³âãã©ã³ã¹ãã§ã©ãŒãŒïŒïŒ§ïŒ³ïŒŽïŒã䌎ãèåèçœãšããŠå€æ¥ããªãããããçºçŸãããã®ã«äœ¿çšã§ãããäžè¬ã«ããã®ãããªèåèçœã¯å¯æº¶æ§ã§ãããã°ã«ã¿ããªã³âã¢ã¬ããŒã¹ããŒãºã«åžçããããã®åŸéé¢ã°ã«ã¿ããªã³ã®ååšäžã§æº¶é¢ããããšã«ããã溶èããã现èãã容æã«ç²Ÿè£œã§ããããã®ãããªç³»ã§èª¿è£œããèçœã¯ããããªã³ãããã³ãã³ããŸãã¯ç¬¬ïŒžïœå åãããã¢ãŒãŒéè£éšäœãå«ãããèšèšã§ãããã®çµæãç®çãšããã¯ããŒã³ããªãããããéšåããéæã«è§£æŸããããšãã§ããã
现èç³»ã§ã¯ãã«å¯ŸããŠæå³ããçšéã«å¿ããŠå¹Ÿã€ãã®çºçŸãã¯ã¿ãŒãéžæã§ãããäŸãã°ãæäœã®èªå°ã®ãã倧éã®ïŒ§ïŒšïŒ³ãå¿ èŠã§ããå Žåã¯ã容æã«ç²Ÿè£œã§ããèåèçœã®é«ã¬ãã«çºçŸãæ什ãããã¯ã¿ãŒã䜿çšã§ããããã®ãããªãã¯ã¿ãŒã¯ãBLUESCRIPT(Stratagene)ã®ãããªå€æ©èœE.coliã¯ããŒãã³ã°ããã³çºçŸãã¯ã¿ãŒãå å«ããããããã«éå®ãããèš³ã§ã¯ãªããBLUESCRIPTãã¯ã¿ãŒã«ãããŠã¯ãïŒïŒµïŒãã³ãŒãããŠããé åããβâã¬ã©ã¯ãã·ããŒãŒã®ã¢ããæ«ç«¯ïŒïœ ïœãšããã«ç¶ãïŒæ®åºã®é åãšå ±ã«ãã¬ãŒã å ã§è©²ãã¯ã¿ãŒäžã«ã©ã€ã²ãŒã·ã§ã³ããããšãã§ãããã®çµæãã€ããªããèçœãç£çããããïœïŒ©ïŒ®ãã¯ã¿ãŒïŒVan Heeke & Schuster, J.Biol.Chem. 264, 5503-5509, 1989ïŒãŸãã¯ïœïŒ§ïŒ¥ïŒžãã¯ã¿ãŒïŒPromega, Madison, Wis.ïŒããŸããã°ã«ã¿ããªã³ïŒ³âãã©ã³ã¹ãã§ã©ãŒãŒïŒïŒ§ïŒ³ïŒŽïŒã䌎ãèåèçœãšããŠå€æ¥ããªãããããçºçŸãããã®ã«äœ¿çšã§ãããäžè¬ã«ããã®ãããªèåèçœã¯å¯æº¶æ§ã§ãããã°ã«ã¿ããªã³âã¢ã¬ããŒã¹ããŒãºã«åžçããããã®åŸéé¢ã°ã«ã¿ããªã³ã®ååšäžã§æº¶é¢ããããšã«ããã溶èããã现èãã容æã«ç²Ÿè£œã§ããããã®ãããªç³»ã§èª¿è£œããèçœã¯ããããªã³ãããã³ãã³ããŸãã¯ç¬¬ïŒžïœå åãããã¢ãŒãŒéè£éšäœãå«ãããèšèšã§ãããã®çµæãç®çãšããã¯ããŒã³ããªãããããéšåããéæã«è§£æŸããããšãã§ããã
æ€ç©ããã³æè«çºçŸç³»
æ€ç©çºçŸãã¯ã¿ãŒã䜿çšããå ŽåãïŒïŒµïŒãã³ãŒãããŠããé åã®çºçŸã¯ã幟ã€ãã®ããã¢ãŒã¿ãŒã®ãã¡ä»»æã®ãã®ã«ããé§åã§ãããäŸãã°ãïœïŒïŒ¶ã®ïŒïŒïŒ³ããã³ïŒïŒïŒ³ããã¢ãŒã¿ãŒã®ãããªãŠã€ã«ã¹ããã¢ãŒã¿ãŒããåç¬ã§ããŸãã¯ïŒŽïŒïŒ¶ç±æ¥ã®ãªã¡ã¬ãªãŒããŒé åãšçµã¿åãããŠäœ¿çšã§ãããå¥æ³ãšããŠãRUBISCOã®å°ãµããŠãããã®ãããªæ€ç©ããã¢ãŒã¿ãŒãŸãã¯ç±ã·ã§ãã¯ããã¢ãŒã¿ãŒã䜿çšããããšãã§ããããããã®çµã¿ç«ãŠç©ã¯ãçŽæ¥ïŒ€ïŒ®ïŒ¡åœ¢è³ªè»¢æãŸãã¯ç åäœä»²ä»ãã©ã³ã¹ãã§ã¯ã·ã§ã³ã«ããæ€ç©çŽ°èäžã«å°å ¥ã§ããã
æ€ç©çºçŸãã¯ã¿ãŒã䜿çšããå ŽåãïŒïŒµïŒãã³ãŒãããŠããé åã®çºçŸã¯ã幟ã€ãã®ããã¢ãŒã¿ãŒã®ãã¡ä»»æã®ãã®ã«ããé§åã§ãããäŸãã°ãïœïŒïŒ¶ã®ïŒïŒïŒ³ããã³ïŒïŒïŒ³ããã¢ãŒã¿ãŒã®ãããªãŠã€ã«ã¹ããã¢ãŒã¿ãŒããåç¬ã§ããŸãã¯ïŒŽïŒïŒ¶ç±æ¥ã®ãªã¡ã¬ãªãŒããŒé åãšçµã¿åãããŠäœ¿çšã§ãããå¥æ³ãšããŠãRUBISCOã®å°ãµããŠãããã®ãããªæ€ç©ããã¢ãŒã¿ãŒãŸãã¯ç±ã·ã§ãã¯ããã¢ãŒã¿ãŒã䜿çšããããšãã§ããããããã®çµã¿ç«ãŠç©ã¯ãçŽæ¥ïŒ€ïŒ®ïŒ¡åœ¢è³ªè»¢æãŸãã¯ç åäœä»²ä»ãã©ã³ã¹ãã§ã¯ã·ã§ã³ã«ããæ€ç©çŽ°èäžã«å°å ¥ã§ããã
æè«ç³»ããŸãïŒïŒµïŒã®çºçŸã«äœ¿çšã§ãããäŸãã°ãä¿ãç³»ã®ïŒã€Autographa californicaæ žå€è§äœç
ãŠã€ã«ã¹ïŒïŒ¡ïœïŒ®ïŒ°ïŒ¶ïŒã¯ãSpodoptera frugiperda现èãŸãã¯Trichoplusiaã®å¹Œè«ã§å€æ¥éºäŒåãçºçŸããããã¯ã¿ãŒãšããŠäœ¿çšãããïŒïŒµïŒãã³ãŒãããŠããé
åããããªãããªã³éºäŒåã®ãããªè©²ãŠã€ã«ã¹ã®éå¿
é é åäžã«ã¯ããŒãã³ã°ããããªãããªã³ããã¢ãŒã¿ãŒã®èª¿ç¯äžã«çœ®ãããšãã§ãããïŒïŒµïŒãããŸãæ¿å
¥ãããšãããªãããªã³éºäŒåã¯äžæŽ»æ§åããã³ãŒãèçœãæ¬ ãçµæããŠã€ã«ã¹ãçæããã次ãã§ãã®çµæããŠã€ã«ã¹ãS.frugiperda现èãŸãã¯Trichoplusiaã®å¹Œè«ãžã®ææã«äœ¿çšããããã§ïŒ®ïŒïŒµïŒãçºçŸãããããšãã§ããã
åºä¹³åç©çºçŸç³»
ãŠã€ã«ã¹ã«åºã¥ãå€ãã®çºçŸç³»ãçšããŠåºä¹³åç©å®¿äž»çŽ°èã§ïŒ®ïŒïŒµïŒãçºçŸãããããšãã§ãããäŸãã°ãçºçŸãã¯ã¿ãŒãšããŠã¢ãããŠã€ã«ã¹ã䜿çšããå ŽåãïŒïŒµïŒãã³ãŒãããŠããé åã¯ãåŸæããã¢ãŒã¿ãŒããã³ïŒéšã«åããããªãŒããŒé åãå«ãã¢ãããŠã€ã«ã¹è»¢åïŒç¿»èš³è€åäœäžã«ã©ã€ã²ãŒã·ã§ã³ã§ããã該ãŠã€ã«ã¹ã²ãã ã®éå¿ é ïŒãŸãã¯ïŒ¥ïŒé åã«ãããæ¿å ¥ãçšããŠãææ宿䞻现èã«ãããŠïŒ®ïŒïŒµïŒãçºçŸã§ããçåãŠã€ã«ã¹ãååŸã§ããEngelhard et al.(1994)]ãææã«ããã©ãŠã¹èè «ãŠã€ã«ã¹ïŒïŒ²ïŒ³ïŒ¶ïŒãšã³ãã³ãµãŒã®ãããªè»¢åãšã³ãã³ãµãŒãçšããŠåºä¹³åç©å®¿äž»çŽ°èã§ã®çºçŸãå¢å€§ãããããšãã§ããã
ãŠã€ã«ã¹ã«åºã¥ãå€ãã®çºçŸç³»ãçšããŠåºä¹³åç©å®¿äž»çŽ°èã§ïŒ®ïŒïŒµïŒãçºçŸãããããšãã§ãããäŸãã°ãçºçŸãã¯ã¿ãŒãšããŠã¢ãããŠã€ã«ã¹ã䜿çšããå ŽåãïŒïŒµïŒãã³ãŒãããŠããé åã¯ãåŸæããã¢ãŒã¿ãŒããã³ïŒéšã«åããããªãŒããŒé åãå«ãã¢ãããŠã€ã«ã¹è»¢åïŒç¿»èš³è€åäœäžã«ã©ã€ã²ãŒã·ã§ã³ã§ããã該ãŠã€ã«ã¹ã²ãã ã®éå¿ é ïŒãŸãã¯ïŒ¥ïŒé åã«ãããæ¿å ¥ãçšããŠãææ宿䞻现èã«ãããŠïŒ®ïŒïŒµïŒãçºçŸã§ããçåãŠã€ã«ã¹ãååŸã§ããEngelhard et al.(1994)]ãææã«ããã©ãŠã¹èè «ãŠã€ã«ã¹ïŒïŒ²ïŒ³ïŒ¶ïŒãšã³ãã³ãµãŒã®ãããªè»¢åãšã³ãã³ãµãŒãçšããŠåºä¹³åç©å®¿äž»çŽ°èã§ã®çºçŸãå¢å€§ãããããšãã§ããã
ãã人工æè²äœïŒïŒšïŒ¡ïŒ£ïŒããŸãããã©ã¹ãããå
å
ãçºçŸããæçããã倧ããªïŒ€ïŒ®ïŒ¡æçã®éæ¬ã«äœ¿çšã§ãããïŒïŒãªããïŒïŒïŒã®ïŒšïŒ¡ïŒ£ãçµã¿ç«ãŠãåžžå¥çããªããªãŒæ³ã«ãã现èã«å°éãããïŒäŸãã°ããªããœãŒã ãããªã«ããªã³ã¢ããããªããŒããŸãã¯å°èïŒãããã«ãïŒïŒµïŒãã³ãŒãããŠããé
åã®ãããå¹ççãªç¿»èš³ãéæããããã«ãç¹ç°çéå§ã·ã°ãã«ã䜿çšã§ãããä¿ãã·ã°ãã«ã¯ïŒ¡ïŒŽïŒ§éå§ã³ãã³ããã³é£ç¶é
åãå
å«ããïŒKozaké
åïŒãïŒïŒµïŒãã³ãŒãããŠããé
åããã®éå§ã³ãã³ãããã³äžæµé
åãé©åœãªçºçŸãã¯ã¿ãŒäžã«æ¿å
¥ããå Žåããããªã転åãŸãã¯ç¿»èš³èª¿ç¯ã·ã°ãã«ã¯å¿
èŠãªãã§ããããããããªãããã³ãŒãåé
åãŸãã¯ãã®æçã®ã¿ãæ¿å
¥ããå Žåã¯ãå€å æ§ã®ç¿»èš³èª¿ç¯ã·ã°ãã«ïŒïŒ¡ïŒŽïŒ§éå§ã³ãã³ãå
å«ããïŒãäŸçµŠãã¹ãã§ãããéå§ã³ãã³ã¯æ¿å
¥ç©å
šäœã確å®ã«ç¿»èš³ãããããã«ãæ£ãããªãŒãã£ã³ã°ãã¬ãŒã ã«ãªããã°ãªããªããå€å æ§ç¿»èš³èŠçŽ ããã³éå§ã³ãã³ã¯å€©ç¶ããã³åæäž¡è
ã®æ§ã
ãªèµ·æºã§ãã£ãŠããã
宿䞻现è
宿䞻现èèæ ªã¯ãæ¿å ¥ããé åã®çºçŸã調ç¯ããèœåãŸãã¯çºçŸãããïŒïŒµïŒãææã®æ¹æ³ã§åŠçã§ããèœåãç®çãšããŠéžæã§ããã該ããªããããã®ãã®ãããªä¿®é£Ÿã«ã¯ãã¢ã»ãã«åãã«ã«ããã·åãã°ãªã³ã·ã«åãçé žåãè質åãããã³ã¢ã·ã«åãå å«ãããããããã«éå®ãããªãã該ããªããããã®ããã¬ãããåãéè£ãã翻蚳åŸããã»ã·ã³ã°ããŸããæ£ããæ¿å ¥ãæãç³ã¿ãããã³ïŒãŸãã¯æ©èœãä¿é²ããããã«äœ¿çšã§ããã翻蚳åŸæŽ»æ§ã®ããã®ç¹ç°çãªçŽ°èæ©æ§ããã³ç¹åŸŽçã¡ã«ããºã ãæã€ç°ãªã宿䞻现èïŒäŸãã°ïŒ£ïŒšïŒ¯ãïŒšïœ ïŒ¬ïœãïŒïŒ€ïŒ£ïŒ«ãïŒïŒïŒãïŒïŒïŒïŒïŒ®ïŒããã³ïŒ·ïŒ©ïŒïŒïŒããAmerican Type Culture CollectionïŒïŒ¡ïŒŽïŒ£ïŒ£ïŒ10801 University Boulevard, Manassas, VA 20110-2209ïŒããå ¥æã§ããå€æ¥èçœã®æ£ãã修食ããã³ããã»ã·ã³ã°ã確å®ãšããããã«éžæã§ããã
宿䞻现èèæ ªã¯ãæ¿å ¥ããé åã®çºçŸã調ç¯ããèœåãŸãã¯çºçŸãããïŒïŒµïŒãææã®æ¹æ³ã§åŠçã§ããèœåãç®çãšããŠéžæã§ããã該ããªããããã®ãã®ãããªä¿®é£Ÿã«ã¯ãã¢ã»ãã«åãã«ã«ããã·åãã°ãªã³ã·ã«åãçé žåãè質åãããã³ã¢ã·ã«åãå å«ãããããããã«éå®ãããªãã該ããªããããã®ããã¬ãããåãéè£ãã翻蚳åŸããã»ã·ã³ã°ããŸããæ£ããæ¿å ¥ãæãç³ã¿ãããã³ïŒãŸãã¯æ©èœãä¿é²ããããã«äœ¿çšã§ããã翻蚳åŸæŽ»æ§ã®ããã®ç¹ç°çãªçŽ°èæ©æ§ããã³ç¹åŸŽçã¡ã«ããºã ãæã€ç°ãªã宿䞻现èïŒäŸãã°ïŒ£ïŒšïŒ¯ãïŒšïœ ïŒ¬ïœãïŒïŒ€ïŒ£ïŒ«ãïŒïŒïŒãïŒïŒïŒïŒïŒ®ïŒããã³ïŒ·ïŒ©ïŒïŒïŒããAmerican Type Culture CollectionïŒïŒ¡ïŒŽïŒ£ïŒ£ïŒ10801 University Boulevard, Manassas, VA 20110-2209ïŒããå ¥æã§ããå€æ¥èçœã®æ£ãã修食ããã³ããã»ã·ã³ã°ã確å®ãšããããã«éžæã§ããã
çµæãèçœã®ãé·æé«åéç£çã®ããã«ãå®å®ãªçºçŸã奜ãŸãããäŸãã°ãïŒïŒµïŒãå®å®ã«çºçŸããã»ã«ã©ã€ã³ã¯ããŠã€ã«ã¹è€è£œèµ·ç¹ããã³ïŒãŸãã¯å
å æ§çºçŸèŠçŽ ãããã³åããŸãã¯å¥ã®ãã¯ã¿ãŒäžã«ããéžæããŒã«ãŒéºäŒåãå«ãçºçŸãã¯ã¿ãŒã䜿çšããŠããã©ã³ã¹ãã§ã¯ãããåŸãã該ãã¯ã¿ãŒã®å°å
¥ã«ç¶ããŠã现èã匷åå¹å°ã§ïŒâïŒæ¥éçè²ãããåŸãå¹å°ãéžæå¹å°ã«äº€æããããšãã§ãããéžæããŒã«ãŒã®ç®çã¯éžæã«å¯Ÿããæµææ§ãä»äžããããšã§ããããã®ååšããå°å
¥ãããïŒïŒµïŒé
åãããŸãçºçŸãã现èã®çè²ãšååãå¯èœã«ãããå®å®ã«åœ¢è³ªè»¢æããã现èã®èæ§ã¯ããŒã³ã¯ããã®çŽ°èåã«ãšã£ãŠé©åœãªçµç¹å¹é€æè¡ãçšããŠå¢æ®ãããããšãã§ããã幟ã€ãã®éžæç³»ãçšããŠã圢質転æãããã»ã«ã©ã€ã³ãååã§ããããããã«ã¯ãããããïœïœ-ãŸãã¯ïœïœïœïœ-现èã§äœ¿çšã§ããåçŽãã«ãã¹ãŠã€ã«ã¹ãããžã³ãããŒãŒïŒ»Logan, (1984)]ããã³ã¢ããã³ãã¹ããªãã·ã«ãã©ã³ã¹ãã§ã©ãŒãŒ[Wigler, (1977)]éºäŒåãå
å«ãããããããã«éå®ãããèš³ã§ã¯ãªããããã«ã代è¬æ®æç©è³ªãæçç©è³ªããŸãã¯é€èå€èæ§ãéžæã®åºæºã«çšããããšãã§ãããäŸãã°ãdhfrã¯ã¡ãœãã¬ããµãŒã[Lowy, (1980)]ã«å¯Ÿããèæ§ãä»äžããnptã¯ã¢ããã°ãªã³ã·ããããªãã€ã·ã³ããã³ïŒ§âïŒïŒïŒã«å¯Ÿããèæ§ãä»äžããG-418 [Wigler, (1980)]ããããŠalsããã³patã¯ããããã¯ãã«ã¹ã«ããã³ããã³ãã¹ãã£ãããªã·ã³ã¢ã»ãã«ãã©ã³ã¹ãã§ã©ãŒãŒã«å¯Ÿããèæ§ãä»äžãã[Colbere-Garapin et al., (1981) ]ããããªãéžæéºäŒåãèšèŒãããŠãããäŸãã°ãtrpBã¯çŽ°èãããªãããã¡ã³ã®ä»£ããã«ã€ã³ããŒã«ãå©çšããããã«ãããhisDã¯çŽ°èããã¹ããžã³ã®ä»£ããã«ãã¹ãããŒã«ãå©çšããããã«ããã[Murray,(1992)]ãã¢ã³ãã·ã¢ãã³ã®ãããªå¯èŠããŒã«ãŒãβâã°ã«ã¯ããããŒãŒãšãã®åºè³ªïŒ§ïŒµïŒ³ãããã³ã«ã·ãã§ã©ãŒãŒãšãã®åºè³ªã«ã·ãã§ãªã³ã¯ã圢質転æäœãåå®ããç¹ç°çãã¯ã¿ãŒç³»ã«åž°ãããšã®ã§ããäžéæ§ãŸãã¯å®å®ãªèçœçºçŸã®éãå®éããããã«äœ¿çšã§ããã
ããªããããçºçŸã®æ€åº
ããŒã«ãŒéºäŒåçºçŸã®ååšã¯ïŒ®ïŒïŒµïŒããªãã¯ã¬ãªããããŸãååšããããšã瀺åããŠãããããã®ååšãšçºçŸã¯ç¢ºèªããå¿ èŠããããäŸãã°ãããïŒïŒµïŒãã³ãŒãããŠããé åãããŒã«ãŒéºäŒåé åå éšã«æ¿å ¥ããããªãã°ãïŒïŒµïŒãã³ãŒãããŠããé åãå«ã圢質転æããã现èã¯ãããŒã«ãŒéºäŒåæ©èœã®äžåšã«ãã£ãŠåå®ã§ãããããã«ä»£ãããããŒã«ãŒéºäŒåã¯ãåäžã®ããã¢ãŒã¿ãŒã®èª¿ç¯äžã«ïŒ®ïŒïŒµïŒãã³ãŒãããŠããé åãšã¿ã³ãã ã«äžŠã¹ãŠäœçœ®ãããããšãã§ãããèªå°ãŸãã¯éžæã«å¿çããããŒã«ãŒéºäŒåã®çºçŸã¯ãéåžžãïŒïŒµïŒããªãã¯ã¬ãªããã®çºçŸã瀺ãã
ããŒã«ãŒéºäŒåçºçŸã®ååšã¯ïŒ®ïŒïŒµïŒããªãã¯ã¬ãªããããŸãååšããããšã瀺åããŠãããããã®ååšãšçºçŸã¯ç¢ºèªããå¿ èŠããããäŸãã°ãããïŒïŒµïŒãã³ãŒãããŠããé åãããŒã«ãŒéºäŒåé åå éšã«æ¿å ¥ããããªãã°ãïŒïŒµïŒãã³ãŒãããŠããé åãå«ã圢質転æããã现èã¯ãããŒã«ãŒéºäŒåæ©èœã®äžåšã«ãã£ãŠåå®ã§ãããããã«ä»£ãããããŒã«ãŒéºäŒåã¯ãåäžã®ããã¢ãŒã¿ãŒã®èª¿ç¯äžã«ïŒ®ïŒïŒµïŒãã³ãŒãããŠããé åãšã¿ã³ãã ã«äžŠã¹ãŠäœçœ®ãããããšãã§ãããèªå°ãŸãã¯éžæã«å¿çããããŒã«ãŒéºäŒåã®çºçŸã¯ãéåžžãïŒïŒµïŒããªãã¯ã¬ãªããã®çºçŸã瀺ãã
ãããšã¯å¥ã«ãïŒïŒµïŒããªãã¯ã¬ãªãããå«ã¿ïŒ®ïŒïŒµïŒãçºçŸãã宿䞻现èã¯ãåœæ¥è
ã«ç¥ãããæ§ã
ãªæ¹æ³ã«ãã£ãŠåå®ã§ããããããã®æ¹æ³ã«ã¯ãâãŸãã¯ïŒ€ïŒ®ïŒ¡âãã€ããªãã€ãŒãŒã·ã§ã³ããã³èçœçæ€ãŸãã¯ã€ã ãã¢ãã»ã€æè¡ïŒæ žé
žãŸãã¯èçœã®æ€åºããã³ïŒãŸãã¯å®éã®ããã®èã溶液ããŸãã¯ãããã«åºã¥ãæè¡ãå
å«ããïŒãå
å«ãããããããã«éå®ãããªããäŸãã°ãïŒïŒµïŒãã³ãŒãããŠããããªãã¯ã¬ãªããé
åã®ååšã¯ããããŒããŸãã¯æçãŸãã¯ïŒ®ïŒïŒµïŒãã³ãŒãããŠããããªãã¯ã¬ãªããã®æçã䜿çšããâãŸãã¯ïŒ€ïŒ®ïŒ¡âãã€ããªãã€ãŒãŒã·ã§ã³ãŸãã¯å¢å¹
ã«ãã£ãŠæ€åºã§ãããæ žé
žå¢å¹
ã«åºã¥ãæ€å®ã¯ãïŒïŒµïŒããªãã¯ã¬ãªãããå«ã圢質転æäœãæ€åºããããã®ãïŒïŒµïŒãã³ãŒãããŠããé
åããéžæããããªãªãŽãã¯ã¬ãªããã®äœ¿çšãå«ãã
ïŒïŒµïŒã«å¯Ÿãç¹ç°çãªããªã¯ããŒãã«ãŸãã¯ã¢ãã¯ããŒãã«æäœã®ããããã䜿çšããŠè©²ããªããããã®çºçŸãæ€åºããã³æž¬å®ããããã®æ§ã
ãªãããã³ã«ãåœåéã§ç¥ãããŠãããäŸãšããŠãé
µçŽ çµåã€ã ããœã«ãã³ãæ€å®ïŒïŒ¥ïŒ¬ïŒ©ïŒ³ïŒ¡ïŒãã©ãžãªã€ã ãã¢ãã»ã€ïŒïŒ²ïŒ©ïŒ¡ïŒãããã³èå
掻æ§åã»ã«ãœãŒãã£ã³ã°ïŒïŒŠïŒ¡ïŒ£ïŒ³ïŒããããïŒïŒµïŒäžã®ïŒåã®éå¹²æžæ§ãšãããŒãã«åå¿ããã¢ãã¯ããŒãã«æäœãçšãããïŒéšäœã®ã¢ãã¯ããŒãã«ã«åºã¥ãã€ã ãã¢ãã»ã€ã䜿çšã§ãããŸãã¯ã競åççµåæ€å®ã䜿çšããããšãã§ããã
å€å²ã«ãããæšèããã³ã³ã³ãžã¥ã²ãŒã·ã§ã³æè¡ãåœæ¥è
ã«ç¥ãããŠãããæ§ã
ãªæ žé
žããã³ã¢ããé
žæ€å®ã«äœ¿çšã§ãããïŒïŒµïŒãã³ãŒãããŠããããªãã¯ã¬ãªããã«é¢é£ããé
åãæ€åºããããã®æšèåãã€ããªãã€ãŒãŒã·ã§ã³ãŸãã¯ïŒ°ïŒ£ïŒ²ãããŒãã調補ããæ段ã¯ãæšèãããã¯ã¬ãªããã䜿çšããããªãªãŽæšèåãããã¯ç¿»èš³ãæ«ç«¯æšèåããŸãã¯ïŒ°ïŒ£ïŒ²å¢å¹
ãå
å«ããããããšã¯å¥ã«ãïŒïŒµïŒãã³ãŒãããŠããé
åããïœïŒ²ïŒ®ïŒ¡ãããŒãã®ç£çã®ããã®ãã¯ã¿ãŒäžã«ã¯ããŒãã³ã°ããããšãã§ããããã®ãããªãã¯ã¿ãŒã¯åœåéã§æ¢ç¥ã§ãããåžè²©åãå
¥æã§ããæšèåãã¯ã¬ãªããããã³é©åœãªïŒ²ïŒ®ïŒ¡ããªã¡ã©ãŒãŒãäŸãã°ïŒŽïŒãïŒããŸãã¯ïŒ³ïŒ°ïŒãæ·»å ããããšã«ããã€ã³ãããã§ã®ïŒ²ïŒ®ïŒ¡ãããŒãã®åæã«äœ¿çšããããšãã§ããããããã®æ¹æ³ã¯ãåžè²©ã®æ§ã
ãªããããçšããŠå®æœã§ããïŒAmersham Pharmacia Biotechã Promegaãããã³US BiochemicalïŒãæ€åºã容æã«ããããã«äœ¿çšã§ããé©åœãªãªããŒã¿ãŒååãŸãã¯æšèã«ã¯ãæŸå°æ§æ žçš®ãé
µçŽ ãããã³èå
ãååŠã«ããã»ã³ãããŸãã¯è²çŽ çæç©è³ªããªãã³ã«åºè³ªãè£å©å åãã€ã³ããã¿ãŒãç£æ§ç²åãªã©ãå
å«ãããã
ããªããããã®çºçŸããã³ç²Ÿè£œ
ïŒïŒµïŒãã³ãŒãããŠãããã¯ã¬ãªããé åã§åœ¢è³ªè»¢æããã宿䞻现èã¯ãçºçŸãšã现èå¹é€ããã®èçœã®ååã«é©ããæ¡ä»¶äžã§å¹é€ã§ããã圢質転æ现èã«ããç£çãããããªããããã¯ããã®é åããã³ïŒãŸãã¯äœ¿çšãããã¯ã¿ãŒã«å¿ããŠåæ³ãããŸãã¯çŽ°èå ã«è²¯çããåŸããåœæ¥è ã«ã¯ç解ã§ããã§ãããããïŒïŒµïŒãã³ãŒãããŠããããªãã¯ã¬ãªãããå«ãçºçŸãã¯ã¿ãŒã¯ãåæ žãŸãã¯çæ žçŽ°èèãéã£ãå¯æº¶æ§ïŒ®ïŒïŒµïŒã®åæ³ãæ什ããããŸãã¯èçµåïŒïŒµïŒã®ãèæ¿å ¥ãæ什ãããã·ã°ãã«é åãå«ãããèšèšã§ããã
ïŒïŒµïŒãã³ãŒãããŠãããã¯ã¬ãªããé åã§åœ¢è³ªè»¢æããã宿䞻现èã¯ãçºçŸãšã现èå¹é€ããã®èçœã®ååã«é©ããæ¡ä»¶äžã§å¹é€ã§ããã圢質転æ现èã«ããç£çãããããªããããã¯ããã®é åããã³ïŒãŸãã¯äœ¿çšãããã¯ã¿ãŒã«å¿ããŠåæ³ãããŸãã¯çŽ°èå ã«è²¯çããåŸããåœæ¥è ã«ã¯ç解ã§ããã§ãããããïŒïŒµïŒãã³ãŒãããŠããããªãã¯ã¬ãªãããå«ãçºçŸãã¯ã¿ãŒã¯ãåæ žãŸãã¯çæ žçŽ°èèãéã£ãå¯æº¶æ§ïŒ®ïŒïŒµïŒã®åæ³ãæ什ããããŸãã¯èçµåïŒïŒµïŒã®ãèæ¿å ¥ãæ什ãããã·ã°ãã«é åãå«ãããèšèšã§ããã
äžã«è«ããããã«ãä»ã®çµã¿ç«ãŠç©ãçšããŠãïŒïŒµïŒãã³ãŒãããŠããé
åããå¯æº¶æ§èçœã®ç²Ÿè£œãä¿é²ããããªãããããã¡ã€ã³ãã³ãŒãããŠãããã¯ã¬ãªããé
åãšçµåãããããšãã§ããããã®ãããªç²Ÿè£œä¿é²ãã¡ã€ã³ã¯ãéå±ãã¬ãŒãåãããããäŸãã°åºå®åéå±äžã§ã®ç²Ÿè£œãå¯èœã«ãããã¹ããžã³âããªãããã¡ã³ã¢ãžã¥ãŒã«ãåºå®åå
ç«ã°ãããªã³äžã§ã®ç²Ÿè£œãå¯èœã«ããèçœïŒ¡ãã¡ã€ã³ãããã³ïŒŠïŒ¬ïŒ¡ïŒ§ïŒ³äŒžé·ïŒèŠªå粟補系ã§å©çšãããã¡ã€ã³ãå
å«ããããããããã«éå®ãããªãïŒImmunex Corp., Seattle, Wash.ïŒã粟補ãã¡ã€ã³ãšïŒ®ïŒïŒµïŒãšã®éã«éè£å¯èœãªã³ã«ãŒé
åãäŸãã°ç¬¬ïŒžïœå åãŸãã¯ãšã³ãããããŒãŒã«ç¹ç°çãªãªã³ã«ãŒé
åãå
¥ããããšïŒInvitrogen, San Diego, CAïŒããŸãã粟補ãä¿é²ããããã«å©çšã§ããããã®ãããªçºçŸãã¯ã¿ãŒã®ïŒã€ã¯ãïŒïŒµïŒãšãããªã¬ããã·ã³ãŸãã¯ãšã³ãããããŒãŒéè£éšäœã«å
ç«ã€ïŒåã®ãã¹ããžã³æ®åºãšãå«ãèåèçœã®çºçŸãæäŸããããã®ãã¹ããžã³æ®åºã¯ïŒ©ïŒïŒ¡ïŒ£ïŒåºå®åéå±ã€ãªã³èŠªåã¯ãããã°ã©ãã£ãŒïŒMaddox et al., (1983)ã«ãã粟補ãä¿é²ããäžæ¹ãšã³ãããããŒãŒéè£éšäœã¯èåèçœããã®ïŒ®ïŒïŒµïŒã®ç²Ÿè£œæ段ãæäŸãããèåèçœãå«ããã¯ã¿ãŒã¯ïŒ»Porath et al., (1992)ã«é瀺ãããŠããã
ååŠåæ
ïŒïŒµïŒãã³ãŒãããŠããé åã¯ããã®å šäœãŸãã¯äžéšããåœåéã§åšç¥ã®ååŠçæ¹æ³ãçšããŠåæã§ããããããšã¯å¥ã«ãïŒïŒµïŒèªèº«ãããã®ã¢ããé žé åãåæããããã®ååŠçæ¹æ³ãäŸãã°åºçžæè¡ãçšããçŽæ¥ããããåæãçšããŠèª¿è£œã§ãããèçœåæã¯æåæè¡ãŸãã¯ãªãŒãã¡ãŒã·ã§ã³ãçšããŠå®æœã§ãããèªåååæã¯ãäŸãã°Applied Biosystems 431Aããããåææ©ïŒPerkin ElmerïŒãçšããŠéæã§ãããææã«ãããïŒïŒµïŒã®æçãå¥ã ã«åæããååŠçæ¹æ³ãçšããŠåããŠå®å šé·ã®ååã調補ããããšãã§ããã
ïŒïŒµïŒãã³ãŒãããŠããé åã¯ããã®å šäœãŸãã¯äžéšããåœåéã§åšç¥ã®ååŠçæ¹æ³ãçšããŠåæã§ããããããšã¯å¥ã«ãïŒïŒµïŒèªèº«ãããã®ã¢ããé žé åãåæããããã®ååŠçæ¹æ³ãäŸãã°åºçžæè¡ãçšããçŽæ¥ããããåæãçšããŠèª¿è£œã§ãããèçœåæã¯æåæè¡ãŸãã¯ãªãŒãã¡ãŒã·ã§ã³ãçšããŠå®æœã§ãããèªåååæã¯ãäŸãã°Applied Biosystems 431Aããããåææ©ïŒPerkin ElmerïŒãçšããŠéæã§ãããææã«ãããïŒïŒµïŒã®æçãå¥ã ã«åæããååŠçæ¹æ³ãçšããŠåããŠå®å šé·ã®ååã調補ããããšãã§ããã
æ°ãã«åæããããããã¯ã調補çšé«é液äœã¯ãããã°ã©ãã€ãŒã«ããå®è³ªçã«ç²Ÿè£œã§ãããåæïŒïŒµïŒã®çµæã¯ã¢ããé
žåæãŸãã¯é
å決å®ã«ãã確èªã§ãããããã«ãçŽæ¥åæäžã«ïŒ®ïŒïŒµïŒã®ã¢ããé
žé
åã®ä»»æã®éšåãæ¹å€ããããããŠïŒãŸãã¯ååŠçæ¹æ³ãçšããŠä»ã®èçœç±æ¥ã®é
åãšåããŠãå€ç°äœããªãããããŸãã¯èåèçœã調補ããããšãã§ããã
æ¹å€ïŒ®ïŒïŒµïŒã®èª¿è£œ
åœæ¥è ã«ã¯ç解ã§ããã§ããããã倩ç¶ã«ååšããªãã³ãã³ãæããïŒïŒµïŒã³ãŒãåãã¯ã¬ãªããã調補ããããšã¯æå©ã§ããåŸããäŸãã°ãç¹å®ã®åæ žãŸãã¯çæ žå®¿äž»ã奜ãã³ãã³ãéžæããŠãèçœçºçŸã®é床ãå¢å€§ããããŸãã¯ææã®æ§è³ªãäŸãã°å€©ç¶ã«ååšããé åããç£ã¿åºããã転åç©ã®åæžæããé·ãåæžæãæã€ïŒ²ïŒ®ïŒ¡è»¢åç©ã調補ããããšãã§ããã
åœæ¥è ã«ã¯ç解ã§ããã§ããããã倩ç¶ã«ååšããªãã³ãã³ãæããïŒïŒµïŒã³ãŒãåãã¯ã¬ãªããã調補ããããšã¯æå©ã§ããåŸããäŸãã°ãç¹å®ã®åæ žãŸãã¯çæ žå®¿äž»ã奜ãã³ãã³ãéžæããŠãèçœçºçŸã®é床ãå¢å€§ããããŸãã¯ææã®æ§è³ªãäŸãã°å€©ç¶ã«ååšããé åããç£ã¿åºããã転åç©ã®åæžæããé·ãåæžæãæã€ïŒ²ïŒ®ïŒ¡è»¢åç©ã調補ããããšãã§ããã
æ¬æ现æžã«é瀺ãããã¯ã¬ãªããé
åã¯ãåœåéã§äžè¬çã«ç¥ãããæ¹æ³ãçšããŠã該ããªãããããŸãã¯ïœïŒ²ïŒ®ïŒ¡ç£ç©ã®ã¯ããŒãã³ã°ãããã»ã·ã³ã°ãããã³ïŒãŸãã¯çºçŸã修食ããæ¹å€ãå
å«ããïŒäœããããã«éå®ãããèš³ã§ã¯ãªãïŒæ§ã
ãªçç±ã§ãïŒïŒµïŒã³ãŒãåé
åãæ¹å€ãããããã«èšèšã§ãããç¡äœçºæçåã«ããã·ã£ããªã³ã°ãšéºäŒåæçããã³åæãªãªãŽãã¯ã¬ãªããã®ïŒ°ïŒ£ïŒ²åéåãçšããŠãã¯ã¬ãªããé
åãèšèšã§ãããäŸãã°ãäœçœ®æå®çªç¶å€ç°èªçºãçšããŠãæ°ããªå¶ééšäœãæ¿å
¥ããã°ãªã³ã·ã«åãã¿ãŒã³ãå€ããã³ãã³ã®åªå
æ§ãå€ããã¹ãã©ã€ã¹å€ç°äœã調補ããçªç¶å€ç°ãå°å
¥ããçãå®æœã§ããã
æäœ
åœåéã§ç¥ãããŠãããããªãåã®æäœããïŒïŒµïŒã®ãšãããŒãã«ç¹ç°çã«çµåããããäœè£œã§ããã
åœåéã§ç¥ãããŠãããããªãåã®æäœããïŒïŒµïŒã®ãšãããŒãã«ç¹ç°çã«çµåããããäœè£œã§ããã
æ¬æ现æžã§äœ¿çšãããæäœããšã¯ãç¡å·ã®å
ç«ã°ãããªã³ååãããã³ãã®æçãäŸãã°ïŒŠïœïœãïŒïœïœâïŒ2ãããã³ïŒŠïœãå
å«ãããããã¯ïŒ®ïŒïŒµïŒã®ãšãããŒãã«çµåã§ãããå
žåçã«ã¯ããšãããŒãã圢æããããã«ã¯å°ãªããšãïŒãïŒãïŒïŒããŸãã¯ïŒïŒã®é£ç¶ããã¢ããé
žãå¿
èŠã§ãããããããªãããéé£ç¶ã¢ããé
žãå«ããšãããŒãã¯ããå€ãã®ãäŸãã°å°ãªããšãïŒïŒãïŒïŒããŸãã¯ïŒïŒã®ã¢ããé
žãå¿
èŠãšããããç¥ããªããïŒïŒµïŒã®ãšãããŒãã«ç¹ç°çã«çµåããæäœã¯æ²»çã«äœ¿çšã§ãããããŠå
ç«ååŠæ€å®ãäŸãã°ãŠã§ã¹ã¿ã³ããããããã©ãžãªã€ã ãã¢ãã»ã€ãå
ç«çµç¹ååŠæ€å®ãå
ç«æ²éããŸãã¯ãã®ä»ã®åœåéã§æ¢ç¥ã®å
ç«ååŠçæ€å®ã«äœ¿çšã§ãããææã®ç¹ç°æ§ãæããæäœã®åå®ã®ãããæ§ã
ãªã€ã ãã¢ãã»ã€ã䜿çšã§ããã競åççµåãŸãã¯å
ç«æŸå°æ€å®ã®ããã®å€æ°ã®ãããã³ã«ãåœåéã§ããç¥ãããŠããããã®ãããªã€ã ãã¢ãã»ã€ã¯å
žåçã«ã¯ãå
ç«åãšããã®å
ç«åã«ç¹ç°çµåããæäœãšã®éã®è€åäœåœ¢æã®æž¬å®ãå«ãã§ããã
å
žåçã«ã¯ãïŒïŒµïŒã«ç¹ç°çã«çµåããæäœã¯ãå
ç«ååŠæ€å®ã«äœ¿çšããæãä»ã®èçœãæäŸããæ€åºã·ã°ãã«ããå°ãªããšãïŒãïŒïŒããŸãã¯ïŒïŒåé«ãæ€åºã·ã°ãã«ãæäŸããã奜ãŸããã¯ãïŒïŒµïŒã«ç¹ç°çµåããæäœã¯ãå
ç«ååŠæ€å®ã§ä»ã®èçœãæ€åºãããïŒïŒµïŒã溶液ããå
ç«æ²éãããããšãã§ããã
ïŒïŒµïŒã¯ãåºä¹³åç©ãäŸãã°ããŠã¹ãã©ããããŠãµã®ãã¢ã«ã¢ããããµã«ããŸãã¯ãããå
ç«ããŠããªã¯ããŒãã«æäœãç£çãããã®ã«äœ¿çšã§ãããææã«ãããïŒïŒµïŒã¯ãæ
äœèçœãäŸãã°çè¡æž
ã¢ã«ããã³ãããã°ãããªã³ãããã³ã¹ã«ã·ã¬ã€ãã¢ã·ã¢ãã³ãšã³ã³ãžã¥ã²ãŒããããããšãã§ããã宿䞻ã®çš®ã«å¿ããŠãå
ç«åŠçåå¿ãå¢å€§ãããããã«çš®ã
ã®ã¢ãžã¥ãã³ãã䜿çšã§ããããã®ãããªã¢ãžã¥ãã³ãã¯ãããã€ã³ãã¢ãžã¥ãã³ããé±ç©æ§ã²ã«ïŒäŸãã°æ°Žé
žåã¢ã«ãããŠã ïŒãããã³çé¢æŽ»æ§ç©è³ªïŒäŸãã°ãªãŸã¬ã·ãã³ããã«ãããã¯ããªãªãŒã«ãããªã¢ããªã³ããããããæ²¹æ§ãšãã«ãžã§ã³ãã¹ã«ã·ã¬ã€ãã¢ã·ã¢ãã³ãããã³ãžããããã§ããŒã«ïŒãå
å«ããããããã«éå®ãããªããããã«äœ¿çšããã¢ãžã¥ãã³ãã®äžã§ã¯ïŒ¢ïŒ£ïŒ§ïŒbacilli Calmette-GuerinïŒããã³Corynebacterium parvumãç¹ã«æçšã§ããã
ïŒïŒµïŒã«ç¹ç°çã«çµåããã¢ãã¯ããŒãã«æäœã¯ãå¹é€äžã®é£ç¶çã»ã«ã©ã€ã³ã«ããæäœååã®ç£çãæäŸããä»»æã®æè¡ãçšããŠèª¿è£œã§ããããããã®æè¡ã«ã¯ããã€ããªããŒãæè¡ããã现èãã€ããªããŒãæè¡ãããã³ïŒ¥ïŒ¢ïŒ¶âãã€ããªããŒãæè¡ãããããããã«éå®ãããªãRoberge et al., (1995)ã
ããã«ãããŠã¹æäœéºäŒåãããæäœéºäŒåã«ã¹ãã©ã€ã·ã³ã°ããŠé©åœãªæåç¹ç°æ§ãšçç©æŽ»æ§ãæã€ååãåŸããããã¡ã©æäœãã®ç£çã®ããã«éçºãããæè¡ãå©çšã§ãããã¢ãã¯ããŒãã«ããã³ãã®ä»ã®æäœã¯ãŸãããããæ²»çã«äœ¿çšããå Žåã«æ£è
ã該æäœã«å¯Ÿããå
ç«åå¿ãèµ·ããã®ãé²ãããããããåãããããšãã§ããããã®ãããªæäœã¯ãæ²»çã«çŽæ¥äœ¿çšã§ããã»ã©é
åãå
åããã«é¡äŒŒããŠããããç¥ããããŸãã¯å¹Ÿã€ãã®éèŠæ®åºã®å€æŽãå¿
èŠãšããããç¥ããªãã霧æ¯é¡ã®æäœãšããé
åã®éã®é
åçžéã¯ãåã
ã®æ®åºã®äœçœ®æå®çªç¶å€ç°èªçºã«ããããŸãã¯çžè£æ§æ±ºå®é åå
šäœã®ïœïœïœïœïœïœïœã«ãããããé
åå
ã®æ®åºãšçžéããæ®åºã眮ãæããããšã«ãã£ãŠæå°åããããšãã§ãããïŒïŒµïŒã«ç¹ç°çã«çµåããæäœã¯ãç±³åœç¹èš±ç¬¬ïŒïŒïŒïŒïŒïŒïŒå·ã«é瀺ã®ããã«ãéšåçãŸãã¯å®å
šã«ããåããæåçµåéšäœãå«ãããšãã§ããã
ããã«ä»£ãããåœåéã§æ¢ç¥ã®æ¹æ³ãçšããŠãäžæ¬éæäœã®èª¿è£œã®ããã«èšèŒããæè¡ãé©åãããïŒïŒµïŒã«ç¹ç°çµåããäžæ¬éæäœã調補ããããšãã§ãããé¢é£ããç¹ç°æ§ãæã€ãå¥åã®ã€ãã£ãªã¿ã€ãçµæãæããæäœããç¡äœçºçµã¿åããå
ç«ã°ãããªã³ã©ã€ãã©ãªãŒããéã·ã£ããªã³ã°ã«ãã£ãŠèª¿è£œããããšãã§ãããäžæ¬éæäœã¯ãŸãããã€ããªããŒãïœïŒ€ïŒ®ïŒ¡ãé³åã«çšããŠãã®ãããªïŒ€ïŒ®ïŒ¡å¢å¹
æ³ãçšããŠçµã¿ç«ãŠãããšãã§ãããäžæ¬éæäœã¯åäžãŸãã¯äºéç¹ç°æ§ã§ããåŸããŸããäºäŸ¡ãŸãã¯å䟡ã§ããåŸããå䟡äºéç¹ç°æ§äžæ¬éæäœã®çµã¿ç«ãŠã¯æ瀺ãããŠãããäºäŸ¡äºéç¹ç°æ§äžæ¬éæäœã®çµã¿ç«ãŠã¯æ瀺ãããŠãããäžèšã®ããã«ãäžæ¬éæäœãã³ãŒãããŠãããã¯ã¬ãªããé
åãæåãŸãã¯èªåãã¯ã¬ãªããåæãçšããŠçµã¿ç«ãŠãæšæºççµæãæ³ãçšããŠçºçŸçµã¿ç«ãŠç©äžã«ã¯ããŒãã³ã°ãããããŠçŽ°èäžã«å°å
¥ããŠã³ãŒãåé
åãçºçŸãããããšãã§ãããå¥æ³ãšããŠãäžæ¬éæäœããäŸãã°ç³žç¶ãã¡ãŒãžæè¡ãçšããŠçŽæ¥èª¿è£œããããšãã§ããã
ïŒïŒµïŒã«ç¹ç°çµåããæäœã¯ãŸãããªã³ãçéå£ã«ãããŠã€ã³ããç£çãèªå°ããããšã«ãã£ãŠããŸãã¯ãæç®ã«é瀺ãããŠãã極ããŠç¹ç°çãªçµåè©Šè¬ã®ããã«ãŸãã¯å
ç«ã°ãããªã³ã©ã€ãã©ãªãŒãã¹ã¯ãªãŒãã³ã°ããããšã«ãã£ãŠèª¿è£œããããšãã§ããããã®ä»ã®åã®æäœããæ¬çºææ¹æ³ã«ãããŠçµã¿ç«ãŠãæ²»çã«äœ¿çšããããšãã§ãããäŸãã°ãïŒïŒïŒïŒïŒïŒïŒïŒã«é瀺ã®ããã«ããã¡ã©æäœãçµã¿ç«ãŠãããšãã§ãããå
ç«ã°ãããªã³ããèªå°ããå€äŸ¡äžã€å€éç¹ç°çã§ããçµåèçœãäŸãã°ïŒ·ïŒ¯ïŒïŒïŒïŒïŒïŒïŒïŒã«èšèŒã®ãdiabodiesãããŸã調補ã§ããã
æ¬çºæã«ä¿ãæäœã¯åœåéã§åšç¥ã®æ¹æ³ã«ãã粟補ã§ãããäŸãã°ãæäœã¯ãïŒïŒµïŒãçµåããŠããã«ã©ã ãééãããããšã«ãã芪å粟補ã§ããã次ãã§ãçµåããæäœããé«ãå¡©æ¿åºŠã®ç·©è¡æ¶²ãçšããŠã«ã©ã ãã溶åºããããšãã§ããã
ã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªãã
ã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªããã¯ãç¹å®ã®ïŒ€ïŒ®ïŒ¡ãŸãã¯ïŒ²ïŒ®ïŒ¡é åã«å¯Ÿãçžè£çãªãã¯ã¬ãªããé åã§ããããã£ãã现èäžã«å°å ¥ããããšãã®çžè£çãã¯ã¬ãªããã¯ã該现èãç£çãã倩ç¶é åãšçµåããŠè€åäœã圢æãã転åãŸãã¯ç¿»èš³ã®ãããããé®æããã奜ãŸããã¯ã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªããã¯å°ãªããšãïŒïŒãã¯ã¬ãªããé·ã§ããããå°ãªããšãïŒïŒãïŒïŒãïŒïŒãïŒïŒãïŒïŒãïŒïŒãïŒïŒãïŒïŒããããã¯ïŒïŒãŸãã¯ãã以äžã®ãã¯ã¬ãªããé·ã§ãã£ãŠããããããé·ãé åããŸã䜿çšã§ãããã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªããååãçµã¿ç«ãŠç©ã«æäŸããäžèšã®ããã«çŽ°èäžã«å°å ¥ããŠããã®çŽ°èã«ãããïŒïŒµïŒéºäŒåç£ç©ã®ã¬ãã«ãäœäžãããããšãã§ããã
ã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªããã¯ãç¹å®ã®ïŒ€ïŒ®ïŒ¡ãŸãã¯ïŒ²ïŒ®ïŒ¡é åã«å¯Ÿãçžè£çãªãã¯ã¬ãªããé åã§ããããã£ãã现èäžã«å°å ¥ããããšãã®çžè£çãã¯ã¬ãªããã¯ã該现èãç£çãã倩ç¶é åãšçµåããŠè€åäœã圢æãã転åãŸãã¯ç¿»èš³ã®ãããããé®æããã奜ãŸããã¯ã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªããã¯å°ãªããšãïŒïŒãã¯ã¬ãªããé·ã§ããããå°ãªããšãïŒïŒãïŒïŒãïŒïŒãïŒïŒãïŒïŒãïŒïŒãïŒïŒãïŒïŒããããã¯ïŒïŒãŸãã¯ãã以äžã®ãã¯ã¬ãªããé·ã§ãã£ãŠããããããé·ãé åããŸã䜿çšã§ãããã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªããååãçµã¿ç«ãŠç©ã«æäŸããäžèšã®ããã«çŽ°èäžã«å°å ¥ããŠããã®çŽ°èã«ãããïŒïŒµïŒéºäŒåç£ç©ã®ã¬ãã«ãäœäžãããããšãã§ããã
ã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªããã¯ãããªãã·ãªããã¯ã¬ãªããããªããã¯ã¬ãªããããŸãã¯ãã®äž¡è
ã®çµã¿åããã§ãã£ãŠããããªãªãŽãã¯ã¬ãªããã¯ãïŒã€ã®ãã¯ã¬ãªããã®ïŒâæ«ç«¯ããã¢ã«ãã«ãã¹ãããŒãããã¹ããããªãšãŒãããã¹ãããžããªãšãŒããã¢ã«ãã«ãã¹ããããªãšãŒããã¢ã«ãã«ãã¹ãããŒãããã¹ããã¢ãããŒããçé
žãšã¹ãã«ãã«ã«ãã¡ãŒããã¢ã»ãã¢ãããŒããã«ã«ããã·ã¡ãã«ãšã¹ãã«ãã«ã«ãããŒããããã³çé
žããªãšã¹ãã«ãšãã£ãéãã¹ããžãšã¹ãã«ãã¯ã¬ãªããéçµåãæããå¥ã®ãã¯ã¬ãªããã®ïŒâæ«ç«¯ãšå
±æçµåãããããšã«ãããæåã§ããŸãã¯èªååææ©ã«ãã£ãŠåæã§ããã
ïŒïŒµïŒéºäŒåã®å¶åŸ¡ãïŒâããŸãã¯èª¿ç¯é åãšäºæ¬éã圢æããã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªãããèšèšããããšã«ãããïŒïŒµïŒéºäŒåçºçŸã®ä¿®é£ŸãåŸãããã転åéå§éšäœãäŸãã°éå§éšäœããâïŒïŒããã³ïŒïŒïŒäœã®éããèªå°ããããªãªãŽãã¯ã¬ãªããã奜ãŸãããåæ§ã«ããäžéããããå¡©åºå¯Ÿåæ³ãçšããŠé»å®³ãéæã§ãããäžéããã察åã¯ãäºéããããããªã¡ã©ãŒãŒã転åå åãŸãã¯ã·ã£ããã³ã®çµåã«è¶³ãã»ã©éãèœåã®é»å®³ãæ¹èµ·ãããããæçšã§ãããäžæ¬éãçšããæ²»çäžã®é²æ©ãæç®ã«èšèŒãããŠããNicholls, (1993)ã転åç©ããªããœãŒã ã«çµåããã®ãé²ãããšã«ããïœïŒ²ïŒ®ïŒ¡ã®ç¿»èš³ãé®æããã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªããããŸãèšèšã§ããã
ã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªãããšïŒ®ïŒïŒµïŒããªãã¯ã¬ãªããã®çžè£é
åãšã®éã«å¥œçµæã®è€åäœã圢æãããããã«ã¯ãæ£ç¢ºãªçžè£æ§ã¯å¿
èŠãªããäŸãã°ïŒ®ïŒïŒµïŒããªãã¯ã¬ãªããã«å¯Ÿãæ£ç¢ºã«çžè£çã§ããïŒãïŒãïŒããããã¯ïŒãŸãã¯ãã以äžã®é·ãã®é£ç¶ãããã¯ã¬ãªããã§ãã£ãŠããã®åã
ããé£æ¥ããïŒïŒµïŒãã¯ã¬ãªãããšã¯çžè£çã§ã¯ãªãé£ç¶ããããé·ãã®ãã¯ã¬ãªããã«ãã£ãŠéãŠãããŠãããã®ãå«æããã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªããã¯ãïŒïŒµïŒïœïŒ²ïŒ®ïŒ¡ã«å¯Ÿããå
åãªæšçåç¹ç°æ§ãæäŸã§ããã奜ãŸããã¯ãçžè£çãªé£ç¶ãã¯ã¬ãªããã®é·ãã¯ããããå°ãªããšãïŒãïŒãïŒãïŒãããã¯ïŒãŸãã¯ãã以äžã®ãã¯ã¬ãªããé·ã§ãããéçžè£çãªä»åšé
åã¯ã奜ãŸããã¯ïŒãïŒãïŒããŸãã¯ïŒãã¯ã¬ãªããé·ã§ãããåœæ¥è
ã¯ãã¢ã³ãã»ã³ã¹âã»ã³ã¹ã®å¯Ÿã®ç®åºèç¹ã容æã«äœ¿çšããŠãç¹å®ã®ã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªãããšç¹å®ã®ïŒ®ïŒïŒµïŒããªãã¯ã¬ãªããé
åéã§å¯å®¹ããããã¹ãããã®çšåºŠã決å®ã§ããã§ããããã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªããã¯ãïŒïŒµïŒããªãã¯ã¬ãªãããšãã€ããªãã€ãºããèœåã«åœ±é¿ãåãŒãããšãªã修食ã§ããããããã®ä¿®é£Ÿã¯è©²ã¢ã³ãã»ã³ã¹ååã®å
éšããŸãã¯äžç«¯ãããã¯äž¡ç«¯ã§ãããäŸãã°ããã¯ã¬ãªã·ãéã®çé
žçµåã¯ãã¢ããåºãšæ«ç«¯ãªããŒã¹ã®éã«ãããããªæ°ã®ççŽ æ®åºãæããã³ã¬ã¹ããªã«ãŸãã¯ãžã¢ãã³éšåãå ããããšã«ãã£ãŠä¿®é£Ÿã§ããã修食ãããå¡©åºããã³ïŒãŸãã¯ç³ãäŸãã°ãªããŒã¹ã®ä»£ããã®ã¢ã©ãããŒã¹ããŸãã¯ïŒâããããã·åºãŸãã¯ïŒâçé
žåºã眮æãããŠããïŒâãïŒââ眮æãªãªãŽãã¯ã¬ãªããããŸã修食ã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªããã«äœ¿çšã§ããããããã®ä¿®é£ŸãªãªãŽãã¯ã¬ãªããã¯åœåéã§åšç¥ã®æ¹æ³ã«ãã調補ã§ããã
ãªãã¶ã€ã
ãªãã¶ã€ã ã¯è§ŠåªæŽ»æ§ãæããååã§ããUhlmann, (1987)ãåœåéã§ç¥ãããããã«ããªãã¶ã€ã ã¯ãé åãéè£ããããšã«ããéºäŒåæ©èœãé»å®³ããã®ã«äœ¿çšã§ããããªãã¶ã€ã ã®äœçšæ©æ§ã¯ãçžè£çæšçã«å¯Ÿãããªãã¶ã€ã ååã®é åç¹ç°çãã€ããªãã€ãŒãŒã·ã§ã³ãšããã®åŸã®endonucleolyticãªéè£ãå«ããäŸã«ã¯ãç¹ç°çãã¯ã¬ãªããé åã®endonucleolyticãªéè£ãç¹ç°çäžã€å¹æçã«è§Šåªã§ãããèšèšããããã³ããŒãããã¢ããŒããªãã¶ã€ã ååããããïŒïŒµïŒããªãã¯ã¬ãªããã®ã³ãŒãåé åãçšããŠãïŒïŒµïŒããªãã¯ã¬ãªãããã転åãããïœïŒ²ïŒ®ïŒ¡ã«ç¹ç°çµåãããªãã¶ã€ã ãäœè£œã§ãããä»ã®ãã©ã³ã¹ã®ïŒ²ïŒ®ïŒ¡ååã極ããŠé åç¹ç°çã«éè£ã§ãããªãã¶ã€ã ãèšèšãçµã¿ç«ãŠãæ¹æ³ãéçºãããåœåéã§èšèŒãããŠãããäŸãã°ããªãã¶ã€ã ã®éè£æŽ»æ§ã¯ãå¥åã®ããã€ããªãã€ãŒãŒã·ã§ã³ãé åã該ãªãã¶ã€ã äžã«çµã¿å ¥ããããšã«ãã£ãŠãç¹å®ã®ïŒ²ïŒ®ïŒ¡ãæšçãšãããããšãã§ããããã®ãã€ããªãã€ãŒãŒã·ã§ã³é åã¯æšçã«å¯Ÿãçžè£çãªé åãå«ãã§ããããããã£ãŠãã®æšçãšç¹ç°çã«ãã€ããªãã€ãºãããïŒïŒµïŒïŒ²ïŒ®ïŒ¡æšçå éšã®ç¹ç°çãªãã¶ã€ã éè£éšäœã¯ããã®æšçååãã以äžã®é åïŒïŒ§ïŒµïŒ¡ããããã³ïŒ§ïŒµïŒ£ãå å«ãããªãã¶ã€ã éè£éšäœã«ã€ããŠã¹ãã£ã³ããããšã«ããåå®ã§ãããåå®ã§ãããªãã°ã該éè£éšäœãå«ãæšçã®é åã«å¯Ÿå¿ãããïŒïŒããã³ïŒïŒã®éã®ãªããã¯ã¬ãªãããæããçãé åããæšçãéæ©èœçã«ãåŸãäºæ¬¡æ§é ã®ç¹åŸŽã«ã€ããŠè©äŸ¡ã§ãããããã«ãåè£ã®ïŒ®ïŒïŒµïŒïŒ²ïŒ®ïŒ¡æšçã®é©åæ§ãããªããã¯ã¬ã¢ãŒãŒé²è·æ€å®ãçšããŠçžè£çãªãªãŽãã¯ã¬ãªãããšã®ãã€ããªãã€ãŒãŒã·ã§ã³ã«å¯Ÿããå©çšå¯èœæ§ãè©Šéšããããšã«ãã£ãŠè©äŸ¡ã§ãããé åçªå·ïŒã«ç€ºããã¯ã¬ãªããé åããã³ãããã®çžè£ç©ã¯ãé©åœãªãã€ããªãã€ãŒãŒã·ã§ã³é åé åã®äŸçµŠæºãæäŸãããããé·ãçžè£é åãçšããŠãæšçã«å¯Ÿãããã€ããªãã€ãŒãŒã·ã§ã³é åã®èŠªåæ§ãå¢å€§ãããããšãã§ããããªãã¶ã€ã ã®ãã€ããªãã€ãºããã³éè£ããé åã¯ãçžè£é åãä»ããŠæšçã«ãã€ããªãã€ãºããæããªãã¶ã€ã ã®è§Šåªé åãæšçãéè£ãåŸããšãã£ãããã«ãå®å šã«çžé¢ããŠããã
ãªãã¶ã€ã ã¯è§ŠåªæŽ»æ§ãæããååã§ããUhlmann, (1987)ãåœåéã§ç¥ãããããã«ããªãã¶ã€ã ã¯ãé åãéè£ããããšã«ããéºäŒåæ©èœãé»å®³ããã®ã«äœ¿çšã§ããããªãã¶ã€ã ã®äœçšæ©æ§ã¯ãçžè£çæšçã«å¯Ÿãããªãã¶ã€ã ååã®é åç¹ç°çãã€ããªãã€ãŒãŒã·ã§ã³ãšããã®åŸã®endonucleolyticãªéè£ãå«ããäŸã«ã¯ãç¹ç°çãã¯ã¬ãªããé åã®endonucleolyticãªéè£ãç¹ç°çäžã€å¹æçã«è§Šåªã§ãããèšèšããããã³ããŒãããã¢ããŒããªãã¶ã€ã ååããããïŒïŒµïŒããªãã¯ã¬ãªããã®ã³ãŒãåé åãçšããŠãïŒïŒµïŒããªãã¯ã¬ãªãããã転åãããïœïŒ²ïŒ®ïŒ¡ã«ç¹ç°çµåãããªãã¶ã€ã ãäœè£œã§ãããä»ã®ãã©ã³ã¹ã®ïŒ²ïŒ®ïŒ¡ååã極ããŠé åç¹ç°çã«éè£ã§ãããªãã¶ã€ã ãèšèšãçµã¿ç«ãŠãæ¹æ³ãéçºãããåœåéã§èšèŒãããŠãããäŸãã°ããªãã¶ã€ã ã®éè£æŽ»æ§ã¯ãå¥åã®ããã€ããªãã€ãŒãŒã·ã§ã³ãé åã該ãªãã¶ã€ã äžã«çµã¿å ¥ããããšã«ãã£ãŠãç¹å®ã®ïŒ²ïŒ®ïŒ¡ãæšçãšãããããšãã§ããããã®ãã€ããªãã€ãŒãŒã·ã§ã³é åã¯æšçã«å¯Ÿãçžè£çãªé åãå«ãã§ããããããã£ãŠãã®æšçãšç¹ç°çã«ãã€ããªãã€ãºãããïŒïŒµïŒïŒ²ïŒ®ïŒ¡æšçå éšã®ç¹ç°çãªãã¶ã€ã éè£éšäœã¯ããã®æšçååãã以äžã®é åïŒïŒ§ïŒµïŒ¡ããããã³ïŒ§ïŒµïŒ£ãå å«ãããªãã¶ã€ã éè£éšäœã«ã€ããŠã¹ãã£ã³ããããšã«ããåå®ã§ãããåå®ã§ãããªãã°ã該éè£éšäœãå«ãæšçã®é åã«å¯Ÿå¿ãããïŒïŒããã³ïŒïŒã®éã®ãªããã¯ã¬ãªãããæããçãé åããæšçãéæ©èœçã«ãåŸãäºæ¬¡æ§é ã®ç¹åŸŽã«ã€ããŠè©äŸ¡ã§ãããããã«ãåè£ã®ïŒ®ïŒïŒµïŒïŒ²ïŒ®ïŒ¡æšçã®é©åæ§ãããªããã¯ã¬ã¢ãŒãŒé²è·æ€å®ãçšããŠçžè£çãªãªãŽãã¯ã¬ãªãããšã®ãã€ããªãã€ãŒãŒã·ã§ã³ã«å¯Ÿããå©çšå¯èœæ§ãè©Šéšããããšã«ãã£ãŠè©äŸ¡ã§ãããé åçªå·ïŒã«ç€ºããã¯ã¬ãªããé åããã³ãããã®çžè£ç©ã¯ãé©åœãªãã€ããªãã€ãŒãŒã·ã§ã³é åé åã®äŸçµŠæºãæäŸãããããé·ãçžè£é åãçšããŠãæšçã«å¯Ÿãããã€ããªãã€ãŒãŒã·ã§ã³é åã®èŠªåæ§ãå¢å€§ãããããšãã§ããããªãã¶ã€ã ã®ãã€ããªãã€ãºããã³éè£ããé åã¯ãçžè£é åãä»ããŠæšçã«ãã€ããªãã€ãºããæããªãã¶ã€ã ã®è§Šåªé åãæšçãéè£ãåŸããšãã£ãããã«ãå®å šã«çžé¢ããŠããã
ãªãã¶ã€ã ã¯ïŒ€ïŒ®ïŒ¡çµã¿ç«ãŠç©ã®äžéšãšããŠçŽ°èå
ã«å°å
¥ã§ããããã€ã¯ã泚å
¥ããªããœãŒã 仲ä»ãã©ã³ã¹ãã§ã¯ã·ã§ã³ãé»æ°ç©¿åããŸãã¯çé
žã«ã«ã·ãŠã æ²æ®¿ãšãã£ãæ©æ¢°çæ¹æ³ãçšããŠãïŒïŒµïŒçºçŸã®äœäžãæãŸãã现èäžã«ãªãã¶ã€ã å«æçµã¿ç«ãŠç©ãå°å
¥ããããšãã§ããããããšã¯å¥ã«ã现èãçµã¿ç«ãŠç©ãå®å®çã«ä¿æããããšãæãŸããå Žåã¯ã該çµã¿ç«ãŠç©ããã©ã¹ããäžã§äŸçµŠããåœåéã§ç¥ãããããã«ãå¥åã®èŠçŽ ãšããŠç¶æãããããŸãã¯çŽ°èã®ã²ãã äžã«çµã¿èŸŒãããšãã§ããããªãã¶ã€ã ã³ãŒãåçµã¿ç«ãŠç©ã¯ã现èäžã®ãªãã¶ã€ã ã®è»¢åã調ç¯ããããã«ãããã¢ãŒã¿ãŒèŠçŽ ããšã³ãã³ãµãŒãŸãã¯ïŒµïŒ¡ïŒ³èŠçŽ ãããã³è»¢åã¿ãŒãããŒã¿ãŒã·ã°ãã«ãšãã£ã転å調ç¯èŠçŽ ãå«ã¿åŸãïŒç±³åœç¹èš±ïŒïŒïŒïŒïŒïŒïŒïŒããªãã¶ã€ã ã¯ãŸããè¿œå ã¬ãã«ã®èª¿ç¯ãæäŸããããèšèšã§ãããã®çµæãïœïŒ²ïŒ®ïŒ¡ã®ç Žå£ã¯ãªãã¶ã€ã ãšæšçéºäŒåã®äž¡è
ã现èã«èªå°ãããæã«ã®ã¿èµ·ããã
ã¹ã¯ãªãŒãã³ã°ïŒã¹ã¯ãªãŒãã³ã°ã¢ãã»ã€
調ç¯ç©è³ª
æ¬æ现æžã«ãããŠçšãããã調ç¯ç©è³ªã¯ãin vivoãŸã㯠in vitroã§ïŒ®ïŒïŒµïŒã®æŽ»æ§ã«åœ±é¿ãåãŒãååç©ãæå³ããã調ç¯ç©è³ªã¯ãïŒïŒµïŒããªããããã®ã¢ãŽãã¹ããŸãã¯ã¢ã³ã¿ãŽãã¹ãã§ãããçºçŸãä»ããŠã翻蚳åŸä¿®é£Ÿãä»ããŠãŸãã¯ãã®ä»ã®æ段ã«ãã£ãŠïŒ®ïŒïŒµïŒæŽ»æ§ã«å¯Ÿãããã®åœ±é¿ãçºæ®ããååç©ã§ãããïŒïŒµïŒã®ã¢ãŽãã¹ãã¯ãïŒïŒµïŒã«çµåãããšãã«ïŒ®ïŒïŒµïŒã®æŽ»æ§ãå¢å€§ãŸãã¯é·åŒãããååã§ãããïŒïŒµïŒã®ã¢ãŽãã¹ããšããŠã¯ãã¿ã³ãã¯è³ªãæ žé žãçåæ°ŽçŽ ãå°ååãŸãã¯ïŒ®ïŒïŒµïŒã掻æ§åããä»»æã®ä»ã®ååãæãããããïŒïŒµïŒã®ã¢ã³ã¿ãŽãã¹ãã¯ãïŒïŒµïŒãšçµåãããšãã«ãïŒïŒµïŒã®æŽ»æ§ã®éãŸãã¯æç¶ãæžå°ãããååã§ãããã¢ã³ã¿ãŽãã¹ããšããŠã¯ãã¿ã³ãã¯è³ªãæ žé žãçåæ°ŽçŽ ãæäœãå°ååãŸãã¯ïŒ®ïŒïŒµïŒã®æŽ»æ§ãæžå°ãããä»»æã®ä»ã®ååãæããããã
調ç¯ç©è³ª
æ¬æ现æžã«ãããŠçšãããã調ç¯ç©è³ªã¯ãin vivoãŸã㯠in vitroã§ïŒ®ïŒïŒµïŒã®æŽ»æ§ã«åœ±é¿ãåãŒãååç©ãæå³ããã調ç¯ç©è³ªã¯ãïŒïŒµïŒããªããããã®ã¢ãŽãã¹ããŸãã¯ã¢ã³ã¿ãŽãã¹ãã§ãããçºçŸãä»ããŠã翻蚳åŸä¿®é£Ÿãä»ããŠãŸãã¯ãã®ä»ã®æ段ã«ãã£ãŠïŒ®ïŒïŒµïŒæŽ»æ§ã«å¯Ÿãããã®åœ±é¿ãçºæ®ããååç©ã§ãããïŒïŒµïŒã®ã¢ãŽãã¹ãã¯ãïŒïŒµïŒã«çµåãããšãã«ïŒ®ïŒïŒµïŒã®æŽ»æ§ãå¢å€§ãŸãã¯é·åŒãããååã§ãããïŒïŒµïŒã®ã¢ãŽãã¹ããšããŠã¯ãã¿ã³ãã¯è³ªãæ žé žãçåæ°ŽçŽ ãå°ååãŸãã¯ïŒ®ïŒïŒµïŒã掻æ§åããä»»æã®ä»ã®ååãæãããããïŒïŒµïŒã®ã¢ã³ã¿ãŽãã¹ãã¯ãïŒïŒµïŒãšçµåãããšãã«ãïŒïŒµïŒã®æŽ»æ§ã®éãŸãã¯æç¶ãæžå°ãããååã§ãããã¢ã³ã¿ãŽãã¹ããšããŠã¯ãã¿ã³ãã¯è³ªãæ žé žãçåæ°ŽçŽ ãæäœãå°ååãŸãã¯ïŒ®ïŒïŒµïŒã®æŽ»æ§ãæžå°ãããä»»æã®ä»ã®ååãæããããã
çšèªã調ç¯ãã¯ãæ¬æ现æžã«ç€ºãããããã«ãïŒïŒµïŒã®æŽ»æ§ã®å€åãæå³ãããäŸãã°ã調ç¯ã«ãã£ãŠãïŒïŒµïŒã®ã¿ã³ãã¯è³ªæŽ»æ§ãçµåç¹æ§ãŸãã¯ä»»æã®ä»ã®çç©åŠçãæ©èœçãŸãã¯å
ç«åŠçç¹æ§ã®å¢å€§ãŸãã¯æžå°ãåŒãèµ·ããããã
æ¬æ现æžã«ãããŠçšããããŠãããšãããçšèªãç¹ç°çãªçµåããŸãã¯ãç¹ç°çã«çµåãããã¯ãã¿ã³ãã¯è³ªãŸãã¯ãããããšã¢ãŽãã¹ããæäœãŸãã¯ã¢ã³ã¿ãŽãã¹ããšã®éã®çžäºäœçšãæå³ãããæ¬çºæã¯ãçµåããååã«ãã£ãŠèªèãããã¿ã³ãã¯è³ªã®ç¹å®ã®æ§é ïŒå³ã¡ãæå決å®åºãŸãã¯ãšãããŒãïŒã®ååšã«äŸåãããäŸãã°ãæäœããšãããŒãã«ç¹ç°çã§ããå ŽåãããªãŒã®æšèããããšæäœãå«ãåå¿ç©ã«ãããããšãããŒããå«ãããªããããã®ååšãŸãã¯ããªãŒã®æšèãããã®ååšã¯ãæäœãšçµåããæšèãããã®éãæžå°ããã§ãããã
æ¬çºæã¯ãè¡æ¶²çŸæ£ããã³å¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ããåæ¯ãçæ®æ³å°¿ç³»ã®çŸæ£ããã³ççæ§çŸæ£ã®åŠçœ®ã«äœ¿çšããããšãã§ããååç©ãåå®ããããã®æ¹æ³ïŒæ¬æ现æžã§ã¯ãã¹ã¯ãªãŒãã³ã°ã¢ãã»ã€ããšãããïŒãæäŸãããæ¬æ¹æ³ã¯ãïŒïŒµïŒã«çµåãããããã³ïŒãŸãã¯ïŒ®ïŒïŒµïŒã®çç©åŠç掻æ§ãŸãã¯ãã®çºçŸã«å¯ŸããŠåºæ¿ãŸãã¯é»å®³å¹æãæããåè£ååç©ãŸãã¯è©Šéšååç©ãŸãã¯è©Šè¬ïŒäŸãã°ããããããããããæš¡æ¬ç©ãå°ååããŸãã¯ä»ã®ååïŒãåå®ãã次ãã§ãè¡æ¶²çŸæ£ããã³å¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ããåæ¯ãçæ®æ³å°¿ç³»ã®çŸæ£ããã³ççæ§çŸæ£ã«é¢ããçç¶ãŸãã¯é害ã«å¯ŸããŠå¹æãæããååç©ã®çºçŸã枬å®ããããšãå¿
èŠãšããã
ïŒïŒµïŒã«çµåãããããã³ïŒãŸãã¯ïŒ®ïŒïŒµïŒã®æŽ»æ§ãŸãã¯çºçŸã«å¯ŸããŠåºæ¿ãŸãã¯é»å®³å¹æãæãããåè£ãŸãã¯è©Šéšååç©ãŸãã¯è©Šè¬ã¯ã现èè¡šé¢ã«ïŒ®ïŒïŒµïŒãçºçŸãã现èãçšããã¢ãã»ã€ïŒçŽ°èããŒã¹ã®ã¢ãã»ã€ïŒãããŸãã¯åé¢ãããïŒïŒµïŒãçšããã¢ãã»ã€ïŒçŽ°èäžå«ã¢ãã»ã€ïŒã®ããããã«ãããŠåå®ãããæ§ã
ãªã¢ãã»ã€ã«ã¯æ§ã
ãªïŒ®ïŒïŒµïŒã®å€ç°äœïŒäŸãã°ãå®å
šé·ã®ïŒ®ïŒïŒµïŒãïŒïŒµïŒã®çç©åŠçã«æŽ»æ§ãªæçãŸãã¯ïŒ®ïŒïŒµïŒã®å
šéšãŸãã¯äžéšåãå«ãèåã¿ã³ãã¯è³ªïŒãçšããããšãã§ãããããã«ãïŒïŒµïŒã¯ãä»»æã®é©åœãªåºä¹³é¡ïŒäŸãã°ãããïŒïŒµïŒãã©ããïŒïŒµïŒãŸãã¯ããŠã¹ïŒ®ïŒïŒµïŒïŒã«ç±æ¥ãåŸããã¢ãã»ã€ã¯ãè©Šéšååç©ãŸãã¯ïŒ®ïŒïŒµïŒã«å¯Ÿããæ¢ç¥ã®ïŒ®ïŒïŒµïŒãªã¬ã³ãã®çµåã®éæ¥çãŸãã¯çŽæ¥çãªæž¬å®ã䌎ãçµåã¢ãã»ã€ã§ãã£ãŠãããã¢ãã»ã€ã¯ãŸããïŒïŒµïŒã®æŽ»æ§ã®çŽæ¥çãŸãã¯éæ¥ç枬å®ã䌎ã掻æ§åæã§ããåŸãããã®ã¢ãã»ã€ã¯ãŸããïŒïŒµïŒïœïŒ²ïŒ®ïŒ¡ãŸãã¯ïŒ®ïŒïŒµïŒã¿ã³ãã¯è³ªã®çºçŸã®çŽæ¥çãŸãã¯éæ¥ç枬å®ã䌎ãçºçŸã¢ãã»ã€ã§ããåŸããæ§ã
ãªã¹ã¯ãªãŒãã³ã°ã¢ãã»ã€ããè¡æ¶²çŸæ£ããã³å¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ããåæ¯ãçæ®æ³å°¿ç³»ã®çŸæ£ããã³ççæ§çŸæ£ã®çç¶ã«å¯Ÿããè©Šéšååç©ã®å¹æã®æž¬å®ã䌎ãin vivoã¢ãã»ã€ãšçµã¿åãããã
ïŒã€ã®æ
æ§ã§ã¯ãæ¬çºæã¯ãïŒïŒµïŒã®èã«çµåããïŒçŽ°èè¡šé¢ã§çºçŸããïŒåœ¢æ
ã«çµåãŸãã¯ãã®æŽ»æ§ã調ç¯ããåè£ååç©ãŸãã¯è©Šéšååç©ãã¹ã¯ãªãŒãã³ã°ããããã®ã¢ãã»ã€ãæäŸããããã®ãããªã¢ãã»ã€ã¯ãå®å
šé·ã®ïŒ®ïŒïŒµïŒãïŒïŒµïŒã®çç©åŠçã«æŽ»æ§ãªæçãŸãã¯ïŒ®ïŒïŒµïŒã®å
šéšãŸãã¯äžéšåãå«ãèåã¿ã³ãã¯è³ªãçšããããšãã§ããã以äžã«ãã詳现ã«èšèŒããããã«ãè©Šéšååç©ãä»»æã®é©åœãªæ段ã«ãã£ãŠãäŸãã°ãæ
£çšã®ååç©ã©ã€ãã©ãªãŒããåŸãããšãã§ãããïŒïŒµïŒã®èçµå圢æ
ã«çµåããè©Šéšååç©ã®èœåã®æž¬å®ã¯ãäŸãã°ãäŸãã°ãè©Šéšååç©ãšïŒ®ïŒïŒµïŒãçºçŸããŠãã现èãšã®çµåããè€åäœã«ãããæšèååç©ã®æ€åºã«ãã£ãŠæž¬å®ããããšãã§ããããã«ãæŸå°éé
å
çŽ ãŸãã¯é
µçŽ æšèãšãã«ãããªã³ã°ãããããšã«ããè¡ãããšãã§ãããäŸãã°ãè©Šéšååç©ãã125ã35ã14ãŸãã¯3ã§ãçŽæ¥çãŸãã¯éæ¥çã«æšèããæŸå°èœæŸå°ã®çŽæ¥çèšæž¬ã«ããããŸãã¯ã·ã³ãã¬ãŒã·ã§ã³èšæž¬ã«ããæŸå°æ§åäœå
çŽ ãæ€åºããããšãã§ããããããã¯ãè©Šéšååç©ããäŸãã°ããŒã¹ã©ãã£ãã·ã¥ã»ãã«ãªãã·ããŒãŒãã¢ã«ã«ãªãã¹ãã¡ã¿ãŒãŒããŸãã¯ã«ã·ãã§ã©ãŒãŒã§é
µçŽ çã«æšèããé
µçŽ æšèãé©åœãªåºè³ªã®çæç©ãžã®å€æã枬å®ããããšã«ããæ€åºããããšãã§ããã
競åçµåæ¹åŒã§ã¯ãã¢ãã»ã€ã¯ãïŒïŒµïŒãçºçŸããŠãã现èããïŒïŒµïŒã«çµåãåææ··åç©ã圢æããæ¢ç¥ã®ååç©ã«æ¥è§Šããããã®åææ··åç©ãè©Šéšååç©ãšæ¥è§ŠãããŠãè©Šéšååç©ãïŒïŒµïŒãçºçŸããŠãã现èãšçžäºäœçšããèœåã枬å®ããããšãå«ã¿ãããã§ãïŒïŒµïŒãçºçŸããŠãã现èãšçžäºäœçšããèœåã®æž¬å®ã¯ãïŒïŒµïŒãçºçŸããŠãã现èã«åªå
çã«çµåããè©Šéšååç©ã®æ¢ç¥ã®ååç©ãšæ¯èŒããèœåã枬å®ããããšãå«ãã
ãããªãæ
æ§ã§ã¯ãã¢ãã»ã€ã¯ã现èè¡šé¢ã«çºçŸããïŒïŒµïŒã®èçµå圢æ
ïŒäŸãã°ãå®å
šé·ïŒ®ïŒïŒµïŒãïŒïŒµïŒã®çç©åŠçã«æŽ»æ§ãªæçãŸãã¯ïŒ®ïŒïŒµïŒã®å
šéšãŸãã¯äžéšåãå«ãèåã¿ã³ãã¯è³ªïŒãçºçŸããŠãã现èãè©Šéšååç©ãšæ¥è§Šãããããšãããã³ïŒ®ïŒïŒµïŒã®èçµå圢æ
ã®æŽ»æ§ãã調ç¯ããïŒäŸãã°ãåºæ¿ãŸãã¯é»å®³ããïŒè©Šéšååç©ã®èœåã枬å®ããããšãå«ãã现èããŒã¹ã®ã¢ãã»ã€ã§ãããïŒïŒµïŒã®èçµå圢æ
ã®æŽ»æ§ã調ç¯ããè©Šéšååç©ã®èœåã®æž¬å®ã¯ãïŒïŒµïŒã®æŽ»æ§ã枬å®ããã®ã«é©åœãªæ¹æ³ãäŸãã°ïŒ§ã¿ã³ãã¯è³ªå
±åœ¹å容äœãŸãã¯ä»ã®ïŒåè貫éåå容äœã®æŽ»æ§ã®æž¬å®ã«ãŠé©åœãªä»»æã®æ¹æ³ïŒä»¥äžã«ãã詳现ã«èšèŒïŒã«ãã£ãŠè¡ãããšãã§ãããïŒåè貫éåå容äœã¯ãæ°å€ãã®æ¹æ³ïŒä»»æã®äžããããå容äœã«é©åœãªæ¹æ³ããããã®ãã¹ãŠã§ã¯ãªãïŒã«ãã£ãŠæž¬å®ããããšãã§ããã掻æ§ã®æž¬å®ã®ãªãã«ã¯ä»¥äžã®ãã®ãããïŒçŽ°èå
ïœ2+æ¿åºŠã®å€åããã¹ããªããŒãŒïŒ£ã®æŽ»æ§åã现èå
ã€ãã·ããŒã«äžãªã³é
žïŒïŒ©ïŒ°3ïŒæ¿åºŠã®å€åã现èå
ãžã¢ã·ã«ã°ãªã»ããŒã«ïŒïŒ€ïŒ¡ïŒ§ïŒæ¿åºŠã®å€åãããã³çŽ°èå
ã¢ããã·ã³ãµã€ã¯ãªãã¯ïŒâãïŒââäžãªã³é
žïŒïœïŒ¡ïŒïŒ°ïŒæ¿åºŠã®å€åã
ïŒïŒµïŒã®æŽ»æ§ã調ç¯ããè©Šéšååç©ã®èœåã®æž¬å®ã¯ãäŸãã°ãæšçååã«çµåãŸãã¯çžäºäœçšããïŒïŒµïŒã®èœåã枬å®ããããšã«ãã£ãŠè¡ãããšãã§ãããæšçååã¯ãïŒïŒµïŒãçŸå®ã«çµåãããŸãã¯çžäºäœçšããååãäŸãã°ãïŒïŒµïŒãçºçŸããŠãã现èã®è¡šé¢äžã®ååã第ïŒã®çŽ°èã®è¡šé¢äžã®ååã现èå€ã®ç°å¢ã®ååã现èèã®å
éšè¡šé¢ã«äŒåããŠããååãŸãã¯çŽ°è質ã®ååã§ããåŸããæšçååã¯çŽ°èå€ã·ã°ãã«ïŒäŸãã°ãïŒïŒµïŒãªã¬ã³ãã®çµåã«ãã£ãŠçãã现èèãä»ãã现èãžã®ã·ã°ãã«ïŒã®äŒéãå©é·ããã·ã°ãã«äŒéçµè·¯ãæ§æãããã®ã§ãã£ãŠãããæšçååã¯ãäŸãã°ã觊åªæŽ»æ§ãæãã第ïŒã®çŽ°èå
ã¿ã³ãã¯è³ªãŸãã¯äžæµã®ã·ã°ãã«äŒéååãšïŒ®ïŒïŒµïŒãšã®äŒåãä¿é²ããã¿ã³ãã¯è³ªã§ãã£ãŠããã
æšçååãšçµåãŸãã¯çžäºäœçšããïŒïŒµïŒã®èœåã®æž¬å®ã¯ãçŽæ¥çãªçµåã«ã€ããŠäžèšããæ¹æ³ã®ïŒã€ã«ãã£ãŠè¡ãããšãã§ãããïŒã€ã®æ
æ§ã§ã¯ãæšçååãšçµåãããŸãã¯çžäºäœçšããæ¬çºæã®ããªããããã®èœåã®æž¬å®ã¯æšçååã®æŽ»æ§ã枬å®ããããšã«ãã£ãŠè¡ãããšãã§ãããäŸãã°ãæšçååã®æŽ»æ§ã¯ãæšçã®çŽ°èã®ç¬¬ïŒã®ã¡ãã»ã³ãžã£ãŒïŒäŸãã°ã现èå
ïœ2+ããžã¢ã·ã«ã°ãªã»ããŒã«ã3ãªã©ïŒã®èªå°ãæ€åºããããšãé©åœãªåºè³ªã«å¯Ÿããæšçã®è§ŠåªïŒé
µçŽ 掻æ§ãæ€åºããããšãã¬ããŒã¿ãŒéºäŒåïŒäŸãã°ãæ€åºå¯èœãªããŒã«ãŒäŸãã°ã«ã·ãã§ã©ãŒãŒãã³ãŒãããæ žé
žã«äœåå¯èœãªæ§ã«é£çµããæ¬çºæã®ããªããããã«å¿çãã調ç¯ãšã¬ã¡ã³ãïŒã®èªå°ãæ€åºããããšããŸãã¯çŽ°èã®å¿çãæ€åºããããšã«ãã£ãŠæž¬å®ããããšãã§ããã
æ¬çºæã¯ãããã«çŽ°èäžå«ã®ã¢ãã»ã€ãå«ãããã®ãããªã¢ãã»ã€ã¯ãïŒïŒµïŒã®åœ¢æ
ã®ïŒäŸãã°ãå®å
šé·ã®ïŒ®ïŒïŒµïŒãçç©åŠçã«æŽ»æ§ãªïŒ®ïŒïŒµïŒã®æçãŸãã¯ïŒ®ïŒïŒµïŒã®ãã¹ãŠãŸãã¯äžéšãå«ãèåã¿ã³ãã¯è³ªïŒãšè©Šéšååç©ãšã®æ¥è§Šãããã³ïŒ®ïŒïŒµïŒã«çµåããè©Šéšååç©ã®èœåã®æž¬å®ã䌎ããïŒïŒµïŒã«å¯Ÿããè©Šéšååç©ã®çµåã¯ãäžèšã®ããã«çŽæ¥çãŸãã¯éæ¥çã«æž¬å®ããããšãã§ãããïŒã€ã®æ
æ§ã§ã¯ãã¢ãã»ã€ã¯ãïŒïŒµïŒãšïŒ®ïŒïŒµïŒã«çµåããæ¢ç¥ã®ååç©ãšæ¥è§ŠãããŠã¢ãã»ã€æ··åç©ã圢æããã¢ãã»ã€æ··åç©ãè©Šéšååç©ãšæ¥è§Šãããããã³ïŒ®ïŒïŒµïŒãšçžäºäœçšããè©Šéšååç©ã®èœåã®æž¬å®ããããšãå«ã¿ãïŒïŒµïŒãšçžäºäœçšããè©Šéšååç©ã®èœåã®æž¬å®ã¯ãæ¢ç¥ã®ååç©ãšæ¯èŒããŠãïŒïŒµïŒã«åªå
çã«çµåããè©Šéšååç©ã®èœåã枬å®ããããšãå«ãã
æ¬çºæã®çŽ°èäžå«ã¢ãã»ã€ã¯ãïŒïŒµïŒã®èçµå圢æ
ãçšããããŸãã¯å¯æº¶æ§ã®æçãçšãããã«åœ±é¿ãåãããããããªããããã®èçµå圢æ
ãçšãã现èäžå«ã¢ãã»ã€ã§ã¯ãå¯æº¶åå€ãçšããŠãããªããããã®èçµå圢æ
ã溶液äžã«ç¶æããããšãæãŸããã§ãããããã®ãããªå¯æº¶åå€ã®äŸãšããŠã¯ãéã€ãªã³çé¢æŽ»æ§å€ãäŸãã°ïœâãªã¯ãã«ã°ã«ã³ã·ããïœâããã·ã«ã°ã«ã³ã·ããïœâããã·ã«ãã«ãã·ãããªã¯ã¿ãã€ã«ââã¡ãã«ã°ã«ã«ããããã«ãã€ã«ââã¡ãã«ã°ã«ã«ãããTritonX-100ãTritonX-114ãThesitãã€ãœããªãã·ããªïŒãšãã¬ã³ã°ãªã³ãŒã«ãšãŒãã«ïŒïœãïŒâïŒïŒâã³ã©ãããããã«ïŒãžã¡ãã«ã¢ããâïŒâãããã³ã¹ã«ãããŒãïŒïŒ£ïŒšïŒ¡ïŒ°ïŒ³ïŒãïŒâïŒïŒâã³ã©ãããããã«ïŒãžã¡ãã«ã¢ããâïŒâããããã·âïŒâãããã³ã¹ã«ãããŒãïŒïŒ£ïŒšïŒ¡ïŒ°ïŒ³ïŒ¯ïŒããŸãã¯ïŒ®âããã·ã«ïŒïŒ®ãâãžã¡ãã«âïŒâã¢ã³ã¢ããªâïŒâãããã³ã¹ã«ãããŒããæããããã
æ¬çºæã®äžèšã¢ãã»ã€æ³ã®æ§ã
ãªæ
æ§ã§ã¯ãïŒïŒµïŒïŒãŸãã¯ïŒ®ïŒïŒµïŒæšçååïŒãåºå®åããŠãïŒã€ã®ãŸãã¯äž¡æ¹ã®ã¿ã³ãã¯è³ªã®ãè€åäœã圢æããŠããªã圢æ
ããã®è€åäœã®åé¢ã容æã«ãã䞊ã³ã«ãã®ã¢ãã»ã€ãèªååã«é©å¿ãããããšãæãŸããã§ããããåè£ååç©ã®ååšäžããã³éååšäžã§ã®ïŒ®ïŒïŒµïŒã«å¯Ÿããè©Šéšååç©ã®çµåãïŒïŒµïŒãšæšçååãšã®çžäºäœçšã¯ãè©Šè¬ãå
¥ããã®ã«é©åœãªä»»æã®å®¹åšå
ã§è¡ãããšãã§ããããã®ãããªå®¹åšã®äŸãšããŠã¯ããã€ã¯ãã¿ã€ã¿ãŒãã¬ãŒããè©Šéšç®¡ããã³ãã€ã¯ãé å¿ãã¥ãŒããæãããããïŒã€ã®æ
æ§ã§ã¯ãèåã¿ã³ãã¯è³ªã¯ãäžæ¹ãŸãã¯äž¡æ¹ã®ã¿ã³ãã¯è³ªããããªãã¯ã¹ã«çµåããããšãå¯èœãªãã¡ã€ã³ãä»å ããŠæäŸããããäŸãã°ãã°ã«ã¿ããªã³ââãã©ã³ã¹ãã§ã©ãŒãŒïŒïŒ§ïŒ³ïŒŽïŒèåã¿ã³ãã¯è³ªãŸãã¯ã°ã«ã¿ããªã³ââãã©ã³ã¹ãã§ã©ãŒãŒèåã¿ã³ãã¯è³ªãã°ã«ã¿ããªã³ã»ãã¡ããŒã¹ããŒãºïŒSigma Chemical; St. Louis, Mo.)ãŸãã¯ã°ã«ã¿ããªã³èªå°ãã€ã¯ãã¿ã€ã¿ãŒãã¬ãŒãäžã«åžçãããåŸããããè©Šéšååç©ããŸãã¯è©Šéšååç©ããã³åžçãããŠããªãæšçã¿ã³ãã¯è³ªãŸãã¯ïŒ®ïŒïŒµïŒã®ãããããšæ··åãããã®æ··åç©ãè€åäœåœ¢æãåŒãèµ·ããæ¡ä»¶äžïŒäŸãã°ãå¡©ããã³ïœïŒšã«ã€ããŠã®ççåŠçæ¡ä»¶ïŒã§ã€ã³ãã¥ããŒã·ã§ã³ãããããšãã§ãããã€ã³ãã¥ããŒã·ã§ã³ããåŸãããŒãºãŸãã¯ãã€ã¯ãã¿ã€ã¿ãŒãã¬ãŒãã®ãŠã§ã«ãæŽæµããŠãçµåããªãã£ãæåãé€å»ããè€åäœåœ¢æãçŽæ¥çãŸãã¯éæ¥çã«ãäŸãã°äžèšã®ããã«æž¬å®ããããããã¯ãè€åäœããããªãã¯ã¹ãã解é¢ãããçµåã®ã¬ãã«ãŸãã¯ïŒ®ïŒïŒµïŒã®æŽ»æ§ãæšæºçãªæè¡ãçšããŠæž¬å®ããããšãã§ããã
ã¿ã³ãã¯è³ªããããªãã¯ã¹äžã«åºå®åãããã®ä»ã®æè¡ãæ¬çºæã®ã¹ã¯ãªãŒãã³ã°ã¢ãã»ã€ã«çšããããšãã§ãããäŸãã°ãïŒïŒµïŒãŸãã¯ãã®æšçååã®ãããããããªãã³ããã³ã¹ãã¬ãã¿ããžã³ã®ã³ã³ãžã¥ã²ãŒã·ã§ã³ãçšããŠåºå®åããããšãã§ãããæ¬çºæã®ããªãã³åãããããªãããããŸãã¯æšçååã¯ãåœåéã«åšç¥ã®æè¡ãçšããŠããªãã³âïŒïŒ®âããããã·âãµã¯ã·ã³ã€ããïŒãã調補ããããšãã§ãïŒäŸãã°ãããªããã«åããããPierce Chemicals; Rockford, 111.ïŒãã¹ãã¬ãã¿ããžã³ãã³ãŒãã£ã³ã°ãããã¬ãŒãïŒPierce ChemicalïŒã®ãŠã§ã«ã«ãããŠåºå®åããããšãã§ããããããã¯ãïŒïŒµïŒãŸãã¯æšçååãšåå¿ããããæ¬çºæã®ããªãããããšãã®æšçååãšã®çµåã«å¹²æžããªãæäœããã¬ãŒãã®ãŠã§ã«ã«èªå°ããçµåããªãã£ãæšçãŸãã¯æ¬çºæã®ããªãããããæäœçµåã«ãã£ãŠãŠã§ã«ã«ãããŠãã©ããããããšãã§ãããåºå®åè€åäœã«ã€ããŠäžèšããæ¹æ³ã«å ããŠããã®ãããªè€åäœãæ€åºããæ¹æ³ãšããŠã¯ãïŒïŒµïŒãŸãã¯æšçååãšåå¿ããæäœãçšããè€åäœã®å
ç«æ€åºã䞊ã³ã«ïŒ®ïŒïŒµïŒãŸãã¯æšçååã«é¢é£ããé
µçŽ 掻æ§ãæ€åºããããšã«ããé
µçŽ çµåã¢ãã»ã€ãæããããã
ã¹ã¯ãªãŒãã³ã°ã¢ãã»ã€ã¯ãŸããïŒïŒµïŒã®çºçŸã®ã¢ãã¿ãªã³ã°ã䌎ããäŸãã°ãïŒïŒµïŒã®çºçŸã®èª¿ç¯ç©è³ªãã现èãåè£ååç©ãšæ¥è§ŠãããïŒïŒµïŒã¿ã³ãã¯è³ªãŸãã¯çŽ°èå
ã®ïœïŒ²ïŒ®ïŒ¡ã枬å®ããæ¹æ³ã«ãããŠåå®ããããšãã§ãããåè£ååç©ååšäžã§ã®ïŒ®ïŒïŒµïŒã¿ã³ãã¯è³ªãŸãã¯ïœïŒ²ïŒ®ïŒ¡ã®çºçŸã®ã¬ãã«ããåè£ååç©éååšäžã§ã®ïŒ®ïŒïŒµïŒã¿ã³ãã¯è³ªãŸãã¯ïœïŒ²ïŒ®ïŒ¡ã®çºçŸã®ã¬ãã«ãšæ¯èŒããã次ãã§ããã®æ¯èŒã«åºã¥ããåè£ååç©ãïŒïŒµïŒã®çºçŸã®èª¿ç¯ç©è³ªãšããŠåå®ããããšãã§ãããäŸãã°ãåè£ååç©ã®ååšäžã§éååšäžãããïŒïŒµïŒã¿ã³ãã¯è³ªãŸãã¯ïœïŒ²ïŒ®ïŒ¡ã®çºçŸããã倧ããïŒå®è³ªçã«ææã«å€§ããïŒå Žåãåè£ååç©ãïŒïŒµïŒã¿ã³ãã¯è³ªãŸãã¯ïœïŒ²ïŒ®ïŒ¡çºçŸã®åºæ¿ç©è³ªãšããŠåå®ããããããã¯ãåè£ååç©ã®ååšäžã§éååšäžãããïŒïŒµïŒã¿ã³ãã¯è³ªãŸãã¯ïœïŒ²ïŒ®ïŒ¡ã®çºçŸãããå°ããïŒå®è³ªçã«ææã«å°ããïŒå Žåãåè£ååç©ãïŒïŒµïŒã¿ã³ãã¯è³ªãŸãã¯ïœïŒ²ïŒ®ïŒ¡çºçŸã®é»å®³ç©è³ªãšããŠåå®ããã现èã«ãããïŒïŒµïŒã¿ã³ãã¯è³ªãŸãã¯ïœïŒ²ïŒ®ïŒ¡çºçŸã®ã¬ãã«ãã以äžã«èšèŒã®æ¹æ³ã«ãã£ãŠæž¬å®ããããšãã§ããã
çµåæ€å®
çµåæ€å®ã«ã€ããŠã¯ã被éšååç©ã¯å¥œãŸããã¯ãïŒïŒµïŒã®æŽ»æ§éšäœã«çµåããŠãããå æããããã«ããåºè³ªããªã¬ã³ãçµåéšäœã«æ¥è¿ã§ããªãããããã®çµææ£åžžãªçç©æŽ»æ§ã劚ãããããããªå°ååã§ããããã®ãããªå°ååã®äŸã¯å°ãããããŸãã¯ããããæ§ååãå å«ãããããããã«éå®ãããèš³ã§ã¯ãªããæ¬çºæã«ä¿ãããªããããã«çµåããå¯èœæ§ãããªã¬ã³ãã¯ãæ¢ç¥ã®ïŒ®ïŒïŒµïŒã®å€©ç¶ãªã¬ã³ãããã³ãã®é¡äŒŒäœãŸãã¯èªå°äœãå å«ãããããããã«éå®ãããªãã
çµåæ€å®ã«ã€ããŠã¯ã被éšååç©ã¯å¥œãŸããã¯ãïŒïŒµïŒã®æŽ»æ§éšäœã«çµåããŠãããå æããããã«ããåºè³ªããªã¬ã³ãçµåéšäœã«æ¥è¿ã§ããªãããããã®çµææ£åžžãªçç©æŽ»æ§ã劚ãããããããªå°ååã§ããããã®ãããªå°ååã®äŸã¯å°ãããããŸãã¯ããããæ§ååãå å«ãããããããã«éå®ãããèš³ã§ã¯ãªããæ¬çºæã«ä¿ãããªããããã«çµåããå¯èœæ§ãããªã¬ã³ãã¯ãæ¢ç¥ã®ïŒ®ïŒïŒµïŒã®å€©ç¶ãªã¬ã³ãããã³ãã®é¡äŒŒäœãŸãã¯èªå°äœãå å«ãããããããã«éå®ãããªãã
çµåæ€å®ã§ã¯ã被éšååç©ãŸãã¯ïŒ®ïŒïŒµïŒã®ãããããæ€åºå¯èœãªæšèãäŸãã°èå
ãæŸå°æ§åäœå
çŽ ãååŠã«ããã»ã³ãããŸãã¯é
µçŽ æšèïŒäŸãã°è¥¿æŽã¯ãµããã«ãªãã·ããŒãŒãã¢ã«ã«ãªãã¹ãã¡ã¿ãŒãŒããŸãã¯ã«ã·ãã§ã©ãŒãŒïŒãå«ãããšãã§ãããããã§ãïŒïŒµïŒã«çµåããŠãã被éšååç©ã®æ€åºã¯ãäŸãã°æŸå°èœã®æŸåºãçŽæ¥èšæ°ããããšã«ããããŸãã¯ã·ã³ãã¬ãŒã·ã§ã³èšæ°ã«ããããŸãã¯æ€åºå¯èœç£ç©ãžã®é©åœãªåºè³ªã®å€æã枬å®ããããšã«ãããéæã§ãããå¥æ³ãšããŠãïŒïŒµïŒãžã®è¢«éšååç©ã®çµåããåå¿äœã®ãããããæšèããã«æž¬å®ããããšãã§ãããäŸãã°ããã€ã¯ããã£ãžãªã¡ãŒã¿ãŒãçšããŠã被éšååç©ãšïŒ®ïŒïŒµïŒãšã®çµåãæ€åºã§ããããã€ã¯ããã£ãžãªã¡ãŒã¿ãŒïŒäŸãã°ãµã€ãã»ã³ãµãŒïŒãšã¯ã现èããã®ç°å¢ãé
žæ§åããé床ãå
ã¢ãã¬ããµãã«é»äœå·®ã»ã³ãµãŒïŒïŒ¬ïŒ¡ïŒ°ïŒ³ïŒãçšããŠæž¬å®ããåææ©åšã§ããããã®é
žæ§åé床ã®å€åã¯ã被éšååç©ãšïŒ®ïŒïŒµïŒã®çžäºäœçšã®ææšãšããŠäœ¿çšã§ããHaseloff, (1988)]ã
被éšååç©ãïŒïŒµïŒã«çµåããèœåã®æž¬å®ã¯ãŸãããªã¢ã«ã¿ã€ã çç©ååçžäºäœçšè§£æïŒïŒ¢ïŒ©ïŒ¡ïŒã®ãããªæè¡ãçšããŠéæã§ãã[McConnell et al. (1992), Sjolander & Urbaniczky (1991)]ãã¯ããããªãåå¿äœããæšèããã«ãçäœç¹ç°ççžäºäœçšãå®æéã§ç 究ããããã®æè¡ã§ããïŒäŸãã°BIAcore(ç»é²åæš)ïŒãå
åŠççŸè±¡è¡šé¢ãã©ãºã¢ã³å
±é³ŽïŒïŒ³ïŒ°ïŒ²ïŒã®å€åããçäœååéã®å®æéåå¿ã®ææšã«äœ¿çšã§ããã
æ¬çºæã®ããã«å¥ã®æ
æ§ã§ã¯ãïŒïŒµïŒãäºãã€ããªããæ€å®ãŸãã¯äžãã€ããªããæ€å®ïŒäŸãã°ãSzabo et al., (1995); Zervos et al. (1993); Madura et al. (1993); Bartel et al. (1993)];ç±³åœç¹èš±ç¬¬5,283,317ïŒã«ããããããšãèçœããšããŠäœ¿çšããïŒïŒµïŒã«çµåãŸãã¯ãããšçžäºäœçšããŠãã®æŽ»æ§ã調ç¯ããä»ã®èçœãåå®ããããšãã§ããã
äºãã€ããªããç³»ã¯æ®ã©ã®è»¢åå åã®ã¢ãžã¥ãŒã«çæ§æ Œã«åºã¥ããã®ã§ãããããã¯ãåé¢å¯èœãªïŒ€ïŒ®ïŒ¡çµåããã³æŽ»æ§åãã¡ã€ã³ããæã£ãŠãããç°¡æœã«è¿°ã¹ããšããã®æ€å®ã¯äºçš®ã®ç°ãªãçµã¿ç«ãŠç©ãå©çšãããäŸãã°ãäžæ¹ã®çµã¿ç«ãŠç©ã«ãããŠã¯ãïŒïŒµïŒãã³ãŒãããŠããããªãã¯ã¬ãªããããæ¢ç¥ã®è»¢åå åã®ïŒ€ïŒ®ïŒ¡çµåãã¡ã€ã³ãã³ãŒãããŠããããªãã¯ã¬ãªããã«èåã§ããïŒäŸãã°ïŒ§ïŒ¡ïŒ¬âïŒïŒãå¥ã®çµã¿ç«ãŠç©ã«ãããŠã¯ãæªåå®èçœïŒãé€ããŸãã¯ãè©ŠæãïŒãã³ãŒãããŠããé
åããæ¢ç¥ã®è»¢åå åã®æŽ»æ§åãã¡ã€ã³ãã³ãŒãããŠããããªãã¯ã¬ãªããã«èåã§ããããããããšããããã³ãé€ãèçœãã€ã³ããã§çžäºäœçšããŠèçœäŸåè€åäœã圢æã§ãããªãã°ã該転åå åã®ïŒ€ïŒ®ïŒ¡çµåããã³æŽ»æ§åãã¡ã€ã³ã¯æ¥µããŠè¿äœã«ææ¥ãããããã®è¿äœæ§ãã転åå åã«å¿çãã転å調ç¯éšäœãšæ©èœçã«çµåããŠãããªããŒã¿ãŒéºäŒåïŒäŸãã°ïŒ¬ïœïœïŒºïŒã®è»¢åãå¯èœã«ããããªããŒã¿ãŒéºäŒåã®çºçŸãæ€åºã§ããæ©èœç転åå åãå«ã现èã³ãããŒãåé¢ããïŒïŒµïŒãšçžäºäœçšããèçœãã³ãŒãããŠããé
åååŸã«äœ¿çšããããšãã§ããã
åå¿äœã®äžæ¹ãŸãã¯äž¡æ¹ã®éçµååããã®çµååã®åé¢ãä¿é²ããããããããŠæ€å®ã®èªååã®äŸ¿å®ãå³ããããïŒïŒµïŒïŒãŸãã¯ããªãã¯ã¬ãªããïŒãŸãã¯è¢«éšååç©ã®ãããããåºå®åããããšãæãŸããããç¥ããªãããããã£ãŠãïŒïŒµïŒïŒãŸãã¯ããªãã¯ã¬ãªããïŒãŸãã¯è¢«éšååç©ã®ãããããåºäœæ¯æäœã«çµåãããããšãã§ããã奜é©ãªåºäœæ¯æäœã¯ãã¬ã©ã¹ãŸãã¯ãã©ã¹ããã¯ã¹ã©ã€ããçµç¹å¹é€ãã¬ãŒãã埮éå®éãŠã§ã«ã管ãã·ãªã³ã³ãããããŸãã¯ããŒãºïŒã©ããã¯ã¹ãããªã¹ãã¬ã³ããŸãã¯ã¬ã©ã¹ããŒãºãå
å«ããããããã«éå®ãããªãïŒã®ãããªç²åãå
å«ããããããã«éå®ãããªããå
±æããã³éå
±æçµåãåååžåããŸãã¯ããããããªããããïŒãŸãã¯ããªãã¯ã¬ãªããïŒãŸãã¯è¢«éšååç©ã«ä»çãããçµåéšåãšåºäœæ¯æäœã®å¯Ÿãã®äœ¿çšãå
å«ãããåœåéã§æ¢ç¥ã®ä»»æã®æ¹æ³ãçšããŠïŒ®ïŒïŒµïŒïŒãŸãã¯ããªãã¯ã¬ãªããïŒãŸãã¯è¢«éšååç©ãåºäœæ¯æäœã«ä»çãããããšãã§ããã被éšååç©ã¯å¥œãŸããã¯æŽåããŠåºäœæ¯æäœã«çµåããããã®çµæåã
ã®è¢«éšååç©ã®äœçœ®ã远跡ããããšãã§ãããïŒïŒµïŒïŒãŸãã¯ããªãã¯ã¬ãªããïŒãžã®è¢«éšååç©ã®çµåã¯ãåå¿äœãå
¥ããã®ã«é©ããä»»æã®å®¹åšã§éæã§ãããä¿ã容åšã®äŸã«ã¯åŸ®éå®éãã¬ãŒããè©Šéšç®¡ãããã³åŸ®éé æ²ç®¡ãããã
äžã€ã®æ
æ§ã«ãããŠãïŒïŒµïŒã¯ãïŒïŒµïŒãåºäœæ¯æäœã«çµåããããã¡ã€ã³ãå«ãèåèçœã§ãããäŸãã°ãã°ã«ã¿ããªã³ââãã©ã³ã¹ãã§ã©ãŒãŒèåèçœãã°ã«ã¿ããªã³ã»ãã¡ããŒã¹ããŒãºïŒSigma Chemical, St.Louis, Mo.ïŒäžãŸãã¯ã°ã«ã¿ããªã³èªå°äœå埮éå®éãã¬ãŒãäžã«åžçããã次ãã§ããã被éšååç©ãŸãã¯è¢«éšååç©ããã³éåžçïŒïŒµïŒã«åãïŒæ¬¡ã«ãã®æ··åç©ãè€åäœåœ¢æãè¡ãããæ¡ä»¶äžã§ã€ã³ãã¥ããŒãããïŒäŸãã°ãå¡©ããã³ïœïŒšã«é¢ããŠçççæ¡ä»¶ïŒãã€ã³ãã¥ããŒã·ã§ã³ã®åŸãããŒãºãŸãã¯åŸ®éå®éãã¬ãŒãã®ãŠã§ã«ãæŽæµããŠæªçµåæåãé€å»ãããåå¿äœã®çµåã¯äžèšã®ããã«çŽæ¥çãŸãã¯éæ¥çã«æž¬å®ã§ãããå¥æ³ãšããŠãè€åäœãåºäœæ¯æäœãã解é¢ãããåŸã«çµåã枬å®ããããšãã§ããã
æ¬çºæã«ä¿ãã¹ã¯ãªãŒãã³ã°æ€å®ã«ã¯ãèçœãŸãã¯ããªãã¯ã¬ãªãããåºäœæ¯æäœäžã«åºå®åããããã®ãã®ä»ã®æè¡ã䜿çšããããšãã§ãããäŸãã°ãïŒïŒµïŒïŒãŸãã¯ïŒ®ïŒïŒµïŒãã³ãŒãããããªãã¯ã¬ãªããïŒãŸãã¯è¢«éšååç©ã®ããããããããªãã³ãšã¹ãã¬ããã¢ããžã³ã®ã³ã³ãžã¥ã²ãŒã·ã§ã³ãå©çšããŠåºå®åã§ãããåœåéã§åšç¥ã®æè¡ïŒäŸãã°ããªããã«åããããPierce Chemicals, Rockford,Ill.ïŒãçšããŠãããªããã«åããïŒïŒµïŒïŒãŸãã¯ããªãã¯ã¬ãªããïŒãŸãã¯è¢«éšååç©ãããªãã³âïŒïŒ®âããããã·ã¹ã¯ã·ã³ã€ããïŒãã調補ããã¹ãã¬ããã¢ããžã³è¢«èŠãããŠã§ã«ãã¬ãŒãïŒPierce ChemicalïŒã®ãŠã§ã«ã«åºå®åã§ãããå¥æ³ãšããŠãïŒïŒµïŒãããªãã¯ã¬ãªããããŸãã¯è¢«éšååç©ã«ç¹ç°çã«çµåããããææã®çµåéšäœãäŸãã°ïŒ®ïŒïŒµïŒã®æŽ»æ§éšäœã«å¹²æžããªãæäœããã¬ãŒãã®ãŠã§ã«ã«èªå°äœåããããšãã§ãããæªçµåã®æšçãŸãã¯èçœãæäœã³ã³ãžã¥ã²ãŒã·ã§ã³ã«ãããŠã§ã«äžã«ææã§ãããâåºå®åè€åäœã«ã€ããŠäžã«èšèŒããæ¹æ³ã«å ãããã®ãããªè€åäœãæ€åºããæ¹æ³ã«ã¯ãïŒïŒµïŒãŸãã¯è¢«éšååç©ã«ç¹ç°çµåããæäœãçšãããè€åäœã®å
ç«æ€åºãïŒïŒµïŒã®æŽ»æ§æ€åºãžãšåŒãç¶ãããé
µçŽ çµåæ€å®ãããã³ééå
æ¡ä»¶äžã§ã®ïŒ³ïŒ€ïŒ³ã²ã«é»æ°æ³³åãããã
ïŒïŒµïŒãŸãã¯ããªãã¯ã¬ãªããã«çµåãã被éšååç©ãæ±ããã¹ã¯ãªãŒãã³ã°ã¯ãç¡å·ã®çŽ°èã§å®æœããããšãã§ãããïŒïŒµïŒãŸãã¯ããªãã¯ã¬ãªãããå«ãä»»æã®çŽ°èãã现èã«åºã¥ãæ€å®ç³»ã§äœ¿çšã§ãããïŒïŒµïŒããªãã¯ã¬ãªããã¯çŽ°èäžã«å€©ç¶ã«ååšãããŸãã¯äžèšã®ãããªæè¡ãçšããŠå°å
¥ã§ãããïŒïŒµïŒãŸãã¯ããªãã¯ã¬ãªããã«å¯Ÿãã被éšååç©ã®çµåã¯ãäžèšã®ããã«æž¬å®ããã
æ©èœæ€å®
ïŒïŒµïŒã®çç©åŠçå¹æãå¢å€§ãŸãã¯äœäžãããèœåã«ã€ããŠè¢«éšååç©ãè©Šéšã§ãããïŒïŒµïŒã®æŽ»æ§ã¯ãäžèšã®å ·äœçå®æœäŸã«èšèŒã®æ©èœæ€å®ãçšããŠæž¬å®ã§ãããïŒïŒµïŒæŽ»æ§ã¯ã粟補ããïŒïŒµïŒã现èè調補ç©ããŸãã¯ç¡å·ã®çŽ°èã被éšååç©ãšæ¥è§ŠãããåŸã«å®æœã§ãããïŒïŒµïŒæŽ»æ§ãå°ãªããšãçŽïŒïŒã奜ãŸããã¯çŽïŒïŒããã奜ãŸããã¯çŽïŒïŒãïŒïŒããŸãã¯ïŒïŒïŒïŒ äœäžããã被éšååç©ããïŒïŒµïŒæŽ»æ§ãäœäžãããå¯èœæ§ããç©è³ªãšããŠåå®ãããïŒïŒµïŒã®æŽ»æ§ãå°ãªããšãçŽïŒïŒã奜ãŸããã¯çŽïŒïŒããã奜ãŸããã¯çŽïŒïŒãïŒïŒããŸãã¯ïŒïŒïŒïŒ å¢å€§ããã被éšååç©ããïŒïŒµïŒæŽ»æ§ãå¢å€§ãããå¯èœæ§ããç©è³ªãšããŠåå®ããã
ïŒïŒµïŒã®çç©åŠçå¹æãå¢å€§ãŸãã¯äœäžãããèœåã«ã€ããŠè¢«éšååç©ãè©Šéšã§ãããïŒïŒµïŒã®æŽ»æ§ã¯ãäžèšã®å ·äœçå®æœäŸã«èšèŒã®æ©èœæ€å®ãçšããŠæž¬å®ã§ãããïŒïŒµïŒæŽ»æ§ã¯ã粟補ããïŒïŒµïŒã现èè調補ç©ããŸãã¯ç¡å·ã®çŽ°èã被éšååç©ãšæ¥è§ŠãããåŸã«å®æœã§ãããïŒïŒµïŒæŽ»æ§ãå°ãªããšãçŽïŒïŒã奜ãŸããã¯çŽïŒïŒããã奜ãŸããã¯çŽïŒïŒãïŒïŒããŸãã¯ïŒïŒïŒïŒ äœäžããã被éšååç©ããïŒïŒµïŒæŽ»æ§ãäœäžãããå¯èœæ§ããç©è³ªãšããŠåå®ãããïŒïŒµïŒã®æŽ»æ§ãå°ãªããšãçŽïŒïŒã奜ãŸããã¯çŽïŒïŒããã奜ãŸããã¯çŽïŒïŒãïŒïŒããŸãã¯ïŒïŒïŒïŒ å¢å€§ããã被éšååç©ããïŒïŒµïŒæŽ»æ§ãå¢å€§ãããå¯èœæ§ããç©è³ªãšããŠåå®ããã
ãã®ãããªã¹ã¯ãªãŒãã³ã°æ¹æ³ã®ïŒã€ã¯ãïŒïŒµïŒãçºçŸãããããã©ã³ã¹ãã§ã¯ãããã¡ã©ãã³ä¿æ现èã®äœ¿çšãå«ããä¿ãã¹ã¯ãªãŒãã³ã°æè¡ã¯ïŒïŒïŒïŒå¹ŽïŒæïŒæ¥å
¬éã®ïŒ·ïŒ¯ïŒïŒïŒïŒïŒïŒïŒïŒã«èšèŒãããŠããããããã£ãŠãäŸãã°ãã®ãããªæ€å®ã䜿çšããŠã該ã¬ã»ãã¿ãŒãå«ãã¡ã©ãã³ä¿æ现èããã¬ã»ãã¿ãŒãªã¬ã³ããšãã¹ã¯ãªãŒãã³ã°ããã被éšååç©ã®äž¡è
ã«æ¥è§Šãããããšã«ãããã¬ã»ãã¿ãŒããªããããã®æŽ»æ§åãé»å®³ããååç©ãæ±ããã¹ã¯ãªãŒãã³ã°ãã§ããããªã¬ã³ããçæããã·ã°ãã«ã®é»å®³ã¯ã被éšååç©ããã®ã¬ã»ãã¿ãŒã«ã€ããŠã®å¯èœæ§ããã¢ã³ã¿ãŽãã¹ãã§ããããšãå³ã¡è©²ã¬ã»ãã¿ãŒã®æŽ»æ§åãé»å®³ããããšã瀺ãããã®ã¹ã¯ãªãŒãã³ã°ã¯ãä¿ã现èãã¹ã¯ãªãŒãã³ã°ãã¹ãååç©ãšæ¥è§Šãããããšã«ãããã¬ã»ãã¿ãŒã掻æ§åãã被éšååç©ãåå®ããããã«ããããŠå被éšååç©ãã·ã°ãã«ãçæãããã©ãããå³ã¡ã¬ã»ãã¿ãŒã掻æ§åãããã©ããã決å®ããããã«äœ¿çšã§ããã
ãã®ä»ã®ã¹ã¯ãªãŒãã³ã°æè¡ã¯ãã¬ã»ãã¿ãŒæŽ»æ§åã«ããæ¹èµ·ããã现èå€ïœïŒšå€åã枬å®ããç³»ã«ãããŠããïŒïŒµïŒãçºçŸãã现èïŒäŸãã°ããã©ã³ã¹ãã§ã¯ãããã现èïŒã䜿çšããããšãå
å«ããIwabuchi, (1993)ãäŸãã°ãååç©ãæ¬çºæã®å容äœããªãããããçºçŸãã现èã«æ¥è§Šãããäºæ¬¡ã¡ãã»ã³ãžã£ãŒåå¿ãäŸãã°ã·ã°ãã«äŒéãŸãã¯ïœïŒšå€åã枬å®ããŠã被éšååç©ã該ã¬ã»ãã¿ãŒã掻æ§åãããé»å®³ãããã決å®ã§ãããå¥ã®ãã®ãããªã¹ã¯ãªãŒãã³ã°æè¡ã¯ãïŒïŒµïŒãã³ãŒãããŠãããXenopusåµæ¯çŽ°èå
ã«å°å
¥ãã該ã¬ã»ãã¿ãŒãäžéæ§çºçŸãããããšãå«ãã次ãã§ãã©ã³ã¹ãã§ã¯ããããåµæ¯çŽ°èãã¬ã»ãã¿ãŒãªã¬ã³ãããã³ã¹ã¯ãªãŒãã³ã°ãã¹ã被éšååç©ã«æ¥è§Šããããã®åŸã該ã¬ã»ãã¿ãŒã®æŽ»æ§åãé»å®³ãããšæããã被éšååç©ã«ã€ããŠã¹ã¯ãªãŒãã³ã°ããå Žåã¯ãã«ã«ã·ãŠã ã·ã°ãã«ã®æŽ»æ§åãŸãã¯é»å®³ã®æ€åºãè¡ãã
å¥ã®ã¹ã¯ãªãŒãã³ã°æè¡ã¯ãã¬ã»ãã¿ãŒããã¹ããªããŒãŒïŒ£ãŸãã¯ïŒ€ã«çµåããŠãã现èã§ïŒ®ïŒïŒµïŒãçºçŸãããããšãå«ãããã®ãããªçŽ°èã«ã¯ãå
ç®çŽ°èãå¹³æ»ç现èãèæ§è
现èãªã©ããããã¹ã¯ãªãŒãã³ã°ã¯äžèšã®ããã«ããã¹ããªããŒãŒæŽ»æ§ã®å€åãã該ã¬ã»ãã¿ãŒã®æŽ»æ§åçšåºŠãå®éããããšã«ããéæã§ããã
éºäŒåçºçŸ
å¥ã®æ æ§ã§ã¯ãïŒïŒµïŒéºäŒåã®çºçŸãå¢å€§ãŸãã¯æžå°ããã被éšååç©ãåå®ãããæ¬æ现æžã«ãããŠçšãããããããªãã¯ã¬ãªããã®çºçŸã«é¢é£ããããªãèªã¯ãããŒã¶ã³è§£æãŸãã¯ãªã¢ã«ã¿ã€ã ã«ãããïŒïŒµïŒãã³ãŒãããæ žé žé åãã®ãã®ãŸãã¯ããã«é¢é£ããæ žé žã®ååšã®æ€åºããµã³ãã«å ã®ïŒ®ïŒïŒµïŒãã³ãŒãããæ žé žã®ååšã®ææšãšãªããããã«ãã£ãŠïŒ®ïŒïŒµïŒãã³ãŒãããããªãã¯ã¬ãªããããã®è»¢åã®çºçŸãšé¢é£ãããããšã瀺ããæ¬æ现æžã«ãããŠçšããããããã€ã¯ãã¢ã¬ã€ãã¯ãçŽããã€ãã³ãŸãã¯ä»»æã®ä»ã®ã¿ã€ãã®èããã£ã«ã¿ãŒãããããã¹ã©ã€ãã¬ã©ã¹ãŸãã¯ä»»æã®ä»ã®é©åœãªåºäœã®æ¯æäœçã®åºæäžã«äžŠã¹ãããåã ã®ããªãã¯ã¬ãªãããŸãã¯ãªãªãŽãã¯ã¬ãªããã®äžŠã³ãæå³ãããïŒïŒµïŒããªãã¯ã¬ãªããã被éšååç©ãšæ¥è§ŠããããŸãã¯ïŒ®ïŒïŒµïŒããªãã¯ã¬ãªããã®ããªããããç£ç©ã®çºçŸã枬å®ããã被éšååç©ååšäžã§ã®é©åœãªïœïŒ²ïŒ®ïŒ¡ãŸãã¯ããªããããã®çºçŸã¬ãã«ãã該被éšååç©äžåšäžã§ã®ïœïŒ²ïŒ®ïŒ¡ãŸãã¯ããªããããã®çºçŸã¬ãã«ãšæ¯èŒããããããšè¢«éšååç©ãããã®æ¯èŒã«åºã¥ãçºçŸã®ã¢ãžã¥ã¬ãŒã¿ãŒãšããŠåå®ã§ãããäŸãã°ãïœïŒ²ïŒ®ïŒ¡ãŸãã¯ããªããããã®çºçŸãã被éšååç©ã®äžåšæãããååšæã«ãã倧ããå Žåã¯ããã®è¢«éšååç©ãã該ïœïŒ²ïŒ®ïŒ¡ãŸãã¯ããªããããçºçŸã®åºæ¿ç©è³ªãŸãã¯å¢åŒ·ç©è³ªãšåå®ãããããã§ã¯ãªããïœïŒ²ïŒ®ïŒ¡ãŸãã¯ããªããããã®çºçŸãã被éšååç©ã®äžåšæãããååšæã«ããå°ããå Žåã¯ããã®è¢«éšååç©ãã該ïœïŒ²ïŒ®ïŒ¡ãŸãã¯ããªããããçºçŸã®ã€ã³ããã¿ãŒãšåå®ããã
å¥ã®æ æ§ã§ã¯ãïŒïŒµïŒéºäŒåã®çºçŸãå¢å€§ãŸãã¯æžå°ããã被éšååç©ãåå®ãããæ¬æ现æžã«ãããŠçšãããããããªãã¯ã¬ãªããã®çºçŸã«é¢é£ããããªãèªã¯ãããŒã¶ã³è§£æãŸãã¯ãªã¢ã«ã¿ã€ã ã«ãããïŒïŒµïŒãã³ãŒãããæ žé žé åãã®ãã®ãŸãã¯ããã«é¢é£ããæ žé žã®ååšã®æ€åºããµã³ãã«å ã®ïŒ®ïŒïŒµïŒãã³ãŒãããæ žé žã®ååšã®ææšãšãªããããã«ãã£ãŠïŒ®ïŒïŒµïŒãã³ãŒãããããªãã¯ã¬ãªããããã®è»¢åã®çºçŸãšé¢é£ãããããšã瀺ããæ¬æ现æžã«ãããŠçšããããããã€ã¯ãã¢ã¬ã€ãã¯ãçŽããã€ãã³ãŸãã¯ä»»æã®ä»ã®ã¿ã€ãã®èããã£ã«ã¿ãŒãããããã¹ã©ã€ãã¬ã©ã¹ãŸãã¯ä»»æã®ä»ã®é©åœãªåºäœã®æ¯æäœçã®åºæäžã«äžŠã¹ãããåã ã®ããªãã¯ã¬ãªãããŸãã¯ãªãªãŽãã¯ã¬ãªããã®äžŠã³ãæå³ãããïŒïŒµïŒããªãã¯ã¬ãªããã被éšååç©ãšæ¥è§ŠããããŸãã¯ïŒ®ïŒïŒµïŒããªãã¯ã¬ãªããã®ããªããããç£ç©ã®çºçŸã枬å®ããã被éšååç©ååšäžã§ã®é©åœãªïœïŒ²ïŒ®ïŒ¡ãŸãã¯ããªããããã®çºçŸã¬ãã«ãã該被éšååç©äžåšäžã§ã®ïœïŒ²ïŒ®ïŒ¡ãŸãã¯ããªããããã®çºçŸã¬ãã«ãšæ¯èŒããããããšè¢«éšååç©ãããã®æ¯èŒã«åºã¥ãçºçŸã®ã¢ãžã¥ã¬ãŒã¿ãŒãšããŠåå®ã§ãããäŸãã°ãïœïŒ²ïŒ®ïŒ¡ãŸãã¯ããªããããã®çºçŸãã被éšååç©ã®äžåšæãããååšæã«ãã倧ããå Žåã¯ããã®è¢«éšååç©ãã該ïœïŒ²ïŒ®ïŒ¡ãŸãã¯ããªããããçºçŸã®åºæ¿ç©è³ªãŸãã¯å¢åŒ·ç©è³ªãšåå®ãããããã§ã¯ãªããïœïŒ²ïŒ®ïŒ¡ãŸãã¯ããªããããã®çºçŸãã被éšååç©ã®äžåšæãããååšæã«ããå°ããå Žåã¯ããã®è¢«éšååç©ãã該ïœïŒ²ïŒ®ïŒ¡ãŸãã¯ããªããããçºçŸã®ã€ã³ããã¿ãŒãšåå®ããã
现èã«ãããïŒïŒµïŒïœïŒ²ïŒ®ïŒ¡ãŸãã¯ããªããããçºçŸã®ã¬ãã«ã¯ãïœïŒ²ïŒ®ïŒ¡ãŸãã¯ããªãããããæ€åºããããã®åœåéã§åšç¥ã®æ¹æ³ã«ãã決å®ã§ãããå®æ§ãŸãã¯å®éçæ¹æ³ã®ããããã䜿çšã§ãããïŒïŒµïŒããªãã¯ã¬ãªããã®ããªããããç£ç©ã®ååšã¯ãäŸãã°ã©ãžãªã€ã ãã¢ãã»ã€ã®ãããªå
ç«ååŠçæ¹æ³ããŠãšã¹ã¿ã³ããããã£ã³ã°ãããã³å
ç«çµç¹ååŠãå
å«ãããåœåéã§åšç¥ã®æ§ã
ãªæè¡ãçšããŠæ±ºå®ã§ãããå¥æ³ãšããŠãããªããããåæã¯ãïŒïŒµïŒå
ãžã®æšèã¢ããé
žã®åã蟌ã¿ãæ€åºããããšã«ãããã€ã³ããã§ã现èå¹é€ã§ããŸãã¯ã€ã³ããã翻蚳系ã§æ±ºå®ã§ããã
ãã®ãããªã¹ã¯ãªãŒãã³ã°ã¯ãç¡çŽ°èæ€å®ç³»ãŸãã¯ç¡å·ã®çŽ°èã®ããããã§å®æœã§ãããïŒïŒµïŒããªãã¯ã¬ãªãããçºçŸãããããªã现èã现èã«åºã¥ãæ€å®ç³»ã§äœ¿çšã§ãããïŒïŒµïŒããªãã¯ã¬ãªããã¯çŽ°èå
ã«å€©ç¶ã«ååšãããããŸãã¯äžèšã®ãããªæè¡ãçšããŠå°å
¥ããããšãã§ãããäžæ¬¡å¹é€ãŸãã¯ç¢ºç«ãããã»ã«ã©ã€ã³ã®ããããã䜿çšã§ããã
被éšååç©
æ¬çºæã®ã¹ã¯ãªãŒãã³ã°è§£æã«ãããŠçšããããã®é©åœãªè¢«éšååç©ã¯ãä»»æã®é©åœãªäŸçµŠæºãäŸãã°æ £çšã®ååç©ã©ã€ãã©ãªãŒããå ¥æããããšãã§ãããè©Šéšååç©ã¯ãçç©åŠçã©ã€ãã©ãªãŒã空éçã¢ãã¬ã¹ç¹å®å¯èœãªäžŠè¡åºçžãŸãã¯æ¶²çžã©ã€ãã©ãªãŒããã³ã³ãã«ãŒã·ã§ã³ãèŠããåæã©ã€ãã©ãªãŒæ³ããäžããŒãºäžååç©ãã©ã€ãã©ãªãŒæ³ãããã³èŠªåã¯ãããã°ã©ãã£ãŒéžæãçšããåæã©ã€ãã©ãªãŒæ³ãå å«ããïŒäœããããã«éå®ãããèš³ã§ã¯ãªãïŒåœåéã§æ¢ç¥ã®æ°å€ãã®çµã¿åããã©ã€ãã©ãªãŒæ³ã®ãããããçšããŠååŸã§ãããçç©åŠçã©ã€ãã©ãªãŒã¢ãããŒãã¯ããªããããã©ã€ãã©ãªãŒã«éå®ãããŠããããä»ã®ïŒçš®ã®ã¢ãããŒãã¯ãããããéãããããªãªãŽããŒããŸãã¯ååç©ã®å°ååã©ã€ãã©ãªãŒã«é©çšã§ãããLam, (1997)ãååã©ã€ãã©ãªãŒã®åææ³ã¯åœåéã§ããç¥ãããŠãããååç©ã®ã©ã€ãã©ãªãŒã¯æº¶æ¶²ã§ãŸãã¯ããŒãºããããã现èãŸãã¯èåããã©ã¹ãããŸãã¯ãã¡ãŒãžäžã«æäŸã§ããã
æ¬çºæã®ã¹ã¯ãªãŒãã³ã°è§£æã«ãããŠçšããããã®é©åœãªè¢«éšååç©ã¯ãä»»æã®é©åœãªäŸçµŠæºãäŸãã°æ £çšã®ååç©ã©ã€ãã©ãªãŒããå ¥æããããšãã§ãããè©Šéšååç©ã¯ãçç©åŠçã©ã€ãã©ãªãŒã空éçã¢ãã¬ã¹ç¹å®å¯èœãªäžŠè¡åºçžãŸãã¯æ¶²çžã©ã€ãã©ãªãŒããã³ã³ãã«ãŒã·ã§ã³ãèŠããåæã©ã€ãã©ãªãŒæ³ããäžããŒãºäžååç©ãã©ã€ãã©ãªãŒæ³ãããã³èŠªåã¯ãããã°ã©ãã£ãŒéžæãçšããåæã©ã€ãã©ãªãŒæ³ãå å«ããïŒäœããããã«éå®ãããèš³ã§ã¯ãªãïŒåœåéã§æ¢ç¥ã®æ°å€ãã®çµã¿åããã©ã€ãã©ãªãŒæ³ã®ãããããçšããŠååŸã§ãããçç©åŠçã©ã€ãã©ãªãŒã¢ãããŒãã¯ããªããããã©ã€ãã©ãªãŒã«éå®ãããŠããããä»ã®ïŒçš®ã®ã¢ãããŒãã¯ãããããéãããããªãªãŽããŒããŸãã¯ååç©ã®å°ååã©ã€ãã©ãªãŒã«é©çšã§ãããLam, (1997)ãååã©ã€ãã©ãªãŒã®åææ³ã¯åœåéã§ããç¥ãããŠãããååç©ã®ã©ã€ãã©ãªãŒã¯æº¶æ¶²ã§ãŸãã¯ããŒãºããããã现èãŸãã¯èåããã©ã¹ãããŸãã¯ãã¡ãŒãžäžã«æäŸã§ããã
調ç¯ç©è³ªã®ã¢ããªã³ã°
ã³ã³ãã¥ãŒã¿ã¢ããªã³ã°ããã³ãµãŒãæè¡ãã£ãŠãååç©ã®åå®ããŸãã¯ïŒ®ïŒïŒµïŒçºçŸãŸãã¯æŽ»æ§ã調ç¯ããããšãã§ããæ¢ã«åå®ãããŠããååç©ã®æ¹è¯ãå¯èœã§ããããã®ãããªååç©ãŸãã¯çµæç©ãåå®ãããŠããã°ã掻æ§éšäœãŸãã¯é åãåå®ãããããã®ãããªæŽ»æ§éšäœã¯å žåçã«ã¯ãïŒïŒµïŒã«å¯Ÿãããªã¬ã³ãã®çžäºäœçšãã¡ã€ã³ã®ãããªãªã¬ã³ãçµåã§ãããã掻æ§éšäœã¯ãäŸãã°ãããããã®ã¢ããé žé åãããæ žé žã®ãã¯ã¬ãªããé åããããŸãã¯é¢é£ããååç©ãŸãã¯çµæç©ãšãã®å€©ç¶ãªã¬ã³ããšã®è€åäœã®ç 究ãããåœåéã§åšç¥ã®æ¹æ³ãçšããŠåå®ããããšãã§ãããåŸè ã®å ŽåãååŠçãŸãã¯ïŒžç·çµæ¶åŠçæ¹æ³ãçšããŠããã®å åã«ãããŠè€åäœåãããªã¬ã³ããèªããããå ŽæãèŠã€ããããšã«ãã掻æ§éšäœãèŠã€ããããšãã§ããã
ã³ã³ãã¥ãŒã¿ã¢ããªã³ã°ããã³ãµãŒãæè¡ãã£ãŠãååç©ã®åå®ããŸãã¯ïŒ®ïŒïŒµïŒçºçŸãŸãã¯æŽ»æ§ã調ç¯ããããšãã§ããæ¢ã«åå®ãããŠããååç©ã®æ¹è¯ãå¯èœã§ããããã®ãããªååç©ãŸãã¯çµæç©ãåå®ãããŠããã°ã掻æ§éšäœãŸãã¯é åãåå®ãããããã®ãããªæŽ»æ§éšäœã¯å žåçã«ã¯ãïŒïŒµïŒã«å¯Ÿãããªã¬ã³ãã®çžäºäœçšãã¡ã€ã³ã®ãããªãªã¬ã³ãçµåã§ãããã掻æ§éšäœã¯ãäŸãã°ãããããã®ã¢ããé žé åãããæ žé žã®ãã¯ã¬ãªããé åããããŸãã¯é¢é£ããååç©ãŸãã¯çµæç©ãšãã®å€©ç¶ãªã¬ã³ããšã®è€åäœã®ç 究ãããåœåéã§åšç¥ã®æ¹æ³ãçšããŠåå®ããããšãã§ãããåŸè ã®å ŽåãååŠçãŸãã¯ïŒžç·çµæ¶åŠçæ¹æ³ãçšããŠããã®å åã«ãããŠè€åäœåãããªã¬ã³ããèªããããå ŽæãèŠã€ããããšã«ãã掻æ§éšäœãèŠã€ããããšãã§ããã
次ã«ã掻æ§éšäœã®ïŒæ¬¡å
幟äœæ§é ã決å®ãããããã¯ãå®å
šãªååæ§é ã決å®ããããšãã§ãããç·çµæ¶åŠãå«ãåœåéã«ãããŠåšç¥ã®æ¹æ³ã«ãã£ãŠè¡ãããšãã§ãããä»æ¹ãåºçžãŸãã¯æ¶²çžïŒ®ïŒïŒ²ãçšããŠç¹å®ã®ååå
è·é¢ã決å®ããããšãã§ãããä»ã®ä»»æã®æ§é 決å®ã®å®éšæ¹æ³ãçšããŠéšåçãŸãã¯å®å
šãªå¹Ÿäœæ§é ãåŸãããšãã§ããã幟äœæ§é ã¯ã倩ç¶ãŸãã¯äººå·¥ã®ã決å®ããã掻æ§éšäœã®ç²ŸåºŠãå¢ãåŸãè€åäœåãããªã¬ã³ããçšããŠæž¬å®ããããšãã§ããã
粟床ã®äžå®å
šãªãŸãã¯äžååãªæ§é ã決å®ããå Žåãã³ã³ãã¥ãŒã¿ããŒã¹ã®æ°å€ã¢ããªã³ã°ã®æ¹æ³ãçšããŠæ§é ãæ¯èŒãŸãã¯ç²ŸåºŠãæ¹åããããšãã§ãããã¿ã³ãã¯è³ªãŸãã¯æ žé
žã®ãããªå
·äœçãªçç©é«ååã«å¯ŸããŠç¹ç°çãªãã©ã¡ãŒã¿ãŒåãããã¢ãã«ãååéåã®èšç®ã«åºã¥ãåååååŠã¢ãã«ãç±éå£ïŒthermal ensembleïŒã«åºã¥ãçµ±èšååŠã¢ãã«ããŸãã¯çµåãã¢ãã«ãå«ããèªèãããŠããä»»æã®ã¢ããªã³ã°æ¹æ³ãçšããããšãã§ããã倧éšåã®ã¿ã€ãã®ã¢ãã«ãšããŠã¯ãæ§æååãšåºãšã®éã®åã瀺ãæšæºåååå Žããå¿
èŠãšããç©çååŠã«ãããŠç¥ãããŠããåå Žããéžæããããšãã§ãããäžå®å
šãŸãã¯ç²ŸåºŠã®äœããå®éšã§åŸãããæ§é ã¯ããããã®ã¢ããªã³ã°æ¹æ³ã«ãã£ãŠèšç®ãããå®å
šãªãããŠãã粟床ã®é«ãæ§é ã«å¯Ÿããå¶çŽãšããŠäŸããã
æåŸã«ã掻æ§éšäœã®æ§é ã決å®ãããã°ãå®éšçã«ãã¢ããªã³ã°ã«ãããŸãã¯çµåãã«ãããåè£ã®èª¿ç¯ååç©ããã®ååæ§é ã«é¢ããæ
å ±ãšå
±ã«å«ãããŒã¿ããŒã¹ãæ€çŽ¢ããããšã«ããåå®ããããšãã§ããããã®ãããªæ€çŽ¢ã¯ã決å®ããã掻æ§éšäœã®æ§é ãšåèŽãã掻æ§éšäœãå®çŸ©ããåºãšçžäºäœçšããæ§é ãæããååç©ãæ¢ãããã®ãããªæ€çŽ¢ã¯ãæåã§ãããããã³ã³ãã¥ãŒã¿ã䜿çšãããã®ã§ããããšã奜ãŸããããã®æ€çŽ¢ããèŠãã ããããããã®ååç©ã¯ãå¯èœæ§ã®ããïŒïŒµïŒèª¿ç¯ååç©ã§ããã
ãããã¯ããããã®æ¹æ³ãçšããŠæ¢ã«ç¥ãããŠãã調ç¯ååç©ãŸãã¯ãªã¬ã³ãããæ¹åããã調ç¯ååç©ãåå®ããããšãã§ãããæ¢ç¥ã®ååç©ã®çµæç©ã修食ããå®éšçãªããã³æ°ããªçµæç©ã«é©çšãããäžèšã®ã³ã³ãã¥ãŒã¿ã¢ããªã³ã°æ³ãçšããŠä¿®é£Ÿã®æ§é äžã®å¹æã決å®ããããšãã§ããã次ãã§ãå€åããæ§é ãååç©ã®æŽ»æ§éšäœã®æ§é ãšæ¯èŒããŠãæ¹åãããé©åããŸãã¯çžäºäœçšã®çµæãã決å®ããããã®ããæ¹ã§ã¯ãäŸãã°æ§ã
ãªåŽéåºã«ãããçµæã«ãããäœç³»çãªå€åãè¿
éã«è©äŸ¡ããŠä¿®é£Ÿããã調ç¯ååç©ãŸãã¯æ¹åããã掻æ§ãŸãã¯ç¹ç°æ§ãæãããªã¬ã³ããåŸãããšãã§ããã
æ²»çäžã®é©å¿ããã³æ¹æ³
æ¬é¡ã«ããïŒïŒµïŒãæ§ã ãªããçµç¹ã«ãããŠçºçŸããããšãåãã£ãã
æ¬é¡ã«ããïŒïŒµïŒãæ§ã ãªããçµç¹ã«ãããŠçºçŸããããšãåãã£ãã
äžæ¢ç¥çµç³»ïŒïŒ£ïŒ®ïŒ³ïŒé害
é害ã¯ãäžæ¢ç¥çµç³»ã®é害䞊ã³ã«æ«æ¢¢ç¥çµç³»ã®é害ãå å«ããã
é害ã¯ãäžæ¢ç¥çµç³»ã®é害䞊ã³ã«æ«æ¢¢ç¥çµç³»ã®é害ãå å«ããã
é害ã«ã¯ãè³æå·ãè³è¡ç®¡çŸæ£ããã³ãã®åž°çµãããŒãã³ãœã³ç
ã倧è³ç®è³ªåºåºæ žå€æ§çãéåãã¥ãŒãã³çŸæ£ããå«ãçŽåãå€çºæ§ç¡¬åçãå€å·æ§è³æå·ãè³åäžãè³åäžåŸãå€å·åŸè³æå·ãããã³å°è¡ç®¡è³è¡ç®¡çŸæ£ãªã©ãå«ãŸããããŸããã¢ã«ããã€ããŒç
ãè¡ç®¡æ§çŽåãã¬ãå°äœã䌎ãçŽåãïŒïŒçªæè²äœã«é£éããåé åŽé åçŽåããã³ããŒãã³ãœããºã ãããã¯ç
ãå«ãåé åŽé åçŽåãé²è¡æ§æ žæ§éº»çºã倧è³ç®è³ªåºåºæ žå€æ§çããã³ãã³ãã³ç
ãèŠåºå€æ§çãã¯ãã€ããã§ã«ãã€ã³ãçŽåãçŽåãçŽåã䌎ã粟ç¥åè£ç
ãããã³ã³ã«ãµã³ã粟ç¥ç
ãªã©ã®çŽåããæ¬çºæã®æå³ã«ãããŠïŒ£ïŒ®ïŒ³é害ã§ãããšãããã
åæ§ã«ã軜床èªç¥é害ãå 霢æ§èšæ¶é害ãå 霢æ§èªç¥äœäžãè¡ç®¡æ§èªç¥é害ã泚ææ¬ é¥é害ã泚ææ¬ é¥å€åé害ãããã³åŠç¿é害ã䌎ãå°å
ã«ãããèšæ¶é害ãªã©ã®èªèé¢é£é害ããŸãé害ãšèããããã
æ¬çºæã®æå³ã«ãããŠãçŒçããŸãé害ã«é¢é£ãããšèãããããçŒçã¯ãå€çºæ§ç¡¬åçãèé«æå·ãå骚ç¥çµçã倱æããè
°éšæè¡ïŒfailed back surgeryïŒçå矀ãå€å·æ§è³æå·ãç²çãããŒãã³ãœã³ç
ãè³åäžåŸãåã³è³ãèé«ã«ãããè¡ç®¡ç Žå£ïŒäŸãã°ãæ¢å¡ãåºè¡ãè¡ç®¡æ°çç°åžžïŒçã®ïŒ£ïŒ®ïŒ³é害ãšé¢é£ããããéäžæ¢ç¥çµå æ§çŒçã«ã¯ãä¹³æ¿åé€è¡åŸçŒçãå¹»èŠãåå°æ§äº€æç¥çµæ§ãžã¹ãããã£ãŒïŒïŒ²ïŒ€ïŒ³ïŒãäžåç¥çµçã©ãžãªãã¥ããã·ãŒïŒtrigeminal neuralgiaradio-culopathyïŒãè¡åŸã®çŒçãïŒïŒ¡ïŒ©ïŒ€ïŒ³é¢é£çŒçãççŒçã代è¬ç¥çµçïŒäŸãã°ãç³å°¿ç
æ§ç¥çµé害ãçµåçµç¹çŸæ£ã«å¯Ÿãã第ïŒã®è¡ç®¡çç¥çµé害ïŒãäŸãã°èºçãçœè¡ç
ããªã³ãè
«ãåç«è
ºã倧è
žè¥ããã¯èã®ççš®ãäžåç¥çµçåã³ç±ç¹åŸç¥çµçãšé¢é£ããè
«çé䌎æ§å€çºç¥çµé害ãæãããããçŒçã¯ãæ«æ¢¢ç¥çµã®æå·ãäžæ¢æ§çŒçïŒå³ã¡ãè³èè¡ã«èµ·å ããïŒãããã³æ§ã
ãªæ
¢æ§çŒçãå³ã¡è
°çãèçïŒè
°çïŒlow back painïŒïŒãççæ§ããã³ãªãŠããçããšé¢é£ãããé çïŒäŸãã°åå
ã䌎ãçé çãåå
ã䌎ããªãçé çãããã³ä»ã®çé çé害ïŒãå¶çºæ§åã³æ
¢æ§ç·åŒµæ§é çãç·åŒµåæ§é çã矀çºæ§é çãæ
¢æ§çºäœæ§çé çãé害ã§ãããèµèçãèè±çãæçµå°é£ãéææ§å€§è
žçå矀ãã¯ãŒãã³ç
ãèç³ççã尿管ççãå¿çæ¢å¡ããã³éªšç€è
ã®çŒççå矀ãäŸãã°äŒé°éšçã粟巣çãå°¿éçå矀ããã³protatodyniaçã®å
èã®çŒçããŸãé害ã§ãããäŸãã°ãè¡åŸçŒçãå€å·åŸçŒççã®æ¥æ§çŒçããŸããç¥çµç³»ã®é害ã§ãããšèããããã
ïŒïŒµïŒã¯ãæ§ã
ãªè³çµç¹ã«ãããŠé«åºŠã«çºçŸãããè³çµç¹ã«ãããçºçŸã¯ãïŒïŒµïŒãšç¥çµç³»ã®çŸæ£ãšã®é¢é£ã瀺åããŠãããã¢ã«ããã€ããŒç¶æ
ã®è³ã«ãããïŒïŒµïŒå容äœã®çºçŸã¯ãå¥åº·ãªè³ã«ãããçºçŸã®ïŒïŒåé«ããïŒïŒµïŒã¯ç¥çµç³»ã®çŸæ£ãåŠçœ®ãŸãã¯èšºæããããã«äœ¿çšããããšãã§ããã
å¿çŸæ£ïŒ
å¿äžå šãšã¯ãå¿æ©èœã®ç°åžžãã代è¬ããŠããçµç¹ã®èŠæ±ã«çžå¿ããé床ã§å¿èãè¡æ¶²ãéãåºããªãããšã«èµ·å ãããç æ ççåŠçç¶æ ãšããŠå®çŸ©ããããããã¯ãåºç€åå ã«é¢ãããªããäŸãã°é«æåºéããã³äœæåºéãæ¥æ§ããã³æ ¢æ§ãå³åŽããã³å·ŠåŽãåçž®æããã³æ¡åŒµæãšãã£ããããªå šãŠã®åã®ãã³ãäžå šãå å«ããã
å¿äžå šãšã¯ãå¿æ©èœã®ç°åžžãã代è¬ããŠããçµç¹ã®èŠæ±ã«çžå¿ããé床ã§å¿èãè¡æ¶²ãéãåºããªãããšã«èµ·å ãããç æ ççåŠçç¶æ ãšããŠå®çŸ©ããããããã¯ãåºç€åå ã«é¢ãããªããäŸãã°é«æåºéããã³äœæåºéãæ¥æ§ããã³æ ¢æ§ãå³åŽããã³å·ŠåŽãåçž®æããã³æ¡åŒµæãšãã£ããããªå šãŠã®åã®ãã³ãäžå šãå å«ããã
å¿çæ¢å¡ïŒïŒïŒ©ïŒã¯äžè¬ã«ãå è¡æµã®çªç¶ã®äœäžãšãããã«ç¶ãæ¢ã«åè硬åã«ãã£ãŠçéåããŠããå åèãè¡æ ã«ããéå¡ããããšã«ããæ¹èµ·ããããïŒïŒ©äºé²ïŒäžæ¬¡ããã³äºæ¬¡çé²æ¢ïŒããªãã³ã«ïŒïŒ©ã®æ¥æ§ææ²»çããã³å䜵çã®é²æ¢ãå
å«ãããã
èè¡æ§çŸæ£ã¯ãå è¡æµãå¶éããããã®çµæãå¿çã®é
žçŽ èŠæ±ãæºããã«å
åã§ãªãçæµãšãªãç¶æ
ã§ããããã®çŸ€ã®çŸæ£ã«ã¯ãå®å®ã¢ã³ã®ããäžå®å®ã¢ã³ã®ããããã³ç¡çåæ§èè¡ãããã
äžæŽèãšã¯å
šãŠã®åœ¢ã®å¿æ¿æ§ããã³å¿å®€æ§é »èïŒå¿æ¿æ§é »èãå¿æ¿æ§ç²åãå¿æ¿æ§çŽ°åãå¿æ¿âå¿å®€ãªãšã³ããªãŒé »èãæ©æè奮çå矀ãå¿å®€æ§é »èãå¿å®€æ§ç²åãããã³å¿å®€æ§çŽ°åïŒãããã³åŸèåã®äžæŽèãå
å«ããã
é«è¡å§æ§è¡ç®¡çŸæ£ã¯ãåçºæ§ããã³å
šãŠã®çš®ã®äºæ¬¡æ§åèæ§é«è¡å§çïŒè
æ§ãå
åæ³æ§ãç¥çµæ§ããã®ä»ïŒãå
å«ãããããã«é瀺ããéºäŒåããã³ãã®ç£ç©ã¯ãé«è¡å§çã®æ²»çããã³å¿çŸæ£ããçããå
šå䜵çã®é²æ¢ã®ããã®è¬ç©æšçãšããŠäœ¿çšã§ããã
æ«æ¢¢è¡ç®¡çŸæ£ãšã¯ãåèããã³ïŒãŸãã¯éèè¡æµãæžå°ãããã®çµæãè¡æ¶²äŸçµŠãšçµç¹ã®é
žçŽ èŠæ±ã®éã«äžåè¡¡ãçããŠããè¡ç®¡çŸæ£ãšããŠå®çŸ©ãããããã«ã¯ãæ
¢æ§æ«æ¢¢åèéå¡çŸæ£ïŒïŒ°ïŒ¡ïŒ¯ïŒ€ïŒãæ¥æ§åèè¡æ çããã³å¡æ çãççæ§è¡ç®¡çŸæ£ãã¬ã€ããŒçŸè±¡ãããã³éèçŸæ£ãå
å«ãããã
ã¢ãããŒã æ§åè硬åçã¯ãè¡ç®¡ã®å£ãæ¹é ïŒãªã¢ããªã³ã°ïŒãããè¡ç®¡ã®å
匵ãè
ããããå¿çŸæ£ã§ãããã¢ãããŒã 硬åã®ãªã¢ããªã³ã°éçšã«ã¯ãè¡ç®¡ã®å
èã«ããããå¹³æ»ç现èãšåçïŒãã¯ããã¡ãŒãžçç现èã®äž¡æ¹ã®éç©ã䌎ãããããã®çŽ°èã¯ã埪ç°è¡ãšåæ§ãè質ãå蟌ã¿ãæçããã¢ãããŒã æ§åè硬åç
å€ã圢æããããããç
å€ã®åœ¢æã¯ãæ
¢æ§éçšã§ãããæ人ã®ããã®äººçã®æ°å幎ã«ããã£ãŠèµ·ãããã¢ãããŒã æ§åè硬åçã®ç
çç¶æ
ã®å€§éšåã¯ãç
å€ãç Žæããè¡æ 圢æã®ç Žçãéé¢ããåèãããã«éå¡ããå Žåã«èµ·ããããã®ãããªæ¥æ§ã®äºè±¡ãå ç¶åèã«ãããŠèµ·ãããšããçµæãšããŠå¿çæ¢å¡ãèµ·ããåŸãææªã®å Žåã«æ»ã«è³ãã
ã¢ãããŒã æ§åè硬åçã®ç
å€ã®åœ¢æã¯ãéèµ°ãè質ã®èç©ãçç现èã®åå¡ãè¡ç®¡å¹³æ»ç现èã®å¢æ®ããã³çŽ°èå€ãããªãã¯ã¹ã®æ²ç©ã®ãããªãïŒã€ã®éè€ãã段éã«ãããŠèµ·ãããšèããããããããéçšã¯ãããããããããã³ã¢ãããŒã æ§åè硬åçã®åç©ã¢ãã«ã«ãããŠèµ·ããããšã瀺ãããšãã§ããããç
çããã³ç
å€ã®èšåºçæå³ã«å¯Ÿããããããã®é¢é£ããå¯äžã¯æããã§ã¯ãªãã
ãããã£ãŠãã¢ãããŒã æ§åè硬åçãå ç¶åèçŸæ£ã«é¢é£ããä»ã®ç¶æ
ãªã©ã®å¿çŸæ£ã®ç
ç¶ãåŠçœ®ããããã®æ²»çæ¹æ³ãæ²»çå€ã«å¯Ÿããå¿
èŠæ§ãããã
å¿çŸæ£ãšããŠã¯ãå¿èããã³è¡ç®¡ç³»ã®ä»¥äžã®é害ãæããããããããã«éå®ãããªãïŒé¬±è¡æ§å¿äžå
šãå¿çæ¢å¡ãå¿èã®èè¡æ§çŸæ£ãæ§ã
ãªå¿æ¿ããã³å¿å®€äžæŽèé«è¡å§è¡ç®¡é害ãæ«æ¢¢è¡ç®¡ã®çŸæ£ãããã³ã¢ãããŒã æ§åè硬åçã
ïŒïŒµïŒã¯ãå¿èãå åèå¹³æ»ç现èçã®å¿èè¡ç®¡ã«é¢é£ããçµç¹ã«ãããŠé«åºŠã«çºçŸãããäžèšçµç¹ã«ãããçºçŸã¯ãïŒïŒµïŒãšå¿çŸæ£ãšã®éã®é¢é£ã瀺åããŠãããå¿çŸæ£ãåŠçœ®ãŸãã¯èšºæããããã«ïŒ®ïŒïŒµïŒã調ç¯ããããšãã§ããã
è¡æ¶²çŸæ£
è¡æ¶²çŸæ£ã«ã¯ãè¡æ¶²ããã³ãã®æåã®ãã¹ãŠã®é害ã䞊ã³ã«è¡æ¶²ã®ç£çãŸãã¯å解ã«é¢ããèåšã®çŸæ£ãå«ãŸããããããã«ã¯ã以äžã®ã¢ããå«ãŸãããããã«éå®ãããªãïŒïŒïŒè²§è¡ãïŒïŒéªšé«å¢æ®çå矀ãïŒïŒåºè¡æ§é害ãïŒïŒçœè¡çæžå°çãïŒïŒå¥œé žçå¢å çãïŒïŒçœè¡ç ãïŒïŒãªã³ãè «ãïŒïŒè¡æŒ¿çŽ°èçŸæ£ãïŒïŒè¡æ¶²çŸæ£ã«ãããèµèé害ãïŒïŒã®é害ã«ã¯ä»¥äžã®ãã®ãæããããããããã«éå®ãããªãïŒæ¬ é¥ã®ãããŸãã¯äžååãªè¡çåæã«èµ·å ãã貧è¡ãäžå®å šãªèµ€è¡ççæãïŒïŒã®é害ã«ã¯ä»¥äžã®ãã®ãæããããããããã«éå®ãããªãïŒçæ§èµ€è¡çå¢å ãè «çé¢é£èµ€è¡çå¢å çã骚é«ç·ç¶çãè¡å°æ¿è¡çãïŒïŒã®é害ã«ã¯ä»¥äžã®ãã®ãæããããããããã«éå®ãããªãïŒè管çãè¡å°æ¿æžå°çããžããªã³èªå°æ§è¡å°æ¿æžå°çãè¡æ æ§è¡å°æ¿æžå°æ§çŽ«æç ã溶è¡æ§å°¿æ¯ççå矀ãè¡å°æ¿æ©èœã®éºäŒæ§ã®ããã³åŸå€©æ§ã®é害ãéºäŒæ§ã®ååºé害ãïŒïŒã®é害ã«ã¯ä»¥äžã®ãã®ãæããããããããã«éå®ãããªãïŒå¥œäžçæžå°çããªã³ãçæžå°çãïŒïŒã®é害ã«ã¯ä»¥äžã®ãã®ãæããããããããã«éå®ãããªãïŒéå¥œé žçå¢å çãçªçºæ§å¥œé žçå¢å çå矀ãïŒïŒã®é害ã«ã¯ä»¥äžã®ãã®ãæããããããããã«éå®ãããªãïŒæ¥æ§éªšé«æ§çœè¡ç ãæ¥æ§ãªã³ãèœçæ§çœè¡ç ãæ ¢æ§éªšé«æ§çœè¡ç ãæ ¢æ§ãªã³ãçæ§çœè¡ç ã骚é«ç°åœ¢æçå矀ãïŒïŒã®é害ã«ã¯ä»¥äžã®ãã®ãæããããããããã«éå®ãããªãïŒããžãã³ç ãéããžãã³ãªã³ãè «ãããŒããããªã³ãè «ãèç¶æ¯èè «ç®è现èãªã³ãè «ãïŒïŒã®é害ã«ã¯ä»¥äžã®ãã®ãæããããããããã«éå®ãããªãïŒå€çºæ§éªšé«è «ããã¯ãã°ãããªã³è¡çãééç ãçªçºæ§è¡å°æ¿æžå°çŽ«æãéæ¬ ä¹æ§è²§è¡ãå·šèµ€èœçæ§è²§è¡ïŒãã¿ãã³ïŒ¢ïŒïŒæ¬ ä¹ïŒãåçäžè¯æ§è²§è¡ããµã©ã»ãã¢ãæªæ§ãªã³ãè «éªšé«äŸµè¥²ãæªæ§ãªã³ãè «ç®è䟵襲ã溶è¡æ§å°¿æ¯ççå矀ã巚倧è¡å°æ¿çŸæ£ããŸãè¡æ¶²çŸæ£ã§ãããšèããããã
è¡æ¶²çŸæ£ã«ã¯ãè¡æ¶²ããã³ãã®æåã®ãã¹ãŠã®é害ã䞊ã³ã«è¡æ¶²ã®ç£çãŸãã¯å解ã«é¢ããèåšã®çŸæ£ãå«ãŸããããããã«ã¯ã以äžã®ã¢ããå«ãŸãããããã«éå®ãããªãïŒïŒïŒè²§è¡ãïŒïŒéªšé«å¢æ®çå矀ãïŒïŒåºè¡æ§é害ãïŒïŒçœè¡çæžå°çãïŒïŒå¥œé žçå¢å çãïŒïŒçœè¡ç ãïŒïŒãªã³ãè «ãïŒïŒè¡æŒ¿çŽ°èçŸæ£ãïŒïŒè¡æ¶²çŸæ£ã«ãããèµèé害ãïŒïŒã®é害ã«ã¯ä»¥äžã®ãã®ãæããããããããã«éå®ãããªãïŒæ¬ é¥ã®ãããŸãã¯äžååãªè¡çåæã«èµ·å ãã貧è¡ãäžå®å šãªèµ€è¡ççæãïŒïŒã®é害ã«ã¯ä»¥äžã®ãã®ãæããããããããã«éå®ãããªãïŒçæ§èµ€è¡çå¢å ãè «çé¢é£èµ€è¡çå¢å çã骚é«ç·ç¶çãè¡å°æ¿è¡çãïŒïŒã®é害ã«ã¯ä»¥äžã®ãã®ãæããããããããã«éå®ãããªãïŒè管çãè¡å°æ¿æžå°çããžããªã³èªå°æ§è¡å°æ¿æžå°çãè¡æ æ§è¡å°æ¿æžå°æ§çŽ«æç ã溶è¡æ§å°¿æ¯ççå矀ãè¡å°æ¿æ©èœã®éºäŒæ§ã®ããã³åŸå€©æ§ã®é害ãéºäŒæ§ã®ååºé害ãïŒïŒã®é害ã«ã¯ä»¥äžã®ãã®ãæããããããããã«éå®ãããªãïŒå¥œäžçæžå°çããªã³ãçæžå°çãïŒïŒã®é害ã«ã¯ä»¥äžã®ãã®ãæããããããããã«éå®ãããªãïŒéå¥œé žçå¢å çãçªçºæ§å¥œé žçå¢å çå矀ãïŒïŒã®é害ã«ã¯ä»¥äžã®ãã®ãæããããããããã«éå®ãããªãïŒæ¥æ§éªšé«æ§çœè¡ç ãæ¥æ§ãªã³ãèœçæ§çœè¡ç ãæ ¢æ§éªšé«æ§çœè¡ç ãæ ¢æ§ãªã³ãçæ§çœè¡ç ã骚é«ç°åœ¢æçå矀ãïŒïŒã®é害ã«ã¯ä»¥äžã®ãã®ãæããããããããã«éå®ãããªãïŒããžãã³ç ãéããžãã³ãªã³ãè «ãããŒããããªã³ãè «ãèç¶æ¯èè «ç®è现èãªã³ãè «ãïŒïŒã®é害ã«ã¯ä»¥äžã®ãã®ãæããããããããã«éå®ãããªãïŒå€çºæ§éªšé«è «ããã¯ãã°ãããªã³è¡çãééç ãçªçºæ§è¡å°æ¿æžå°çŽ«æãéæ¬ ä¹æ§è²§è¡ãå·šèµ€èœçæ§è²§è¡ïŒãã¿ãã³ïŒ¢ïŒïŒæ¬ ä¹ïŒãåçäžè¯æ§è²§è¡ããµã©ã»ãã¢ãæªæ§ãªã³ãè «éªšé«äŸµè¥²ãæªæ§ãªã³ãè «ç®è䟵襲ã溶è¡æ§å°¿æ¯ççå矀ã巚倧è¡å°æ¿çŸæ£ããŸãè¡æ¶²çŸæ£ã§ãããšèããããã
ïŒïŒµïŒã¯ãçœè¡çããã³ä»ã®è¡æ¶²çµç¹ã«ãããŠé«åºŠã«çºçŸãããäžèšçµç¹ã«ãããçºçŸã¯ãïŒïŒµïŒãšè¡æ¶²çŸæ£ãšã®éã®é¢é£ã瀺åããŠãããè¡æ¶²çŸæ£ãåŠçœ®ãŸãã¯èšºæããããã«ïŒ®ïŒïŒµïŒã調ç¯ããã³æž¬å®ããããšãã§ããã
ççæ§çŸæ£
ççæ§çŸæ£ã«ã¯ãå ç«ç³»ã®çŽ°èæ§ãŸãã¯é现èæ§ã®ã¡ãã£ãšãŒã¿ãŒããŸãã¯ççãåŒãããåŸã«æ¥æ§ãŸãã¯æ ¢æ§ã®ççç¶æ ãããããã身äœçµç¹ãåŒãéãšãªãçŸæ£ãå«ãŸããããã®ãããªççæ§çŸæ£ã®äŸãšããŠããåã®éææ§åå¿ãäŸãã°ä»¥äžã®ãã®ãæãããããããã«éå®ãããªãïŒåæ¯ãå«ãèºã®éææ§çå矀ãã¢ãããŒçå矀ãã¢ã¬ã«ã®ãŒæ§éŒ»çãçŒã®è¡ç®¡æµ®è «ãéºäŒæ§ã®è¡ç®¡æµ®è «ãã¢ã³ãã¬ã»ãã¿ãŒéææ§åå¿ããã³èªå·±å ç«çŸæ£ãæ©æ¬ç²ç¶è ºçãå šèº«æ§ãšãªããããŒãã¹ãã°ãããã¹ãã£ãŒçå矀ã倩ç±ç¡ãéççç¡åçãã°ã©ãŒãç ããã³ã¬ã€ããŒç ãåã€ã³ã¹ãªã³æµææ§ç³å°¿ç ãæ ¢æ§é¢ç¯ãªãŠããã也ç¬ãã¯ãŒãã³ç ã匷ç®çãæ··åçµåçµç¹ç ãå€çºççããµã«ã³ã€ããŒã·ã¹ã糞çäœè çãæ¥æ§ãŸãã¯æ ¢æ§ã®ç§»æ€ç察宿䞻åå¿ã
ççæ§çŸæ£ã«ã¯ãå ç«ç³»ã®çŽ°èæ§ãŸãã¯é现èæ§ã®ã¡ãã£ãšãŒã¿ãŒããŸãã¯ççãåŒãããåŸã«æ¥æ§ãŸãã¯æ ¢æ§ã®ççç¶æ ãããããã身äœçµç¹ãåŒãéãšãªãçŸæ£ãå«ãŸããããã®ãããªççæ§çŸæ£ã®äŸãšããŠããåã®éææ§åå¿ãäŸãã°ä»¥äžã®ãã®ãæãããããããã«éå®ãããªãïŒåæ¯ãå«ãèºã®éææ§çå矀ãã¢ãããŒçå矀ãã¢ã¬ã«ã®ãŒæ§éŒ»çãçŒã®è¡ç®¡æµ®è «ãéºäŒæ§ã®è¡ç®¡æµ®è «ãã¢ã³ãã¬ã»ãã¿ãŒéææ§åå¿ããã³èªå·±å ç«çŸæ£ãæ©æ¬ç²ç¶è ºçãå šèº«æ§ãšãªããããŒãã¹ãã°ãããã¹ãã£ãŒçå矀ã倩ç±ç¡ãéççç¡åçãã°ã©ãŒãç ããã³ã¬ã€ããŒç ãåã€ã³ã¹ãªã³æµææ§ç³å°¿ç ãæ ¢æ§é¢ç¯ãªãŠããã也ç¬ãã¯ãŒãã³ç ã匷ç®çãæ··åçµåçµç¹ç ãå€çºççããµã«ã³ã€ããŒã·ã¹ã糞çäœè çãæ¥æ§ãŸãã¯æ ¢æ§ã®ç§»æ€ç察宿䞻åå¿ã
ïŒïŒµïŒã¯ãå
ç«ç³»ã®çš®ã
ã®çµç¹ããã³å
ç«ç³»ã®æ§ææååå¿ããçµç¹äžŠã³ã«ççã®ã¡ãã£ãšãŒã¿ãŒãšåå¿ãåŸãçµç¹ã«ãããŠé«åºŠã«çºçŸãããäžèšçµç¹ã«ãããçºçŸã¯ãïŒïŒµïŒãšççæ§çŸæ£ãšã®éã®é¢é£ã瀺åããŠãããççæ§çŸæ£ãåŠçœ®ããããã«ïŒ®ïŒïŒµïŒã調ç¯ãããã®ãããªçŸæ£ã蚺æããããã«ïŒ®ïŒïŒµïŒã枬å®ããããšãã§ããã
èèçŸæ£
ææ³çŸæ£ã«ã¯åçºæ§ãŸãã¯äºæ¬¡çãªãåŸå€©çãŸãã¯éºäŒæ§ã®ãè¯æ§ãŸãã¯æªæ§ã®ãèèãŸãã¯èº«äœå šäœã«åœ±é¿ãåãŒãåŸããæ¥æ§ãŸãã¯æ ¢æ§çãªçŸæ£ãŸãã¯èèã®æå·ãå«ãŸããããããã«ã¯ã以äžã®æ該ãå«ãŸããããããã«éå®ãããªãïŒããªã«ãã³ä»£è¬ãé»çžãã®ã«ããŒããCrigler-Najjar, Dubin- Johnsonããã³Rotorã®çå矀ïŒèå èæ±ãã£æ»ãèè¥å€§ãéèå§äº¢é²çãè ¹æ°ŽçãBudd-Chiariçå矀ãéèäœåŸªç°æ§è³çãèèªèãèèªçãïŒ²ïœ ïœïœ âïœçå矀ãã¢ã«ã³ãŒã«ã«èµ·å ããèé害ãã¢ã«ã³ãŒã«æ§èçãŸãã¯è硬å€ãå 倩æ§ã®ãŸãã¯å€çç©è³ªã®ä»£è¬é害ã«èµ·å ããç·ç¶çããã³è硬å€ãæ²ççãGaucher'sçå矀ãZellweger'sçå矀, Wilson'sç ãæ¥æ§ãŸãã¯æ ¢æ§èçããŠã€ã«ã¹æ§èçããŠã€ã«ã¹ã现èãçèãåçåç©ãå¯çè«ã«èµ·å ããèèã®ççç¶æ ïŒè¬ç©ã«ããèèé害ãæ ¢æ§ã®èèçŸæ£ãäŸãã°åçºæ§ç¡¬åæ§è管çãα1æããªãã·ã³æ¬ ä¹çãåçºæ§èæ±æ§è硬å€ãæè¡åŸã®èèé害ãäŸãã°æè¡åŸã®èå èæ±ãã£æ»ãèèèèœè «ãå šèº«æ§çŸæ£ã«é¢é£ããèèè¡ç®¡é害ãèèã®è¯æ§ãŸãã¯æªæ§ã®æ°çç©ãæ°çå ãŸãã¯æªçå ã®èè代è¬é害ã
ææ³çŸæ£ã«ã¯åçºæ§ãŸãã¯äºæ¬¡çãªãåŸå€©çãŸãã¯éºäŒæ§ã®ãè¯æ§ãŸãã¯æªæ§ã®ãèèãŸãã¯èº«äœå šäœã«åœ±é¿ãåãŒãåŸããæ¥æ§ãŸãã¯æ ¢æ§çãªçŸæ£ãŸãã¯èèã®æå·ãå«ãŸããããããã«ã¯ã以äžã®æ該ãå«ãŸããããããã«éå®ãããªãïŒããªã«ãã³ä»£è¬ãé»çžãã®ã«ããŒããCrigler-Najjar, Dubin- Johnsonããã³Rotorã®çå矀ïŒèå èæ±ãã£æ»ãèè¥å€§ãéèå§äº¢é²çãè ¹æ°ŽçãBudd-Chiariçå矀ãéèäœåŸªç°æ§è³çãèèªèãèèªçãïŒ²ïœ ïœïœ âïœçå矀ãã¢ã«ã³ãŒã«ã«èµ·å ããèé害ãã¢ã«ã³ãŒã«æ§èçãŸãã¯è硬å€ãå 倩æ§ã®ãŸãã¯å€çç©è³ªã®ä»£è¬é害ã«èµ·å ããç·ç¶çããã³è硬å€ãæ²ççãGaucher'sçå矀ãZellweger'sçå矀, Wilson'sç ãæ¥æ§ãŸãã¯æ ¢æ§èçããŠã€ã«ã¹æ§èçããŠã€ã«ã¹ã现èãçèãåçåç©ãå¯çè«ã«èµ·å ããèèã®ççç¶æ ïŒè¬ç©ã«ããèèé害ãæ ¢æ§ã®èèçŸæ£ãäŸãã°åçºæ§ç¡¬åæ§è管çãα1æããªãã·ã³æ¬ ä¹çãåçºæ§èæ±æ§è硬å€ãæè¡åŸã®èèé害ãäŸãã°æè¡åŸã®èå èæ±ãã£æ»ãèèèèœè «ãå šèº«æ§çŸæ£ã«é¢é£ããèèè¡ç®¡é害ãèèã®è¯æ§ãŸãã¯æªæ§ã®æ°çç©ãæ°çå ãŸãã¯æªçå ã®èè代è¬é害ã
ïŒïŒµïŒå容äœã¯ãèèçµç¹ã«ãããŠé«åºŠã«çºçŸãããèèçµç¹ã«ãããçºçŸã¯ãïŒïŒµïŒãšèèçŸæ£ãšã®éã®é¢é£ã瀺åããŠãããèèçŸæ£ãåŠçœ®ããããã«ïŒ®ïŒïŒµïŒã調ç¯ãããã®ãããªçŸæ£ã蚺æããããã«ïŒ®ïŒïŒµïŒã枬å®ããããšãã§ããã
çé害
æ¬çºæã®ç¯å²ã«å«ãŸããçé害ã«ã¯ãå¶åŸ¡ãäžååã§ããããŸãã¯å¶åŸ¡ãããªããæ£åžžãªãŸãã¯ç°åžžãªçŽ°èã®å¢æ®ã«ãã£ãŠç¹åŸŽä»ãããããåºä¹³é¡ã«ãããèåšãŸãã¯çµç¹ã®ä»»æã®çŸæ£ãå«ãŸãããæ¬çºæã®ç¯å²ã®ççŸæ£ã«ã¯ãè¯æ§ã®æ°çç©ãç°åœ¢æãé圢æã䞊ã³ã«è»¢ç§»æ§ã®å¢æ®ã瀺ãæ°çç©ããŸãã¯ä»ã®ããããã®åœ¢è³ªè»¢æãäŸãã°ãã°ãã°çã®çºçã«å ç«ã€çœæçãå«ãŸããã现èããã³çµç¹ã¯ãå¢æ®ãæ£åžžã®çŽ°èãããæ¥éã«ãªããåšå²ã®å¥åº·ãªçµç¹ãŸãã¯ä»ã®ããããã®ä»ã®çµç¹ãžãšè»¢ç§»ãŸãã¯åºããã転移æ§ã®å¢æ®ãæããã¯ç°åžžãªåœ¢ç¶ãšããŠèšè¿°ããããããã®æ žçŽ°è質ã®æ¯çïŒnucleocytoplasmatic ratioïŒãæ žå€è²æ§ã«ãããå€åã瀺ããæåŸã«ã¯åæ¢ããå Žåã«çã«ãªããçã«ãªã£ã现èããã³çµç¹ã¯ãè «çé䌎çå矀ãåŒãèµ·ããããšãã«èº«äœå šäœã«åœ±é¿ãåãŒãããŸãã¯ãçãçåœç¶æã«å¿ èŠãªèåšãŸãã¯çµç¹ã«èµ·ãã£ããšããæ£åžžãªæ©èœã害ãããŸãã¯åæ¢ããèŽåœçã«ãªãããšããããéèŠèåšãæçµçã«çã«åããããšãåçºæ§ãŸãã¯è»¢ç§»æ§ã«é¢ããããåãããåºä¹³é¡ã¯æ»ã«è³ãããšããããçã¯åºããåŸåã«ããããã®åºããé床ã¯éåžžãã®äººã®çåããæ©äŒãšé¢é£ãããçã¯ãäžè¬ã«ïŒã€ã®é²è¡æ®µéã®ããããã§èšãããïŒåæãŸãã¯å±åšãçãäŸç¶ãšããŠèåšã®çµç¹ãŸãã¯æåã®å Žæã«çãŸã£ãŠããç¶æ ïŒçŽæ¥çæ¡åŒµïŒdirect extensionïŒãè «çããç现èãé£æ¥ããçµç¹ã«äŸµè¥²ããåã«é åãªã³ãç¯ã«åºããå ŽåïŒãŸãã¯è»¢äœãç现èãè¡æ¶²ãŸãã¯ãªã³ãç³»ãä»ããŠæåã®éšäœããé¢ãã身äœã®éšåã«ç§»åããäŒæ¬ã®äºæ¬¡çéšäœã確ç«ããç¶æ ãçã¯ãåŠçœ®ããªããã°æ»ãåŒãèµ·ããåŸåã®ããã«ãæªæ§ã§ãããšããããŠãããè¯æ§ã®è «çã¯ãéåžžã¯æ»ãåŒãèµ·ãããªããããã®å Žæã倧ããããŸãã¯è «çé䌎æ§ã®å¯äœçšã«ãã£ãŠã¯ãæ£åžžãªèº«äœæ©èœã劚害ããå Žåæ»ãããããããšãããããããã£ãŠãè¯æ§è «çãåæ§ã«æ¬çºæã®çã®å®çŸ©ã«å«ãŸãããäžè¬ã«ãç现èã¯æ£åžžãªçŽ°èãããéãé床ã§åè£ããããããã¯ç现èã«ãããå¢æ®æå¶ã®éšåçãŸãã¯å®å šãªåªå€±ã§ãããæ£åžžçµç¹ã®æ©èœçã«åçãªå¢æ®ãç¹åŸŽä»ããæçšãªãéãããçš®é¡ã®çµç¹ã«åºå¥ããããšãã§ããªãã®ã§ãççµç¹ãšæ£åžžçµç¹ã®å¢æ®ã¯ããŸãåºå¥ã§ããªããççµç¹ã¯ããç¹å®ã®ååéã®å容äœãçºçŸããä¹³çããã³åç«è ºçãäŸãã°ãããã®ååšã®ããã®ç¹å®ã®ãã«ã¢ã³ã«äŸåããããšãç¥ãããŠããããã«ã宿䞻ã®æåæ§ããã³å ç«ã«ãã£ãŠåœ±é¿ãåããããšããããæ¬çºæã®ç¯å²ã«ããããçããªãçšèªã¯ãåçŽãªè¯æ§ã®æ°çç©ã«éãããªãããä»»æã®ä»ã®è¯æ§ããã³æªæ§ã®æ°çç©ãå å«ãããäŸãã°ïŒïŒïŒçè «ãïŒïŒèè «ãïŒïŒçèè «ãïŒïŒè¡æ¶²åœ¢æçµç¹ã®çãïŒïŒè³ãå«ãç¥çµçµç¹ã®çãïŒïŒç®è现èã®çãïŒïŒã®çã¯ã身äœã®å€åŽãèŠã£ãŠããäžç®çµç¹ïŒç®èïŒãããã³ã©ã€ã³ç²èããã³å è æ§é ç²èãäŸãã°ä¹³æ¿ãèºãåŒåžåšããã³æ¶å管ãå åæ³è ºããã³å°¿çæ®åšç³»ãå«ãèåšã«èµ·ããã管ç¶ãŸãã¯ç·ç¶ã®ãšã¬ã¡ã³ãããè ºçãšããŠäžç®çµç¹ã«ååšãåŸããäŸãã°ãç²ç¶è ºçãèã®è ºçãåå®®è ºçãç®èã®äžç®ã®ããã³ç¹å®ã®ç²èã®èè£ çŽ°èïŒpavement-cellïŒçãäŸãã°ãèãåãåœé ãèè±ãåå®®é žãŸãã¯é°èã¯ãåçµç¹ã®é¡è¡šç®ã®ãŸãã¯æå¹³äžç®çŽ°èã®çãšç§°ããåæ§ã«æ¬çºæã®çã®å®çŸ©ã«å å«ããããïŒïŒã®çã¯ãç¹ç¶ç¶çµç¹ãèèªïŒïœïœïœïŒçµç¹ãçèãè¡ç®¡ã骚ããã³é¢ç¯çã®çµåçµç¹ã«ãããŠé²è¡ãããäŸãã°éªšèè «ãèèªèè «ãç¹ç¶èè «ãæ»æ¶²èè «çãïŒïŒã®çã¯äžç®çŽ°èããã³çµåçµç¹ã®äž¡æ¹ã§é²è¡ãããæ¬å®çŸ©ã«å«ãŸããççŸæ£ã¯ãåçºæ§ãŸãã¯ç¶çºæ§ã§ããåŸãããã«ãã£ãŠåçºæ§ã¯ããããèŠã€ãã£ãå Žæããå¥ã®ç å·£ããã®è»¢äœã«ããäºæ¬¡çéšäœã確ç«ããå Žæãšå¥ã®å Žæã«ããšããšååšããŠããããšã瀺ããæ¬ææ矩ã«ãããçããã³è «ççŸæ£ã¯è¯æ§ãŸãã¯æªæ§ã§ãããåºä¹³é¡ã®èº«äœã®ãã¹ãŠã®è§£ååŠçæ§é ã«åœ±é¿ãåãŒãããããã«ã¯ã以äžã®çããã³è «ççŸæ£ãäŸç€ºããããããã«éå®ãããªãïŒïŒ©ïŒéªšé«ããã³éªšé«ã«ç±æ¥ãã现èïŒçœè¡ç ïŒãïŒå åæ³è ºããã³å€åæ³è ºãç²ç¶è ºãäžç®å°äœãäžåäœãå¯è ãåŸæ¶²è ºãèµèãïŒä¹³æ¿ãäŸãã°ç·æ§ãŸãã¯å¥³æ§ã®ä¹³è ºã®è¯æ§ãŸãã¯æªæ§è «çã乳管ãè ºçãé«æ§çãé¢ç±çãä¹³éŠã®ããŒãžã§ããç ãè¥ã女æ§ã®ççæ§ä¹³çãïŒèºãïŒèãïŒèãèèããã³èŸèãïŒå°è žãïŒçµè žãïŒéªšããã³ãã®æ¯æã»çµåçµç¹ïŒæªæ§ãŸãã¯è¯æ§ã®éªšçãäŸãã°æªæ§éªšèè «ãè¯æ§ã®éªšè «ãè»éªšè «çãæªæ§ã®è»éªšè «çãŸãã¯è¯æ§ã®éªšé«è «ãŸãã¯æªæ§ã®éªšé«è «ã®ãããªïŒãŸãã¯è¯æ§ã®å¥œé žçæ§èèœè «ã䞊ã³ã«éªšçµç¹ããã®èº«äœã®ä»ã®å Žæã§ã®è»¢ç§»æ§ã®è «çïŒïŒžïŒå£ãåœãåœé ãããã³é£å ãïŒç·æ§ãŸãã¯å¥³æ§ã®èè±ããã³çæ®æ³å°¿åšç³»ã®å éšããã³å€éšæ°ç®¡ããã³æ§é ãäŸãã°åµå·£ãåå®®ãåå®®é žã粟巣ãããã³åç«è ºãïŒåç«è ºãïŒèµèãäŸãã°èµèã®è ºç®¡çïŒïŒžïŒ©ïŒ¶ïŒãªã³ãçµç¹ãäŸãã°ãªã³ãè «ããã³ä»ã®ãªã³ãç¯ã®è «çãïŒç®èãïŒåŒåžããã³åŒåžåšç³»ã«å±ããèžçããã³å é¢ãå«ããã¹ãŠã®è§£ååŠçæ§é ã®çããã³è «ççŸæ£ãïŒãªã³ãç¯ã®åçºæ§ãŸãã¯ç¶çºæ§ã®çãïŒèããã³ç¡¬å£èãŸãã¯æŽã®éªšæ§æ§é ãïŒå£ãé ¬ãé žããã³åŸæ¶²è ºãïŒå¿èãŸãã¯ãã®å 匵ãå«ãè¡ç®¡ãïŒå¹³æ»çãŸãã¯éªšæ Œçããã³ãããã®é±åž¯ããã³å 匵ããïŒæ«æ¢¢ç¥çµãèªåŸç¥çµãäžæ¢ç¥çµç³»ïŒè³ãå«ãïŒãïŒèèªçµç¹ã
æ¬çºæã®ç¯å²ã«å«ãŸããçé害ã«ã¯ãå¶åŸ¡ãäžååã§ããããŸãã¯å¶åŸ¡ãããªããæ£åžžãªãŸãã¯ç°åžžãªçŽ°èã®å¢æ®ã«ãã£ãŠç¹åŸŽä»ãããããåºä¹³é¡ã«ãããèåšãŸãã¯çµç¹ã®ä»»æã®çŸæ£ãå«ãŸãããæ¬çºæã®ç¯å²ã®ççŸæ£ã«ã¯ãè¯æ§ã®æ°çç©ãç°åœ¢æãé圢æã䞊ã³ã«è»¢ç§»æ§ã®å¢æ®ã瀺ãæ°çç©ããŸãã¯ä»ã®ããããã®åœ¢è³ªè»¢æãäŸãã°ãã°ãã°çã®çºçã«å ç«ã€çœæçãå«ãŸããã现èããã³çµç¹ã¯ãå¢æ®ãæ£åžžã®çŽ°èãããæ¥éã«ãªããåšå²ã®å¥åº·ãªçµç¹ãŸãã¯ä»ã®ããããã®ä»ã®çµç¹ãžãšè»¢ç§»ãŸãã¯åºããã転移æ§ã®å¢æ®ãæããã¯ç°åžžãªåœ¢ç¶ãšããŠèšè¿°ããããããã®æ žçŽ°è質ã®æ¯çïŒnucleocytoplasmatic ratioïŒãæ žå€è²æ§ã«ãããå€åã瀺ããæåŸã«ã¯åæ¢ããå Žåã«çã«ãªããçã«ãªã£ã现èããã³çµç¹ã¯ãè «çé䌎çå矀ãåŒãèµ·ããããšãã«èº«äœå šäœã«åœ±é¿ãåãŒãããŸãã¯ãçãçåœç¶æã«å¿ èŠãªèåšãŸãã¯çµç¹ã«èµ·ãã£ããšããæ£åžžãªæ©èœã害ãããŸãã¯åæ¢ããèŽåœçã«ãªãããšããããéèŠèåšãæçµçã«çã«åããããšãåçºæ§ãŸãã¯è»¢ç§»æ§ã«é¢ããããåãããåºä¹³é¡ã¯æ»ã«è³ãããšããããçã¯åºããåŸåã«ããããã®åºããé床ã¯éåžžãã®äººã®çåããæ©äŒãšé¢é£ãããçã¯ãäžè¬ã«ïŒã€ã®é²è¡æ®µéã®ããããã§èšãããïŒåæãŸãã¯å±åšãçãäŸç¶ãšããŠèåšã®çµç¹ãŸãã¯æåã®å Žæã«çãŸã£ãŠããç¶æ ïŒçŽæ¥çæ¡åŒµïŒdirect extensionïŒãè «çããç现èãé£æ¥ããçµç¹ã«äŸµè¥²ããåã«é åãªã³ãç¯ã«åºããå ŽåïŒãŸãã¯è»¢äœãç现èãè¡æ¶²ãŸãã¯ãªã³ãç³»ãä»ããŠæåã®éšäœããé¢ãã身äœã®éšåã«ç§»åããäŒæ¬ã®äºæ¬¡çéšäœã確ç«ããç¶æ ãçã¯ãåŠçœ®ããªããã°æ»ãåŒãèµ·ããåŸåã®ããã«ãæªæ§ã§ãããšããããŠãããè¯æ§ã®è «çã¯ãéåžžã¯æ»ãåŒãèµ·ãããªããããã®å Žæã倧ããããŸãã¯è «çé䌎æ§ã®å¯äœçšã«ãã£ãŠã¯ãæ£åžžãªèº«äœæ©èœã劚害ããå Žåæ»ãããããããšãããããããã£ãŠãè¯æ§è «çãåæ§ã«æ¬çºæã®çã®å®çŸ©ã«å«ãŸãããäžè¬ã«ãç现èã¯æ£åžžãªçŽ°èãããéãé床ã§åè£ããããããã¯ç现èã«ãããå¢æ®æå¶ã®éšåçãŸãã¯å®å šãªåªå€±ã§ãããæ£åžžçµç¹ã®æ©èœçã«åçãªå¢æ®ãç¹åŸŽä»ããæçšãªãéãããçš®é¡ã®çµç¹ã«åºå¥ããããšãã§ããªãã®ã§ãççµç¹ãšæ£åžžçµç¹ã®å¢æ®ã¯ããŸãåºå¥ã§ããªããççµç¹ã¯ããç¹å®ã®ååéã®å容äœãçºçŸããä¹³çããã³åç«è ºçãäŸãã°ãããã®ååšã®ããã®ç¹å®ã®ãã«ã¢ã³ã«äŸåããããšãç¥ãããŠããããã«ã宿䞻ã®æåæ§ããã³å ç«ã«ãã£ãŠåœ±é¿ãåããããšããããæ¬çºæã®ç¯å²ã«ããããçããªãçšèªã¯ãåçŽãªè¯æ§ã®æ°çç©ã«éãããªãããä»»æã®ä»ã®è¯æ§ããã³æªæ§ã®æ°çç©ãå å«ãããäŸãã°ïŒïŒïŒçè «ãïŒïŒèè «ãïŒïŒçèè «ãïŒïŒè¡æ¶²åœ¢æçµç¹ã®çãïŒïŒè³ãå«ãç¥çµçµç¹ã®çãïŒïŒç®è现èã®çãïŒïŒã®çã¯ã身äœã®å€åŽãèŠã£ãŠããäžç®çµç¹ïŒç®èïŒãããã³ã©ã€ã³ç²èããã³å è æ§é ç²èãäŸãã°ä¹³æ¿ãèºãåŒåžåšããã³æ¶å管ãå åæ³è ºããã³å°¿çæ®åšç³»ãå«ãèåšã«èµ·ããã管ç¶ãŸãã¯ç·ç¶ã®ãšã¬ã¡ã³ãããè ºçãšããŠäžç®çµç¹ã«ååšãåŸããäŸãã°ãç²ç¶è ºçãèã®è ºçãåå®®è ºçãç®èã®äžç®ã®ããã³ç¹å®ã®ç²èã®èè£ çŽ°èïŒpavement-cellïŒçãäŸãã°ãèãåãåœé ãèè±ãåå®®é žãŸãã¯é°èã¯ãåçµç¹ã®é¡è¡šç®ã®ãŸãã¯æå¹³äžç®çŽ°èã®çãšç§°ããåæ§ã«æ¬çºæã®çã®å®çŸ©ã«å å«ããããïŒïŒã®çã¯ãç¹ç¶ç¶çµç¹ãèèªïŒïœïœïœïŒçµç¹ãçèãè¡ç®¡ã骚ããã³é¢ç¯çã®çµåçµç¹ã«ãããŠé²è¡ãããäŸãã°éªšèè «ãèèªèè «ãç¹ç¶èè «ãæ»æ¶²èè «çãïŒïŒã®çã¯äžç®çŽ°èããã³çµåçµç¹ã®äž¡æ¹ã§é²è¡ãããæ¬å®çŸ©ã«å«ãŸããççŸæ£ã¯ãåçºæ§ãŸãã¯ç¶çºæ§ã§ããåŸãããã«ãã£ãŠåçºæ§ã¯ããããèŠã€ãã£ãå Žæããå¥ã®ç å·£ããã®è»¢äœã«ããäºæ¬¡çéšäœã確ç«ããå Žæãšå¥ã®å Žæã«ããšããšååšããŠããããšã瀺ããæ¬ææ矩ã«ãããçããã³è «ççŸæ£ã¯è¯æ§ãŸãã¯æªæ§ã§ãããåºä¹³é¡ã®èº«äœã®ãã¹ãŠã®è§£ååŠçæ§é ã«åœ±é¿ãåãŒãããããã«ã¯ã以äžã®çããã³è «ççŸæ£ãäŸç€ºããããããã«éå®ãããªãïŒïŒ©ïŒéªšé«ããã³éªšé«ã«ç±æ¥ãã现èïŒçœè¡ç ïŒãïŒå åæ³è ºããã³å€åæ³è ºãç²ç¶è ºãäžç®å°äœãäžåäœãå¯è ãåŸæ¶²è ºãèµèãïŒä¹³æ¿ãäŸãã°ç·æ§ãŸãã¯å¥³æ§ã®ä¹³è ºã®è¯æ§ãŸãã¯æªæ§è «çã乳管ãè ºçãé«æ§çãé¢ç±çãä¹³éŠã®ããŒãžã§ããç ãè¥ã女æ§ã®ççæ§ä¹³çãïŒèºãïŒèãïŒèãèèããã³èŸèãïŒå°è žãïŒçµè žãïŒéªšããã³ãã®æ¯æã»çµåçµç¹ïŒæªæ§ãŸãã¯è¯æ§ã®éªšçãäŸãã°æªæ§éªšèè «ãè¯æ§ã®éªšè «ãè»éªšè «çãæªæ§ã®è»éªšè «çãŸãã¯è¯æ§ã®éªšé«è «ãŸãã¯æªæ§ã®éªšé«è «ã®ãããªïŒãŸãã¯è¯æ§ã®å¥œé žçæ§èèœè «ã䞊ã³ã«éªšçµç¹ããã®èº«äœã®ä»ã®å Žæã§ã®è»¢ç§»æ§ã®è «çïŒïŒžïŒå£ãåœãåœé ãããã³é£å ãïŒç·æ§ãŸãã¯å¥³æ§ã®èè±ããã³çæ®æ³å°¿åšç³»ã®å éšããã³å€éšæ°ç®¡ããã³æ§é ãäŸãã°åµå·£ãåå®®ãåå®®é žã粟巣ãããã³åç«è ºãïŒåç«è ºãïŒèµèãäŸãã°èµèã®è ºç®¡çïŒïŒžïŒ©ïŒ¶ïŒãªã³ãçµç¹ãäŸãã°ãªã³ãè «ããã³ä»ã®ãªã³ãç¯ã®è «çãïŒç®èãïŒåŒåžããã³åŒåžåšç³»ã«å±ããèžçããã³å é¢ãå«ããã¹ãŠã®è§£ååŠçæ§é ã®çããã³è «ççŸæ£ãïŒãªã³ãç¯ã®åçºæ§ãŸãã¯ç¶çºæ§ã®çãïŒèããã³ç¡¬å£èãŸãã¯æŽã®éªšæ§æ§é ãïŒå£ãé ¬ãé žããã³åŸæ¶²è ºãïŒå¿èãŸãã¯ãã®å 匵ãå«ãè¡ç®¡ãïŒå¹³æ»çãŸãã¯éªšæ Œçããã³ãããã®é±åž¯ããã³å 匵ããïŒæ«æ¢¢ç¥çµãèªåŸç¥çµãäžæ¢ç¥çµç³»ïŒè³ãå«ãïŒãïŒèèªçµç¹ã
ïŒïŒµïŒå容äœã¯ãçµè
žçã¯èºççã®çš®ã
ã®ççµç¹ã«ãããŠé«åºŠã«çºçŸãããäžèšã®çµç¹ã«ãããçºçŸã¯ãïŒïŒµïŒãšçãšã®éã®é¢é£ã瀺åããŠãããçãåŠçœ®ãŸãã¯èšºæããããã«ïŒ®ïŒïŒµïŒã調ç¯ãŸãã¯æž¬å®ããããšãã§ããã
å¿çš
æ¬çºæã¯ãè¡æ¶²çŸæ£ãå¿çŸæ£ãæ«æ¢¢ããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãççŸæ£ããã³èèé害ã®äºé²æ¹æ³ããã³æ²»çæ¹æ³ã®äž¡æ¹ãæäŸããã
æ¬çºæã¯ãè¡æ¶²çŸæ£ãå¿çŸæ£ãæ«æ¢¢ããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãççŸæ£ããã³èèé害ã®äºé²æ¹æ³ããã³æ²»çæ¹æ³ã®äž¡æ¹ãæäŸããã
æ¬çºæã®èª¿ç¯æ¹æ³ã¯ãïŒïŒµïŒã®ïŒãŸãã¯ãã以äžã®æŽ»æ§ã調ç¯ããè¬å€ãšçŽ°èãæ¥è§Šãããããšã䌎ãã掻æ§ã調ç¯ããè¬å€ã¯ãæ žé
žãŸãã¯ã¿ã³ãã¯è³ªãããªããããã®å€©ç¶ã®åæã®ãªã¬ã³ãããããããããããæš¡æ¬ç©ãŸãã¯ä»»æã®å°ååãªã©ã®æ¬æ现æžã«èšèŒã®è¬å€ã§ãã£ãŠãããïŒã€ã®æ
æ§ã§ã¯ããã®è¬å€ã¯ãïŒïŒµïŒã®ïŒãŸãã¯ãã以äžã®çç©åŠç掻æ§ãåºæ¿ããããã®ãããªåºæ¿ç©è³ªã®äŸãšããŠã¯ã掻æ§ãªïŒ®ïŒïŒµïŒããã³ïŒ®ïŒïŒµïŒã®äžéšãã³ãŒãããæ žé
žååãæãããããå¥ã®æ
æ§ã§ã¯ããã®è¬å€ã¯ãïŒïŒµïŒã®ïŒãŸãã¯ãã以äžã®çç©åŠç掻æ§ãé»å®³ããããã®ãããªé»å®³ç©è³ªã®äŸãšããŠã¯ãã¢ã³ãã»ã³ã¹æ žé
žååããã³æäœãæããããããããã®èª¿ç¯æ¹æ³ã¯ãïœïœïœïœïœïœïœïŒäŸãã°ã现èãè¬å€ãšãšãã«å¹é€ããããšã«ãã£ãŠïŒã§è¡ãããŸãã¯ããããã¯ïœïœïœïœïœïœïŒäŸãã°ãè¬å€ãæ£è
ã«æäžããããšã«ãã£ãŠïŒã§è¡ãããšãã§ããããããã£ãŠãæ¬çºæã¯ãæãŸãããªãçºçŸãŸãã¯ïŒ®ïŒïŒµïŒã®æŽ»æ§ãŸãã¯ïŒ®ïŒïŒµïŒã·ã°ãã«äŒéçµè·¯ã«ãããã¿ã³ãã¯è³ªã«ãã£ãŠç¹åŸŽä»ããããçŸæ£ãŸãã¯é害ã«åãããŠãã人ãåŠçœ®ããæ¹æ³ãæäŸãããïŒã€ã®æ
æ§ã§ã¯ãæ¬æ¹æ³ã¯ãæ¬æ现æžã«èšèŒã®ã¹ã¯ãªãŒãã³ã°ã¢ãã»ã€ã«ãã£ãŠåå®ããããŸãã¯åå®å¯èœãªä»»æã®è¬å€ã®ãããªè¬å€ãŸãã¯çºçŸãŸãã¯ïŒ®ïŒïŒµïŒã®æŽ»æ§ãŸãã¯ïŒ®ïŒïŒµïŒã·ã°ãã«çµè·¯ã«ãããä»»æã®ã¿ã³ãã¯è³ªã®æŽ»æ§ãäžæ¹èª¿ç¯ãŸãã¯äžæ¹èª¿ç¯ãããã®ãããªè¬å€ã®çµåããæäžããããšã䌎ããå¥ã®æ
æ§ã§ã¯ãæ¬æ¹æ³ã¯ãïŒïŒµïŒããïŒïŒµïŒãŸãã¯ïŒ®ïŒïŒµïŒã·ã°ãã«äŒéçµè·¯ã«ãããã¿ã³ãã¯è³ªã®æžå°ãããŸãã¯æãŸãããªãäœãçºçŸãŸãã¯æŽ»æ§ãè£ãããã®æ²»çãšããŠæäžããããšãå«ãã
ïŒïŒµïŒã®æŽ»æ§ãŸãã¯çºçŸã®åºæ¿ã¯ã掻æ§ãŸãã¯çºçŸã以äžã«äœããå¢å ãã掻æ§ãæçãªå¹æãæãããšæãããç¶æ³ã«ãããŠæãŸãããéã«ãïŒïŒµïŒã®æŽ»æ§ãŸãã¯é»å®³ã¯ãïŒïŒµïŒã®æŽ»æ§ãŸãã¯çºçŸãç°åžžã«é«ãããã®æŽ»æ§ãæçãªå¹æãæãããšæãããç¶æ³ã«ãããŠæãŸããã
æ¬çºæã¯ããã«ãéå®ãšããŠè§£éããŠã¯ãªããªã以äžã®å®æœäŸã«ãã£ãŠèª¬æããããæ¬é¡ã«ãããŠåŒçšãããã¹ãŠã®æç®ãç¹èš±ããã³å
¬éãããç¹èš±åºé¡ã®å
容ã¯ãããã«åèãšããŠæ¬æ现æžã®äžéšãæ§æããã
å»è¬çµæç©
æ¬çºæã¯ããã«ãäžèšã®ã¹ã¯ãªãŒãã³ã°ã¢ãã»ã€ã«ãã£ãŠåå®ãããæ°èŠã®è¬å€ããã³æ¬æ现æžã«èšèŒããåŠçœ®ã®ããã®ãã®äœ¿çšã«é¢ããã
æ¬çºæã¯ããã«ãäžèšã®ã¹ã¯ãªãŒãã³ã°ã¢ãã»ã€ã«ãã£ãŠåå®ãããæ°èŠã®è¬å€ããã³æ¬æ现æžã«èšèŒããåŠçœ®ã®ããã®ãã®äœ¿çšã«é¢ããã
æ¬çºæã®æ žé
žååãããªãããããããã³æäœïŒã掻æ§ååç©ããšãããïŒã¯ãæäžã«é©åœãªå»è¬çµæç©ã«çµã¿èŸŒãããšãã§ããããã®ãããªçµæç©ã¯å
žåçã«æ žé
žååãã¿ã³ãã¯è³ªãŸãã¯æäœãšè£œè¬çã«èš±å®¹ãåŸãæ
äœãšãå«ããæ¬æ现æžã«ãããŠçšããããã補è¬çã«èš±å®¹ãåŸãæ
äœããªãèªã¯ãå»è¬ã®æäžã«é©åãããããã溶åªãåæ£åªäœãã³ãŒãã£ã³ã°ãæèå€ããã³æçèå€ãç匵ããã³åžåé
延å€ãªã©ãå«æããããšãæå³ããã補è¬çã«æŽ»æ§ãªç©è³ªã®ããã®ãã®ãããªåªäœãè©Šè¬ã®äœ¿çšã¯åœåéã«ãããŠããç¥ãããŠãããä»»æã®æ
£çšã®åªäœãŸãã¯è©Šè¬ã掻æ§ååç©ãšé©åããªãå Žåãé€ããŠãçµæç©ã«ããããã®äœ¿çšãäŒå³ãããããã«æŽ»æ§ååç©ãæ¬çµæç©ã«æ·»å ããããšãã§ããã
æ¬çºæã¯ãïŒïŒµïŒçºçŸãŸãã¯æŽ»æ§ïŒããã³ïŒãŸãã¯ïŒ®ïŒïŒµïŒã·ã°ãã«äŒéçµè·¯ã«ãããã¿ã³ãã¯è³ªã®æŽ»æ§ãŸãã¯çºçŸã®èª¿ç¯ç©è³ªïŒã®èª¿ç¯ç©è³ªãå«ãå»è¬çµæç©ãªãã³ã«ïŒãŸãã¯ãã以äžã®ãã®ãããªèª¿ç¯ç©è³ªã補è¬çã«èš±å®¹ãåŸãæ
äœãšçµã¿åãããããšã«ãããã®ãããªçµæç©ã®è£œé æ¹æ³ãå
å«ãããããã«ã䜿çšèª¬ææžãšå
±ã«å
è£
ããããæ¬çºæã®ã¹ã¯ãªãŒãã³ã°ã¢ãã»ã€ãçšããŠåå®ããã調ç¯ç©è³ªãå«ãå»è¬çµæç©ããŸãæ¬çºæã®ç¯å²ã«å«ãŸãããïŒïŒµïŒæŽ»æ§ã®ã¢ã³ã¿ãŽãã¹ãã§ãããïŒïŒµïŒçºçŸãæžå°ããã調ç¯ç©è³ªã«ã€ããŠã該䜿çšèª¬ææžã¯ãè¡æ¶²çŸæ£ããã³å¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ããåæ¯ãçæ®æ³å°¿ç³»ã®çŸæ£ããã³ççæ§çŸæ£ã®åŠçœ®ã®ããã®ãã®å»è¬çµæç©ã®äœ¿çšã«ã€ããŠè©³çŽ°ã«èšèŒãããïŒïŒµïŒæŽ»æ§ã®ã¢ãŽãã¹ãã§ãããŸãã¯ïŒ®ïŒïŒµïŒçºçŸãå¢å€§ãã調ç¯ç©è³ªã«ã€ããŠã該䜿çšèª¬ææžã¯ãè¡æ¶²çŸæ£ããã³å¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ããåæ¯ãçæ®æ³å°¿ç³»ã®çŸæ£ããã³ççæ§çŸæ£ã®åŠçœ®ã®ããã®ãã®å»è¬çµæç©ã®äœ¿çšã«ã€ããŠè©³çŽ°ã«èšèŒããã
åœåéã§äžè¬çã«ç¥ãããŠããæ¹æ³ãçšããŠïŒ®ïŒïŒµïŒã®ã¢ã³ã¿ãŽãã¹ãã補é ããããšãã§ãããç¹ã«ã粟補ããïŒïŒµïŒãçšããŠãæäœã補é ãããããŸãã¯å»è¬ã®ã©ã€ãã©ãªãŒãã¹ã¯ãªãŒãã³ã°ããŠïŒ®ïŒïŒµïŒã«ç¹ç°çã«çµåããå»è¬ãåå®ããããšãã§ãããïŒïŒµïŒã«å¯Ÿããæäœã¯ãŸããåœåéã«åšç¥ã®æ¹æ³ãçšããŠäœè£œããããšãã§ããããã®ãããªæäœãšããŠã¯ãããªã¯ããŒãã«ãã¢ãã¯ããŒãã«ããã¡ã©ãäžæ¬éæäœãïœïœæçãããã³ïŒŠïœïœçºçŸã©ã€ãã©ãªãŒã«ãã£ãŠç£çããæçãæãããããäºéäœåœ¢æãé»å®³ãããããªäžåæäœã¯ãæ²»çç䜿çšã«ç¹ã«å¥œãŸããã
æ¬çºæã®ãããªãæ
æ§ã§ã¯ãïŒïŒµïŒãã³ãŒãããããªãã¯ã¬ãªãããŸãã¯ãã®ä»»æã®æçãŸãã¯çžè£äœãæ²»çç®çã§çšããããšãã§ãããïŒã€ã®æ
æ§ã§ã¯ãïŒïŒµïŒãã³ãŒãããããªãã¯ã¬ãªããããïœïŒ²ïŒ®ïŒ¡ã®è»¢åããããã¯ããããšãæãŸããç¶æ³ã«ãããŠäœ¿çšããããšãã§ãããç¹ã«ã现èããïŒïŒµïŒãã³ãŒãããããªãã¯ã¬ãªããã«çžè£çãªé
åã§åœ¢è³ªè»¢æããããšãã§ããããããã£ãŠãçžè£çãªååãŸãã¯æçãçšããŠïŒ®ïŒïŒµïŒæŽ»æ§ã調ç¯ãããŸãã¯éºäŒåæ©èœã®èª¿ç¯ãéæããããšãã§ããããã®ãããªæè¡ã¯ä»ãåœåéã«ãããŠããç¥ãããŠãããïŒïŒµïŒãã³ãŒãããé
åã®ã³ãŒãé
åãŸãã¯å¶åŸ¡é åã«æ²¿ã£ãæ§ã
ãªäœçœ®ããã»ã³ã¹ãŸãã¯ã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªãããŸãã¯ããé·ãæçãèšèšããããšãã§ããã
ã¬ãããŠã€ã«ã¹ãã¢ãããŠã€ã«ã¹ããŸãã¯ãã«ãã¹ãŸãã¯ã¯ã¯ã·ãã¢ãŠã€ã«ã¹ãããŸãã¯æ§ã
ãªçŽ°èãã©ã¹ããèªå°ãããçºçŸãã¯ã¿ãŒãçšããŠããã¯ã¬ãªããé
åã®æšçã®åšå®ãçµç¹ãŸãã¯çŽ°èéå£ãžééããããšãã§ãããåœæ¥è
ã«åšç¥ã®æ¹æ³ãçšããŠãïŒïŒµïŒãã³ãŒãããéºäŒåã®ããªãã¯ã¬ãªããã«çžè£çãªæ žé
žé
åãçºçŸãããã¯ã¿ãŒãæ§ç¯ããããšãã§ããããããã®æè¡ã¯ãäŸãã°ãScott and Smith (1990) Science 249:386-390ã«èšèŒãããŠããã
äžèšã®ä»»æã®æ²»çæ¹æ³ããã®ãããªæ²»çãå¿
èŠãšããæ£è
ïŒäŸãã°ãã€ãããã³ããŠã·ããŠãããŠãµã®ããµã«ããã³ãã£ãšå¥œãŸããã¯ãããªã©ã®åºä¹³é¡ãå«ãïŒã«é©çšããããšãã§ããã
æ¬çºæã®ãããªãæ
æ§ã¯ãäžèšã®æ²»çå¹æã®ããããã®ããã®è£œè¬çã«èš±å®¹ãåŸãæ
äœãšãšãã«ãïŒïŒµïŒãå«æããå»è¬çµæç©ã®æäžã«é¢ããããã®ãããªå»è¬çµæç©ã¯ãïŒïŒµïŒãïŒïŒµïŒã«å¯Ÿããæäœããã³æš¡æ¬ç©ãïŒïŒµïŒã®ã¢ãŽãã¹ããã¢ã³ã¿ãŽãã¹ããŸãã¯é»å®³ç©è³ªãããªãããšãã§ãããçµæç©ãåç¬ã§æäžããããŸãã¯å°ãªããšãïŒã€ã®ä»ã®è©Šè¬ãäŸãã°ãå®å®åååç©ãšçµã¿åãããŠæäžããããšãã§ããä»»æã®æ»
èããããçç©çã«é©åãã補è¬çæ
äœïŒççé£å¡©æ°Žãç·©è¡åççé£å¡©æ°Žãããã¹ããªã³ããã³æ°Žãå«ããããã«éå®ãããªãïŒæ
äœäžã§æäžããããšãã§ãããæ¬çµæç©ã¯ãåç¬ã§æ£è
ã«æäžããããŸãã¯ä»ã®è©Šè¬ãè¬ç©ãŸãã¯ãã«ã¢ã³ãšçµã¿åãããŠæäžããããšãã§ããã
æ¬çºæã®å»è¬çµæç©ã¯ããã®æå³ããæäžçµè·¯ã«é©åããããã«è£œå€åãããæäžçµè·¯ã®äŸãšããŠã¯ãéçµå£ãäŸãã°ãéèå
ãç®å
ãç®äžããã³çµå£ïŒäŸãã°åžå
¥ïŒãçµç®ïŒå±æïŒãçµç²èããã³çŽè
žæäžãæãããããéçµå£ãç®å
ããŸãã¯ç®äžé©çšã«çšããããšãã§ãã溶液å€ãŸãã¯æžæ¿å€ãšããŠã¯ã以äžã®æåãå«ãŸããïŒæ»
èåžéå€ãäŸãã°æ³šå°çšã®æ°Žãççé£å¡©æ°Žæº¶æ¶²ãäžæ®çºæ§æ²¹ãããªãšãã¬ã³ã°ãªã³ãŒã«ãã°ãªã»ãªã³ããããã¬ã³ã°ãªã³ãŒã«ãŸãã¯ä»ã®åæ溶åªïŒæèå€ãäŸãã°ãã³ãžã«ã¢ã«ã³ãŒã«ãŸãã¯ã¡ãã«ãã©ãã³ïŒæé
žåå€ãäŸãã°ã¢ã¹ã³ã«ãã³é
žãŸãã¯ç¡«é
žæ°ŽçŽ ãããªãŠã ïŒãã¬ãŒãå€ãäŸãã°ãšãã¬ã³ãžã¢ãã³åé
¢é
žïŒç·©è¡å€ãäŸãã°ãé
¢é
žå¡©ãã¯ãšã³é
žå¡©ãŸãã¯ãªã³é
žå¡©ãªã©ïŒããã³æµžéå§ã調æŽããããã®è©Šè¬ãå¡©åãããªãŠã ãŸãã¯ããã¹ãããŒã¹ãªã©ãïœïŒšã¯ãå¡©é
žå¡©ãŸãã¯æ°Žé
žåãããªãŠã ãªã©ã®é
žãŸãã¯å¡©åºã«ãã調æŽããããšãã§ãããéçµå£çšèª¿è£œç©ã¯ãã¬ã©ã¹ãŸãã¯ãã©ã¹ããã¯è£œã®ã¢ã³ãã«ã䜿ãæšãŠã®æ³šå°åšãŸãã¯è€æ°åçšéã®ãã€ã¢ã«ã«å
¥ããããã
泚å°ã§ã®äœ¿çšã«é©ããå»è¬çµæç©ã¯ãæ»
è氎溶液ïŒæ°Žã«å¯æº¶ã§ããå ŽåïŒãŸãã¯æ»
è泚å°æº¶æ¶²ãŸãã¯åæ£æ¶²ã®å³åžã®èª¿è£œã®ããã®åæ£æ¶²ããã³ç²æ«ãæãããããéèå
æäžã«ã€ããŠãé©åœãªæ
äœãšããŠã¯ãççé£å¡©æ°Žãéèæ§ã®æ°ŽãCremophor ELïŒç»é²åæšïŒ(BASF; Parsippany, N. J.ïŒãŸãã¯ãªã³é
žç·©è¡ççé£å¡©æ°ŽïŒïŒ°ïŒ¢ïŒ³ïŒããã¹ãŠã®å Žåã«ãããŠãçµæç©ã¯ç¡èã§æ³šå°åšã«å®¹æã«å
¥ããããçšåºŠã«æµåæ§ã§ããã補é ããã³ä¿åã®æ¡ä»¶äžã§å®å®ã§ãªããã°ãªããã现èããã³å¿çãªã©ã®åŸ®çç©ã®æ±æããå®ãããŠããªããã°ãªããªããæ
äœã¯ãäŸãã°æ°Žããšã¿ããŒã«ã補è¬çã«èš±å®¹ãåŸãããªãªãŒã«ïŒã°ãªã»ããŒã«ããããã¬ã³ã°ãªã³ãŒã«ã液äœããªãšãã¬ã³ã°ãªã³ãŒã«ãããã³ããããã®é©åœãªæ··åç©ïŒãå«ã溶åªãŸãã¯åæ£åªäœã§ãã£ãŠãããäŸãã°ãã¬ã·ãã³çã®ã³ãŒãã£ã³ã°ã®äœ¿çšã«ãããåæ£å€ã®å Žåå¿
èŠç²åãµã€ãºãç¶æããããšã«ãããããã³çé¢æŽ»æ§å€ã®äœ¿çšã«ãããé©åœãªæµåæ§ãç¶æããããšãã§ããã埮çç©ã®äœçšã®é»æ¢ã¯ãäŸãã°ããã©ãã³ãã¯ãããã¿ããŒã«ããã§ããŒã«ãã¢ã¹ã³ã«ãã³é
žããã¡ããµãŒã«ãªã©ã®æ§ã
ãªæèããã³æçèå€ã«ãã£ãŠéæããããšãã§ãããå€ãã®å Žåãç匵å€ãäŸãã°ç³ãããªã¢ã«ã³ãŒã«ïŒäŸãã°ãã³ãããŒã«ããœã«ãããŒã«ãå¡©åãããªãŠã ïŒãçµæç©ã«å«æãããããšã奜ãŸããã§ãããã泚å°çšçµæç©ã®é·æéã®åžåã¯ãäŸãã°ãã¢ãã¹ãã¢ãªã³é
žã¢ã«ãããŠã ããŒã©ãã³çã®åžåãé
ãããè©Šè¬ãçµæç©ã«å«æãããããšã«ããåŒãèµ·ããããšãã§ãããæ»
è泚å°çšæº¶æ¶²ã¯ãå¿
èŠãªéã®æŽ»æ§ååç©ïŒäŸãã°ããªãããããŸãã¯æäœïŒããå¿
èŠã§ããã°ãäžã«åæããæåã®ïŒã€ãŸãã¯çµåããšå
±ã«é©åœãªæº¶åªäžã«å«æãããåŸãæ»
èæ¿Ÿéããããšã«ãã調補ããããšãã§ãããäžè¬ã«ãåæ£ç©ã¯ãããŒã¹ãšãªãåæ£åªäœããã³äžã«åæããå¿
èŠãªä»ã®æåãå«æããæ»
èããŒã¯ã«ã«æŽ»æ§ååç©ãå
¥ããããšã«ãã£ãŠèª¿è£œãããæ»
è泚å°çšæº¶æ¶²ã®èª¿è£œã®ããã®æ»
èç²æ«ã®å Žåã奜ãŸãã補é æ¹æ³ã¯ã掻æ§æåãšãããªãææã®æåã®ç²æ«ãåŸããäºãæ»
èæ¿Ÿéããã溶液ããã®æžå§ä¹Ÿç¥ãåçµä¹Ÿç¥ã§ããã
çµå£çšçµæç©ã¯äžè¬ã«ãäžæŽ»æ§ãªåžéå€ãŸãã¯é£çšã«é©ããæ
äœãæããããããããã¯ããŒã©ãã³ã«ãã»ã«ã«å
¥ããããŸãã¯å§çž®ããŠé å€ã«ããããšãã§ãããçµå£ã§ã®æ²»ççæäžãç®çãšããå Žåã掻æ§ååç©ãå
¥ããããšãã§ããã
æ·»å å€ãšãšãã«å«æãããé å€ããããŒããŸãã¯ã«ãã»ã«ã®åœ¢æ ã§äœ¿çšããããšãã§ãããçµå£çšçµæç©ã¯ãŸããå£æŽå€ãšããŠäœ¿çšããããã®æµåæ§æ äœãçšããŠèª¿è£œããããšãã§ããååç©ãæµåæ§æ äœäžã§çµå£ã§é©çšããå£ã®äžã§ããããåãåºãããŸãã¯é£²ã¿èŸŒãã
æ·»å å€ãšãšãã«å«æãããé å€ããããŒããŸãã¯ã«ãã»ã«ã®åœ¢æ ã§äœ¿çšããããšãã§ãããçµå£çšçµæç©ã¯ãŸããå£æŽå€ãšããŠäœ¿çšããããã®æµåæ§æ äœãçšããŠèª¿è£œããããšãã§ããååç©ãæµåæ§æ äœäžã§çµå£ã§é©çšããå£ã®äžã§ããããåãåºãããŸãã¯é£²ã¿èŸŒãã
補è¬çã«é©åãåŸãçµåå€ããã³ïŒãŸãã¯ã¢ãžã¥ãã³ãç©è³ªãçµæç©ã®äžéšãšããŠå«æãããããšãã§ãããé å€ãäžžå€ãã«ãã»ã«å€ããããŒããªã©ã¯ãä»»æã®ä»¥äžã®æåãŸãã¯åæ§ã®æ§è³ªã®ååç©ãå«æãåŸãïŒåŸ®æ¶æ§ã»ã«ããŒã¹ããã©ã¬ã«ã³ãã»ãŽã ãŸãã¯ãŒã©ãã³çã®çµåå€ïŒãã³ãã³ãŸãã¯ã©ã¯ããŒã¹çã®è³Šåœ¢å€ïŒã¢ã«ã®ã³é
žãPrimogelãŸãã¯ããŠã¢ãã³ã·ãã³ãã³çã®åŽ©å£å€ïŒã¹ãã¢ãªã³é
žãã°ãã·ãŠã ãŸãã¯ã¹ãããŒãïŒsterotesïŒçã®æ»æ²¢å€ïŒã³ãã€ãç¶äºé
žåã±ã€çŽ çã®æµåä¿é²å€ïŒã¹ã¯ããŒã¹ãŸãã¯ãµãã«ãªã³çã®çå³æïŒãŸãã¯ãããŒãã³ãããµãªãã«é
žã¡ãã«ãŸãã¯ãªã¬ã³ãžãã¬ãŒããŒçã®éŠæã
åžå
¥ã«ããæäžã«ã€ããŠã¯ãååç©ãé©åœãªãããã©ã³ãïŒäŸãã°ãäºé
žåççŽ çã®æ°äœïŒãå«ãå å§ããã容åšãŸãã¯ãã£ã¹ãã³ãµãŒãŸãã¯åŽé§åšãããšã¢ããŸã«ã¹ãã¬ãŒã®åœ¢æ
ã§å°åºããã
å
šèº«æäžã¯ãçµç²èãŸãã¯çµç®çæ段ã«ãã£ãŠãè¡ãããšãã§ãããçµç²èãŸãã¯çµç®æäžã«ã€ããŠã¯ã浞éãããã¹ãããªã¢ãŒã«é©åœãªæµžéå€ã補å€ã«ãããŠçšããããã®ãããªæµžéå€ã¯äžè¬ã«åœåéã«ãããŠç¥ãããŠãããäŸãã°ãçµç²èæäžãçé¢æŽ»æ§å€ãèæ±å¡©ãããã³ãã·ãžã³é
žèªå°äœãæãããããçµç²èæäžã¯ã錻çšã¹ãã¬ãŒãŸãã¯åå€ã®äœ¿çšã«ãã£ãŠè¡ãããšãã§ãããçµç®æäžã«ã€ããŠã¯ã掻æ§ååç©ããåœåéã§äžè¬çã«ç¥ãããŠããè»èãå¡è¬ïŒsalveïŒãã²ã«ããŸãã¯ã¯ãªãŒã ã«è£œå€åããã
ååç©ãåè¬ïŒäŸãã°ãã³ã³ã¢ãã¿ãŒããã³ä»ã®ã°ãªã»ãªãçã®æ
£çšçãªåå€åºå€ãçšããŠïŒãŸãã¯çŽè
žééã®ããã®åçæµ£è
žã®åœ¢æ
ã«è£œé ããããšãã§ããã
ïŒã€ã®æ
æ§ã§ã¯ã掻æ§ååç©ããå¶åŸ¡ãããæŸåºè£œå€ïŒã€ã³ãã©ã³ãããã³ãã€ã¯ãã«ãã»ã«ã«å
¥ããããããªããªãŒã·ã¹ãã ãå«ãïŒçã®ãäœå
ããã®ååç©ã®æ¥éãªæ¶å€±ã«å¯ŸããŠååç©ãä¿è·ããæ
äœãšãšãã«èª¿è£œãããããã«é
¢é
žãšãã«ãããªç¡æ°Žç©ãããªã°ãªã³ãŒã«é
žãã³ã©ãŒã²ã³ãããªãªã«ããšã¹ãã«ãããã³ããªä¹³é
žçã®çç©é©åæ§ã®ããªããŒãçšããããšãã§ãããããããªè£œå€ã®è£œé æ¹æ³ã¯ãåœæ¥è
ã«ã¯æããã§ããããææã¯Alza Corporationããã³Nova Pharmaceuticals, Inc.ããåæ¥çã«å
¥æå¯èœã§ããããªããœãŒã æžæ¿æ¶²ïŒãŠã€ã«ã¹æåã«å¯Ÿããã¢ãã¯ããŒãã«æäœã§ææ现èã«æšçåãããªããœãŒã ãå«ãïŒã補è¬çã«èš±å®¹ãåŸãæ
äœãšããŠçšããããšãã§ããããããã¯ãäŸãã°ãç±³åœç¹èš±ç¬¬ïŒãïŒïŒïŒãïŒïŒïŒå·ã«èšèŒã®ããã«ãåœæ¥è
ã«åšç¥ã®æ¹æ³ã«ãããã£ãŠè£œé ããããšãã§ããã
çµå£ãŸãã¯éçµå£çµæç©ããæäžã容æã«ããçšéãåäžã«ããããã®åäœæäžåœ¢æ
ã«è£œå€åããããšã¯ç¹ã«æçšã§ãããæ¬æ现æžã«ãããŠäœ¿çšããåäœæäžåœ¢æ
ã¯ãåŠçœ®ãããæ£è
ã«ãšã£ãŠã®åäœçšéãšããŠé©ããç©ççã«åé¢ãããåäœãæå³ãïŒååäœã¯ãææã®æ²»çå¹æãããããããã«èšç®ãããäºã決ããããéã®æŽ»æ§ååç©ãå¿
èŠãªå»è¬æ
äœãšå
±ã«å«æããŠãããæ¬çºæã®åäœæäžåœ¢æ
ã®èŠæ Œã¯ã掻æ§ååç©åºæã®ç¹æ§ãéæãã¹ãå
·äœçãªæ²»çå¹æãããã³å人ã®åŠçœ®ã®ããã«ãã®ãããªæŽ»æ§ååç©ãé
åããåéã«ãããŠå
åšããå¶éã«ãã£ãŠå€ãããçŽæ¥çã«äŸåããã
å»è¬çµæç©ã¯ãæäžã®èª¬ææžãšå
±ã«ã容åšãããã¯ãŸãã¯ãã£ã¹ãã³ãµãŒã«å
¥ããããšãã§ãããïŒïŒµïŒæŽ»æ§ã®ã¢ã³ã¿ãŽãã¹ããïŒïŒµïŒã®çºçŸãæžå°ãããååç©ããŸãã¯ïŒ®ïŒïŒµïŒã·ã°ãã«äŒéçµè·¯ã«ãããã¿ã³ãã¯è³ªã®çºçŸãŸãã¯æŽ»æ§ãæžå°ãããååç©ããŸãã¯ãã®ä»»æã®çµåããå«ãå»è¬çµæç©ã«ã€ããŠãæäžã®èª¬ææžã¯ãè¡æ¶²çŸæ£ããã³å¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ããåæ¯ãçæ®æ³å°¿ç³»ã®çŸæ£ããã³ççæ§çŸæ£ã«å¯Ÿããçµæç©ã®äœ¿çšã«ã€ããŠè©³çŽ°ã«èšèŒãããïŒïŒµïŒæŽ»æ§ã®ã¢ãŽãã¹ããïŒïŒµïŒã®çºçŸãå¢å€§ããååç©ãïŒïŒµïŒã·ã°ãã«äŒéçµè·¯ã«ãããã¿ã³ãã¯è³ªã®çºçŸãŸãã¯æŽ»æ§ãå¢å€§ããååç©ããŸãã¯ãã®ä»»æã®çµåããå«ãå»è¬çµæç©ã«ã€ããŠãæäžã®èª¬ææžã¯ãè¡æ¶²çŸæ£ããã³å¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ããåæ¯ãçæ®æ³å°¿ç³»ã®çŸæ£ããã³ççæ§çŸæ£ã«å¯Ÿããçµæç©ã®äœ¿çšã«ã€ããŠè©³çŽ°ã«èšèŒããã
蚺æ
ãããªãæ æ§ã«ãããŠãïŒïŒµïŒã«ç¹ç°çã«çµåããæäœããïŒïŒµïŒã®çºçŸã«ãã£ãŠç¹åŸŽä»ããããé害ã®èšºæã®ããããŸãã¯ïŒ®ïŒïŒµïŒãŸãã¯ïŒ®ïŒïŒµïŒã®ã¢ãŽãã¹ããã¢ã³ã¿ãŽãã¹ãããã³é»å®³å€ã§åŠçœ®ãããŠããæ£è ãã¢ãã¿ãŒããããã®åæã«ãããŠäœ¿çšããããšãã§ããã蚺æç®çã«æçšãªæäœã¯ãæ²»çç©è³ªã«ã€ããŠäžã«èšèŒãããã®ãšåæ§ã«è£œé ããããšãã§ãããïŒïŒµïŒã«ã€ããŠã®èšºæåæã«ã¯ãæäœããã³ïŒ®ïŒïŒµïŒãããã®äœæ¶²ãŸãã¯çŽ°èãããã¯çµç¹ã®æœåºç©ã«ãããŠæ€åºããããã®æšèãå©çšããæ¹æ³ãå«ããæäœã¯ã修食ããŠãŸãã¯ä¿®é£Ÿããã«çšããããšãã§ããã¬ããŒã¿ãŒååãšå ±æçµåãŸãã¯éå ±æçµåã«ããé£çµãããããšã«ããæšèããããšãã§ãããäžã«ãã®ããã€ããèšèŒããæ§ã ãªã¬ããŒã¿ãŒååã¯ãåœåéã«ãããŠåšç¥ã§ããã䜿çšããããšãã§ããã
ãããªãæ æ§ã«ãããŠãïŒïŒµïŒã«ç¹ç°çã«çµåããæäœããïŒïŒµïŒã®çºçŸã«ãã£ãŠç¹åŸŽä»ããããé害ã®èšºæã®ããããŸãã¯ïŒ®ïŒïŒµïŒãŸãã¯ïŒ®ïŒïŒµïŒã®ã¢ãŽãã¹ããã¢ã³ã¿ãŽãã¹ãããã³é»å®³å€ã§åŠçœ®ãããŠããæ£è ãã¢ãã¿ãŒããããã®åæã«ãããŠäœ¿çšããããšãã§ããã蚺æç®çã«æçšãªæäœã¯ãæ²»çç©è³ªã«ã€ããŠäžã«èšèŒãããã®ãšåæ§ã«è£œé ããããšãã§ãããïŒïŒµïŒã«ã€ããŠã®èšºæåæã«ã¯ãæäœããã³ïŒ®ïŒïŒµïŒãããã®äœæ¶²ãŸãã¯çŽ°èãããã¯çµç¹ã®æœåºç©ã«ãããŠæ€åºããããã®æšèãå©çšããæ¹æ³ãå«ããæäœã¯ã修食ããŠãŸãã¯ä¿®é£Ÿããã«çšããããšãã§ããã¬ããŒã¿ãŒååãšå ±æçµåãŸãã¯éå ±æçµåã«ããé£çµãããããšã«ããæšèããããšãã§ãããäžã«ãã®ããã€ããèšèŒããæ§ã ãªã¬ããŒã¿ãŒååã¯ãåœåéã«ãããŠåšç¥ã§ããã䜿çšããããšãã§ããã
ããããã³ïŒŠïŒ¡ïŒ£ïŒ³ãå«ãïŒïŒµïŒã枬å®ããããã®æ§ã
ãªãããã³ã«ã¯ãåœåéã§åšç¥ã§ãããïŒïŒµïŒçºçŸã®å€åãããŸãã¯ç°åžžãªã¬ãã«ã蚺æããããã®åºç€ãæäŸãããïŒïŒµïŒçºçŸã«ã€ããŠã®æ£åžžãŸãã¯æšæºçãªå€ã¯ãæ£åžžãªåºä¹³é¡æ£è
ã奜ãŸããã¯ãããããæ¡åããäœæ¶²ãŸãã¯çŽ°èæœåºç©ããïŒïŒµïŒã«å¯Ÿããæäœãšãè€åäœåœ¢æã«é©åœãªæ¡ä»¶äžã§æ··åããããšã«ãã£ãŠç¢ºç«ãããæšæºã®è€åäœåœ¢æã®éã¯ãæ§ã
ãªæ¹æ³ã奜ãŸããã¯åå
çæ段ã«ãããå®éããããšãã§ãããçæ€çµç¹ããã®æ£è
ã®è©Šæã«ãããŠçºçŸããïŒïŒµïŒã®éãæšæºå€ãšæ¯èŒãããæšæºãšå¯Ÿè±¡ã®å€ãšã®åå·®ããçŸæ£ã蚺æããããã®ãã©ã¡ãŒã¿ãŒã§ããã
æ¬çºæã®ãããªãæ
æ§ã§ã¯ãïŒïŒµïŒãã³ãŒãããããªãã¯ã¬ãªããã蚺æç®çã§äœ¿çšããããšãã§ãããçšããããšãã§ããããªãã¯ã¬ãªãããšããŠã¯ããªãªãŽãã¯ã¬ãªããé
åãçžè£ïŒ²ïŒ®ïŒ¡ããã³ïŒ€ïŒ®ïŒ¡ååãããã³ïŒ°ïŒ®ïŒ¡ãæãããããããªãã¯ã¬ãªãããçšããŠãïŒïŒµïŒã®çºçŸãçŸæ£ãšçžé¢ãåŸãçæ€çµç¹ã«ãããéºäŒåçºçŸãæ€åºããå®éããããšãã§ããããã®èšºæã¢ãã»ã€ãçšããŠãïŒâïŒã®äžåšãååšããã³éå°çºçŸãåºå¥ããæ²»ççä»å
¥ãè¡ã£ãŠããéã®ïŒ®ïŒïŒµïŒã¬ãã«ã®èª¿ç¯ãã¢ãã¿ãŒããããšãã§ããã
ïŒïŒµïŒãã³ãŒãããããªãã¯ã¬ãªããé
åããè¡æ¶²çŸæ£ããã³å¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãççŸæ£ããã³ïŒ®ïŒïŒµïŒã®çºçŸã«é¢é£ããèèçŸæ£ã®èšºæã«çšããããšãã§ãããïŒïŒµïŒãã³ãŒãããããªãã¯ã¬ãªããé
åãããµã¶ã³ãããããããŒã¶ã³ãããããŸãã¯ããããããã解æïŒãŸãã¯ä»ã®èããŒã¹ã®æè¡ïŒïŒ°ïŒ£ïŒ²æè¡ïŒãã£ããã¹ãã£ãã¯ããã³ãããã³ïŒ¥ïŒ¬ïŒ©ïŒ³ïŒ¡ã¢ãã»ã€ïŒããã³æ£è
ã®çæ€çµç¹ããã®äœæ¶²ãŸãã¯çµç¹ãå©çšãããã€ã¯ãã¢ã¬ã€ã«ãããŠçšããå€åããïŒïŒµïŒçºçŸãæ€åºããããšãã§ããããã®ãããªå®æ§ãŸãã¯å®éæ¹æ³ã¯åœåéã«ãããŠåšç¥ã§ããã
å
·äœçãªæ
æ§ã§ã¯ãïŒïŒµïŒãã³ãŒããããã¯ã¬ãªããé
åã¯ãäžã«å
·äœçã«èšèŒãããããªé¢é£ããé害ã®ååšãæ€åºããã¢ãã»ã€ã«ãããŠæçšã§ããããïŒïŒµïŒãã³ãŒããããã¯ã¬ãªããé
åãæšæºçãªæ¹æ³ã«ããæšèãããã€ããªãã€ãŒãŒã·ã§ã³è€åäœã®åœ¢æã«é©åœãªæ¡ä»¶äžã§æ£è
ããåŸãäœæ¶²ãŸãã¯çµç¹ãµã³ãã«ã«å ãããé©åœãªã€ã³ãã¥ããŒã·ã§ã³æéã®åŸããµã³ãã«ãæŽæµããã·ã°ãã«ãå®éããæšæºå€ãšæ¯èŒãããæ£è
ã®ãµã³ãã«äžã®ã·ã°ãã«ã®éããæ¯èŒãã察ç
§ã®ãµã³ãã«ã®ã·ã°ãã«ãããææã«å€åããŠããå Žåããã¯ã¬ãªããé
åã¯ããµã³ãã«äžã®ãã¯ã¬ãªããé
åãšãã€ããªãã€ãºããŠããããµã³ãã«äžã®ïŒ®ïŒïŒµïŒãã³ãŒããããã¯ã¬ãªããé
åã«ãããå€åããã¬ãã«ã®ååšã¯ãé¢é£ããé害ã®ååšã瀺ããŠããããã®ãããªã¢ãã»ã€ã¯åç©å®éšãèšåºè©ŠéšãŸãã¯æ£è
ã®åŠçœ®ãç£èŠããããšã«ãããŠãæ²»ççåŠçœ®ã¬ãžã¡ã®å¹åãè©äŸ¡ããã®ã«ã䜿çšããããšãã§ããã
è¡æ¶²çŸæ£ããã³å¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãççŸæ£ããã³ïŒ®ïŒïŒµïŒã®çºçŸã«é¢é£ããèèçŸæ£ã®èšºæã®åºç€ãæäŸããããã«ãçºçŸã«é¢ããæ£åžžãŸãã¯æšæºçãªãããã¡ã€ã«ã確ç«ãããããã¯ãåç©ãŸãã¯ããã®ããããã®æ£åžžãªæ£è
ããæ¡åããäœæ¶²ãŸãã¯çŽ°èæœåºç©ãšãïŒïŒµïŒãã³ãŒãããé
åãŸãã¯ãã®æçãšãããã€ããªãã€ãŒãŒã·ã§ã³ãŸãã¯å¢å¹
ã«é©ããæ¡ä»¶äžã§æ··åããããšã«ãã£ãŠè¡ãããšãã§ãããæšæºã®ãã€ããªãã€ãŒãŒã·ã§ã³ã¯ãæ£åžžãªæ£è
ããåŸãããå€ãšãæ¢ç¥ã®éã®å®è³ªçã«ç²Ÿè£œãããããªãããããçšããå®éšããåŸãããå€ãšãæ¯èŒããããšã«ãã£ãŠå®éããããšãã§ãããæ£åžžãªãµã³ãã«ããåŸãããæšæºå€ã¯ãé害ã®çç¶ã瀺ããŠããæ£è
ããæ¡åãããµã³ãã«ããåŸãããå€ãšæ¯èŒããããšãã§ãããæšæºå€ãšã®åå·®ãçšããŠé害ã®ååšã蚌æããã
䜿çšããããšãã§ããè¬ç©ã¹ã¯ãªãŒãã³ã°ã®ãããªãæè¡ã¯ãå
¬éãããåºé¡ïŒ·ïŒïŒïŒïŒïŒïŒïŒïŒïŒã«èšèŒã®ãç®çã®ã¿ã³ãã¯è³ªã«å¯ŸããŠé©åœãªçµå芪åæ§ãæããååç©ã®ãã€ã¹ã«ãŒãããã¹ã¯ãªãŒãã³ã°ã§ããããã®æ¹æ³ã§ã¯ã倧éã®çš®ã
ã®å°ããè©Šéšååç©ãããã©ã¹ããã¯ãã³ãªã©ã®åºåœ¢ç©è³ªäžãŸãã¯ä»ã®è¡šé¢äžã«åæãããè©Šéšååç©ãïŒïŒµïŒãŸãã¯ãã®æçãšåå¿ãããæŽæµããã次ãã§ãçµåããïŒïŒµïŒãåœåéã«ãããŠåšç¥ã®æ¹æ³ã«ãã£ãŠæ€åºããã粟補ããïŒïŒµïŒããåè¿°ã®è¬ç©ã¹ã¯ãªãŒãã³ã°æ³ã«äœ¿çšããããã«çŽæ¥ãã¬ãŒãäžã«ã³ãŒãã£ã³ã°ããããšãã§ããããããã¯ãéäžåæäœãçšããŠãããããææãããããåºäœã®æ¯æäœã«åºå®åããããšãã§ããã
ãããªãæ
æ§ã§ã¯ãïŒïŒµïŒã«çµåããããšãã§ããäžåæäœããïŒïŒµïŒã®çµåã«é¢ããŠè©Šéšååç©ãšç¹ç°çã«ç«¶åãã競åçè¬ç©ã¹ã¯ãªãŒãã³ã°ã¢ãã»ã€ãçšããŠãããããã®æ¹æ³ã§ã¯ãæäœãçšããŠãïŒïŒµïŒãšïŒãŸãã¯ãã以äžã®æå決å®åºãå
±æããããããã®ååšãæ€åºããããšãã§ããã
ã¿ã³ãã¯è³ªå
±åœ¹åå容äœã¯ãåºä¹³é¡ã®å®¿äž»ã«éåšããå€ãã®ç
ç¶ãå«ãå€ãã®çç©åŠçæ©èœã«å¿çããããããã£ãŠãäžæ¹ã§ïŒ§ã¿ã³ãã¯è³ªå
±åœ¹åå容äœãåºæ¿ããä»æ¹ã§ïŒ§ã¿ã³ãã¯è³ªå
±åœ¹åå容äœã®æ©èœãé»å®³ããããšãã§ããååç©ãè¬ç©ãèŠãã ãããšãæãŸãããäŸãã°ãã¿ã³ãã¯è³ªå
±åœ¹åå容äœã掻æ§åããååç©ãæ²»çç®çãäŸãã°åæ¯ãããŒãã³ãœã³ç
ãæ¥æ§å¿äžå
šãå°¿éããã³éªšç²é¬çãªã©ã«çšããããšãã§ãããç¹ã«ãæ¬çºæã®å容äœã掻æ§åããååç©ã¯ãèºã®è¡æµã®æ¬ åŠãŸãã¯é«è¡å§ã«ãã£ãŠåŒãèµ·ãããããããªæ§ã
ãªå¿èè¡ç®¡ã®ç
æ°ã®åŠçœ®ã«æçšã§ãããããã«ããããã®ååç©ãäœæ¶²ããã³é»è§£æ¶²ã®ãã¡ãªã¹ã¿ã·ã¹ã®å¶åŸ¡ã®ç°åžžã«é¢é£ããæ§ã
ãªççåŠçé害ã®åŠçœ®ã«ãããã³ç°åžžãªã¢ã³ãžãªãã³ã·ã³èªçºæ§ã¢ã«ãã¹ããã³åæ³ã«é¢é£ããçŸæ£ã«ãããŠäœ¿çšããããšãã§ããã
äžè¬ã«ãã¿ã³ãã¯è³ªå
±åœ¹åå容äœãé»å®³ããååç©ã¯ãæ§ã
ãªæ²»çç®çã«çšããããšãã§ãããäŸãã°ãäœè¡å§ããã³ïŒãŸãã¯é«è¡å§ã®åŠçœ®ãçå¿çãå¿çæ¢å¡ã朰çãåæ¯ãã¢ã¬ã«ã®ãŒãè¯æ§åç«è
ºè¥å€§ãããã³ç²Ÿç¥åŠçããã³ç¥çµåŠçé害ïŒçµ±å倱調çãèºç
æ§è奮ã鬱ç
ã粟ç¥é¯ä¹±ãçŽåãŸãã¯é節ãªç¥èœçºè²äžå
šããžã¹ãããžãŒãäŸãã°ãã³ãã³ãã³èèžç
ãŸãã¯ãã¥ã¬ããçå矀çãå«ãïŒã«çšããããšãã§ãããã¿ã³ãã¯è³ªå
±åœ¹åå容äœãé»å®³ããååç©ã¯ãå
å æ§ã®æé£çã®é転ããã³éé£çã®æå¶ã«ãããŠæçšã§ããã
æ²»ççæå¹éã®æ±ºå®
æ²»ççæå¹éã®æ±ºå®ã¯ãå ååœæ¥è ã®èœåã®ç¯å²å ã«ãããæ²»ççæå¹éãšã¯ãæ²»ççæå¹éã®äžåšäžã§èµ·ããïŒïŒµïŒã®æŽ»æ§ã«æ¯èŒããŠïŒ®ïŒïŒµïŒã®æŽ»æ§ãå¢å€§ãããŸãã¯äœäžããã掻æ§æåã®éãæãããããªãååç©ã«é¢ããŠããæ²»ççæå¹éã¯æåã«çŽ°èå¹é€æ€å®ã§ããŸãã¯åç©ã¢ãã«ãéåžžããŠã¹ããŠãµã®ãã€ãããŸãã¯ãã¿ã§èŠç©ããããšãã§ãããåç©ã¢ãã«ã¯é©åœãªæ¿åºŠç¯å²ããã³æäžçµè·¯ã®æ±ºå®ã«ã䜿çšã§ããã次ã«ãã®ãããªæ å ±ãçšããŠäººéã§ã®æçšãªçšéãšæäžçµè·¯ã決å®ã§ããã
æ²»ççæå¹éã®æ±ºå®ã¯ãå ååœæ¥è ã®èœåã®ç¯å²å ã«ãããæ²»ççæå¹éãšã¯ãæ²»ççæå¹éã®äžåšäžã§èµ·ããïŒïŒµïŒã®æŽ»æ§ã«æ¯èŒããŠïŒ®ïŒïŒµïŒã®æŽ»æ§ãå¢å€§ãããŸãã¯äœäžããã掻æ§æåã®éãæãããããªãååç©ã«é¢ããŠããæ²»ççæå¹éã¯æåã«çŽ°èå¹é€æ€å®ã§ããŸãã¯åç©ã¢ãã«ãéåžžããŠã¹ããŠãµã®ãã€ãããŸãã¯ãã¿ã§èŠç©ããããšãã§ãããåç©ã¢ãã«ã¯é©åœãªæ¿åºŠç¯å²ããã³æäžçµè·¯ã®æ±ºå®ã«ã䜿çšã§ããã次ã«ãã®ãããªæ å ±ãçšããŠäººéã§ã®æçšãªçšéãšæäžçµè·¯ã決å®ã§ããã
æ²»ççæå¹æ§ããã³æ¯æ§ãäŸãã°ïŒ¥ïŒ€50ïŒéå£ã®ïŒïŒïŒ
ã§æ²»ççã«æå¹ãªçšéïŒããã³ïŒ¬ïŒ€50ïŒéå£ã®ïŒïŒïŒ
ã§èŽæ»çãªçšéïŒã¯ã现èå¹é€ãŸãã¯å®éšåç©ã«ãããæšæºçè¬åŠçæ¹æ³ã«ãã決å®ã§ãããæ²»çå¹æã«å¯Ÿããæ¯æ§å¹æã®çšéæ¯ãæ²»çææ°ã§ãããæ¯ïŒ¬ïŒ€50ïŒïŒ¥ïŒ€50ã§è¡šãããšãã§ããã倧ããªæ²»çææ°ã瀺ãå»è¬çµæç©ã奜ãŸããã现èå¹é€æ€å®ããã³åç©ç 究ããåŸãããããŒã¿ãã人éãžã®äœ¿çšã®ããã®çšéç¯å²ãåŠæ¹ããéã«äœ¿çšãããä¿ãçµæç©ã«å«ãŸããçšéã¯ã奜ãŸããã¯æ®ã©ãŸãã¯å
šãæ¯æ§ãæããªã50ãå
å«ãã埪ç°æ¿åºŠã®ç¯å²å
ã§ããããã®çšéã¯ã䜿çšããçšéåãæ£è
ã®æåæ§ãããã³æäžçµè·¯ã«å¿ããŠãã®ç¯å²å
ã§å€ãããæ£ç¢ºãªçšéã¯ãæ²»çãå¿
èŠãšãã察象ã«é¢é£ããå åã«ç
§ãããŠå»åž«ã決å®ãããçšéããã³æäžã¯ãå
åãªã¬ãã«ã®æŽ»æ§æåãæäŸããããããŸãã¯ææã®å¹æãç¶æããããã調ç¯ãããèæ
®ã§ããå åã¯ãçŸç
ç¶æ
ã®é節床ã察象ã®å
šèº«å¥åº·ç¶æ
ã幎霢ãäœéãããã³å¯Ÿè±¡ã®æ§å¥ãé£é€ãæäžã®æéããã³é »åºŠãè¬ç©ã®çµã¿åãããåå¿ã®æåæ§ãããã³çæ³ã«å¯Ÿããå¯å®¹ïŒå¿çãå
å«ãããé·æéäœçšæ§å»è¬çµæç©ã¯ããã®è£œå€ã®åæžæããã³ã¯ãªã¢ã©ã³ã¹çã«å¿ããŠïŒãªããïŒæ¥æ¯ãæ¯é±ããŸãã¯ïŒé±éã«ïŒåæäžããããšãã§ããã
æšæºçãªçšéã¯æäžçµè·¯ã«å¿ããŠïŒïŒïŒããïŒïŒïŒïŒïŒïŒãã€ã¯ãã°ã©ã ãŸã§å€ããããšãã§ããçŽïŒïœãŸã§ã®ç·çšéãšããããšãã§ãããç¹å®ã®çšéããã³ããªããªãŒæ¹æ³ã«ã€ããŠã®æéã¯æç®ã«æäŸãããŠãããäžè¬ã«åœåéã®å»åž«ãå
¥æã§ãããåœæ¥è
ã¯ããã¯ã¬ãªããçšã«ã¯èçœãŸãã¯ãããã®ã€ã³ããã¿ãŒçšã®ãã®ãšã¯ç°ãªã補å€ã䜿çšããã§ããããåæ§ã«ãããªãã¯ã¬ãªãããŸãã¯ããªããããã®ããªããªãŒã¯ç¹å®ã®çŽ°èãç¶æ
ãå Žæãªã©ã«ç¹ç°çã§ããããã®è©Šè¬ãäžæ¬éæäœã§ããå Žåããã®æäœãã³ãŒãããŠããããªãã¯ã¬ãªãããçµã¿ç«ãŠããã©ã³ã¹ãã§ãªã³âããªã«ããªã³â仲ä»ïŒ€ïŒ®ïŒ¡è»¢ç§»ã裞ã®ãŸãã¯ã«ãã»ã«å
æ žé
žãçšãããã©ã³ã¹ãã§ã¯ã·ã§ã³ããªããœãŒã ã®ä»²ä»ãã现èèåã被èŠã©ããã¯ã¹ããŒãºã®çŽ°èå
茞éãããããã©ã¹ãèåããŠã€ã«ã¹ææãé»æ°ç©¿åããéºäŒåéããããã³ïŒ€ïŒ¥ïŒ¡ïŒ¥âãŸãã¯çé
žã«ã«ã·ãŠã â仲ä»ãã©ã³ã¹ãã§ã¯ã·ã§ã³ãå
å«ããïŒäœããããã«éå®ãããèš³ã§ã¯ãªãïŒå
å確ç«ããæè¡ãçšããŠãïœ
ïœïœïœïœïœãŸãã¯ã€ã³ããã§çŽ°èå
ã«å°å
¥ã§ããã
çºçŸç£ç©ãïœïŒ²ïŒ®ïŒ¡ã§ããå Žåãè©Šè¬ã¯å¥œãŸããã¯ã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªãããŸãã¯ãªãã¶ã€ã ã§ãããã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªãããŸãã¯ãªãã¶ã€ã ãçºçŸããããªãã¯ã¬ãªããã¯ãäžèšã®ããã«å€å²ã«ãããæ¹æ³ã«ãã£ãŠçŽ°èäžã«å°å
¥ã§ããã奜ãŸããã¯ãè©Šè¬ã¯ãïŒïŒµïŒéºäŒåã®çºçŸãŸãã¯ïŒ®ïŒïŒµïŒã®æŽ»æ§ãã該詊è¬ã®äžåšæãšæ¯èŒããŠå°ãªããšãçŽïŒïŒã奜ãŸããã¯çŽïŒïŒããã奜ãŸããã¯çŽïŒïŒãïŒïŒããŸãã¯ïŒïŒïŒïŒ
äœäžããããïŒïŒµïŒéºäŒåã®çºçŸã¬ãã«ãŸãã¯ïŒ®ïŒïŒµïŒã®æŽ»æ§ãäœäžãããããéžæããæ©æ§ã®æå¹æ§ã¯ãåœåéã§åšç¥ã®æ¹æ³ãäŸãã°ïŒ®ïŒïŒµïŒç¹ç°çïœïŒ²ïŒ®ïŒ¡ãžã®ãã¯ã¬ãªãããããŒãã®ãã€ããªãã€ãŒãŒã·ã§ã³ãå®éçâãïŒïŒµïŒã®å
ç«åŠçæ€åºããŸãã¯ïŒ®ïŒïŒµïŒæŽ»æ§ã®æž¬å®ãçšããŠè©äŸ¡ã§ããã
äžèšã®ãããã®æ
æ§ã«ãããŠããæ¬çºæã«ä¿ãä»»æã®å»è¬çµæç©ã¯ä»ã®é©åœãªæ²»çè¬ãšçµã¿åãããŠæäžã§ããã䜵çšçæ³ã«äœ¿çšããããã®é©åœãªç©è³ªã®éžæã¯ãåžžå¥ç補è¬åçã«åŸããåœæ¥è
ã«ããå®æœããããšãã§ãããæ²»çè¬ã®çµã¿åããã¯ãçžä¹çã«åããŠãäžèšã®æ§ã
ãªçŸæ£ã®æ²»çãŸãã¯äºé²ãå¥å¹ãããããã®ã¢ãããŒããçšããŠãããäœãåç©è³ªã®çšéã§æ²»çå¹æãéæããããšãã§ãããããã£ãŠæ害ãªå¯äœçšã®å¯èœæ§ãäœæžããããšãã§ãããäžèšã®æ²»çæ¹æ³ã®ãããããäŸãã°ã€ãããã³ããŠã·ããŠãããŠãµã®ããµã«ãããã³æã奜ãŸããã¯ãããšãã£ãåºä¹³åç©ãå
å«ããããã®ãããªæ²»çãå¿
èŠãšããä»»æã®å¯Ÿè±¡ã«é©çšããããšãã§ããã
æ¬çºæã®æ žé
žååã¯ã以äžãããªãæ žé
žååã®çŸ€ããéžæãããæ žé
žååã§ããïŒïŒïœïŒé
åçªå·ïŒã®ã¢ããé
žé
åãå«ãããªãããããã³ãŒãããæ žé
žååïŒïŒïœïœïŒé
åçªå·ïŒã®é
åãå«ãæ žé
žååïŒïŒïœïœïœïŒé
åçªå·ïŒã®é
åãæããæ žé
žååïŒïŒïœïœïŒã¹ããªã³ãžã§ã³ããªæ¡ä»¶äžã§ïŒïœïŒãïŒïœïœïŒãŸãã¯ïŒïœïœïœïŒã®æ žé
žååã«ãã€ããªãã€ãºããçžè£çéã®æ žé
žååïŒããã³ïŒïœïŒéºäŒã³ãŒãã®çž®éã«ããïŒïœïœïœïŒã®æ žé
žååã®é
åãšã¯ç°ãªãé
åã®æ žé
žååã§ãã£ãŠãè©²æ žé
žååã«ãã£ãŠã³ãŒããããããªãããããïŒïŒµïŒæŽ»æ§ãæãããæ žé
žååã
æ¬çºæã®ããªããããã¯ã以äžãããªã矀ããéžæãããããªããããã§ããïŒïŒïœïŒé
åçªå·ïŒã®é
åãæããããªããããïŒïŒïœïœïŒé
åçªå·ïŒã®é
åãå«ãããªãããããïŒïœïœïœïŒæ¬çºæã®æ žé
žååã«ãã£ãŠã³ãŒããããããªãããããããã³ïŒïœïœïŒïŒïœïŒãïŒïœïœïŒããŸãã¯ïŒïœïœïœïŒã®ããªãããããšå°ãªããšãïŒïŒïŒ
ãïŒïŒïŒ
ãïŒïŒïŒ
ãïŒïŒïŒ
ããŸãã¯ïŒïŒïŒ
ã®çžåæ§ã瀺ãããªããããã§ãã£ãŠã該粟補ãããããªãããããïŒïŒµïŒæŽ»æ§ãæããããªããããã
æ¬çºæã®ç®çã¯ãåºä¹³é¡ã«ãããè¡æ¶²ã®çŸæ£ãå¿çŸæ£ãæ«æ¢¢ç¥çµç³»ã®é害ãäžæ¢ç¥çµç³»ã®é害ããåæ¯ãçæ®æ³å°¿ç³»ã®çŸæ£ããã³ççæ§çŸæ£ãããªãçŸæ£ã®çŸ€ããéžæãããçŸæ£ã®åŠçœ®ã«ãããŠæçšãªæ²»çå€ã®ã¹ã¯ãªãŒãã³ã°æ³ã§ãã£ãŠã以äžã®å·¥çšãããªãæ¹æ³ãæäŸããããšã§ãããïŒïœïŒè©Šéšååç©ãïŒïŒµïŒããªãããããæ¥è§Šãããå·¥çšãïŒïœïœïŒè©²è©Šéšååç©ã®è©²ïŒ®ïŒïŒµïŒããªãããããžã®çµåãæ€åºããå·¥çšãäŸãã°ãïŒïŒµïŒããªããããã«çµåããååç©ãããã®ãããªçŸæ£ã«å¯Ÿããå¯èœæ§ã®ããæ²»çå€ãšããŠåå®ããã
æ¬çºæã®ãããªãç®çã¯ãåºä¹³é¡ã«ããããè¡æ¶²çŸæ£ããã³å¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãççŸæ£ããã³ïŒ®ïŒïŒµïŒã®çºçŸã«é¢é£ããèèçŸæ£ãããªãçŸæ£ã®çŸ€ã«å«ãŸããçŸæ£ã®åŠçœ®ã«æçšãªæ²»çå€ã®ã¹ã¯ãªãŒãã³ã°æ¹æ³ã§ãã£ãŠã以äžã®å·¥çšãããªãæ¹æ³ãæäŸããïŒïŒïœïŒããç¹å®ã®è©Šéšååç©æ¿åºŠã§ãŸãã¯è©²è©Šéšååç©ã®éååšäžã§ïŒ®ïŒïŒµïŒããªããããã®æŽ»æ§ã枬å®ããå·¥çšãïŒïœïœïŒè©²è©Šéšååç©ã®ç°ãªãæ¿åºŠã§è©²ããªããããã®æŽ»æ§ã枬å®ããå·¥çšãäŸãã°ãïŒïœïŒããã³ïŒïœïœïŒã«ãããŠïŒ®ïŒïŒµïŒããªããããã®æŽ»æ§ã®å€åãããããååç©ããã®ãããªçŸæ£ã®å¯èœæ§ã®ããæ²»çå€ãšããŠåå®ããã
æ¬çºæã®ãããªãç®çã¯ãåºä¹³é¡ã«ãããè¡æ¶²çŸæ£ããã³å¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãççŸæ£ããã³ïŒ®ïŒïŒµïŒã®çºçŸã«é¢é£ããèèçŸæ£ãããªã矀ã«å«ãŸããçŸæ£ã®åŠçœ®ã«æçšãªæ²»çå€ã®ã¹ã¯ãªãŒãã³ã°æ¹æ³ã§ãã£ãŠã以äžã®å·¥çšãå«ãæ¹æ³ã§ããïŒïŒïœïŒããç¹å®ã®è©Šéšååç©ã®æ¿åºŠã§ïŒ®ïŒïŒµïŒããªããããã®æŽ»æ§ã枬å®ããå·¥çšãïŒïœïœïŒïŒ®ïŒïŒµïŒããªããããã®èª¿ç¯ç©è³ªã§ããããšãåãã£ãŠããååç©ã®ååšäžã§ïŒ®ïŒïŒµïŒããªããããã®æŽ»æ§ã枬å®ããå·¥çšãäŸãã°ãïŒïœïœïŒã§äœ¿çšããååç©ãšæ¯èŒããŠïŒïœïŒã«ãããŠïŒ®ïŒïŒµïŒããªããããã®æŽ»æ§ã«å¯Ÿãåºæ¿å¹æã瀺ãååç©ãããã®ãããªçŸæ£ã«å¯Ÿããå¯èœæ§ã®ããæ²»çå€ãšããŠåå®ããã
æ¬çºæã®ä»ã®ç®çã¯ãæ¥è§Šãããå·¥çšã现èå
ãŸãã¯çŽ°èè¡šé¢ã§è¡ãäžèšæ¹æ³ã§ããã
æ¬çºæã®ä»ã®ç®çã¯ã现èãin vitroã§ååšããäžèšæ¹æ³ã§ããã
æ¬çºæã®ä»ã®ç®çã¯ãæ¥è§Šãããå·¥çšã现èãå«ãŸãªãç³»ã§è¡ãäžèšæ¹æ³ã§ããã
æ¬çºæã®ä»ã®ç®çã¯ãããªãããããæ€åºå¯èœãªæšèã«çµåãããäžèšæ¹æ³ã§ããã
æ¬çºæã®ä»ã®ç®çã¯ãååç©ãæ€åºå¯èœãªæšèã«çµåãããäžèšæ¹æ³ã§ããã
äžèšæ¹æ³ã§ããã
äžèšæ¹æ³ã§ããã
æ¬çºæã®ä»ã®ç®çã¯ãè©Šéšååç©ãããªããããã«æåã«çµåããŠãããªã¬ã³ããšçœ®ãæããäžèšæ¹æ³ã§ããã
æ¬çºæã®ä»ã®ç®çã¯ãããªãããããåºäœã®æ¯æäœã«çµåããŠããäžèšæ¹æ³ã§ããã
æ¬çºæã®ä»ã®ç®çã¯ãååç©ãåºäœã®æ¯æäœã«çµåããŠããäžèšæ¹æ³ã§ããã
æ¬çºæã®ãããªãç®çã¯ãåºä¹³é¡ã«ãããè¡æ¶²çŸæ£ããã³å¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãççŸæ£ããã³èèçŸæ£ãããªãçŸæ£ã®çŸ€ã«å«ãŸããçŸæ£ã®åŠçœ®ã«æçšãªæ²»çå€ã®ã¹ã¯ãªãŒãã³ã°æ¹æ³ã§ãã£ãŠã以äžã®å·¥çšãå«ãã§ãªãæ¹æ³ã§ããïŒïŒïœïŒè©Šéšååç©ãïŒïŒµïŒããªãã¯ã¬ãªãããšæ¥è§Šãããå·¥çšãïŒïœïœïŒè©²è©Šéšååç©ãšè©²ïŒ®ïŒïŒµïŒããªãã¯ã¬ãªãããšã®çµåãæ€åºããå·¥çšãäŸãã°ãïŒïŒµïŒããªãã¯ã¬ãªããã«çµåããååç©ã¯ãã®ãããªçŸæ£ã®åŠçœ®ã®å¯èœæ§ã®ããæ²»çå€ã§ããã
æ¬çºæã®ãããªãç®çã¯ãæ žé
žååãã§ããäžèšæ¹æ³ã§ããã
æ¬çºæã®ãããªãç®çã¯ãæ¥è§Šãããå·¥çšã现èå
ãŸãã¯çŽ°èè¡šé¢ã§è¡ãäžèšæ¹æ³ã§ããã
æ¬çºæã®ãããªãç®çã¯ãæ¥è§Šãããå·¥çšã现èãå«ãŸãªãç³»ã§è¡ãäžèšæ¹æ³ã§ããã
æ¬çºæã®ãããªãç®çã¯ãããªãã¯ã¬ãªãããæ€åºå¯èœãªæšèã«çµåãããäžèšæ¹æ³ã§ããã
æ¬çºæã®ãããªãç®çã¯ãè©Šéšååç©ãæ€åºå¯èœãªæšèã«çµåãããäžèšæ¹æ³ã§ããã
æ¬çºæã®ãããªãç®çã¯ãåºä¹³é¡ã«ãããè¡æ¶²çŸæ£ããã³å¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãççŸæ£ããã³èèçŸæ£ãããªã矀ã«å«ãŸããçŸæ£ã蚺æããæ¹æ³ã§ãã£ãŠã以äžã®å·¥çšãå«ãã§ãªãæ¹æ³ã§ããïŒïŒïœïŒè©²åºä¹³é¡ããæ¡åãããµã³ãã«äžã®ïŒ®ïŒïŒµïŒããªãã¯ã¬ãªããã®éã枬å®ããããšïŒïŒïœïœïŒå¥åº·ãªåºä¹³é¡ããã³ïŒãŸãã¯çŸæ£ãæããåºä¹³é¡ã«ãããïŒïŒµïŒããªãã¯ã¬ãªããã®éã枬å®ããããšãäŸãã°ã該詊éšåºä¹³é¡ã«ãããïŒïŒµïŒããªãã¯ã¬ãªããéããçŸæ£ãæããåºä¹³é¡ãšæ¯èŒããŠå®è³ªçã«åæ§ã§ããã°ãçŸæ£ã蚺æãããã
æ¬çºæã®ãããªãç®çã¯ãïŒïŒµïŒããªããããã«çµåããæ²»çå€ãå«æãããåºä¹³é¡ã«ãããè¡æ¶²çŸæ£ããã³å¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãççŸæ£ããã³èèçŸæ£ãããªã矀ã«å«ãŸããçŸæ£ãåŠçœ®ããããã®å»è¬çµæç©ã§ããã
æ¬çºæã®ãããªãç®çã¯ãïŒïŒµïŒããªããããã®æŽ»æ§ã調ç¯ããæ²»çå€ãå«æãããåºä¹³é¡ã«ãããè¡æ¶²çŸæ£ããã³å¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãççŸæ£ããã³èèçŸæ£ãããªã矀ã«å«ãŸããçŸæ£ãåŠçœ®ããããã®å»è¬çµæç©ã§ããã
æ¬çºæã®ãããªãç®çã¯ãïŒïŒµïŒããªããããã®æŽ»æ§ã調ç¯ããæ²»çå€ãå«æãããåºä¹³é¡ã«ãããè¡æ¶²çŸæ£ããã³å¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãççŸæ£ããã³èèçŸæ£ãããªã矀ã«å«ãŸããçŸæ£ãåŠçœ®ããããã®å»è¬çµæç©ã§ãã£ãŠã該治çå€ããïŒïœïŒå°ååãïŒïœïœïŒïŒ²ïŒ®ïŒ¡ååãïŒïœïœïœïŒã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªãããïŒïœïœïŒããªãããããïŒïœïŒæäœãŸãã¯ïŒïœïœïŒãªãŸããŒã ã§ããå»è¬çµæç©ã§ããã
æ¬çºæã®ãããªãç®çã¯ãïŒïŒµïŒããªãã¯ã¬ãªãããå«æãããåºä¹³é¡ã«ãããè¡æ¶²çŸæ£ããã³å¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãççŸæ£ããã³èèçŸæ£ãããªã矀ã«å«ãŸããçŸæ£ãåŠçœ®ããããã®å»è¬çµæç©ã§ããã
æ¬çºæã®ãããªãç®çã¯ãïŒïŒµïŒããªãããããå«æãããåºä¹³é¡ã«ãããè¡æ¶²çŸæ£ããã³å¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãççŸæ£ããã³ïŒ®ïŒïŒµïŒã®çºçŸã«é¢é£ããèèçŸæ£ãããªã矀ã«å«ãŸããçŸæ£ãåŠçœ®ããããã®å»è¬çµæç©ã§ããã
æ¬çºæã®ãããªãç®çã¯ãåºä¹³é¡ã«ãããè¡æ¶²çŸæ£ããã³å¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãççŸæ£ããã³èèçŸæ£ãããªãçŸæ£ã®çŸ€ã«å«ãŸããçŸæ£ãåŠçœ®ããããã®å»è¬çµæç©ã®è£œé ã®ããã®ïŒ®ïŒïŒµïŒã®èª¿ç¯ç©è³ªã®äœ¿çšã§ããã
æ¬çºæã®ãããªãç®çã¯ãåºä¹³é¡ã«ãããè¡æ¶²çŸæ£ããã³å¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãççŸæ£ããã³èèçŸæ£ãããªãçŸæ£ã®çŸ€ã«å«ãŸããçŸæ£ã®åŠçœ®ã«æçšãªå»è¬çµæç©ã®è£œé æ¹æ³ã§ãã£ãŠã以äžã®å·¥çšãå«ã補é æ¹æ³ã§ããïŒïŒïœïŒïŒ®ïŒïŒµïŒã®èª¿ç¯ç©è³ªãåå®ããå·¥çšãïŒïœïœïŒè©²èª¿ç¯ç©è³ªããåºä¹³é¡ã«ãããè¡æ¶²çŸæ£ããã³å¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãççŸæ£ããã³èèçŸæ£ãããªãçŸæ£ã®çŸ€ã«å«ãŸããçŸæ£ã®çç¶ãæ¹åãããã©ããã調ã¹ãå·¥çšïŒããã³ïŒïœïœïœïŒè©²èª¿ç¯ç©è³ªã蚱容ãåŸã補è¬çæ
äœãšçµã¿åãããå·¥çšã
æ¬çºæã®ãããªãç®çã¯ãåºä¹³é¡ã«ãããè¡æ¶²çŸæ£ããã³å¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãççŸæ£ããã³èèçŸæ£ãããªãçŸæ£ã®çŸ€ã«å«ãŸããçŸæ£ãæããåºä¹³é¡ã«ãããïŒïŒµïŒæŽ»æ§ã®èª¿ç¯ã®ããã®ãïŒïŒµïŒã®èª¿ç¯ç©è³ªã®äœ¿çšã§ããã
æ¬çºæã説æããããã«ä»¥äžã®å®æœäŸãèšèŒããããããã®å®æœäŸã¯ã説æããããã«èšèŒãããã®ã§ãã£ãŠãæ¬çºæãéå®ããç®çã§èšèŒãããã®ã§ã¯ãªãã
å®æœäŸïŒïŒ
å ¬éãããé åããŒã¿ããŒã¹ã®çžåçé åã®æ€çŽ¢
çžåæ§ã®çšåºŠã容æã«èšç®ããããšãã§ãããçžåæ§ã決å®ããããã®å¥œãŸããæ¹æ³ã¯ãè©Šéšããé åéã®æã倧ããªäžèŽãäžããæ§ã«èšèšãããçžåæ§ã決å®ããããã®æ¹æ³ã¯ãïŒ¢ïœ ïœïœïŒŠïœïœããããã³ïŒŠïŒ¡ïŒ³ïŒŽïŒ¡çã®å ¬ã«å ¥æå¯èœãªã³ã³ãã¥ãŒã¿ããã°ã©ã ã«ããäœç³»åããããããã°ã©ã ã¯ïŒ®ïŒ£ïŒ¢ïŒ©ããã€ã³ã¿ãŒãããã§å ¬ã«å ¥æå¯èœã§ããã
å ¬éãããé åããŒã¿ããŒã¹ã®çžåçé åã®æ€çŽ¢
çžåæ§ã®çšåºŠã容æã«èšç®ããããšãã§ãããçžåæ§ã決å®ããããã®å¥œãŸããæ¹æ³ã¯ãè©Šéšããé åéã®æã倧ããªäžèŽãäžããæ§ã«èšèšãããçžåæ§ã決å®ããããã®æ¹æ³ã¯ãïŒ¢ïœ ïœïœïŒŠïœïœããããã³ïŒŠïŒ¡ïŒ³ïŒŽïŒ¡çã®å ¬ã«å ¥æå¯èœãªã³ã³ãã¥ãŒã¿ããã°ã©ã ã«ããäœç³»åããããããã°ã©ã ã¯ïŒ®ïŒ£ïŒ¢ïŒ©ããã€ã³ã¿ãŒãããã§å ¬ã«å ¥æå¯èœã§ããã
ïŒïŒµïŒã«ã€ããŠãã¢ã«ãŽãªãºã Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ; Nucleic Acids Res 1997 Sep 1 ; 25 (17): 3389-402ããã³ä»¥äžã®ãã©ã¡ãŒã¿ã®çµãçšããŠæ¢ç¥ã®é
åã«å¯Ÿãã以äžã®ããããåå®ããïŒ
ãããªãã¯ã¹ïŒïŒ¢ïŒ¬ïŒ¯ïŒ³ïŒµïŒïŒïŒããã³äœè€é床ãã£ã«ã¿ãŒã以äžã®ããŒã¿ããŒã¹ãæ€çŽ¢ããïŒïŒ®ïŒ£ïŒ¢ïŒ©ïŒééè€é åïŒããã³ïŒ€ïŒ¥ïŒ²ïŒ·ïŒ¥ïŒ®ïŒŽèŠªããŒã¿ããŒã¹(Geneseq)ã
ãããªãã¯ã¹ïŒïŒ¢ïŒ¬ïŒ¯ïŒ³ïŒµïŒïŒïŒããã³äœè€é床ãã£ã«ã¿ãŒã以äžã®ããŒã¿ããŒã¹ãæ€çŽ¢ããïŒïŒ®ïŒ£ïŒ¢ïŒ©ïŒééè€é åïŒããã³ïŒ€ïŒ¥ïŒ²ïŒ·ïŒ¥ïŒ®ïŒŽèŠªããŒã¿ããŒã¹(Geneseq)ã
以äžã®ããããèŠã€ãã£ãïŒ
> NA2001: AAD08007 AadO8007 ãã ã¿ã³ãã¯è³ªå ±åœ¹åå容äœãSNORF62ãcDNA. 8/2001ãé·ãïŒ 1318ããœãŒã¹ïŒ 2403 bits (1212)ãæåŸ å€ïŒ 0.0ãåäžæ§ïŒ 1212/1212(ïŒïŒïŒïŒ )ããã¬ãŒã ïŒ +1
> NA2000 : AAA30663 Aaa30663 ãã ã¿ã³ãã¯è³ªå ±åœ¹ååå®¹äœ MIGcDNA.
8/2000;é·ãïŒ1212 ;ãœãŒã¹ïŒ 2403 bits (1212),æåŸ å€ïŒ 0.0; åäžæ§ïŒ 1212/1212(100%) ; ãã¬ãŒã ïŒ +1
> gbïœAF272362.1ïœAF272362 ãã¢ã»ãµããšã³ã¹ ãã¥ãŒãã¡ãžã³ïŒµå容äœïŒ(NMUR1)mRNA, å®å šïœïœïœ; é·ãïŒ1318; ãœãŒã¹ïŒ 2403 bits(1212), æåŸ å€ïŒ 0.0 ; åäžæ§ïŒ 1212/1212 (100%) ; ãã¬ãŒã ïŒ +1
> refïœNM_006056. 1ïœãã¢ã»ãµããšã³ã¹ ã¿ã³ãã¯è³ªå ±åœ¹ååå®¹äœ 66(GPR66), mRNA ; é·ãïŒ1212; ãœãŒã¹ïŒ 2403 bits(1212), æåŸ å€ïŒ0.0 ; åäžæ§ïŒ 1212/1212(ïŒïŒïŒïŒ ) ; ãã¬ãŒã ïŒ +1
> NA2001: AAF76231 Aaf76231 ãã ã¿ã³ãã¯è³ªå ±åœ¹ååå®¹äœ FM-3cDNA. 6/2001; é·ãïŒ1209; ãœãŒã¹ïŒ 2397 bits(1209), æåŸ å€ïŒ 0.0 ; åäžæ§ïŒ 1209/1209(100%) ; ãã¬ãŒã ïŒ +1
> NA2001: AAH45072 Aah45072 ãã FM-3 ã³ãŒãé å. 9/2001; é·ãïŒ1209;ãœãŒã¹ïŒ 2397 bits (1209), æåŸ å€ïŒ 0.0 ; åäžæ§ïŒ 1209/1209(100%) ; ãã¬ãŒã ïŒ +1
> NA2000: AAA30739 Aaa30739 DNA ã³ãŒã ãã çªç¶å€ç°ïŒ§ã¿ã³ãã¯è³ªå ±åœ¹ååå®¹äœ MIG (T273K). 8/2000; é·ãïŒ1212;ãœãŒã¹ïŒ 2387 bits(1204), æåŸ å€ïŒ 0.0 ; åäžæ§ïŒ 1210/1212(99%) ; ãã¬ãŒã ïŒ +1
> NA2000: AAZ49707 Aaz49707 ãã æé·ãã«ã¢ã³åæ³ä¿é²é¢é£å容äœDNA. 4/2000; é·ãïŒ1212 ;ãœãŒã¹ïŒ 2379 bits(1200), æåŸ å€ïŒ 0.0 ; åäžæ§ïŒ 1209/1212(99%) ; ãã¬ãŒã ïŒ +1
> gbïœAC017104.8ïœãã¢ã»ãµããšã³ã¹æè²äœïŒã¯ããŒã³RP11-562I5, å®å šé å; é·ãïŒ168880; ãœãŒã¹ïŒ 1643 bits(829), æåŸ å€ïŒ 0.0 ; åäžæ§ïŒ 829/829(100%) ; ãã¬ãŒã ïŒ : +1
> gbïœAF044600.1ïœHSOGPCR1 ãã¢ã»ãµããšã³ã¹ ãªãŒãã¡ã³ïŒ§ã¿ã³ãã¯è³ªå ±åœ¹åå容äœéºäŒåã第ïŒã³ãŒããšã¯ãœã³ïŒé·ãïŒ828; ãœãŒã¹ïŒ 1641 bits(828), æåŸ å€ïŒ 0.0; åäžæ§ïŒ 828/828(100%) ; ãã¬ãŒã ïŒ +1
> gbïœAF044601.1ïœHSOGPCR2 ãã¢ã»ãµããšã³ã¹ãªãŒãã¡ã³ïŒ§ã¿ã³ãã¯è³ªå ±åœ¹åå容äœéºäŒåã第ïŒã³ãŒããšã¯ãœã³ããã³å®å šïœïœïœ; é·ãïŒ384; ãœãŒã¹ïŒ 761 bits(384), æåŸ å€ïŒ 0.0 ; åäžæ§ïŒ 384/384(100%) ; ãã¬ãŒã ïŒ +1
> NA2001: AAH45073 Aah45073 ããŠã¹FM-3ã³ãŒãé å. 9/2001; é·ãïŒ1215; ãœãŒã¹ïŒ 317 bits(160), æåŸ å€ïŒ 8e-84; åäžæ§ïŒ 499/612(81%) ; ãã¬ãŒã ïŒ +1
> NA2000: AAZ49706 Aaz49706 ããŠã¹æé·ãã«ã¢ã³åæ³ä¿é²é¢é£å容äœDNA. 4/2000; é·ãïŒ1526; ãœãŒã¹ïŒ 317 bits(160), æåŸ å€ïŒ 8e-84; åäžæ§ïŒ 499/612 (81%); ãã¬ãŒã ïŒ : +1
> NA2001: AAD08007 AadO8007 ãã ã¿ã³ãã¯è³ªå ±åœ¹åå容äœãSNORF62ãcDNA. 8/2001ãé·ãïŒ 1318ããœãŒã¹ïŒ 2403 bits (1212)ãæåŸ å€ïŒ 0.0ãåäžæ§ïŒ 1212/1212(ïŒïŒïŒïŒ )ããã¬ãŒã ïŒ +1
> NA2000 : AAA30663 Aaa30663 ãã ã¿ã³ãã¯è³ªå ±åœ¹ååå®¹äœ MIGcDNA.
8/2000;é·ãïŒ1212 ;ãœãŒã¹ïŒ 2403 bits (1212),æåŸ å€ïŒ 0.0; åäžæ§ïŒ 1212/1212(100%) ; ãã¬ãŒã ïŒ +1
> gbïœAF272362.1ïœAF272362 ãã¢ã»ãµããšã³ã¹ ãã¥ãŒãã¡ãžã³ïŒµå容äœïŒ(NMUR1)mRNA, å®å šïœïœïœ; é·ãïŒ1318; ãœãŒã¹ïŒ 2403 bits(1212), æåŸ å€ïŒ 0.0 ; åäžæ§ïŒ 1212/1212 (100%) ; ãã¬ãŒã ïŒ +1
> refïœNM_006056. 1ïœãã¢ã»ãµããšã³ã¹ ã¿ã³ãã¯è³ªå ±åœ¹ååå®¹äœ 66(GPR66), mRNA ; é·ãïŒ1212; ãœãŒã¹ïŒ 2403 bits(1212), æåŸ å€ïŒ0.0 ; åäžæ§ïŒ 1212/1212(ïŒïŒïŒïŒ ) ; ãã¬ãŒã ïŒ +1
> NA2001: AAF76231 Aaf76231 ãã ã¿ã³ãã¯è³ªå ±åœ¹ååå®¹äœ FM-3cDNA. 6/2001; é·ãïŒ1209; ãœãŒã¹ïŒ 2397 bits(1209), æåŸ å€ïŒ 0.0 ; åäžæ§ïŒ 1209/1209(100%) ; ãã¬ãŒã ïŒ +1
> NA2001: AAH45072 Aah45072 ãã FM-3 ã³ãŒãé å. 9/2001; é·ãïŒ1209;ãœãŒã¹ïŒ 2397 bits (1209), æåŸ å€ïŒ 0.0 ; åäžæ§ïŒ 1209/1209(100%) ; ãã¬ãŒã ïŒ +1
> NA2000: AAA30739 Aaa30739 DNA ã³ãŒã ãã çªç¶å€ç°ïŒ§ã¿ã³ãã¯è³ªå ±åœ¹ååå®¹äœ MIG (T273K). 8/2000; é·ãïŒ1212;ãœãŒã¹ïŒ 2387 bits(1204), æåŸ å€ïŒ 0.0 ; åäžæ§ïŒ 1210/1212(99%) ; ãã¬ãŒã ïŒ +1
> NA2000: AAZ49707 Aaz49707 ãã æé·ãã«ã¢ã³åæ³ä¿é²é¢é£å容äœDNA. 4/2000; é·ãïŒ1212 ;ãœãŒã¹ïŒ 2379 bits(1200), æåŸ å€ïŒ 0.0 ; åäžæ§ïŒ 1209/1212(99%) ; ãã¬ãŒã ïŒ +1
> gbïœAC017104.8ïœãã¢ã»ãµããšã³ã¹æè²äœïŒã¯ããŒã³RP11-562I5, å®å šé å; é·ãïŒ168880; ãœãŒã¹ïŒ 1643 bits(829), æåŸ å€ïŒ 0.0 ; åäžæ§ïŒ 829/829(100%) ; ãã¬ãŒã ïŒ : +1
> gbïœAF044600.1ïœHSOGPCR1 ãã¢ã»ãµããšã³ã¹ ãªãŒãã¡ã³ïŒ§ã¿ã³ãã¯è³ªå ±åœ¹åå容äœéºäŒåã第ïŒã³ãŒããšã¯ãœã³ïŒé·ãïŒ828; ãœãŒã¹ïŒ 1641 bits(828), æåŸ å€ïŒ 0.0; åäžæ§ïŒ 828/828(100%) ; ãã¬ãŒã ïŒ +1
> gbïœAF044601.1ïœHSOGPCR2 ãã¢ã»ãµããšã³ã¹ãªãŒãã¡ã³ïŒ§ã¿ã³ãã¯è³ªå ±åœ¹åå容äœéºäŒåã第ïŒã³ãŒããšã¯ãœã³ããã³å®å šïœïœïœ; é·ãïŒ384; ãœãŒã¹ïŒ 761 bits(384), æåŸ å€ïŒ 0.0 ; åäžæ§ïŒ 384/384(100%) ; ãã¬ãŒã ïŒ +1
> NA2001: AAH45073 Aah45073 ããŠã¹FM-3ã³ãŒãé å. 9/2001; é·ãïŒ1215; ãœãŒã¹ïŒ 317 bits(160), æåŸ å€ïŒ 8e-84; åäžæ§ïŒ 499/612(81%) ; ãã¬ãŒã ïŒ +1
> NA2000: AAZ49706 Aaz49706 ããŠã¹æé·ãã«ã¢ã³åæ³ä¿é²é¢é£å容äœDNA. 4/2000; é·ãïŒ1526; ãœãŒã¹ïŒ 317 bits(160), æåŸ å€ïŒ 8e-84; åäžæ§ïŒ 499/612 (81%); ãã¬ãŒã ïŒ : +1
å®æœäŸïŒïŒ
çºçŸãããã¡ã€ãªã³ã°
ïŒã€ã®æšæºçæ¹æ³ïŒïŒïŒã°ã¢ããžã³ã€ãœããªã·ã¢ããŒãïŒå¡©åã»ã·ãŠã å¯åºŠåŸé é å¿ïŒ»Kellogg,(1990)ïŒãŸãã¯è£œé æ¥è ã®èª¬ææžã«åŸãTri-Reagentãããã³ã«ïŒ(Molecular Research Center, Inc. , Cincinatti, OhioïŒã®ïŒã€ã«ãã£ãŠçŽ°èããå šçŽ°èãåé¢ãããTri-Reagentãããã³ã«ã«ãã調補ããå šïŒ²ïŒ®ïŒ¡ãaseIã§åŠçããŠã²ãã æ±æãé€å»ããã
çºçŸãããã¡ã€ãªã³ã°
ïŒã€ã®æšæºçæ¹æ³ïŒïŒïŒã°ã¢ããžã³ã€ãœããªã·ã¢ããŒãïŒå¡©åã»ã·ãŠã å¯åºŠåŸé é å¿ïŒ»Kellogg,(1990)ïŒãŸãã¯è£œé æ¥è ã®èª¬ææžã«åŸãTri-Reagentãããã³ã«ïŒ(Molecular Research Center, Inc. , Cincinatti, OhioïŒã®ïŒã€ã«ãã£ãŠçŽ°èããå šçŽ°èãåé¢ãããTri-Reagentãããã³ã«ã«ãã調補ããå šïŒ²ïŒ®ïŒ¡ãaseIã§åŠçããŠã²ãã æ±æãé€å»ããã
ïŒïŒµïŒã®ïœïŒ²ïŒ®ïŒ¡ååžã®çžå¯Ÿçå®éã«ã€ããŠãå现èãŸãã¯çµç¹ç±æ¥ã®å
šïŒ²ïŒ®ïŒ¡ããŸãé転åãããæçµå®¹éïŒïŒïŒÎŒLäžãïŒÎŒmoleã®ã©ã³ãã ãããµããŒãã©ã€ããŒãåïŒïŒïŒÎŒïŒã®ïœïŒ¡ïŒŽïŒ°ãïœïŒ£ïŒŽïŒ°ãïœïŒ§ïŒŽïŒ°ãããã³ïœïŒŽïŒŽïŒ°ïŒQiagen, Hilden, GermanyïŒãïŒïŒïŒïŒïŒµã®RnaseQutïŒInvitrogen, Groningen, NetherlandsïŒãçšããŠïŒïŒÎŒgã®å
šïŒ²ïŒ®ïŒ¡ãé転åããã第ïŒéã®åæç·©è¡æ¶²ããã³Omniscripté転åé
µçŽ ïŒïŒïŒµïŒÎŒLïŒã¯Qiagen, Hilden, Germanyããå
¥æãããåå¿ç©ãïŒïŒâã«ãŠïŒïŒåéã€ã³ãã¥ããŒã·ã§ã³ããæ°·å·ãããäœç©ãæ°Žã§ïŒïŒïŒïŒÎŒïŒ¬ã«èª¿ç¯ããåçºïŒ²ïŒ®ïŒ¡ã®æçµæ¿åºŠãïŒïŒïŒïŒïœïœïŒÎŒïŒ¬ãšããã
现èããã³çµç¹ã«ãããïŒïŒµïŒïœïŒ²ïŒ®ïŒ¡ã®ååžã®çžå¯Ÿçå®éã«ã€ããŠã¯ãPerkin Elmer ABI Prism RTM.7700é
å決å®ã·ã¹ãã ãŸãã¯BioradiCyclerãåãæ±ã説ææžãšãããã³ã«ã«ãããã£ãŠäœ¿çšãããåå¿ãïŒïŒµïŒããã³ããŠã¹ããŒãã³ã°éºäŒåïŒããããµã³ãã³ãã¹ããªãã·ã«ãã©ã³ã¹ãã§ã©ãŒãŒïŒãïŒã°ãªã»ã«ã¢ã«ãããâïŒâãã¹ãã§ãŒãããããã²ããŒãŒïŒãβâã¢ã¯ãã³ãªã©ãå®éããããèšå®ãããïŒïŒµïŒã«å¯Ÿãããã©ã¯ãŒãããã³ãªããŒã¹ãã©ã€ããŒããã³ãããŒãããPerkin Elmer ABI Primer ExpressïŒç»é²åæšïŒãœãããŠã§ã¢ãçšããŠèšèšããTibMolBiol (Berlin, Germany)ã«ãã£ãŠåæãããïŒïŒµïŒãã©ã¯ãŒããã©ã€ããŒé
åã¯ä»¥äžã®éãã§ããïŒãã©ã€ããŒïŒïŒé
åçªå·ïŒïŒãïŒïŒµïŒãªããŒã¹ãã©ã€ããŒã¯ãã©ã€ããŒïŒïŒé
åçªå·ïŒïŒã§ãããã¬ããŒã¿ãŒè²çŽ ãšããŠïŒŠïŒ¡ïŒïŒã«ã«ããã·ãã«ãªã¬ã»ã€ãããžã«ãšã¹ãã«ïŒãã¯ãšã³ãã£ãŒãšããŠïŒŽïŒ¡ïŒïŒ²ïŒ¡ïŒã«ã«ããã·ããã©ã¡ãã«ããŒããã³ïŒã§æšèãããããŒãïŒïŒé
åçªå·ïŒïŒãïŒïŒµïŒã«ã€ããŠã®ãããŒããšããŠçšããã以äžã®è©Šè¬ã調補ããŠç·äœç©ïŒïŒÎŒïŒ¬ãšããïŒïŒÃïœïœïŒïœïœç·©è¡æ¶²ïŒ¡ãïŒïŒïŒïœïŒ ïŒïœïŒ£ïœ2ãïŒïŒïŒïœïŒã®ïœïŒ¡ïŒŽïŒ°ãïœïŒ£ïŒŽïŒ°ãïœïŒ§ïŒŽïŒ°ããã³ïœïŒµïŒŽïŒ°ãïŒïŒïŒïŒïŒïŒµïŒïŒ¬ã®ïŒ¡ïœïœïœïœïŒŽïœïœ ïœïœïœãïŒïŒïŒïŒïŒµïŒïŒ¬ã®ïŒ¡ïœïœïŒ¥ïœïœïœïœ
ããã³ãããŒãïŒïŒé
åçªå·ïŒïŒãåïŒïŒïŒïœïŒã®ïŒ®ïŒïŒµïŒãã©ã¯ãŒãããã³ãªããŒã¹ãã©ã€ããŒãïŒïŒïŒïœïŒã®ïŒ®ïŒïŒµïŒïŒŠïŒ¡ïŒïŒïŒŽïŒ¡ïŒïŒ²ïŒ¡âæšèãããŒãããã³ïŒÎŒLã®ãã³ãã¬ãŒãïœïŒ€ïŒ®ïŒ¡ã枩床ãµã€ã¯ã«ãã©ã¡ãŒã¿ãŒã¯ïŒïŒâã§ïŒåãïŒïŒâã§ïŒïŒåã次ãã§ïŒïŒâã§ïŒïŒç§éãïŒïŒãµã€ã¯ã«ããã³ã¢ããŒãªã³ã°ïŒäŒžåŒµãïŒïŒâã§ïŒåéã§ãã£ãã
è£æ£ãããå€ã®èšç®
ãæ žé žã®å®é枬å®ãã®ç¯ã«èšèŒã®ãšããïŒéŸå€ãµã€ã¯ã«ïŒå€ãèšç®ããã以äžã®ããã«ããŠïŒ£ïŒŠå€ïŒéŸå€ãµã€ã¯ã«è£æ£ã®ããã®ä¿æ°ïŒãèšç®ããïŒ
ïŒïŒïŒ°ïŒ£ïŒ²åå¿ãã»ããã¢ããããŠãåïœïŒ€ïŒ®ïŒ¡ãµã³ãã«ã«ã€ããŠããŠã¹ããŒãã³ã°éºäŒåãå®éãã
ïŒïŒïŒ£ïŒŽHKG-å€ïŒããŠã¹ããŒãã³ã°éºäŒåã«ã€ããŠã®éŸå€ãµã€ã¯ã«ïŒãããæ žé žã®å®é枬å®ãã®ç¯ã«èšèŒã®ãšããèšç®ããã
ïŒïŒåïœïŒ€ïŒ®ïŒ¡ã«ã€ããŠãã¹ãŠã®ïŒšïŒ«ïŒ§ã®ïŒ£ïŒŽHKGâå¹³åå€ïŒïŒã€ã®ïœïŒ€ïŒ®ïŒ¡ã«ã€ããŠè©Šéšãããã¹ãŠã®ïŒšïŒ«ïŒ§ã®ïŒ£ïŒŽå¹³åå€ïŒãèšç®ããïŒïœïŒïŒšïŒ«ïŒ§ã®æ°ïŒïŒ
HKG-nå¹³åå€ïŒïŒïŒ£ïŒŽHKG1å€ïŒïŒ£ïŒŽHKG2å€...ïŒïŒ£ïŒŽHKG-nå€ïŒïŒïœ
ïŒïŒïŒ£ïŒŽpannelå¹³åå€ïŒè©Šéšãããã¹ãŠã®ïœïŒ€ïŒ®ïŒ¡ã«ããããã¹ãŠã®ïŒšïŒ«ïŒ§ã®ïŒ£ïŒŽå¹³åå€ïŒ
ïŒïŒïŒ£ïŒŽHKG1å¹³åå€ïŒïŒ£ïŒŽHKG2å¹³åå€ïŒïŒïŒïŒïŒïŒ£ïŒŽHKG-yå¹³åå€ïŒïŒïœ
ïŒïœïŒïœïŒ€ïŒ®ïŒ¡ã®æ°ïŒ
ïŒïŒïŒ£ïŒŠcDNA-n(ïœïŒ€ïŒ®ïŒ¡ ïœã«ã€ããŠã®è£æ£ä¿æ°ïŒïŒïŒ£ïŒŽpannelå¹³åå€âHKG-nå¹³åå€
ïŒïŒïŒ£ïŒŽcDNA-n(ïœïŒ€ïŒ®ïŒ¡ ïœã«ã€ããŠè©ŠéšããéºäŒåã®ïŒ£ïŒŽå€ïŒïŒïŒ£ïŒŠeDNA-nïŒïœïŒ€ïŒ®ïŒ¡ïœã«ã€ããŠã®è£æ£ä¿æ°ïŒïŒïŒ£ïŒŽcor-cDNA-nïŒïœïŒ€ïŒ®ïŒ¡ïœã«å¯ŸããéºäŒåã«ã€ããŠã®è£æ£ïŒ£ïŒŽå€ïŒ
ãæ žé žã®å®é枬å®ãã®ç¯ã«èšèŒã®ãšããïŒéŸå€ãµã€ã¯ã«ïŒå€ãèšç®ããã以äžã®ããã«ããŠïŒ£ïŒŠå€ïŒéŸå€ãµã€ã¯ã«è£æ£ã®ããã®ä¿æ°ïŒãèšç®ããïŒ
ïŒïŒïŒ°ïŒ£ïŒ²åå¿ãã»ããã¢ããããŠãåïœïŒ€ïŒ®ïŒ¡ãµã³ãã«ã«ã€ããŠããŠã¹ããŒãã³ã°éºäŒåãå®éãã
ïŒïŒïŒ£ïŒŽHKG-å€ïŒããŠã¹ããŒãã³ã°éºäŒåã«ã€ããŠã®éŸå€ãµã€ã¯ã«ïŒãããæ žé žã®å®é枬å®ãã®ç¯ã«èšèŒã®ãšããèšç®ããã
ïŒïŒåïœïŒ€ïŒ®ïŒ¡ã«ã€ããŠãã¹ãŠã®ïŒšïŒ«ïŒ§ã®ïŒ£ïŒŽHKGâå¹³åå€ïŒïŒã€ã®ïœïŒ€ïŒ®ïŒ¡ã«ã€ããŠè©Šéšãããã¹ãŠã®ïŒšïŒ«ïŒ§ã®ïŒ£ïŒŽå¹³åå€ïŒãèšç®ããïŒïœïŒïŒšïŒ«ïŒ§ã®æ°ïŒïŒ
HKG-nå¹³åå€ïŒïŒïŒ£ïŒŽHKG1å€ïŒïŒ£ïŒŽHKG2å€...ïŒïŒ£ïŒŽHKG-nå€ïŒïŒïœ
ïŒïŒïŒ£ïŒŽpannelå¹³åå€ïŒè©Šéšãããã¹ãŠã®ïœïŒ€ïŒ®ïŒ¡ã«ããããã¹ãŠã®ïŒšïŒ«ïŒ§ã®ïŒ£ïŒŽå¹³åå€ïŒ
ïŒïŒïŒ£ïŒŽHKG1å¹³åå€ïŒïŒ£ïŒŽHKG2å¹³åå€ïŒïŒïŒïŒïŒïŒ£ïŒŽHKG-yå¹³åå€ïŒïŒïœ
ïŒïœïŒïœïŒ€ïŒ®ïŒ¡ã®æ°ïŒ
ïŒïŒïŒ£ïŒŠcDNA-n(ïœïŒ€ïŒ®ïŒ¡ ïœã«ã€ããŠã®è£æ£ä¿æ°ïŒïŒïŒ£ïŒŽpannelå¹³åå€âHKG-nå¹³åå€
ïŒïŒïŒ£ïŒŽcDNA-n(ïœïŒ€ïŒ®ïŒ¡ ïœã«ã€ããŠè©ŠéšããéºäŒåã®ïŒ£ïŒŽå€ïŒïŒïŒ£ïŒŠeDNA-nïŒïœïŒ€ïŒ®ïŒ¡ïœã«ã€ããŠã®è£æ£ä¿æ°ïŒïŒïŒ£ïŒŽcor-cDNA-nïŒïœïŒ€ïŒ®ïŒ¡ïœã«å¯ŸããéºäŒåã«ã€ããŠã®è£æ£ïŒ£ïŒŽå€ïŒ
çžå¯ŸççºçŸã®èšç®
å®çŸ©ïŒæãé«ãcor-cDNA-nâ ïŒïŒãcor-cDNA[high]ãšå®çŸ©ãã
çžå¯ŸççºçŸïŒïŒ(CTcor-cDNA[high]-CTcor-cDNA-n)
å®çŸ©ïŒæãé«ãcor-cDNA-nâ ïŒïŒãcor-cDNA[high]ãšå®çŸ©ãã
çžå¯ŸççºçŸïŒïŒ(CTcor-cDNA[high]-CTcor-cDNA-n)
çµç¹
ïŒïŒµïŒã®çºçŸã以äžã®çµç¹ã«ãããŠèª¿ã¹ãïŒè³ãå šã¢ã«ããã€ããŒè³ãèå è³ãå°è³ãèé«ãå¿èãèå å¿èãå¿èãæ«æ¢¢è¡ãå ç¶å¹³æ»ç现èã现èãç²ç¶è ºãç²ç¶è ºçãèŸèãèŸèè硬å€ãèžè ºã骚é«ãèºãèå èºãèºçãèèãèå èèãèèè硬å€ãïŒçŽ°èãèµèãèµèè硬å€ãèãå°è žãçµè žãçµè žçãè èãïŒïŒïŒçŽ°èãéªšæ ŒçãïŒšïœ ïŒ¬ïœçŽ°èãä¹³çãä¹³è ºãïŒïŒ€ïŒ¡ïŒïŒ¢ïŒïŒïŒçŽ°èã粟巣ãæ°ç®¡ãå¯è ãåŸæ¶²è ºãèè±ãåç«è ºãèç€ãåå®®ãèèªã
ïŒïŒµïŒã®çºçŸã以äžã®çµç¹ã«ãããŠèª¿ã¹ãïŒè³ãå šã¢ã«ããã€ããŒè³ãèå è³ãå°è³ãèé«ãå¿èãèå å¿èãå¿èãæ«æ¢¢è¡ãå ç¶å¹³æ»ç现èã现èãç²ç¶è ºãç²ç¶è ºçãèŸèãèŸèè硬å€ãèžè ºã骚é«ãèºãèå èºãèºçãèèãèå èèãèèè硬å€ãïŒçŽ°èãèµèãèµèè硬å€ãèãå°è žãçµè žãçµè žçãè èãïŒïŒïŒçŽ°èãéªšæ ŒçãïŒšïœ ïŒ¬ïœçŽ°èãä¹³çãä¹³è ºãïŒïŒ€ïŒ¡ïŒïŒ¢ïŒïŒïŒçŽ°èã粟巣ãæ°ç®¡ãå¯è ãåŸæ¶²è ºãèè±ãåç«è ºãèç€ãåå®®ãèèªã
çºçŸãããã¡ã€ã«
ïœïŒ²ïŒ®ïŒ¡ã®å®éïŒçºçŸãããã¡ã€ã«ïŒã®çµæã以äžã®è¡šïŒã«ç€ºãã
衚ïŒïŒœ
æ§ã ãªããçµç¹ã«ãããïŒïŒµïŒã®çžå¯ŸççºçŸ
è³ 24,45
å šã¢ã«ããã€ããŒè³ 276,44
èå è³ 18,45
å°è³ 38,77
èé« 8,26
å¿è 2,18
èå å¿è 64,26
å¿è 160,25
æ«æ¢¢è¡ 1318,79
å ç¶å¹³æ»ç现è 802,95
现è 973,81
ç²ç¶è º 307,44
ç²ç¶è ºç 42,44
èŸè 61,62
èŸèèç¡¬å€ 146,27
èžè º 53,48
éªšé« 89,88
èº 54,13
èå èº 97,06
èºç 469,23
èè 759,64
èå èè 17,97
èèèç¡¬å€ 897,13
HEP G2现è 622,03
èµè 72,15
èµèèç¡¬å€ 9,90
è 161,13
å°è ž 290,89
çµè ž 314,08
çµè žç 195,70
è è 402,87
HEK293现è 230,32
éªšæ Œç 10,63
HeLa现è 1,00
ä¹³ç 198,43
ä¹³è º 136,87
MDA MB 231现è 31,83
粟巣 115,11
æ°ç®¡ 186,88
å¯è 57,67
åŸæ¶²è º 10,21
èè± 162,77
åç«è º 207,52
èç€ 156,74
åå®® 285,97
èèª 156,77
ïœïŒ²ïŒ®ïŒ¡ã®å®éïŒçºçŸãããã¡ã€ã«ïŒã®çµæã以äžã®è¡šïŒã«ç€ºãã
衚ïŒïŒœ
æ§ã ãªããçµç¹ã«ãããïŒïŒµïŒã®çžå¯ŸççºçŸ
è³ 24,45
å šã¢ã«ããã€ããŒè³ 276,44
èå è³ 18,45
å°è³ 38,77
èé« 8,26
å¿è 2,18
èå å¿è 64,26
å¿è 160,25
æ«æ¢¢è¡ 1318,79
å ç¶å¹³æ»ç现è 802,95
现è 973,81
ç²ç¶è º 307,44
ç²ç¶è ºç 42,44
èŸè 61,62
èŸèèç¡¬å€ 146,27
èžè º 53,48
éªšé« 89,88
èº 54,13
èå èº 97,06
èºç 469,23
èè 759,64
èå èè 17,97
èèèç¡¬å€ 897,13
HEP G2现è 622,03
èµè 72,15
èµèèç¡¬å€ 9,90
è 161,13
å°è ž 290,89
çµè ž 314,08
çµè žç 195,70
è è 402,87
HEK293现è 230,32
éªšæ Œç 10,63
HeLa现è 1,00
ä¹³ç 198,43
ä¹³è º 136,87
MDA MB 231现è 31,83
粟巣 115,11
æ°ç®¡ 186,88
å¯è 57,67
åŸæ¶²è º 10,21
èè± 162,77
åç«è º 207,52
èç€ 156,74
åå®® 285,97
èèª 156,77
å®æœäŸïŒïŒã¢ã³ãã»ã³ã¹è§£æ
ïŒïŒµïŒãã³ãŒããããæ£ãããå®å šãªïœïŒ€ïŒ®ïŒ¡é åã®ç¥èŠã¯ãéºäŒåæ©èœã®ç 究ã«ãããŠã¢ã³ãã»ã³ã¹æè¡ã®ããã®ããŒã«ãšããŠçšããããšãå¯èœã§ãããïŒïŒµïŒãã³ãŒãããããªãã¯ã¬ãªããã®ã¢ã³ãã»ã³ã¹éãå«ãããªãªãŽãã¯ã¬ãªãããïœïŒ€ïŒ®ïŒ¡ãŸãã¯ã²ãã æçããin vitro ãŸã㯠in vivoã®ããããã§ãïœïŒ²ïŒ®ïŒ¡ã®ç¿»èš³ãé»å®³ããããã«äœ¿çšããããã®ãããªæè¡ã¯ããŸãåšç¥ã§ããããã¯ã¬ãªããé åäžã®æ§ã ãªåº§ã§ã¢ã³ãã»ã³ã¹ååãèšèšããããšãã§ããã现èãŸãã¯è©Šéšåç©å šäœããã®ãããªã¢ã³ãã»ã³ã¹é åã§åŠçããããšã«ãããç®çã®éºäŒåãæå¹ã«æããããšãã§ããããã°ãã°ãéºäŒåã®æ©èœã¯ã现èå ã现èãçµç¹ãŸãã¯çç©ã¬ãã«ã§ã®æ¯ãèãã芳å¯ããããšã«ãã£ãŠç¢ºãããããïŒäŸãã°ãèŽæ»æ§ãååããæ©èœã®åªå€±ã圢質ã®å€åãªã©ïŒã
ïŒïŒµïŒãã³ãŒããããæ£ãããå®å šãªïœïŒ€ïŒ®ïŒ¡é åã®ç¥èŠã¯ãéºäŒåæ©èœã®ç 究ã«ãããŠã¢ã³ãã»ã³ã¹æè¡ã®ããã®ããŒã«ãšããŠçšããããšãå¯èœã§ãããïŒïŒµïŒãã³ãŒãããããªãã¯ã¬ãªããã®ã¢ã³ãã»ã³ã¹éãå«ãããªãªãŽãã¯ã¬ãªãããïœïŒ€ïŒ®ïŒ¡ãŸãã¯ã²ãã æçããin vitro ãŸã㯠in vivoã®ããããã§ãïœïŒ²ïŒ®ïŒ¡ã®ç¿»èš³ãé»å®³ããããã«äœ¿çšããããã®ãããªæè¡ã¯ããŸãåšç¥ã§ããããã¯ã¬ãªããé åäžã®æ§ã ãªåº§ã§ã¢ã³ãã»ã³ã¹ååãèšèšããããšãã§ããã现èãŸãã¯è©Šéšåç©å šäœããã®ãããªã¢ã³ãã»ã³ã¹é åã§åŠçããããšã«ãããç®çã®éºäŒåãæå¹ã«æããããšãã§ããããã°ãã°ãéºäŒåã®æ©èœã¯ã现èå ã现èãçµç¹ãŸãã¯çç©ã¬ãã«ã§ã®æ¯ãèãã芳å¯ããããšã«ãã£ãŠç¢ºãããããïŒäŸãã°ãèŽæ»æ§ãååããæ©èœã®åªå€±ã圢質ã®å€åãªã©ïŒã
æ§ç¯ããé
åãçšããŠç¹å®ã®ãªãŒãã³ãªãŒãã£ã³ã°ãã¬ãŒã ã«åæããããšã«å ããŠãã€ã³ããã³é åãããã¢ãŒã¿ãŒïŒãšã³ãã³ãµãŒãšã¬ã¡ã³ããŸãã¯ããã«ã¯ãã©ã³ã¹äœçšèª¿ç¯éºäŒåã«å¯Ÿããã¢ã³ãã»ã³ã¹é
åãèšèšããããšã«ãã£ãŠéºäŒåçºçŸã修食ããããšãã§ããã
å®æœäŸïŒïŒ
ïŒïŒµïŒã®çºçŸ
ïŒïŒµïŒã®çºçŸã¯ãïœïŒ€ïŒ®ïŒ¡ãé©åœãªçºçŸãã¯ã¿ãŒã«ãµãã¯ããŒãã³ã°ãããã®ãã¯ã¿ãŒãå€§è žèçã®çºçŸå®¿äž»ã«ãã©ã³ã¹ãã§ã¯ãããããšã«ããè¡ããå ·äœçãªå Žåã§ã¯ããã¯ã¿ãŒãæäœããŠãã¯ããŒãã³ã°éšäœã®äžæµã«Î²âã¬ã©ã¯ãã·ããŒãŒã®ããã®ããã¢ãŒã¿ãŒãç¶ããŠã¢ããæ«ç«¯ã®ã¡ããªãã³ããã³ããã«ç¶ãβâã¬ã©ã¯ãã·ããŒãŒã®ïŒã€ã®æ®åºãå«ãé åãå°å ¥ããããããïŒæ®åºã®ããäžæµã¯ã人工çãªãã©ã€ãã³ã°ãšè»¢åããã³ã¯ããŒãã³ã°ã®ããã®å€ãã®ç¬ç¹ãªãšã³ããã¯ã¬ã¢ãŒãŒå¶ééšäœãçããã®ã«æçšãªãéºäŒåæäœããããã¯ããªãªãã¡ãŒãžããã¢ãŒã¿ãŒã§ããã
ïŒïŒµïŒã®çºçŸ
ïŒïŒµïŒã®çºçŸã¯ãïœïŒ€ïŒ®ïŒ¡ãé©åœãªçºçŸãã¯ã¿ãŒã«ãµãã¯ããŒãã³ã°ãããã®ãã¯ã¿ãŒãå€§è žèçã®çºçŸå®¿äž»ã«ãã©ã³ã¹ãã§ã¯ãããããšã«ããè¡ããå ·äœçãªå Žåã§ã¯ããã¯ã¿ãŒãæäœããŠãã¯ããŒãã³ã°éšäœã®äžæµã«Î²âã¬ã©ã¯ãã·ããŒãŒã®ããã®ããã¢ãŒã¿ãŒãç¶ããŠã¢ããæ«ç«¯ã®ã¡ããªãã³ããã³ããã«ç¶ãβâã¬ã©ã¯ãã·ããŒãŒã®ïŒã€ã®æ®åºãå«ãé åãå°å ¥ããããããïŒæ®åºã®ããäžæµã¯ã人工çãªãã©ã€ãã³ã°ãšè»¢åããã³ã¯ããŒãã³ã°ã®ããã®å€ãã®ç¬ç¹ãªãšã³ããã¯ã¬ã¢ãŒãŒå¶ééšäœãçããã®ã«æçšãªãéºäŒåæäœããããã¯ããªãªãã¡ãŒãžããã¢ãŒã¿ãŒã§ããã
æšæºãªæ¹æ³ãçšããŠã€ãœãããã«âβââããªã¬ã©ã¯ããã©ãã·ãïŒïŒ©ïŒ°ïŒŽïŒ§ïŒãçšããŠåé¢ããããã©ã³ã¹ãã§ã¯ãããã现èæ ªã®èªå°ã«ãããβâã¬ã©ã¯ãã·ããŒãŒã®æåã®ïŒæ®åºãçŽïŒïŒæ®åºã®ããªã³ã«ãŒãããã³ïœïŒ€ïŒ®ïŒ¡å
ã§ã³ãŒãããããããããå«ãèåã¿ã³ãã¯è³ªãç£çãããïœïŒ€ïŒ®ïŒ¡ã¯ããŒã³æ¿å
¥ç©ã¯ãæ¬è³ªçã«ã©ã³ãã ãªéçšã§äœè£œãããã®ã§ãé©åãªç¿»èš³ã®ããã«æ£ãããªãŒãã£ã³ã°ãã¬ãŒã ã§ïœïŒ€ïŒ®ïŒ¡ãå°å
¥ãããå¯èœæ§ã¯ïŒïŒïŒ
ã§ãããïœïŒ€ïŒ®ïŒ¡ãé©åãªãªãŒãã£ã³ã°ãã¬ãŒã ã«ãªãå Žåã¯ãin vitroçªç¶å€ç°èªçºããšããœãã¯ã¬ã¢ãŒãŒIIIãŸãã¯ç·è±ãã¯ã¬ã¢ãŒãŒã«ããæ¶åããŸãã¯é©åœãªé·ãã®ãªãªãŽãã¯ã¬ãªãããªã³ã«ãŒã®å°å
¥ãªã©ã®åšç¥ã®æ¹æ³ãçšããŠãé©åœãªæ°ã®å¡©åºãæ¬ å€±ãããããŸãã¯æ¿å
¥ããããšã«ãã£ãŠåŸãããã
ïŒïŒµïŒïœïŒ€ïŒ®ïŒ¡ããç¹å®ã®å®¿äž»ã«ãããã¿ã³ãã¯è³ªã®çºçŸã«æçšã§ãããšç¥ãããŠããä»ã®ãã¯ã¿ãŒã«ã·ã£ãã«ãããã¯ããŒãã³ã°éšäœäžŠã³ã«æšçïœïŒ€ïŒ®ïŒ¡ã®äž¡ç«¯ã§éãå æ°Žå解ããã®ã«ååãªé·ãã®ïŒ€ïŒ®ïŒ¡ã®æçïŒçŽïŒïŒå¡©åºïŒãå«ããªãªãŽãã¯ã¬ãªãããã©ã€ããŒãæšæºçãªæ¹æ³ã«ããååŠçã«åæããã次ãã§ããããã®ãã©ã€ããŒãçšããŠææã®éºäŒåæçãã«ããå¢å¹
ãããåŸãããéºäŒåæçãæšæºçãªæ¡ä»¶äžã§é©åœãªå¶éé
µçŽ ã§æ¶åããã²ã«é»æ°æ³³åã«ããåé¢ããããããã¯ãé©åœãªå¶éé
µçŽ ãçšããïœïŒ€ïŒ®ïŒ¡ã®æ¶åã«ããåæ§ã®éºäŒåæçã補é ãããé©åœãªãã©ã€ããŒãçšããŠãïŒä»¥äžã®éºäŒåã«ç±æ¥ããã³ãŒãé
åãå
±ã«é£çµããé©åœãªãã¯ã¿ãŒã«ã¯ããŒãã³ã°ããããã®ãããªãã¡ã©é
åã®æ§ç¯ã«ãã£ãŠçºçŸãæé©åããããšãå¯èœã§ããã
ãã®ãããªãã¡ã©ååã®é©åœãªçºçŸå®¿äž»ãšããŠã¯ããã£ã€ããŒãºãã ã¹ã¿ãŒåµå·£ïŒïŒ£ïŒšïŒ¯ïŒãããïŒïŒïŒçŽ°èçã®åºä¹³é¡çŽ°èãïœïœïŒçŽ°èçã®æè«çŽ°èãSaccharomyces cerevisiaeçã®é
µæ¯çŽ°èã倧è
žèçã®çŽ°èãæãããããããã«éå®ãããªããããã现èç³»ã®ããããã«ã€ããŠãæçšãªçºçŸãã¯ã¿ãŒã¯ããã«çŽ°èã«ãããå¢æ®ãå¯èœã«ããè€è£œèµ·ç¹ãããã³çŽ°èã«ããããã©ã¹ããéžæãå¯èœã«ããããã®Î²âã©ã¯ã¿ããŒãŒèæ§éºäŒåçã®éžæããŒã«ãŒãå«ããããã«ããã¯ã¿ãŒã¯ãããªãã€ã·ã³ãã¹ããã©ã³ã¹ãã§ã©ãŒãŒéºäŒåçã®ãã©ã³ã¹ãã§ã¯ããããçæ žå®¿äž»çŽ°èã«ãããéžæãå¯èœã«ãã第ïŒã®éžæããŒã«ãŒãå«ãããšãã§ãããçæ žçºçŸå®¿äž»ã«ãããŠäœ¿çšããããã®ãã¯ã¿ãŒã¯ãç®çã®ïœïŒ€ïŒ®ïŒ¡ã®äžéšãšããŠååšããŠããªããã°ãïŒâããªã¢ããã«åé
åãªã©ã®ïŒ²ïŒ®ïŒ¡ããã»ã·ã³ã°ãšã¬ã¡ã³ããå¿
èŠã§ããã
ããã«ããã¯ã¿ãŒã¯ãéºäŒåçºçŸãå¢å€§ãããããã¢ãŒã¿ãŒãŸãã¯ãšã³ãã³ãµãŒãå«ãããã®ãããªããã¢ãŒã¿ãŒã¯ã宿䞻ã«ç¹ç°çã§ããã现èã«å¯ŸããŠã¯ïŒïŒïŒŽïŒ¶ãïŒïŒãããã³ã¡ã¿ãããªãã€ã³ããã¢ãŒã¿ãŒïŒçŽ°è宿䞻ã«å¯ŸããŠã¯ãïœïœïœãïœïœïœãïœïœïœããã³ïŒŽïŒããã¢ãŒã¿ãŒïŒãããŠé
µæ¯ã«å¯ŸããŠã¯ãã¢ã«ãã¡å åãã¢ã«ã³ãŒã«ãªãã·ããŒãŒããã³ïŒ°ïŒ§ïŒšããã¢ãŒã¿ãŒãæãããããåºä¹³é¡çŽ°è宿䞻ã«ãããŠã¯ãã©ãŠã¹èè
«ãŠã€ã«ã¹ãšã³ãã³ãµãŒçã®è»¢åãšã³ãã³ãµãŒãçšãããæšæºçãªå¹é€æ³ã«ããçµæã现èã®åäžãªå¹é€çŽ°èãåŸãããããçµæãã§ç£çãã倧éã®ïŒ®ïŒïŒµïŒãããªããå¹å°ããååããåœåéã§åšç¥ã®ã¯ãããã°ã©ãã£ãŒæ³ãçšããŠè§£æãããäŸãã°ãæ¬æ现æžã«ãããŠäŸç€ºããããã«ãïŒïŒµïŒãçºçŸãã¯ã¿ãŒïœïœïŒ€ïŒ®ïŒ¡ïŒã«ã¯ããŒãã³ã°ããããšãã§ãããçæç©ãçšããŠãåœåéã«ãããæšæºçãªæ¹æ³ã«ãããäŸãã°ïŒšïŒ¥ïŒ«ïŒïŒïŒãŸãã¯ïŒ£ïŒ¯ïŒ³ã圢質転æãããå
·äœçã«ã¯ãäŸãã°ããªããã§ã¯ã¿ãã³ïŒGibco BRL catolog no. 18324-020ïŒä»åšã®éºäŒåå°å
¥ãçšããã
å®æœäŸïŒïŒçµæãïŒïŒµïŒã®åé¢
ïŒïŒµïŒããä»å ããïŒãŸãã¯ãã以äžã®ãããªãããªãããããã¡ã€ã³ãšå ±ã«ãã¡ã©ã¿ã³ãã¯è³ªãšããŠçºçŸãããŠãã¿ã³ãã¯è³ªã®ç²Ÿè£œã容æã«ããããã®ãããªç²Ÿè£œã容æã«ãããã¡ã€ã³ãšããŠã¯ãåºå®åãããéå±äžã§ã®ç²Ÿè£œãå¯èœãªãã¹ããžã³âããªãããã¡ã³ã¢ãžã¥ãŒã«çã®éå±ãã¬ãŒãããããAppa Rao, 1997ãããã³ïŒŠïŒ¬ïŒ¡ïŒ§ïŒ³äŒžåŒµïŒã¢ãã£ããã£ãŒç²Ÿè£œã·ã¹ãã ã«ãããŠçšãããããã¡ã€ã³ïŒImmunex Corp., Seattle, WashingtonïŒãæãããããããã«éå®ãããªãã粟補ãã¡ã€ã³ãšïŒ®ïŒïŒµïŒé åãšã®éã®ãïœå åãŸãã¯ãšã³ãããããŒãŒïŒInvitrogen, Groningen, The NetherlandsïŒçã®éè£å¯èœãªãªã³ã«ãŒé åã®å°å ¥ã¯ãïŒïŒµïŒã®çºçŸãä¿é²ããã®ã«æçšã§ããã
ïŒïŒµïŒããä»å ããïŒãŸãã¯ãã以äžã®ãããªãããªãããããã¡ã€ã³ãšå ±ã«ãã¡ã©ã¿ã³ãã¯è³ªãšããŠçºçŸãããŠãã¿ã³ãã¯è³ªã®ç²Ÿè£œã容æã«ããããã®ãããªç²Ÿè£œã容æã«ãããã¡ã€ã³ãšããŠã¯ãåºå®åãããéå±äžã§ã®ç²Ÿè£œãå¯èœãªãã¹ããžã³âããªãããã¡ã³ã¢ãžã¥ãŒã«çã®éå±ãã¬ãŒãããããAppa Rao, 1997ãããã³ïŒŠïŒ¬ïŒ¡ïŒ§ïŒ³äŒžåŒµïŒã¢ãã£ããã£ãŒç²Ÿè£œã·ã¹ãã ã«ãããŠçšãããããã¡ã€ã³ïŒImmunex Corp., Seattle, WashingtonïŒãæãããããããã«éå®ãããªãã粟補ãã¡ã€ã³ãšïŒ®ïŒïŒµïŒé åãšã®éã®ãïœå åãŸãã¯ãšã³ãããããŒãŒïŒInvitrogen, Groningen, The NetherlandsïŒçã®éè£å¯èœãªãªã³ã«ãŒé åã®å°å ¥ã¯ãïŒïŒµïŒã®çºçŸãä¿é²ããã®ã«æçšã§ããã
å®æœäŸïŒïŒãã¡ã©ïŒ§ïŒ°ïŒ£ïŒ²ã®è©Šéš
æ°ããã¢ã€ãœãã©ãŒã ã®çŽ°èå€ã®å容é åããè©Šéšç®çã§æ¢ç¥ã®åäœäœã®è貫éããã³çŽ°èå é åãšçµã¿åãããããšã«ãããæ©èœçãªïŒ§ïŒ°ïŒ£ïŒ²ãæ§ç¯ããããã®æŠå¿µã¯ã段éçã«å¢å€§ãããéã®Î±ïŒâè貫éé åãβïŒâã«æ¿å ¥ããããšã«ããäžé£ã®ãã¡ã©Î±ïŒâβïŒã¢ãã¬ããªã³äœåæ§å容äœïŒïŒ¡ïŒ²ïŒãäœè£œãããKobilka ã (1988), Science 240: 1310-1316ïŒã«ããå®èšŒããããæ¢ç¥ã®ã¢ã³ã¿ãŽãã¹ãã®çµå掻æ§ã¯ãβïŒã³ã³ãã©ã¡ãŒã·ã§ã³ãããαïŒã³ã³ãã©ã¡ãŒã·ã§ã³ãå€ãæãããšããããã·ããããååãšããŠå€åããäžéäœæ§ç¯ç©ã¯çµã¿åããããç¹ç°æ§ã瀺ãããäœããã¢ã³ã¿ãŽãã¹ãã®çµåã®ç¹ç°æ§ã¯ããã¡ã€ã³ã®äŸçµŠæºãšé¢é£ããŠãããïŒïŒ§ãã¡ã€ã³ïŒ¶ïŒ©ïŒ©ã®éèŠæ§ã¯ãïŒã€ã®é µæ¯Î±å åå容äœãçšããŠãã¡ã©ã«ãããŠèªããããé µæ¯å容äœã¯ãã®ä»ã®å容äœãšåé¡ãããŠããã®ã§ææã§ããããããã£ãŠãç¹ç°çãã¡ã€ã³ã®æ©èœç圹å²ã¯ã«ããŽãªãŒã«é¢ä¿ãªããã¡ããªãŒã«ãããŠä¿åãããŠããããã§ããã
æ°ããã¢ã€ãœãã©ãŒã ã®çŽ°èå€ã®å容é åããè©Šéšç®çã§æ¢ç¥ã®åäœäœã®è貫éããã³çŽ°èå é åãšçµã¿åãããããšã«ãããæ©èœçãªïŒ§ïŒ°ïŒ£ïŒ²ãæ§ç¯ããããã®æŠå¿µã¯ã段éçã«å¢å€§ãããéã®Î±ïŒâè貫éé åãβïŒâã«æ¿å ¥ããããšã«ããäžé£ã®ãã¡ã©Î±ïŒâβïŒã¢ãã¬ããªã³äœåæ§å容äœïŒïŒ¡ïŒ²ïŒãäœè£œãããKobilka ã (1988), Science 240: 1310-1316ïŒã«ããå®èšŒããããæ¢ç¥ã®ã¢ã³ã¿ãŽãã¹ãã®çµå掻æ§ã¯ãβïŒã³ã³ãã©ã¡ãŒã·ã§ã³ãããαïŒã³ã³ãã©ã¡ãŒã·ã§ã³ãå€ãæãããšããããã·ããããååãšããŠå€åããäžéäœæ§ç¯ç©ã¯çµã¿åããããç¹ç°æ§ã瀺ãããäœããã¢ã³ã¿ãŽãã¹ãã®çµåã®ç¹ç°æ§ã¯ããã¡ã€ã³ã®äŸçµŠæºãšé¢é£ããŠãããïŒïŒ§ãã¡ã€ã³ïŒ¶ïŒ©ïŒ©ã®éèŠæ§ã¯ãïŒã€ã®é µæ¯Î±å åå容äœãçšããŠãã¡ã©ã«ãããŠèªããããé µæ¯å容äœã¯ãã®ä»ã®å容äœãšåé¡ãããŠããã®ã§ææã§ããããããã£ãŠãç¹ç°çãã¡ã€ã³ã®æ©èœç圹å²ã¯ã«ããŽãªãŒã«é¢ä¿ãªããã¡ããªãŒã«ãããŠä¿åãããŠããããã§ããã
å¹³è¡ããŠãç¹å®ã®ã¢ã€ãœãã©ãŒã ã«ç±æ¥ããå
éšé åãŸãã¯çŽ°è質ãã¡ã€ã³ããæ¢ç¥ã®ïŒ§ïŒ°ïŒ£ïŒ²ã®åæ§ã®ãã¡ã€ã³ãšäº€æããäžéäœïŒ§ã¿ã³ãã¯è³ªã«å¯Ÿããå容äœã®çµåã®åå ã§ããæ§é çãªæ±ºå®å åãåå®ãããβïŒâãããã¡ã€ã³ïŒ¶ãããã³çŽ°èå
é£çµã«ãŒããαïŒâã«çœ®æããããã¡ã©å容äœã¯ãαïŒâç¹ç°æ§ã§ãã£ãŠãªã¬ã³ãã«çµåããããβïŒâãšåæ§ã«ã¢ããã«é
žãµã€ã¯ã©ãŒãŒãåºæ¿ããããšã瀺ãããããã®ããšã¯ãã¢ãã¬ããªã³äœåæ§å容äœã«ã€ããŠãã¿ã³ãã¯è³ªèªèããã¡ã€ã³ïŒ¶ãããã³ãããã®é£çµã«ãŒãã«ååšããããšã瀺ããŠãããαïŒâã®ïŒ¶âïŒïŒ¶ïŒ©ã«ãŒãã§Î²ïŒâã«ãããŠå¯Ÿå¿ãããã¡ã€ã³ã眮æãããã¡ã©ã«ã€ããŠããããšæ£å察ã®ç¶æ³ãäºæ³ããã芳å¯ãããåŸãããå容äœã¯ãβïŒâç¹ç°æ§ã§ãã£ãŠãªã¬ã³ããšçµåããαïŒâãšåæ§ã«ãã¿ã³ãã¯è³ªä»åšã®ãã¹ãã¡ããžã«ã€ãã·ããŒã«ä»£è¬å転ã掻æ§åãããæåŸã«ãã ã¹ã«ãªã³æ§å容äœããæ§ç¯ãããã¡ã©ã¯ãŸããâïŒïŒ¶ïŒ©ã«ãŒããã¿ã³ãã¯è³ªæŽ»æ§ã®ç¹ç°æ§ã«ã€ããŠã®äž»èŠãªæ±ºå®å åã§ããããšã瀺ããã
现èå€ããã³è貫éé åã«ãããŠçœ®æãå«ããã¡ã©ãŸãã¯ä¿®é£ŸïŒ§ïŒ°ïŒ£ïŒ²ã¯ãå容äœã®ãããã®äœçœ®ããªã¬ã³ãçµåç¹ç°æ§ã決å®ããŠããããšã瀺ãããäŸãã°ããã¹ãŠã®ã¢ãã¬ããªã³äœåæ§ããã³ïŒ€ã«ãã³ãŒã«ã¢ãã³ïŒ§ïŒ°ïŒ£ïŒ²ã®ãã¡ã€ã³ïŒ¶ã«ä¿åãããŠããïŒã€ã®ã»ãªã³æ®åºã¯ã匷åãªã¢ãŽãã¹ã掻æ§ã«å¿
èŠã§ããããããã®ã»ãªã³ã¯ãçµåéšäœå
ã§ã¢ãŽãã¹ãã®ã«ãã³ãŒã«éšåãšæ°ŽçŽ çµåã圢æãããšèããããŠãããåæ§ã«ãçç©ç±æ¥ã®ã¢ãã³ãšçµåãããã¹ãŠã®ïŒ§ïŒ°ïŒ£ïŒ²ã®ãã¡ã€ã³ïŒ©ïŒ©ïŒ©ã«ååšããïœïœæ®åºã¯ãçµåéšäœã«ããããªã¬ã³ãã¢ãã³åºãšã€ãªã³å¯Ÿã圢æãããšèããããŠããã
æ©èœçãªãã¯ããŒãã³ã°ãããã¯ããããããŒã¬ã¹ãªçºçŸç³»ã«ãããŠçºçŸãããããã®çç©åŠç掻æ§ãè©äŸ¡ããããïŒã€ã®ãããããŒã¬ã¹ãªçºçŸç³»ã¯ãåºä¹³é¡ïŒ§ïŒ°ïŒ£ïŒ²ã®éºäŒåãšåºä¹³é¡ïŒ§ã¿ã³ãã¯è³ªãé
µæ¯çŽ°èã«å°å
¥ãããã¯é©åœãªãªã¬ã³ãç¹ç°æ§ãšèŠªåæ§ãæããé
µæ¯çŽ°èã®çç©åŠç掻æ§åïŒæé·é»æ¢ããã³åœ¢è³ªã®å€åïŒã®åŒãéãšãªãããšãåãã£ãŠããã
ãã¡ã©å容äœãè©Šéšããããã®å¥ã®æ¹æ³ã¯ãããªã³å容äœïŒïŒ°ïŒïŒµïŒãçšããæ¹æ³ã«åºã¥ããŠããã2ïœå容äœãæ¬ ããŠããã®ã§å¹é€ããïŒïŒïŒããçœè¡ç
现èã«ãããŠæ©èœã容æã«æž¬å®ããããïŒïŒïŒçŽ°èããæ£åžžãªãŸãã¯ãã¡ã©ïŒ°2ïœã®ãããããå«ãçºçŸãã¯ã¿ãŒã§åœ¢è³ªè»¢æããfura-aãïœ++ã®ããã®èå
ãããŒããå°å
¥ããã现èå€ïŒµïŒŽïŒ°ãŸãã¯ïŒ¡ïŒŽïŒ°ã«ãããé©åã«æ§ç¯ããæ©èœçãªïŒ°2ïœå容äœã®æŽ»æ§åã«ãããïœïœïœïœâïœãšåå¿ããåå
å
床èšã«ãã枬å®ããã现èå
ïœ++ã移åããã
äžèšã®ïŒ§ïŒ°ïŒ£ïŒ²ãšåæ§ã«ãããããã®æ°èŠã®ïŒ§ïŒ°ïŒ£ïŒ²ããªããããã®çŽ°èå€å容é åã®é
åããæ¢ç¥ã®ïŒ°2ïœååã®è貫éããã³çŽ°èå
é åãã³ãŒããããã¯ã¬ãªãããšçµã¿åãããããšã«ããããã¡ã©éºäŒåãäœè£œãããé©åœãªãªã¬ã³ããå«ããã€ã¯ããŠã§ã«ã«ãŠïŒ«ïŒïŒïŒçŽ°èãäžåºŠã«ãã©ã³ã¹ãã§ã¯ãããŠãçµåãåŒãèµ·ãããååã®ãšãã§ã¯ã¿ãŒãèŠå®ããèå
掻æ§ãçããããããªã¬ã³ãããã³æ©èœã確ç«ãããã°ã2系ã¯ãçµåããããã¯ãããã®ãããªèå
åå¿ãé»æ¢ããã¢ã³ã¿ãŽãã¹ããŸãã¯é»å®³å€ãå®çŸ©ããã®ã«æçšã§ããã
å®æœäŸïŒïŒïŒ®ïŒïŒµïŒç¹ç°çæäœã®ç£ç
ïŒã€ã®æ¹æ³ãïŒïŒµïŒã«å¯Ÿããæäœãæ¹èµ·ããããã®å©çšãããããã®æ¹æ³ã¯ãããããããªã¯ããŒãã«ãŸãã¯ã¢ãã¯ããŒãã«æäœã®ãããããæ¹èµ·ããããã«æçšã§ãããïŒã€ã®æ¹æ³ã§ã¯ãéçžïŒšïŒ°ïŒ¬ïŒ£åé¢ã«ãã£ãŠå€æ§ã¿ã³ãã¯è³ªãïŒïŒïœïœãŸã§ã®éã§åŸãããããã®å€æ§ã¿ã³ãã¯è³ªã¯ãæšæºçãªãããã³ã«ãçšããŠå ç«ããã®ã«çšããããããŠã¹ã®å ç«ã«ã€ããŠã¯çŽïŒïŒïŒÎŒïœãé©åœã§ããããŠãµã®ãã®å ç«ã«ã¯ïŒïœïœãŸã§ã䜿çšãããããŠã¹ãã€ããªããŒãã®åå®ã«ã€ããŠã¯ãå€æ§ã¿ã³ãã¯è³ªãæŸå°èœæšèããŠçšããå¯èœæ§ã®ããããŠã¹ïŒ¢çŽ°èãæäœãç£çãããã®ãšããŠã¹ã¯ãªãŒãã³ã°ããããã®æ¹æ³ã¯ãå°éã®ã¿ã³ãã¯è³ªããå¿ èŠãšãããæ°åã®ã¯ããŒã³ã®ã¹ã¯ãªãŒãã³ã°ã«ã¯ïŒïŒïœïœã§ååã§ããã
ïŒã€ã®æ¹æ³ãïŒïŒµïŒã«å¯Ÿããæäœãæ¹èµ·ããããã®å©çšãããããã®æ¹æ³ã¯ãããããããªã¯ããŒãã«ãŸãã¯ã¢ãã¯ããŒãã«æäœã®ãããããæ¹èµ·ããããã«æçšã§ãããïŒã€ã®æ¹æ³ã§ã¯ãéçžïŒšïŒ°ïŒ¬ïŒ£åé¢ã«ãã£ãŠå€æ§ã¿ã³ãã¯è³ªãïŒïŒïœïœãŸã§ã®éã§åŸãããããã®å€æ§ã¿ã³ãã¯è³ªã¯ãæšæºçãªãããã³ã«ãçšããŠå ç«ããã®ã«çšããããããŠã¹ã®å ç«ã«ã€ããŠã¯çŽïŒïŒïŒÎŒïœãé©åœã§ããããŠãµã®ãã®å ç«ã«ã¯ïŒïœïœãŸã§ã䜿çšãããããŠã¹ãã€ããªããŒãã®åå®ã«ã€ããŠã¯ãå€æ§ã¿ã³ãã¯è³ªãæŸå°èœæšèããŠçšããå¯èœæ§ã®ããããŠã¹ïŒ¢çŽ°èãæäœãç£çãããã®ãšããŠã¹ã¯ãªãŒãã³ã°ããããã®æ¹æ³ã¯ãå°éã®ã¿ã³ãã¯è³ªããå¿ èŠãšãããæ°åã®ã¯ããŒã³ã®ã¹ã¯ãªãŒãã³ã°ã«ã¯ïŒïŒïœïœã§ååã§ããã
第ïŒã®æ¹æ³ã§ã¯ãïœïŒ€ïŒ®ïŒ¡ã®ç¿»èš³ããæšå®ããããé©åœãªïŒ®ïŒïŒµïŒãã¡ã€ã³ã®ã¢ããé
žé
åã解æããŠæåæ§ã®é«ãé åã解æãããé©åœãªèŠªæ°Žæ§ã®é åãå«ããªãªãŽãããããåæããŠãé©åœãªå
ç«åã®ãããã³ã«ã«ãããŠçšããŠæäœãæ¹èµ·ããããå
ç«åã«æé©ãªã¢ããé
žé
åã¯ãéåžžããã®ã¿ã³ãã¯è³ªãèªç¶ã®ã³ã³ãã©ãŒã¡ãŒã·ã§ã³ã§ååšããŠãããšãã«å€éšã®ç°å¢ã«é²åºããŠãããšæãããããªããããã®ïŒ£æ«ç«¯ãæ«ç«¯ããã³ãã®éã«ååšãã芪氎æ§ã®é åã«ååšããã
å
žåçã«ã¯ãçŽïŒïŒæ®åºã®é·ãã®éžæãããããããããïœïœïœïœååŠåå¿ãçšããApplied Biosystems Peptide Synthesizer Model431AãçšããŠåæããïŒâãã¬ã€ãããã³ãŸã€ã«ââããããã·ãµã¯ã·ã³ã€ãããšã¹ãã«ãïŒïŒ¢ïŒ³ãšã®åå¿ã«ãã£ãŠããŒããŒã«ãªã³ãããã¢ã·ã¢ãã³ïŒïŒ«ïŒ¬ïŒšïŒSigma, St. Louis, MOïŒãšçµåããããèŠããã°ãã·ã¹ãã€ã³ãããããã®ïŒ®æ«ç«¯ã«å°å
¥ããŠïŒ«ïŒ¬ïŒšãšã®çµåãå¯èœã«ããããŠãµã®ããå®å
šããã€ã³ãã¢ãžã¥ãã³ãäžãããããâè€åäœã§å
ç«ãããããããããã©ã¹ãã£ãã¯ãšçµåãããïŒïŒ
ãŠã·è¡æž
ã¢ã«ããã³ã§ãããã¯ããæè¡æž
ãšåå¿ãããæŽæµããæšèïŒæŸå°èœãŸãã¯èå
ïŒããã¢ãã£ããã£ãŒç²Ÿè£œãããç¹ç°çãªã€ã®æãŠãµã®ïŒ©ïœïŒ§ãšåå¿ãããããšã«ãã£ãŠãåŸãããæè¡æž
ãæãããã掻æ§ã«ã€ããŠè©Šéšããã
æšæºçãªæè¡ãçšããŠãã€ããªããŒãã調補ããã¹ã¯ãªãŒãã³ã°ãããç®çã®ãã€ããªããŒãããæšèïŒïŒµïŒã«ããã¹ã¯ãªãŒãã³ã°ã«ãã£ãŠæ€åºããŠãææã®ç¹ç°æ§ãæããã¢ãã¯ããŒãã«æäœãçããèåç©ãåå®ãããå
žåçãªãããã³ã«ã§ã¯ããã¬ãŒãã®ãŠã§ã«ïŒïŒŠïŒ¡ïŒ³ïŒŽïŒBecton-Dickinson, Palo Alto, CAïŒããã€ã³ãã¥ããŒã·ã§ã³ã®éãã¢ãã£ããã£ãŒç²Ÿè£œããããç¹ç°çãŠãµã®æããŠã¹ïŒãŸãã¯é©åœãªæç¹ç°ç©è³ªïŒantispeciesïŒïŒïœïŒæäœãïŒïŒïœïœïŒïœïŒ¬ã§çšããŠã³ãŒãã£ã³ã°ãããã³ãŒãã£ã³ã°ãããŠã§ã«ãïŒïŒ
ãŠã·è¡æž
ã¢ã«ããã³ïŒïŒ¢ïŒ³ïŒ¡ïŒã§ãããã¯ããæŽæµãããã€ããªããŒãã®äžæž
ãšã€ã³ãã¥ããŒã·ã§ã³ãããæŽæµåŸããŠã§ã«ãïŒïœïœïŒïœïŒ¬ã®æšèããïŒïŒµïŒãšã€ã³ãã¥ããŒã·ã§ã³ãããç¹ç°çãªæäœãæããäžæž
ã¯ãæ€åºå¯èœãªããã¯ã°ã©ãŠã³ããããæšèãããïŒïŒµïŒã«ããçµåããã次ãã§ãç¹ç°çæäœãç£çããã¯ããŒã³ãå¹é€ããåžéçãéå®ããïŒãµã€ã¯ã«ã®ã¯ããŒãã³ã°ã«ä»ãããã¯ããŒãã³ã°ãããã€ããªãªãŒããããªã¹ã¿ã³åŠçããããŠã¹ã«æ³šå°ãè
¹æ°Žçãçããããã¢ãã¯ããŒãã«æäœãããããã€ã³ïŒ¡ã§ã®ã¢ãã£ããã£ãŒã¯ãããã°ã©ãã£ãŒã«ãããããŠã¹ã®è
¹æ°Žãã粟補ãããæšæºçãªæ¹æ³ã«ãã£ãŠãå°ãªããšãïŒïŒ8ïŒ-1ã®èŠªåæ§ã奜ãŸããã¯ïŒïŒ9ãïŒïŒ10ïŒ-1ãŸãã¯ãã以äžããæããã¢ãã¯ããŒãã«æäœãå
žåçã«äœè£œãããã
å®æœäŸïŒïŒïŒ®ïŒïŒµïŒç¹ç°çæäœãçšãã蚺æè©Šéš
ç¹å®ã®ïŒ®ïŒïŒµïŒæäœã¯ãã·ã°ãã«äŒéã®ç 究ãããã³ïŒ®ïŒïŒµïŒãŸãã¯æŽ»æ§ãªã·ã°ãã«äŒéã®ã«ã¹ã±ãŒãã®äžæµã®çæç©ã®éãŸãã¯ååžã®éãã«ãã£ãŠç¹åŸŽä»ããããæææ§ã®ãŸãã¯éºäŒçãªç¶æ ã®èšºæã«æçšã§ããã
ç¹å®ã®ïŒ®ïŒïŒµïŒæäœã¯ãã·ã°ãã«äŒéã®ç 究ãããã³ïŒ®ïŒïŒµïŒãŸãã¯æŽ»æ§ãªã·ã°ãã«äŒéã®ã«ã¹ã±ãŒãã®äžæµã®çæç©ã®éãŸãã¯ååžã®éãã«ãã£ãŠç¹åŸŽä»ããããæææ§ã®ãŸãã¯éºäŒçãªç¶æ ã®èšºæã«æçšã§ããã
ïŒïŒµïŒã®èšºæè©ŠéšãšããŠã¯ãããã®äœæ¶²ãèã现èãçµç¹ãŸãã¯ãããã®æœåºç©ã«ãããïŒïŒµïŒãæ€åºããããã®æäœããã³æšèãçšããæ¹æ³ãæãããããæ¬çºæã®ããªããããããã³æäœã¯ã修食ããããŸãã¯ä¿®é£Ÿããªãã§çšããããã°ãã°ãããªããããããã³æäœã¯ãããããå
±æçµåãŸãã¯éå
±æçµåã«ãããæ€åºå¯èœãªã·ã°ãã«ãçããç©è³ªãšé£çµããããšã«ãã£ãŠæšèãããæ§ã
ãªæšèããã³ã³ã³ãžã¥ã²ãŒã·ã§ã³æ³ãç¥ãããŠãããåŠè¡æç®ãšç¹èš±æç®ã®äž¡æ¹ã«ãããŠåºãå ±åãããŠãããé©åœãªæšèãšããŠã¯ãæŸå°æ§æ žçš®ãé
µçŽ ãåºè³ªãã³ãã¡ã¯ã¿ãŒãé»å®³ç©è³ªãèå
ç©è³ªãååŠã«ããã»ã³ã¹ç©è³ªãçºå
ç©è³ªãç£æ§ç©è³ªãªã©ãæããããã
åœåéã«ãããŠãã¿ã³ãã¯è³ªã«ç¹ç°çãªããªã¯ããŒãã«ãŸãã¯ã¢ãã¯ããŒãã«æäœã®ãããããçšãããå¯èœæ§ãŸãã¯èçµååã®ïŒ®ïŒïŒµïŒã枬å®ããããã®æ§ã
ãªãããã³ã«ãç¥ãããŠãããäŸãšããŠã¯ãé
µçŽ çµåå
ç«åžçåæïŒïŒ¥ïŒ¬ïŒ©ïŒ³ïŒ¡ïŒãã©ãžãªã€ã ãã¢ãã»ã€ïŒïŒ²ïŒ©ïŒ¡ïŒããã³èå
æšç€ºåŒçŽ°èååïŒïŒŠïŒ¡ïŒ£ïŒ³ïŒãæãããããïŒïŒµïŒäžã®ïŒã€ã®éå¹²æžãšãããŒãã«åå¿ããã¢ãã¯ããŒãã«ãçšãããïŒéšäœã¢ãã¯ããŒãã«ããŒã¹ã®ã€ã ãã¢ãã»ã€ã奜ãŸãããã競åçµåã¢ãã»ã€ãçšããããšãã§ããã
å®æœäŸïŒïŒç¹ç°çãªæäœãçšãã倩ç¶ïŒ®ïŒïŒµïŒã®ç²Ÿè£œ
倩ç¶ãŸãã¯çµæãïŒïŒµïŒããïŒïŒµïŒã«ç¹ç°çãªæäœãçšããã€ã ãã¢ãã£ããã£ãŒã¯ãããã°ã©ãã£ãŒã«ãã粟補ãããäžè¬ã«ãã€ã ãã¢ãã£ããã£ãŒã«ã©ã ã¯ãææäœãã掻æ§åããã¯ãããã°ã©ãã£ãŒæš¹èã«å ±æçµåãããããšã«ããæ§ç¯ããã
倩ç¶ãŸãã¯çµæãïŒïŒµïŒããïŒïŒµïŒã«ç¹ç°çãªæäœãçšããã€ã ãã¢ãã£ããã£ãŒã¯ãããã°ã©ãã£ãŒã«ãã粟補ãããäžè¬ã«ãã€ã ãã¢ãã£ããã£ãŒã«ã©ã ã¯ãææäœãã掻æ§åããã¯ãããã°ã©ãã£ãŒæš¹èã«å ±æçµåãããããšã«ããæ§ç¯ããã
ããªã¯ããŒãã«å
ç«ã°ãããªã³ã¯ãç¡«é
žã¢ã³ã¢ããŠã ã«ããæ²æ®¿ãŸãã¯åºå®åãããããã€ã³ïŒ¡ïŒPharmaciaLKB Biotechnology, Piscataway N.J.ïŒã§ã®ç²Ÿè£œã«ãããå
ç«è¡æž
ãã調補ãããåæ§ã«ãã¢ãã¯ããŒãã«æäœããç¡«é
žã¢ã³ã¢ããŠã ã«ããæ²æ®¿ãŸãã¯åºå®åãããããã€ã³ïŒ¡ã§ã®ã¯ãããã°ã©ãã£ãŒã«ããããŠã¹è
¹æ°Žãã調補ãããç¹å®ã®ç²Ÿè£œããå
ç«ã°ãããªã³ããïœïŒ¢ïœâ掻æ§åã»ãã¡ããŒã¹ïŒPharmacia LKB BiotechnologyïŒçã®ã¯ãããã°ã©ãã£ãŒæš¹èã«å
±æçµåããããæäœãæš¹èã«çµåãããæš¹èããããã¯ããåŸãããæš¹èã補é æ¥è
ã®åæ±èª¬ææžã«ãããã£ãŠæŽæµããã
ãã®ãããªã€ã ãã¢ãã£ããã£ãŒã«ã©ã ã¯ãå¯æº¶æ§ã®åœ¢æ
ã§ïŒ®ïŒïŒµïŒãå«ã现èããç»åã調補ããããšã«ãã£ãŠïŒ®ïŒïŒµïŒã®ç²Ÿè£œã«çšããããã®èª¿è£œç©ã¯ãå
šçŽ°èã®ãŸãã¯åç»é å¿ïŒçé¢æŽ»æ§å€ãæ·»å ãããŸãã¯æ·»å ããªãïŒã«ããåŸããã现èæåã®ç»åãå¯æº¶åããããšã«ãã£ãŠããããã¯åœåéã«ãããŠåšç¥ã®ä»ã®æ¹æ³ã«ãã£ãŠåŸãããããããã¯ãã·ã°ãã«é
åãå«ãå¯æº¶æ§ã®ïŒ®ïŒïŒµïŒãããã®çŽ°èãå¹é€ããŠããå¹å°äžã«æçšãªéã§åæ³ãããã
å¯æº¶æ§ã®ïŒ®ïŒïŒµïŒãå«æãã調補ç©ãã€ã ãã¢ãã£ããã£ãŒã«ã©ã ã«éããïŒïŒµïŒã®éžæçã«åžçãå¯èœãªæ¡ä»¶äžïŒäŸãã°ãçé¢æŽ»æ§å€ã®ååšäžã§ã®é«ãã€ãªã³åŒ·åºŠã®ç·©è¡æ¶²ïŒã§ãã®ã«ã©ã ãæŽæµããã次ãã§ãæäœïŒã¿ã³ãã¯è³ªçµåãåæããæ¡ä»¶äžïŒäŸãã°ãïœïŒšïŒãïŒããŸãã¯å°¿çŽ ãŸãã¯ããªã·ã¢ã³é
žã€ãªã³çã®æªä¹±ç©è³ªïŒchaotropeïŒã®é«ãæ¿åºŠã®ç·©è¡æ¶²ïŒã§ã«ã©ã ã溶åºããïŒïŒµïŒãååããã
å®æœäŸïŒïŒïŒè¬ç©ã¹ã¯ãªãŒãã³ã°
æ¬çºæã¯ãïŒïŒµïŒãŸãã¯ãã®çµåæçããæ§ã ãªè¬ç©ã¹ã¯ãªãŒãã³ã°æ³ã®ããããã«ãããŠçšããããšã«ãããæ²»çååç©ã®ã¹ã¯ãªãŒãã³ã°ã«ç¹ã«æçšã§ãããïŒïŒµïŒã¯ïŒ§ã¿ã³ãã¯è³ªå ±åœ¹åå容äœã§ããã®ã§ãåœåéã«ãããŠäžè¬çã«çšããããæ¹æ³ã¯ããããïŒïŒµïŒãªã¬ã³ããåå®ããããã«äœ¿çšããããšãã§ãããäŸãã°ãïŒïŒµïŒçã®ïŒ§ã¿ã³ãã¯è³ªå ±åœ¹åå容äœã®æŽ»æ§ããå容äœã®æŽ»æ§åã«ãã£ãŠã¢ããã«é žãµã€ã¯ã©ãŒãŒãã°ã¢ããªã«ãµã€ã¯ã©ãŒãŒãã«ã«ã·ãŠã 移åãŸãã¯ã€ãã·ããŒã«ãªã³é žå æ°Žå解çã®ããã€ãã®ã»ã«ã³ãã¡ãã»ã³ãžã£ãŒç³»ã®ã¬ãã«ã«ããã芳å¯å¯èœãªå€åããããããããæ§ã ãªé©åœãªæ©èœè§£æã®ãããããçšããŠæž¬å®ããããšãã§ããããããã¯ããã®ãããªè©ŠéšãããŠçšããããããªãããããŸãã¯æçã¯ã溶液äžã«éé¢ããŠããããåºäœã®æ¯æäœã«åºå®ãããŠãããã现èè¡šé¢ã«ååšããããŸãã¯çŽ°èå ã«ååšãããè¬ç©ã¹ã¯ãªãŒãã³ã°ã®ïŒã€ã®æ¹æ³ã¯ãããªãããããŸãã¯æçãçºçŸããçµæãæ žé žã«ãã£ãŠå®å®ã«åœ¢è³ªè»¢æãããçæ žãŸãã¯åæ žå®¿äž»çŽ°èãçšãããçããŠãããŸãã¯åºå®ãããŠãããã®ãããªçŽ°èãæšæºçãªçµåã¢ãã»ã€ã«çšããã
æ¬çºæã¯ãïŒïŒµïŒãŸãã¯ãã®çµåæçããæ§ã ãªè¬ç©ã¹ã¯ãªãŒãã³ã°æ³ã®ããããã«ãããŠçšããããšã«ãããæ²»çååç©ã®ã¹ã¯ãªãŒãã³ã°ã«ç¹ã«æçšã§ãããïŒïŒµïŒã¯ïŒ§ã¿ã³ãã¯è³ªå ±åœ¹åå容äœã§ããã®ã§ãåœåéã«ãããŠäžè¬çã«çšããããæ¹æ³ã¯ããããïŒïŒµïŒãªã¬ã³ããåå®ããããã«äœ¿çšããããšãã§ãããäŸãã°ãïŒïŒµïŒçã®ïŒ§ã¿ã³ãã¯è³ªå ±åœ¹åå容äœã®æŽ»æ§ããå容äœã®æŽ»æ§åã«ãã£ãŠã¢ããã«é žãµã€ã¯ã©ãŒãŒãã°ã¢ããªã«ãµã€ã¯ã©ãŒãŒãã«ã«ã·ãŠã 移åãŸãã¯ã€ãã·ããŒã«ãªã³é žå æ°Žå解çã®ããã€ãã®ã»ã«ã³ãã¡ãã»ã³ãžã£ãŒç³»ã®ã¬ãã«ã«ããã芳å¯å¯èœãªå€åããããããããæ§ã ãªé©åœãªæ©èœè§£æã®ãããããçšããŠæž¬å®ããããšãã§ããããããã¯ããã®ãããªè©ŠéšãããŠçšããããããªãããããŸãã¯æçã¯ã溶液äžã«éé¢ããŠããããåºäœã®æ¯æäœã«åºå®ãããŠãããã现èè¡šé¢ã«ååšããããŸãã¯çŽ°èå ã«ååšãããè¬ç©ã¹ã¯ãªãŒãã³ã°ã®ïŒã€ã®æ¹æ³ã¯ãããªãããããŸãã¯æçãçºçŸããçµæãæ žé žã«ãã£ãŠå®å®ã«åœ¢è³ªè»¢æãããçæ žãŸãã¯åæ žå®¿äž»çŽ°èãçšãããçããŠãããŸãã¯åºå®ãããŠãããã®ãããªçŽ°èãæšæºçãªçµåã¢ãã»ã€ã«çšããã
äŸãã°ãïŒïŒµïŒãšè©Šéšç©è³ªãšã®éã®è€åäœã®åœ¢æã枬å®ããããããã¯ãè©Šéšç©è³ªã«ãã£ãŠåŒãèµ·ãããããïŒïŒµïŒãšãªã¬ã³ããšã®éã®è€åäœåœ¢æã®æžå°ã調ã¹ãã
ãããã£ãŠãæ¬çºæã¯ãã·ã°ãã«äŒéã«å€åãåãŒãè¬ç©åè£ãè¬ç©ããŸãã¯ä»ã®ããããã®ç©è³ªãã¹ã¯ãªãŒãã³ã°ããããã®æ¹æ³ãæäŸãããåœåéã«ãããŠåšç¥ã®ãããã®æ¹æ³ã¯ããã®ãããªç©è³ªãïŒïŒµïŒããªãããããŸãã¯ãã®æçãšæ¥è§ŠãããïŒïœïŒãã®ç©è³ªãšïŒ®ïŒïŒµïŒããªãããããŸãã¯æçãšã®éã®è€åäœã®ååšããŸãã¯ïŒïœïœïŒïŒ®ïŒïŒµïŒããªãããããŸãã¯æçãšçŽ°èãšã®éã®è€åäœã®ååšã«ã€ããŠåæããããšãå«ãããã®ãããªçµååæã§ã¯ãå
žåçã«ã¯ïŒ®ïŒïŒµïŒããªãããããŸãã¯æçãæšèããã
é©åã«ã€ã³ãã¥ããŒã·ã§ã³ããåŸãéé¢ã®ïŒ®ïŒïŒµïŒããªãããããŸãã¯æçããçµåãã圢æ ã§ååšããŠããããªãããããšåé¢ããéé¢ãŸãã¯è€åäœã圢æããŠããªãæšèã®éã¯ãå ·äœçãªç©è³ªãïŒïŒµïŒã«çµåãããŸãã¯ïŒ®ïŒïŒµïŒâç©è³ªè€åäœãšçžäºäœçšããèœåã®ææšãšãªãã
é©åã«ã€ã³ãã¥ããŒã·ã§ã³ããåŸãéé¢ã®ïŒ®ïŒïŒµïŒããªãããããŸãã¯æçããçµåãã圢æ ã§ååšããŠããããªãããããšåé¢ããéé¢ãŸãã¯è€åäœã圢æããŠããªãæšèã®éã¯ãå ·äœçãªç©è³ªãïŒïŒµïŒã«çµåãããŸãã¯ïŒ®ïŒïŒµïŒâç©è³ªè€åäœãšçžäºäœçšããèœåã®ææšãšãªãã
è¬ç©ã¹ã¯ãªãŒãã³ã°ã®å¥ã®æè¡ã¯ãïŒïŒµïŒããªããããã«å¯Ÿããé©åãªçµå芪åæ§ãæãããã€ã¹ã«ãŒãããã¹ã¯ãªãŒã³ã°ãæäŸãããç°¡æœã«èšãã°ã倧éã®ç°ãªã£ãå°ããããããè©Šéšååç©ãããã©ã¹ããã¯è£œã®ãã³ãŸãã¯ä»ã®è¡šé¢ãªã©ã®åºäœã®ç©è³ªäžã«åæãããããããè©Šéšååç©ãïŒïŒµïŒããªãããããšåå¿ãããæŽæµãããçµåããïŒïŒµïŒããªãããããåœåéã§åšç¥ã®æ¹æ³ã«ããæ€åºããã粟補ããïŒïŒµïŒã¯ãäžèšã®è¬ç©ã¹ã¯ãªãŒãã³ã°æè¡ã«ãããŠäœ¿çšãããããçŽæ¥ãã¬ãŒãã«ã³ãŒãã£ã³ã°ããããšãã§ãããããã«ãéäžåæäœãçšããŠãããããææãããããåºäœã®æ¯æäœã«åºå®åããã
æ¬çºæã¯ããã«ãïŒïŒµïŒãšçµåããããšãã§ããäžåæäœããïŒïŒµïŒããªãããããŸãã¯ãã®æçã«å¯Ÿããçµåã«ã€ããŠè©Šéšååç©ãšç¹ç°çã«ç«¶åããã競åè¬ç©ã¹ã¯ãªãŒãã³ã°ã¢ãã»ã€ã®äœ¿çšãæå³ããããã®ããã«ããŠãæäœãçšããŠãïŒïŒµïŒãšïŒãŸãã¯ãã以äžã®æåçµååºãå
±æããããããã®ååšãæ€åºããã
å®æœäŸïŒïŒïŒåççè¬ç©èšèš
åççè¬ç©èšèšã®ç®çã¯ãææã®çç©åŠçã«æŽ»æ§ãªããªããããã®æ§é çé¡çžäœãŸãã¯ããããçžäºäœçšããå°ååãã¢ãŽãã¹ããã¢ã³ã¿ãŽãã¹ããæäŸããããšã§ããããããã®äŸã¯ãããããããªããããã®ãã掻æ§ãªãŸãã¯å®å®ãªåœ¢æ ããŸãã¯in vivoã§ããªããããã®æ©èœãå¢å€§ãŸãã¯çžäºäœçšããè¬ç©ãèšèšããããã«çšããããã
åççè¬ç©èšèšã®ç®çã¯ãææã®çç©åŠçã«æŽ»æ§ãªããªããããã®æ§é çé¡çžäœãŸãã¯ããããçžäºäœçšããå°ååãã¢ãŽãã¹ããã¢ã³ã¿ãŽãã¹ããæäŸããããšã§ããããããã®äŸã¯ãããããããªããããã®ãã掻æ§ãªãŸãã¯å®å®ãªåœ¢æ ããŸãã¯in vivoã§ããªããããã®æ©èœãå¢å€§ãŸãã¯çžäºäœçšããè¬ç©ãèšèšããããã«çšããããã
ïŒã€ã®æ¹æ³ãšããŠã¯ãç®çã®ã¿ã³ãã¯è³ªãã¿ã³ãã¯è³ªâé»å®³ç©è³ªè€åäœã®ïŒæ¬¡å
æ§é ãç·çµæ¶åŠã«ãããã³ã³ãã¥ãŒã¿ã¢ããªã³ã°ã«ããããŸãã¯æãå
žåçã«ã¯ãã®ïŒã€ã®æ¹æ³ã®çµåãã«ãã£ãŠæ±ºå®ãããããªããããã®åœ¢ç¶ããã³é»è·ã®äž¡æ¹ã解æãããã®ååã®æ§é ãæããã«ãã掻æ§éšäœã決å®ããªããã°ãªããªããé »ç¹ã§ã¯ãªããããã¢ããŒã¬ã¹ãªã¿ã³ãã¯è³ªã«åºã¥ãã¢ããªã³ã°ã«ãã£ãŠããªããããã«é¢ããæçšãªæ
å ±ãåŸããããäž¡æ¹ã®å Žåã«ãããŠãé¢é£ããæ§é ã®æ
å ±ãçšããŠæå¹ãªé»å®³å€ãèšèšãããåççè¬ç©èšèšã®æçšãªäŸãšããŠã¯ã倩ç¶ã®ããããã®ãæ¹åããã掻æ§ãŸãã¯å®å®æ§ãæãããŸãã¯é»å®³å€ãã¢ãŽãã¹ããŸãã¯ã¢ã³ã¿ãŽãã¹ããšããŠäœçšããååãæããããã
äžèšã®ããã«ãæ©èœçåæã«ãã£ãŠéžæããããæšçã«ç¹ç°çãªæäœãåé¢ãããã®çµæ¶æ§é ã解æããããšãå¯èœã§ããããã®æ¹æ³ã«ãã£ãŠãååçã«ãåŸã«è¬ç©èšèšãããã«åºã¥ããŠè¡ããããã¡ãŒãã³ã¢ïŒpharmacoreïŒãåŸããããæ©èœçãªã補è¬çã«æŽ»æ§ãªæäœã«å¯Ÿããæã€ãã£ã¿ã€ãæäœïŒanti-idsïŒãäœè£œããããšã«ãã£ãŠãã¿ã³ãã¯è³ªçµæ¶åŠããã¹ãŠçç¥ããããšãå¯èœã§ãããé¡åã®é¡åã®ããã«ãæïœïœïœã®çµåéšäœã¯ãããšã®å容äœã®é¡çžäœã§ãããšæåŸ
ãããã次ãã§ããã®æïœïœïœãçšããŠãååŠçãŸãã¯çç©åŠçã«è£œé ãããããããã®ãã³ã¯ãããããããåå®ãåé¢ãããåé¢ãããããããã¯ãã¡ãŒãã³ã¢ãšããŠäœçšããã
æ¬çºæã«ãã£ãŠãååãªéã®ããªãããããäœè£œããŠãç·çµæ¶åŠãšããŠãã®ãããªåæå®éšãè¡ãããšãå¯èœã«ãããããã«ãæ¬æ现æžã«ãããŠæäŸãããïŒïŒµïŒã¢ããé
žé
åã®ç¥èŠã¯ãç·çµæ¶åŠã®ä»£ãããšããŠãŸãã¯ããã«å ããŠã³ã³ãã¥ãŒã¿ã¢ããªã³ã°æè¡ãçšããããã®æéãäžããã
å®æœäŸïŒïŒïŒã·ã°ãã«äŒéè€åäœã®ä»ã®ã¡ã³ããŒã®åå®
æ¬çºæã®ç²Ÿè£œãããïŒïŒµïŒã¯ãé¢ä¿ããã¿ã³ãã¯è³ªãŸãã¯ä»ã®ã·ã°ãã«äŒéçµè·¯ã®ã¿ã³ãã¯è³ªã®åå®ããã£ã©ã¯ã¿ãªãŒãŒã·ã§ã³ããã³ç²Ÿè£œã®ããã®æ€çŽ¢ããŒã«ã§ãããæŸå°èœæšèããåœåéã§åšç¥ã®æ§ã ãªæ¹æ³ã«ãããéžæããïŒïŒµïŒãã¡ã€ã³ã«å°å ¥ããŠçšããçžäºäœçšããååãææããã奜ãŸããæ¹æ³ãšããŠã¯ã125 Bolton-Hunterè©Šè¬ã«ãããïŒïŒµïŒã«ããã第äžçŽã¢ãã³åºã®æšèã§ããããã®è©Šè¬ã¯ãä»éããçç©åŠç掻æ§ã®æ¶å€±ãªãã«æ§ã ãªååãæšèããããã«çšããããŠããã
æ¬çºæã®ç²Ÿè£œãããïŒïŒµïŒã¯ãé¢ä¿ããã¿ã³ãã¯è³ªãŸãã¯ä»ã®ã·ã°ãã«äŒéçµè·¯ã®ã¿ã³ãã¯è³ªã®åå®ããã£ã©ã¯ã¿ãªãŒãŒã·ã§ã³ããã³ç²Ÿè£œã®ããã®æ€çŽ¢ããŒã«ã§ãããæŸå°èœæšèããåœåéã§åšç¥ã®æ§ã ãªæ¹æ³ã«ãããéžæããïŒïŒµïŒãã¡ã€ã³ã«å°å ¥ããŠçšããçžäºäœçšããååãææããã奜ãŸããæ¹æ³ãšããŠã¯ã125 Bolton-Hunterè©Šè¬ã«ãããïŒïŒµïŒã«ããã第äžçŽã¢ãã³åºã®æšèã§ããããã®è©Šè¬ã¯ãä»éããçç©åŠç掻æ§ã®æ¶å€±ãªãã«æ§ã ãªååãæšèããããã«çšããããŠããã
æšèããïŒïŒµïŒã¯ãããçžäºäœçšããååã®ç²Ÿè£œã®ããã®è©Šè¬ãšããŠæçšã§ãããã¢ãã£ããã£ãŒç²Ÿè£œã®ïŒã€ã®æ
æ§ã§ã¯ãèçµåïŒïŒµïŒãå
±æçµåã«ããã¯ãããã°ã©ãã£ãŒã«ã©ã ã«çµåããããæ»æ¶²çŽ°èããåŸãããç¡çŽ°èæœåºæ¶²ãŸãã¯æšå®ã®æšç现èãã«ã©ã ã«éããé©åœãªèŠªåæ§ãæããååãïŒïŒµïŒã«çµåããããïŒïŒµïŒè€åäœãã«ã©ã ããååããïŒïŒµïŒãçµåãããªã¬ã³ãã解é¢ããæ«ç«¯ã¿ã³ãã¯è³ªé
å決å®ã«ä»ããã次ãã§ãã¢ããé
žé
åã®æ
å ±ãçšããŠãææãããååãåå®ããããŸãã¯é©åœãªïœïŒ€ïŒ®ïŒ¡ã©ã€ãã©ãªãŒããé¢é£ã®éºäŒåãã¯ããŒã³ã°ããããã®çž®éãªãªãŽãã¯ã¬ãªãããããŒããèšèšããã
å¥ã®æ¹æ³ã«ãããŠã¯ãïŒïŒµïŒã«å¯Ÿããæäœãç¹ã«ã¢ãã¯ããŒãã«æäœããæ¹èµ·ããããã¢ãã¯ããŒãã«æäœãã¹ã¯ãªãŒãã³ã°ããŠãæšèãããïŒïŒµïŒã®çµåãé»å®³ããæäœãåå®ããã次ãã§ããããã®ã¢ãã¯ããŒãã«æäœãæ²»çã«çšããã
å®æœäŸïŒïŒïŒæäœãé»å®³å€ãŸãã¯ã¢ã³ã¿ãŽãã¹ãã®äœ¿çšããã³æäž
ã·ã°ãã«äŒéã®æå¶å€ïŒïŒ¬ïŒ³ïŒŽïŒã§ããïŒïŒµïŒã®æäœãé»å®³å€ãŸãã¯ã¢ã³ã¿ãŽãã¹ããŸãã¯ä»ã®æ²»çç©è³ªããã³ååç©ã¯ãæ²»ççã«æäžããå Žåã«çš®ã ã®å¹æããããããã¯ã奜ãŸããã¯çŽïŒãïŒããã奜ãŸããã¯ïœïŒšïŒãïŒã®ãéæ¯æ§ã®ãäžæŽ»æ§ãªè£œè¬çã«èš±å®¹ãåŸãæ°Žæ§æ äœåªäœäžã§åœ¢æãããããïœïŒšã¯åœ¢æããæäœãé»å®³å€ãŸãã¯ã¢ã³ã¿ãŽãã¹ãã®ç¹æ§ããã³åŠçœ®ãããç¶æ ã«ãããã£ãŠå€æŽããããšãã§ãããã®ç¹æ§ãšããŠã¯ãååã®å¯æº¶æ§ããã®åæžæããã³æåæ§ïŒå ç«åæ§ãæããããããããã®ããã³ãã®ä»ã®ç¹æ§ã¯ãæå¹ãªæ äœãèŠå®ãããšãã®å©ããšãªãã倩ç¶ã®ããã¿ã³ãã¯è³ªã¯ããšããŠå¥œãŸããããè¬ç©ã¹ã¯ãªãŒãã³ã°ããã¹ã¯ãªãŒãã³ã°ãããææ©ãŸãã¯åæååã¯ãç¹å®ã®ç¶æ³ã«ãããŠã¯åæ§ã«æå¹ã§ããã
ã·ã°ãã«äŒéã®æå¶å€ïŒïŒ¬ïŒ³ïŒŽïŒã§ããïŒïŒµïŒã®æäœãé»å®³å€ãŸãã¯ã¢ã³ã¿ãŽãã¹ããŸãã¯ä»ã®æ²»çç©è³ªããã³ååç©ã¯ãæ²»ççã«æäžããå Žåã«çš®ã ã®å¹æããããããã¯ã奜ãŸããã¯çŽïŒãïŒããã奜ãŸããã¯ïœïŒšïŒãïŒã®ãéæ¯æ§ã®ãäžæŽ»æ§ãªè£œè¬çã«èš±å®¹ãåŸãæ°Žæ§æ äœåªäœäžã§åœ¢æãããããïœïŒšã¯åœ¢æããæäœãé»å®³å€ãŸãã¯ã¢ã³ã¿ãŽãã¹ãã®ç¹æ§ããã³åŠçœ®ãããç¶æ ã«ãããã£ãŠå€æŽããããšãã§ãããã®ç¹æ§ãšããŠã¯ãååã®å¯æº¶æ§ããã®åæžæããã³æåæ§ïŒå ç«åæ§ãæããããããããã®ããã³ãã®ä»ã®ç¹æ§ã¯ãæå¹ãªæ äœãèŠå®ãããšãã®å©ããšãªãã倩ç¶ã®ããã¿ã³ãã¯è³ªã¯ããšããŠå¥œãŸããããè¬ç©ã¹ã¯ãªãŒãã³ã°ããã¹ã¯ãªãŒãã³ã°ãããææ©ãŸãã¯åæååã¯ãç¹å®ã®ç¶æ³ã«ãããŠã¯åæ§ã«æå¹ã§ããã
ã¯ãå±æã¯ãªãŒã ããã³ã²ã«ïŒçµç²èã¹ãã¬ãŒããã³ãšã¢ãŸãŒã«ïŒçµç®ãããããã³ãã³ããŒãžã泚å°çšãéèçšããã³æŽæµæ¶²è£œå€ïŒããã³ç¹ã«èé
žãšé
µçŽ ã«èããããã«è£œå€åãããçµå£æäžæ¶²å€ããã³äžžå€ãæãããããããã«éå®ãããªããæ¢ç¥ã®æäžçµè·¯ã«ãã£ãŠééããããšãã§ãããå
·äœçãªè£œå€ã詳现ãªçšéããã³æäžçµè·¯ã¯ã䞻治å»ã決å®ããããããã®å
·äœçãªç¶æ³ã«ãããã£ãŠå€åããã
ãã®ãããªæ±ºå®ã¯ãåŠçœ®ãããç¶æ
ãæäžããããããã³å
·äœçãªïŒ¬ïŒ³ïŒŽã®è¬çåŠçãããã£ãŒã«ãã«ãã£ãŠãªããããããã«ãçŸæ£ã®ç¶æ
ã®é節床ãæ£è
ã®å¹Žéœ¢ãäœéãæ§å¥ããã³é£ç¿æ
£ãæäžã®æéãšé »åºŠãä»ã®è¬ç©ã®å¯èœæ§ã®ããçµåããåå¿æåæ§ãããã³æ²»çã«å¯Ÿãã蚱容床ïŒå¿çãå«ããããªãèŠçŽ ãèæ
®ã«å
¥ãããé·æéäœçšãã補å€ã¯ãå
·äœçãªïŒ¬ïŒ³ïŒŽã®åæžæããã³ã¯ãªã¢ã©ã³ã¹é床ã«ãã£ãŠãïŒãïŒæ¥æ¯ãïŒé±éæ¯ããŸãã¯ïŒé±éæ¯ã«æäžããããšãã§ãã
éåžžã®é©ééã¯ãæäžçµè·¯ã«äŸåããŠïŒïŒïŒãïŒïŒ5ÎŒïœã®ç¯å²ã§ãç·çšéçŽïŒïœãŸã§ãå€æŽããããšãã§ãããééã®å
·äœççšéããã³æ¹æ³ã«é¢ããæéã¯æç®ã«èšèŒãããŠããïŒç±³åœç¹èš±ç¬¬ïŒ,ïŒïŒïŒ,ïŒïŒïŒïŒïŒ,ïŒïŒïŒ,ïŒïŒïŒïŒïŒ,ïŒïŒïŒ,ïŒïŒïŒå·å
¬å ±åç
§ãåœæ¥è
ã¯ãç°ãªãã«å¯ŸããŠç°ãªãå
¬åŒãçšãããç¥çµçŽ°èã®ãããªçŽ°èãžã®æäžã¯ãè¡ç®¡å
ç®çŽ°èçã®ä»ã®çŽ°èãšã¯ç°ãªã£ãæ段ã§è¡ãããã
ïŒïŒµïŒæŽ»æ§ãèªçºããç°åžžãªã·ã°ãã«äŒéãå€å·ãèªçºããçŸæ£ãã«ããæ²»çå¯èœã§ãããšèããããããããã®ç¶æ
ãŸãã¯çŸæ£ã¯ãäžã«è«è°ãããè©Šéšã«ãã£ãŠç¹ç°çã«èšºæããããã®ãããªè©Šéšã¯ããŠã€ã«ã¹ã现èãçèææãã¢ã¬ã«ã®ãŒã®å¿çãå€å·ã䌎ãæ©æ¢°çæå·ãéºäŒæ§ã®ç
æ°ããªã³ãè
«ãçãç¥çµçµç¹ã®éºäŒåã掻æ§åãããã®ä»ã®ç¶æ
ãçãããå Žåã«è¡ãããã
å®æœäŸïŒïŒïŒéãããã©ã³ã¹ãžã§ããã¯åç©ã®äœè£œ
ïŒïŒµïŒã®ççåŠçããã³è¡åã«å¯Ÿãã圹å²ã解æããåç©ã¢ãã«ç³»ããæ§ã ãªæè¡ã«ãããïŒïŒµïŒã®æŽ»æ§ãå¢å ãŸãã¯æžå°ããŠããããããã¯çºçŸããïŒïŒµïŒã®ã¢ããé žé åãå€åããŠããéãããã©ã³ã¹ãžã§ããã¯åç©ãäœåºããããšã«ãã£ãŠäœæããããããã®æè¡ã®äŸãšããŠã¯ãïŒïŒãã©ã³ã¹ãžã§ããã¯åç©ãäœè£œããããã®ãïŒïŒµïŒãã³ãŒãããã®æ£åžžãªåœ¢æ ãŸãã¯çªç¶å€ç°äœã®ããã€ã¯ãã€ã³ãžã§ã¯ã·ã§ã³ããšã¬ã¯ãããã¬ãŒã·ã§ã³ãã¬ãããŠã€ã«ã¹ãã©ã³ã¹ãã§ã¯ã·ã§ã³ãŸãã¯åœåéã§åšç¥ã®ä»ã®æè¡ã«ããé©åœãªå粟èãžã®æ¿å ¥ããŸãã¯ïŒïŒãã©ã³ã¹ãžã§ããã¯åç©ã«ãããŠãçªç¶å€ç°äœã®ãŸãã¯æ£åžžãªããããŸãã¯åç©ã®ãããéºäŒåãã倩ç¶ã®éºäŒå座ã«ã€ããŠçžåççµæããè¡ãããããïŒïŒµïŒé åã®çºçŸèª¿ç¯ãŸãã¯æ§é ãå€åãããããšãæãããããçžåççµæãã®æè¡ã¯åœåéã«ãããŠåšç¥ã§ããã倩ç¶ã®éºäŒåãæ¿å ¥éºäŒåã§çœ®æãããã®ãã倩ç¶ã®ïŒ®ïŒïŒµïŒãçºçŸããããšãã§ããªãããäŸãã°ãçµæãã«ãã£ãŠãã®åç©ã®ã²ãã ã«ãããŠå€©ç¶ïŒ®ïŒïŒµïŒãã眮ãæããããã®ãã©ã³ã¹ããŒã¿ãŒã®çºçŸäœäžãããããæ¿å ¥ãããïŒïŒµïŒçªç¶å€ç°äœãçºçŸããåç©ã®äœåºã«æçšã§ããããã€ã¯ãã€ã³ãžã§ã¯ã·ã§ã³ã¯ã²ãã ã«éºäŒåãè¿œå ããéºäŒåã¯é€å»ãããããã®æè¡ã¯ãããšããšã®ãããŠè¿œå ãããïŒïŒµïŒãçºçŸããïŒïŒµïŒã®éå°çºçŸãããããåç©ã®äœåºã«æçšã§ããã
ïŒïŒµïŒã®ççåŠçããã³è¡åã«å¯Ÿãã圹å²ã解æããåç©ã¢ãã«ç³»ããæ§ã ãªæè¡ã«ãããïŒïŒµïŒã®æŽ»æ§ãå¢å ãŸãã¯æžå°ããŠããããããã¯çºçŸããïŒïŒµïŒã®ã¢ããé žé åãå€åããŠããéãããã©ã³ã¹ãžã§ããã¯åç©ãäœåºããããšã«ãã£ãŠäœæããããããã®æè¡ã®äŸãšããŠã¯ãïŒïŒãã©ã³ã¹ãžã§ããã¯åç©ãäœè£œããããã®ãïŒïŒµïŒãã³ãŒãããã®æ£åžžãªåœ¢æ ãŸãã¯çªç¶å€ç°äœã®ããã€ã¯ãã€ã³ãžã§ã¯ã·ã§ã³ããšã¬ã¯ãããã¬ãŒã·ã§ã³ãã¬ãããŠã€ã«ã¹ãã©ã³ã¹ãã§ã¯ã·ã§ã³ãŸãã¯åœåéã§åšç¥ã®ä»ã®æè¡ã«ããé©åœãªå粟èãžã®æ¿å ¥ããŸãã¯ïŒïŒãã©ã³ã¹ãžã§ããã¯åç©ã«ãããŠãçªç¶å€ç°äœã®ãŸãã¯æ£åžžãªããããŸãã¯åç©ã®ãããéºäŒåãã倩ç¶ã®éºäŒå座ã«ã€ããŠçžåççµæããè¡ãããããïŒïŒµïŒé åã®çºçŸèª¿ç¯ãŸãã¯æ§é ãå€åãããããšãæãããããçžåççµæãã®æè¡ã¯åœåéã«ãããŠåšç¥ã§ããã倩ç¶ã®éºäŒåãæ¿å ¥éºäŒåã§çœ®æãããã®ãã倩ç¶ã®ïŒ®ïŒïŒµïŒãçºçŸããããšãã§ããªãããäŸãã°ãçµæãã«ãã£ãŠãã®åç©ã®ã²ãã ã«ãããŠå€©ç¶ïŒ®ïŒïŒµïŒãã眮ãæããããã®ãã©ã³ã¹ããŒã¿ãŒã®çºçŸäœäžãããããæ¿å ¥ãããïŒïŒµïŒçªç¶å€ç°äœãçºçŸããåç©ã®äœåºã«æçšã§ããããã€ã¯ãã€ã³ãžã§ã¯ã·ã§ã³ã¯ã²ãã ã«éºäŒåãè¿œå ããéºäŒåã¯é€å»ãããããã®æè¡ã¯ãããšããšã®ãããŠè¿œå ãããïŒïŒµïŒãçºçŸããïŒïŒµïŒã®éå°çºçŸãããããåç©ã®äœåºã«æçšã§ããã
äŸãã°ããŠã¹ã«ã€ããŠããã©ã³ã¹ãžã§ããã¯åç©ãäœè£œããããã«å©çšã§ããæ段ã¯æ¬¡ã®éãã§ããïŒéæ§ããŠã¹ã亀尟ãããŠåŸãããå粟åµãåµç®¡ããæ¡åãããå粟åµãå¡©åã»ã·ãŠã ïŒïŒå¹å°çã®é©åãªåªäœã§ä¿åãããïŒïŒµïŒãã³ãŒããããŸãã¯ïœïŒ€ïŒ®ïŒ¡ãåœæ¥è
ã«åšç¥ã®æ¹æ³ã«ãããã¯ã¿ãŒãã粟補ãããå°å
¥ããã¢ãŒã¿ãŒãã®ã³ãŒãé åã«èåããŠãå°å
¥éºäŒåã®èª¿ç¯ããããã®å®éšæ段ãæäŸããããšãã§ããããããã¯ãŸãã¯ããã«ãçµç¹ç¹ç°ç調ç¯ãšã¬ã¡ã³ããã³ãŒãé åã«èåããå°å
¥éºäŒåã®çµç¹ç¹ç°ççºçŸãå¯èœã«ããããšãã§ãããé©åã«ç·©è¡åããã溶液äžã§ãããã€ã¯ã泚å°éã«åžã蟌ã¿ïŒpiper pullerãçšããŠãã£ãã©ãªãŒãã¥ãŒãããäœè£œããŠãããïŒã泚å
¥ããåµãå¹ã¿ãä»ããã¹ã©ã€ãã«çœ®ããéãåµã®çæ®æ žã«æ¿å
¥ãã溶液ã泚å
¥ããã次ãã§ã泚å
¥ãããåµãåœåŠåš ããŠã¹ã®åµç®¡ã«ç§»ããåœåŠåš ãç¶æããããã«é©åãªãã«ã¢ã³ã«ãã£ãŠããŠã¹ãåºæ¿ããåµãåå®®ãžãšé²ãŸããçåºãããæéããããŸã§çè²ããããäžã«èšèŒããããã«ããã€ã¯ãã€ã³ãžã§ã¯ã·ã§ã³ã¯åµã«ïŒ€ïŒ®ïŒ¡ãæ¿å
¥ããããã®å¯äžã®æ¹æ³ã§ãªããããã§ã¯åã«äŸç€ºçãªç®çã§çšããã
åèæç®
ç±³åœç¹èš±ç¬¬4,522,811å·å ¬å ±
ç±³åœç¹èš±ç¬¬5,283,317å·å ¬å ±
ç±³åœç¹èš±ç¬¬5,565,332å·å ¬å ±
åœéç¹èš±åºé¡å ¬é第84/03564å·å ¬å ±
åœéç¹èš±åºé¡å ¬é第92/01810å·å ¬å ±
åœéç¹èš±åºé¡å ¬é第93/03151å·å ¬å ±
åœéç¹èš±åºé¡å ¬é第94/13804å·å ¬å ±
åœéç¹èš±åºé¡å ¬é第01/04297å·å ¬å ±
åœéç¹èš±åºé¡å ¬é第200140797å·å ¬å ±
åœéç¹èš±åºé¡å ¬é第200125269å·å ¬å ±
åœéç¹èš±åºé¡å ¬é第200144297å·å ¬å ±
Shan et al., J Biol Chem. 2000 Dec 15; 275 (50) : 39482-6
Raddatz et al., J Biol Chem. 2000 Oct 20; 275 (42): 32452-9
Appa Rao et al., 1997, Protein Expr Purif Nov, 11 (2): 201-8
Barnes, 2000, Chest, 117:10S14S
Botstein et al., 1980, Am J Hum Genet. 32: 314-31
Colbere-Garapin et al., 1981, J. Mol. Biol. 150, 1-14
Engelhard et al., 1994, Proc. Nat. Acad. Sci. 91, 3224-3227
Gergen and Weiss, 1992, Am Rev Respir Dis 146: 823-824
Gibson et al., 1996, Genome Research 6: 995-1001
Haseloff et al., 1988, Nature 334, 585-591
Heid et al., 1996, Genome Research 6: 986-994
Holland et al., 1991, PNAS 88: 7276-7280
Iwabuchi et al., 1993, Oncogene 8, 1693-1696
Jeffreys et al., 1985, Nature 316: 76-9
Johnson et al., 1989, Endoc. Rev. 10, 317-331
Kellogg et al., 1990, Anal. Biochem. 189: 202-208
Lam, 1997, Anticancer Drug Res. 12 (3): 145-67
Lefkowitz, 1991, Nature 351, 353-354
Livak et al., 1995, PCR Methods and Applications 357-362
Logan, Shenk, 1984, Proc. Natl. Acad. Sci. 81, 3655-3659
Lowy et al., 1980, Cell 22, 817-23
Maddox et al., 1983, J Exp. Med 158, 1211-1216
McConnell et al., 1992, Science 257, 1906-1912
Murray, 1992, supra
Nicholls et al. 1993, J. Immunol. Meth. 165, 81-91
Piatak et al., 1993, BioTechniques 14: 70-81
Piatak et al., 1993, Science 259: 1749-1754
Porath et al., 1992, Prot. Exp. Purif 3, 263-281
Roberge et al., 1995, Science 269, 202-204
Sjolander, Urbaniczky, 1991, Anal. Chem. 63, 2338-2345
Szabo et al., 1995, Curr. Opin. Struct. Biol. 5, 699-705
Thomas, 1980, Proc. Nat. Acad. Sci., 77: 5201-5205
Uhlmann et al., 1987, Tetrahedron. Lett. 215, 3539-3542
Weber et al., 1990, Genomics 7: 524-30
Wigler et al., 1977, Cell 11, 223-32
Wigler et al., 1980, Proc. Natl. Acad. Sci. 77, 3567-70
ç±³åœç¹èš±ç¬¬4,522,811å·å ¬å ±
ç±³åœç¹èš±ç¬¬5,283,317å·å ¬å ±
ç±³åœç¹èš±ç¬¬5,565,332å·å ¬å ±
åœéç¹èš±åºé¡å ¬é第84/03564å·å ¬å ±
åœéç¹èš±åºé¡å ¬é第92/01810å·å ¬å ±
åœéç¹èš±åºé¡å ¬é第93/03151å·å ¬å ±
åœéç¹èš±åºé¡å ¬é第94/13804å·å ¬å ±
åœéç¹èš±åºé¡å ¬é第01/04297å·å ¬å ±
åœéç¹èš±åºé¡å ¬é第200140797å·å ¬å ±
åœéç¹èš±åºé¡å ¬é第200125269å·å ¬å ±
åœéç¹èš±åºé¡å ¬é第200144297å·å ¬å ±
Shan et al., J Biol Chem. 2000 Dec 15; 275 (50) : 39482-6
Raddatz et al., J Biol Chem. 2000 Oct 20; 275 (42): 32452-9
Appa Rao et al., 1997, Protein Expr Purif Nov, 11 (2): 201-8
Barnes, 2000, Chest, 117:10S14S
Botstein et al., 1980, Am J Hum Genet. 32: 314-31
Colbere-Garapin et al., 1981, J. Mol. Biol. 150, 1-14
Engelhard et al., 1994, Proc. Nat. Acad. Sci. 91, 3224-3227
Gergen and Weiss, 1992, Am Rev Respir Dis 146: 823-824
Gibson et al., 1996, Genome Research 6: 995-1001
Haseloff et al., 1988, Nature 334, 585-591
Heid et al., 1996, Genome Research 6: 986-994
Holland et al., 1991, PNAS 88: 7276-7280
Iwabuchi et al., 1993, Oncogene 8, 1693-1696
Jeffreys et al., 1985, Nature 316: 76-9
Johnson et al., 1989, Endoc. Rev. 10, 317-331
Kellogg et al., 1990, Anal. Biochem. 189: 202-208
Lam, 1997, Anticancer Drug Res. 12 (3): 145-67
Lefkowitz, 1991, Nature 351, 353-354
Livak et al., 1995, PCR Methods and Applications 357-362
Logan, Shenk, 1984, Proc. Natl. Acad. Sci. 81, 3655-3659
Lowy et al., 1980, Cell 22, 817-23
Maddox et al., 1983, J Exp. Med 158, 1211-1216
McConnell et al., 1992, Science 257, 1906-1912
Murray, 1992, supra
Nicholls et al. 1993, J. Immunol. Meth. 165, 81-91
Piatak et al., 1993, BioTechniques 14: 70-81
Piatak et al., 1993, Science 259: 1749-1754
Porath et al., 1992, Prot. Exp. Purif 3, 263-281
Roberge et al., 1995, Science 269, 202-204
Sjolander, Urbaniczky, 1991, Anal. Chem. 63, 2338-2345
Szabo et al., 1995, Curr. Opin. Struct. Biol. 5, 699-705
Thomas, 1980, Proc. Nat. Acad. Sci., 77: 5201-5205
Uhlmann et al., 1987, Tetrahedron. Lett. 215, 3539-3542
Weber et al., 1990, Genomics 7: 524-30
Wigler et al., 1977, Cell 11, 223-32
Wigler et al., 1980, Proc. Natl. Acad. Sci. 77, 3567-70
Claims (26)
- åºä¹³é¡ã«ããããè¡æ¶²çŸæ£ãå¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãççŸæ£ãããã³èèã®é害ãããªãçŸæ£ã®çŸ€ã«å«ãŸããçŸæ£ã®åŠçœ®ã«æçšãªæ²»çå€ã®ã¹ã¯ãªãŒãã³ã°æ¹æ³ã§ãã£ãŠã
ïŒïœïŒè©Šéšååç©ãïŒïŒµïŒããªãããããšæ¥è§Šãããå·¥çšã
ïŒïœïœïŒè©²è©Šéšååç©ã®è©²ïŒ®ïŒïŒµïŒããªãããããžã®çµåãæ€åºããå·¥çš
ãå«ãã§ãªãæ¹æ³ã - åºä¹³é¡ã«ããããè¡æ¶²çŸæ£ãå¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãççŸæ£ãããã³èèã®é害ãããªãçŸæ£ã®çŸ€ã«å«ãŸããçŸæ£ã®åŠçœ®ã«æçšãªæ²»çå€ã®ã¹ã¯ãªãŒãã³ã°æ¹æ³ã§ãã£ãŠã
ïŒïœïŒè©Šéšååç©ã®ç¹å®ã®æ¿åºŠã§ãŸãã¯è©²è©Šéšååç©ã®éååšäžã§ïŒ®ïŒïŒµïŒããªããããã®æŽ»æ§ã枬å®ããå·¥çšã
ïŒïœïœïŒè©²è©Šéšååç©ã®ç°ãªãæ¿åºŠã§è©²ããªããããã®æŽ»æ§ã枬å®ããå·¥çš
ãå«ãã§ãªãæ¹æ³ã - åºä¹³é¡ã«ããããè¡æ¶²çŸæ£ãå¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãççŸæ£ãããã³èèã®é害ãããªãçŸæ£ã®çŸ€ã«å«ãŸããçŸæ£ã®åŠçœ®ã«æçšãªæ²»çå€ã®ã¹ã¯ãªãŒãã³ã°æ¹æ³ã§ãã£ãŠã
ïŒïœïŒè©Šéšååç©ã®ç¹å®ã®æ¿åºŠã§ïŒ®ïŒïŒµïŒããªããããã®æŽ»æ§ã枬å®ããå·¥çšã
ïŒïœïœïŒïŒ®ïŒïŒµïŒããªããããã®èª¿ç¯ç©è³ªã§ããããšãåãã£ãŠããååç©ã®ååšäžã§ïŒ®ïŒïŒµïŒããªããããã®æŽ»æ§ã枬å®ããå·¥çš
ãå«ãã§ãªãæ¹æ³ã - æ¥è§Šãããå·¥çšã现èå ãŸãã¯çŽ°èè¡šé¢ã§è¡ãè«æ±é ïŒãïŒã®ããããã«èšèŒã®æ¹æ³ã
- 现èãã€ã³ãããã§ååšããè«æ±é ïŒãïŒã®ããããã«èšèŒã®æ¹æ³ã
- æ¥è§Šãããå·¥çšã现èãå«ãŸãªãç³»ã§è¡ãè«æ±é ïŒãïŒã®ããããã«èšèŒã®æ¹æ³ã
- ããªãããããæ€åºå¯èœãªæšèã«çµåãããè«æ±é ïŒãïŒã®ããããã«èšèŒã®æ¹æ³ã
- ååç©ãæ€åºå¯èœãªæšèã«çµåãããè«æ±é ïŒãïŒã®ããããã«èšèŒã®æ¹æ³ã
- è©Šéšååç©ãããªããããã«æåã«çµåããŠãããªã¬ã³ããšçœ®ãæããè«æ±é ïŒãïŒã®ããããã«èšèŒã®æ¹æ³ã
- ããªãããããåºäœã®æ¯æäœã«çµåããŠããè«æ±é ïŒãïŒã®ããããã«èšèŒã®æ¹æ³ã
- ååç©ãåºäœã®æ¯æäœã«çµåããŠããè«æ±é ïŒãïŒã®ããããã«èšèŒã®æ¹æ³ã
- åºä¹³é¡ã«ãããè¡æ¶²çŸæ£ãå¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãççŸæ£ãããã³èèã®é害ãããªãçŸæ£ã®çŸ€ã«å«ãŸããçŸæ£ã®åŠçœ®ã«æçšãªæ²»çå€ã®ã¹ã¯ãªãŒãã³ã°æ¹æ³ã§ãã£ãŠã
ïŒïœïŒè©Šéšååç©ãïŒïŒµïŒããªãã¯ã¬ãªãããšæ¥è§Šãããå·¥çšãïŒïœïœïŒè©²è©Šéšååç©ãšè©²ïŒ®ïŒïŒµïŒããªãã¯ã¬ãªãããšã®çµåãæ€åºããå·¥çš
ãå«ãã§ãªãæ¹æ³ã - æ žé žååãã§ããè«æ±é ïŒïŒã«èšèŒã®æ¹æ³ã
- æ¥è§Šãããå·¥çšã现èå ãŸãã¯çŽ°èè¡šé¢ã§è¡ãè«æ±é ïŒïŒã«èšèŒã®æ¹æ³ã
- æ¥è§Šãããå·¥çšã现èãå«ãŸãªãç³»ã§è¡ãè«æ±é ïŒïŒã«èšèŒã®æ¹æ³ã
- ããªãã¯ã¬ãªãããæ€åºå¯èœãªæšèã«çµåãããè«æ±é ïŒïŒã«èšèŒã®æ¹æ³ã
- è©Šéšååç©ãæ€åºå¯èœãªæšèã«çµåãããè«æ±é ïŒïŒã«èšèŒã®æ¹æ³ã
- åºä¹³é¡ã«ãããè¡æ¶²çŸæ£ãå¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãççŸæ£ãããã³èèã®é害ãããªãçŸæ£ã®çŸ€ã«å«ãŸããçŸæ£ã蚺æããæ¹æ³ã§ãã£ãŠã
ïŒïœïŒè©²åºä¹³é¡ããæ¡åãããµã³ãã«äžã®ïŒ®ïŒïŒµïŒããªãã¯ã¬ãªããã®éã枬å®ããããšïŒ
ïŒïœïœïŒå¥åº·ãªããã³ïŒãŸãã¯çŸæ£ãæããåºä¹³é¡ã«ãããïŒïŒµïŒããªãã¯ã¬ãªããã®éã枬å®ããããš
ãå«ãã§ãªãæ¹æ³ã - ïŒïŒµïŒããªããããã«çµåããæ²»çå€ãå«æãããåºä¹³é¡ã«ãããè¡æ¶²çŸæ£ãå¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãççŸæ£ãããã³èèã®é害ãããªãçŸæ£ã®çŸ€ã«å«ãŸããçŸæ£ã®åŠçœ®ã®ããã®å»è¬çµæç©ã
- ïŒïŒµïŒããªããããã®æŽ»æ§ã調ç¯ããæ²»çå€ãå«æãããåºä¹³é¡ã«ãããè¡æ¶²çŸæ£ãå¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãççŸæ£ãããã³èèã®é害ãããªãçŸæ£ã®çŸ€ã«å«ãŸããçŸæ£ã®åŠçœ®ã®ããã®å»è¬çµæç©ã
- ïŒïŒµïŒããªããããã®æŽ»æ§ã調ç¯ããæ²»çå€ãå«æãããåºä¹³é¡ã«ãããè¡æ¶²çŸæ£ãå¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãççŸæ£ãããã³èèã®é害ãããªãçŸæ£ã®çŸ€ã«å«ãŸããçŸæ£ã®åŠçœ®ã®ããã®å»è¬çµæç©ã§ãã£ãŠã該治çå€ãã
ïŒïœïŒå°ååã
ïŒïœïœïŒïŒ²ïŒ®ïŒ¡ååã
ïŒïœïœïœïŒã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªããã
ïŒïœïœïŒããªããããã
ïŒïœïŒæäœãŸãã¯
ïŒïœïœïŒãªãŸããŒã
ã§ããå»è¬çµæç©ã - ïŒïŒµïŒããªãã¯ã¬ãªãããå«æãããåºä¹³é¡ã«ãããè¡æ¶²çŸæ£ãå¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãççŸæ£ãããã³èèã®é害ãããªãçŸæ£ã®çŸ€ã«å«ãŸããçŸæ£ãåŠçœ®ããããã®å»è¬çµæç©ã
- ïŒïŒµïŒããªãããããå«æãããåºä¹³é¡ã«ãããè¡æ¶²çŸæ£ãå¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãççŸæ£ãããã³èèã®é害ãããªãçŸæ£ã®çŸ€ã«å«ãŸããçŸæ£ãåŠçœ®ããããã®å»è¬çµæç©ã
- åºä¹³é¡ã«ãããè¡æ¶²çŸæ£ãå¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãççŸæ£ãããã³èèã®é害ãããªãçŸæ£ã®çŸ€ã«å«ãŸããçŸæ£ãåŠçœ®ããããã®å»è¬çµæç©ã®è£œé ã®ããã®ïŒ®ïŒïŒµïŒã®èª¿ç¯ç©è³ªã®äœ¿çšã
- åºä¹³é¡ã«ãããè¡æ¶²çŸæ£ãå¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãççŸæ£ãããã³èèã®é害ãããªãçŸæ£ã®çŸ€ã«å«ãŸããçŸæ£ã®åŠçœ®ã«æçšãªå»è¬çµæç©ã®è£œé æ¹æ³ã§ãã£ãŠã
ïŒïœïŒïŒ®ïŒïŒµïŒã®èª¿ç¯ç©è³ªãåå®ããå·¥çšã
ïŒïœïœïŒè©²èª¿ç¯ç©è³ªããåºä¹³é¡ã«ãããè¡æ¶²çŸæ£ãå¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãççŸæ£ãããã³èèã®é害ãããªãçŸæ£ã®çŸ€ã«å«ãŸããçŸæ£ã®çç¶ãæ¹åãããã©ããã決å®ããå·¥çšïŒããã³
ïŒïœïœïœïŒè©²èª¿ç¯ç©è³ªã蚱容ãåŸã補è¬çæ äœãšçµã¿åãããå·¥çš
ãå«ãã§ãªãæ¹æ³ã - åºä¹³é¡ã«ãããè¡æ¶²çŸæ£ãå¿çŸæ£ãæ«æ¢¢ç¥çµããã³äžæ¢ç¥çµç³»ã®é害ãççæ§çŸæ£ãççŸæ£ãããã³èèã®é害ãããªãçŸæ£ã®çŸ€ã«å«ãŸããçŸæ£ãæããåºä¹³é¡ã«ãããïŒïŒµïŒæŽ»æ§ã®èª¿ç¯ã®ããã®ãïŒïŒµïŒã®èª¿ç¯ç©è³ªã®äœ¿çšã
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02002006 | 2002-02-06 | ||
PCT/EP2003/000754 WO2003066077A2 (en) | 2002-02-06 | 2003-01-24 | Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1) |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005534282A JP2005534282A (ja) | 2005-11-17 |
JP2005534282A5 true JP2005534282A5 (ja) | 2006-01-12 |
Family
ID=27675596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003565500A Pending JP2005534282A (ja) | 2002-02-06 | 2003-01-24 | ãã¥ãŒãã¡ãžã³ïœå容äœã«é¢é£ããçŸæ£ã®ããã®èšºæçšããã³æ²»ççšç©è³ª |
Country Status (5)
Country | Link |
---|---|
US (2) | US20060057648A1 (ja) |
EP (1) | EP1471927A2 (ja) |
JP (1) | JP2005534282A (ja) |
AU (1) | AU2003218638A1 (ja) |
WO (1) | WO2003066077A2 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003240469A1 (en) * | 2002-05-02 | 2003-11-17 | Bayer Aktiengesellschaft | Diagnostics and therapeutics for diseases associated with neuromedin b receptor (nmb) |
JP2006042802A (ja) * | 2004-06-28 | 2006-02-16 | Sumitomo Chemical Co Ltd | ã³ã¢ã³ããŒã¢ã»ããç±æ¥ã®ããããµã³ãã³ã°ã¢ãã³ãã¹ããªãã·ã«ãã©ã³ã¹ãã§ã©ãŒãŒéºäŒååã³ãã®å©çš |
MX2019006886A (es) * | 2016-12-13 | 2019-10-30 | Limm Therapeutics Sa | Métodos para tratar enfermedades asociadas con células linfoides innatas del grupo 2 (ilc2). |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6555339B1 (en) * | 1997-04-14 | 2003-04-29 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human protein-coupled receptors |
WO2000002919A1 (en) * | 1998-07-13 | 2000-01-20 | Merck & Co., Inc. | Growth hormone secretagogue related receptors and nucleic acids |
JP2004523203A (ja) * | 2000-06-16 | 2004-08-05 | ã€ã³ãµã€ãã»ã²ãããã¯ã¹ã»ã€ã³ã³ãŒãã¬ã€ããã | ã¿ã³ãã¯è³ªçµååå®¹äœ |
-
2003
- 2003-01-24 US US10/503,511 patent/US20060057648A1/en not_active Abandoned
- 2003-01-24 JP JP2003565500A patent/JP2005534282A/ja active Pending
- 2003-01-24 WO PCT/EP2003/000754 patent/WO2003066077A2/en active Application Filing
- 2003-01-24 EP EP03711867A patent/EP1471927A2/en not_active Ceased
- 2003-01-24 AU AU2003218638A patent/AU2003218638A1/en not_active Abandoned
-
2007
- 2007-12-25 US US11/964,029 patent/US20080124743A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005536187A (ja) | âãã«ãã«ããããå容äœæ§ïŒïŒïœïœïœïœïŒïŒã«é¢é£ããçŸæ£ã®èšºæããã³æ²»ç | |
US20080176234A1 (en) | Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr) | |
JP2005520562A (ja) | æé·ãã«ã¢ã³åæ³ä¿é²å容äœïŒïœïœïœïŒã«é¢é£ããçŸæ£ã®èšºæããã³æ²»ç | |
JP2005528587A (ja) | æ°èŠããïŒâïœïœïŒå容äœã«é¢é£ããçŸæ£ã®ããã®èšºæçšããã³æ²»ççšç©è³ª | |
US20070053911A1 (en) | Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2) | |
WO2005095972A2 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor etb (etb) | |
US20060165679A1 (en) | Diagnostics and therapeutics for diseases associated with vasoactive intestinal peptide receptor 2 (vpac2) | |
EP1606621B1 (en) | Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar) | |
US20080124743A1 (en) | Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (u1) | |
JP2007506951A (ja) | ã¿ã³ãã¯è³ªå ±åœ¹å容äœïŒ¡ïœïœïœïœïŒ²ïŒïŒïŒ¡ïœïœïœïœïŒ²ïŒïŒã«é¢é£ããçŸæ£ã®èšºæããã³æ²»ç | |
JP2005534282A5 (ja) | ||
US20110130347A1 (en) | Identification of new splice-variants of g-protein coupled receptor ep3 and uses thereof | |
JP2007506950A (ja) | ã¿ã³ãã¯è³ªå ±åœ¹å容äœïŒ¡ïœïœïœïœïŒ²ïŒïŒïŒ¡ïœïœïœïœïŒ²ïŒïŒã«é¢é£ããçŸæ£ã®èšºæããã³æ²»ç | |
JP2005526981A (ja) | ãã¥ãŒãã¡ãžã³ïœå容äœïŒïŒïœïœïœïŒïŒã®èšºæããã³æ²»ççäœ¿çš | |
JP2005523427A (ja) | ãã¥ãŒãããããïœïœå容äœïŒïŒïœïœïœïœïŒïŒã«é¢é£ããçŸæ£ã®èšºæããã³æ²»ç | |
WO2003065044A2 (en) | Diagnostics and therapeutics for diseases associated with gpr72 | |
US20060057577A1 (en) | Diagnostics and therapeutics for diseases associated with homo sapiens formyl peptide receptor-like 2 | |
EP1369697A1 (en) | Diagnostics and therapeutics for diseases associated with somatostatin receptor 4 (SSTR4) | |
ES2306983T3 (es) | Diagnosticos y tratamientos para enfermedades hematologicas asociadas con el receptor 5-hidroxitriptamina-1f(5-ht1f). | |
ES2308157T3 (es) | Disgnosticos y tratamientos para enfermedades asociadas con el receptor de la dopamina d3 (drd3). | |
EP1365247A1 (en) | Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 3 (AVPR3) | |
EP1369696A1 (en) | Diagnostics and therapeutics for diseases associated with somatostatin receptor 3 (SSTR3) | |
WO2003096020A2 (en) | Diagnostics and therapeutics for diseases associated with chemokine receptor 8 (ccr8) | |
US20070071753A1 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 85 (gpr85) | |
US20060014218A1 (en) | Diagnostics and therapeutics for diseases associated with neuropeptide ff receptor 1 (npff1) |